PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20338582-6	2011	HYPOTHESIS: Lovastatin inhibits TSP-1-induced VSMC chemotaxis by inhibiting small G proteins via the mevalonate pathway.	Mevalonic Acid	101-111	thrombospondin 1	Homo sapiens	32-37
20338582-13	2011	RESULTS: Lovastatin dose-dependently inhibited TSP-1-induced chemotaxis, which was reversed by mevalonate.	Mevalonic Acid	95-105	thrombospondin 1	Homo sapiens	47-52
21454560-7	2011	Mevalonic acid depletion impaired IGFR processing, decreased the expression of mature IGFRs at the cell surface, and inhibited the downstream activation of Akt and MAPK.	Mevalonic Acid	0-14	insulin like growth factor 1 receptor	Homo sapiens	34-38
21454560-7	2011	Mevalonic acid depletion impaired IGFR processing, decreased the expression of mature IGFRs at the cell surface, and inhibited the downstream activation of Akt and MAPK.	Mevalonic Acid	0-14	AKT serine/threonine kinase 1	Homo sapiens	156-159
21420384-0	2011	Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.	Mevalonic Acid	103-113	farnesyl diphosphate synthase	Homo sapiens	55-86
21353389-3	2011	Recently, we reported that farnesyl pyrophosphate, an endogenous substance produced in the mevalonate pathway, is a specific activator for TRPV3.	Mevalonic Acid	91-101	transient receptor potential cation channel subfamily V member 3	Homo sapiens	139-144
21355014-1	2011	BACKGROUND: Mevalonic acid (MVA) is synthesized at an early and rate-limiting step in the biosynthesis of cholesterol by the enzyme hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, and is a useful measure of statin efficacy or treatment.	Mevalonic Acid	12-26	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	132-184
21285396-5	2011	Consistently, simvastatin reduces RIP140 levels, which can be reversed by mevalonate.	Mevalonic Acid	74-84	nuclear receptor interacting protein 1	Homo sapiens	34-40
21420384-1	2011	A class of drugs successfully used for treatment of metabolic bone diseases is the nitrogen-containing bisphosphonates (N-BPs), which act by inhibiting the vital enzyme, farnesyl pyrophosphate synthase (FPPS), of the mevalonate pathway.	Mevalonic Acid	217-227	farnesyl diphosphate synthase	Homo sapiens	170-201
21420384-1	2011	A class of drugs successfully used for treatment of metabolic bone diseases is the nitrogen-containing bisphosphonates (N-BPs), which act by inhibiting the vital enzyme, farnesyl pyrophosphate synthase (FPPS), of the mevalonate pathway.	Mevalonic Acid	217-227	farnesyl diphosphate synthase	Homo sapiens	203-207
21420384-6	2011	We used IPP/ApppI formation as a surrogate marker for blocking of FPPS in the mevalonate pathway.	Mevalonic Acid	78-88	farnesyl diphosphate synthase	Homo sapiens	66-70
21224482-7	2011	The reductions in protein synthesis and eIF2B expression were prevented by coincubation with mevalonate.	Mevalonic Acid	93-103	eukaryotic translation initiation factor 2B, subunit 4 delta	Mus musculus	40-45
21184137-1	2011	Farnesyl pyrophosphate synthase (FPPS) is an essential enzyme in the mevalonate pathway and might be relevant to hypertension and other cardiovascular diseases.	Mevalonic Acid	69-79	farnesyl diphosphate synthetase	Mus musculus	0-31
21184137-1	2011	Farnesyl pyrophosphate synthase (FPPS) is an essential enzyme in the mevalonate pathway and might be relevant to hypertension and other cardiovascular diseases.	Mevalonic Acid	69-79	farnesyl diphosphate synthetase	Mus musculus	33-37
21478440-2	2011	The enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes a key regulatory step of the mevalonate pathway for isoprenoid biosynthesis and is modulated by many endogenous and external stimuli.	Mevalonic Acid	98-108	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	11-51
21478440-2	2011	The enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes a key regulatory step of the mevalonate pathway for isoprenoid biosynthesis and is modulated by many endogenous and external stimuli.	Mevalonic Acid	98-108	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	53-57
21215324-5	2011	From this analysis, two mevalonate pathway proteins, mevalonate kinase (MK) and phosphomevalonate kinase (PMK) from Saccharomyces cerevisiae, were identified as potential bottlenecks.	Mevalonic Acid	24-34	mevalonate kinase	Saccharomyces cerevisiae S288C	53-70
21292498-4	2011	The inhibition of bFGF, HGF, and TGF-beta mRNA expression, and bFGF, HGF, TGF-beta secretions was reversed when geranylgeranyl pyrophosphate (GGPP), an intermediate in the mevalonate pathway, was used in combination with statins.	Mevalonic Acid	172-182	fibroblast growth factor 2	Mus musculus	18-22
21215324-5	2011	From this analysis, two mevalonate pathway proteins, mevalonate kinase (MK) and phosphomevalonate kinase (PMK) from Saccharomyces cerevisiae, were identified as potential bottlenecks.	Mevalonic Acid	24-34	mevalonate kinase	Saccharomyces cerevisiae S288C	72-74
21215324-5	2011	From this analysis, two mevalonate pathway proteins, mevalonate kinase (MK) and phosphomevalonate kinase (PMK) from Saccharomyces cerevisiae, were identified as potential bottlenecks.	Mevalonic Acid	24-34	phosphomevalonate kinase	Saccharomyces cerevisiae S288C	80-104
20015195-8	2011	The effects of zoledronic acid could be reversed by inclusion of an intermediary of the mevalonate pathway, showing that the loss of Cenp-F from the kinetochore was caused by the inhibition of farnesylation.	Mevalonic Acid	88-98	centromere protein F	Homo sapiens	133-139
21215324-5	2011	From this analysis, two mevalonate pathway proteins, mevalonate kinase (MK) and phosphomevalonate kinase (PMK) from Saccharomyces cerevisiae, were identified as potential bottlenecks.	Mevalonic Acid	24-34	phosphomevalonate kinase	Saccharomyces cerevisiae S288C	106-109
21247791-3	2011	Nitrogen-containing bisphosphonates (N-BPs) are particularly able to inhibit pyrophosphate synthase (FPPS) in the mevalonate pathway (MVP).	Mevalonic Acid	114-124	farnesyl diphosphate synthase	Homo sapiens	101-105
21225243-9	2011	Zoledronic acid (30 muM) also suppressed the TNF-alpha- and RANKL-induced migration of precursors by inhibiting the mevalonic acid pathway.	Mevalonic Acid	116-130	tumor necrosis factor	Mus musculus	45-54
21225243-9	2011	Zoledronic acid (30 muM) also suppressed the TNF-alpha- and RANKL-induced migration of precursors by inhibiting the mevalonic acid pathway.	Mevalonic Acid	116-130	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	60-65
20920623-2	2011	More specifically, once internalized by osteoclasts, N-BPs block the activity of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway.	Mevalonic Acid	141-151	farnesyl diphosphate synthase	Rattus norvegicus	81-112
20920623-2	2011	More specifically, once internalized by osteoclasts, N-BPs block the activity of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway.	Mevalonic Acid	141-151	farnesyl diphosphate synthase	Rattus norvegicus	114-118
21052011-0	2011	Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway.	Mevalonic Acid	154-164	ras homolog family member A	Homo sapiens	194-198
21052011-0	2011	Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway.	Mevalonic Acid	154-164	mitogen-activated protein kinase 14	Homo sapiens	199-235
21052011-10	2011	Together, these results suggest that simvastatin reduces Lp-PLA(2) expression and secreted activity in LPS-stimulated human monocyte-derived macrophages through the inhibition of the mevalonate-GGPP-RhoA-p38 MAPK pathway.	Mevalonic Acid	183-193	phospholipase A2 group VII	Homo sapiens	57-66
21052011-10	2011	Together, these results suggest that simvastatin reduces Lp-PLA(2) expression and secreted activity in LPS-stimulated human monocyte-derived macrophages through the inhibition of the mevalonate-GGPP-RhoA-p38 MAPK pathway.	Mevalonic Acid	183-193	ras homolog family member A	Homo sapiens	199-203
21052011-10	2011	Together, these results suggest that simvastatin reduces Lp-PLA(2) expression and secreted activity in LPS-stimulated human monocyte-derived macrophages through the inhibition of the mevalonate-GGPP-RhoA-p38 MAPK pathway.	Mevalonic Acid	183-193	mitogen-activated protein kinase 3	Homo sapiens	208-212
21304979-8	2011	Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy).	Mevalonic Acid	13-23	tumor protein p53	Homo sapiens	80-83
21304979-8	2011	Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy).	Mevalonic Acid	13-23	tumor protein p53	Homo sapiens	125-128
21304979-8	2011	Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy).	Mevalonic Acid	13-23	autophagy related 5	Homo sapiens	290-294
21304979-8	2011	Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy).	Mevalonic Acid	13-23	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	317-320
21304979-8	2011	Notably both mevalonate cascade inhibition-induced autophagy and apoptosis were p53 dependent: simvastatin increased nuclear p53 accumulation, and both cyclic pifithrin-alpha and p53 shRNAi partially inhibited NOXA, PUMA expression and caspase-3/7 cleavage (apoptosis) and DRAM expression, Atg5-12 complex formation, LC3 lipidation, and autophagosome formation (autophagy).	Mevalonic Acid	13-23	tumor protein p53	Homo sapiens	125-128
20693272-6	2010	The cholesterol pathway intermediate mevalonic acid reversed the simvastatin-mediated protection of cartilage degradation, and the expression and production of collagenase (MMP-1 and MMP-13) and gelatinase (MMP-2 and MMP-9).	Mevalonic Acid	37-51	matrix metallopeptidase 1	Homo sapiens	173-178
21052830-2	2011	In this study, we investigate the effect of atorvastatin on tissue factor (TF) activity in thrombin-stimulated endothelial cells and its regulation through mevalonate or its derivatives.	Mevalonic Acid	156-166	coagulation factor III, tissue factor	Homo sapiens	60-73
21052830-2	2011	In this study, we investigate the effect of atorvastatin on tissue factor (TF) activity in thrombin-stimulated endothelial cells and its regulation through mevalonate or its derivatives.	Mevalonic Acid	156-166	coagulation factor III, tissue factor	Homo sapiens	75-77
21052830-7	2011	Mevalonate and geranylgeranyl pyrophosphate reversed this inhibitory effect of atorvastatin on tissue factor activity, while the presence of farnesyl pyrophosphate did not prevent the atorvastatin effect on thrombin-induced tissue factor activity.	Mevalonic Acid	0-10	coagulation factor III, tissue factor	Homo sapiens	95-108
20863785-5	2010	In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin.	Mevalonic Acid	130-140	tumor necrosis factor	Homo sapiens	47-55
20863785-5	2010	In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin.	Mevalonic Acid	130-140	vascular cell adhesion molecule 1	Homo sapiens	76-82
20863785-5	2010	In static culture, simvastatin potentiated the TNFalpha-induced increase in VCAM-1 and ICAM-1 mRNA but not total protein at 24 h. Mevalonate, a precursor to cholesterol biosynthesis, eliminated the effect of simvastatin.	Mevalonic Acid	130-140	intercellular adhesion molecule 1	Homo sapiens	87-93
21187473-1	2010	BACKGROUND: The rate-limiting enzyme of the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, provides essential intermediates for the prenylation or dolichylation of growth-related proteins.	Mevalonic Acid	44-54	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	64-121
20884711-3	2011	DESIGN AND METHODS: We exposed mesenchymal stromal cells to inhibitors, such as fluvastatin, of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase, responsible for the synthesis of mevalonate, the precursor of cholesterol.	Mevalonic Acid	182-192	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	100-147
21282739-1	2011	BACKGROUND/AIM: The inhibition of the mevalonate pathway through genetic defects such as mevalonate kinase deficiency (MKD) or pharmacological drugs such as aminobisphosphonates causes a shortage of intermediate compounds, in particular geranylgeranyl-pyrophosphate (GGPP), which is associated with the consequent augmented IL-1beta release in monocytes.	Mevalonic Acid	38-48	mevalonate kinase	Mus musculus	89-106
21282739-1	2011	BACKGROUND/AIM: The inhibition of the mevalonate pathway through genetic defects such as mevalonate kinase deficiency (MKD) or pharmacological drugs such as aminobisphosphonates causes a shortage of intermediate compounds, in particular geranylgeranyl-pyrophosphate (GGPP), which is associated with the consequent augmented IL-1beta release in monocytes.	Mevalonic Acid	38-48	interleukin 1 beta	Mus musculus	324-332
20693272-6	2010	The cholesterol pathway intermediate mevalonic acid reversed the simvastatin-mediated protection of cartilage degradation, and the expression and production of collagenase (MMP-1 and MMP-13) and gelatinase (MMP-2 and MMP-9).	Mevalonic Acid	37-51	matrix metallopeptidase 13	Homo sapiens	183-189
20693272-6	2010	The cholesterol pathway intermediate mevalonic acid reversed the simvastatin-mediated protection of cartilage degradation, and the expression and production of collagenase (MMP-1 and MMP-13) and gelatinase (MMP-2 and MMP-9).	Mevalonic Acid	37-51	matrix metallopeptidase 2	Homo sapiens	207-212
20693272-6	2010	The cholesterol pathway intermediate mevalonic acid reversed the simvastatin-mediated protection of cartilage degradation, and the expression and production of collagenase (MMP-1 and MMP-13) and gelatinase (MMP-2 and MMP-9).	Mevalonic Acid	37-51	matrix metallopeptidase 9	Homo sapiens	217-222
20804742-1	2010	Farnesyl pyrophosphate synthase (FPPS, EC 2.5.1.10), an essential enzyme in the mevalonate pathway, catalyzes the synthesis of isoprenoid intermediates.	Mevalonic Acid	80-90	farnesyl diphosphate synthase	Rattus norvegicus	0-31
20804742-1	2010	Farnesyl pyrophosphate synthase (FPPS, EC 2.5.1.10), an essential enzyme in the mevalonate pathway, catalyzes the synthesis of isoprenoid intermediates.	Mevalonic Acid	80-90	farnesyl diphosphate synthase	Rattus norvegicus	33-37
20838437-1	2010	BACKGROUND: In a recent study, we demonstrated the ability of lovastatin, a potent inhibitor of mevalonate synthesis, to inhibit the function of the epidermal growth factor receptor (EGFR).	Mevalonic Acid	96-106	epidermal growth factor receptor	Homo sapiens	149-181
21078495-5	2010	We hypothesized that simvastatin treatment of ovalbumin (OVA)-exposed mice would attenuate early features of airway remodeling by a mevalonate-dependent mechanism.	Mevalonic Acid	132-142	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	46-55
21118482-1	2010	BACKGROUND: PUFAs are potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an enzyme catalyzing the conversion of HMGCoA to mevalonate, the rate limiting step in cholesterol biosynthesis.	Mevalonic Acid	151-161	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	43-100
20843083-1	2010	Density functional theory was applied to study the binding mode of new flavonoids as possible inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), an enzyme that catalyzes the four-electron reduction of HMGCoA to mevalonate, the committed step in the biosynthesis of sterols.	Mevalonic Acid	227-237	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	112-152
20843083-1	2010	Density functional theory was applied to study the binding mode of new flavonoids as possible inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), an enzyme that catalyzes the four-electron reduction of HMGCoA to mevalonate, the committed step in the biosynthesis of sterols.	Mevalonic Acid	227-237	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	154-158
20838437-1	2010	BACKGROUND: In a recent study, we demonstrated the ability of lovastatin, a potent inhibitor of mevalonate synthesis, to inhibit the function of the epidermal growth factor receptor (EGFR).	Mevalonic Acid	96-106	epidermal growth factor receptor	Homo sapiens	183-187
20544107-0	2010	Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway.	Mevalonic Acid	73-83	farnesyl diphosphate synthase	Homo sapiens	34-65
20696928-3	2010	The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids.	Mevalonic Acid	4-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	65-107
20696928-3	2010	The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids.	Mevalonic Acid	4-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	109-114
20696928-3	2010	The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids.	Mevalonic Acid	16-19	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	65-107
20696928-3	2010	The mevalonate (MVA) pathway, paced by its rate-limiting enzyme, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is required for the generation of several fundamental end-products including cholesterol and isoprenoids.	Mevalonic Acid	16-19	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	109-114
20519142-10	2010	These results strongly indicate that bcl-2 reduction in bisphosphonate-treated PC-3 cells is dependent on inhibition of the mevalonate pathway.	Mevalonic Acid	124-134	BCL2 apoptosis regulator	Homo sapiens	37-42
21472326-9	2010	Notably, treatment with mevalonate, an intermediate in the cholesterol and isoprenoid biosynthetic pathways, led to the inhibition of SATB1 down-regulation and cytotoxicity mediated by statins.	Mevalonic Acid	24-34	SATB homeobox 1	Homo sapiens	134-139
20408897-5	2010	We demonstrate here that simvastatin blockade of the mevalonate pathway can mediate induction of mouse Foxp3(+) T cells and that simvastatin can synergize with low levels of TGF-beta to induce Foxp3(+) T cells.	Mevalonic Acid	53-63	forkhead box P3	Mus musculus	103-108
20581679-1	2010	PURPOSE OF REVIEW: Statins, by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, decrease the synthesis not only of cholesterol but also of nonsteroidal mevalonate derivatives.	Mevalonic Acid	163-173	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-89
20466804-10	2010	In contrast, the beneficial effects of pravastatin-induced connexin43 were abolished by the addition of mevalonate and a protein kinase C inducer.	Mevalonic Acid	104-114	gap junction protein, alpha 1	Rattus norvegicus	59-69
20472098-5	2010	Co-treatment of LPS-stimulated cells with both atorvastatin and mevalonate rescued NF-kappaB activation and TLR4 blockade demonstrated that atorvastatin does not exert its inhibitory effect via TLR4 receptor-ligand binding mechanism.	Mevalonic Acid	64-74	toll-like receptor 4	Mus musculus	108-112
20472098-7	2010	In contrast, mevalonate repaired lipid raft function leading to TLR4 clustering in the lipid raft.	Mevalonic Acid	13-23	toll-like receptor 4	Mus musculus	64-68
20466804-12	2010	Thus chronic use of pravastatin after infarction, resulting in enhanced connexin43 amount by attenuation of mevalonate-dependent endothelin-1 through a protein kinase C-dependent pathway, may attenuate the arrhythmogenic response to programmed electrical stimulation.	Mevalonic Acid	108-118	gap junction protein, alpha 1	Rattus norvegicus	72-82
20466804-12	2010	Thus chronic use of pravastatin after infarction, resulting in enhanced connexin43 amount by attenuation of mevalonate-dependent endothelin-1 through a protein kinase C-dependent pathway, may attenuate the arrhythmogenic response to programmed electrical stimulation.	Mevalonic Acid	108-118	endothelin 1	Rattus norvegicus	129-141
20304105-1	2010	The inhibition of mevalonate pathway through genetic defects (mevalonate kinase deficiency, MKD) or pharmacologic drugs (aminobisphosphonates) causes a shortage of intermediate compounds and, in particular, of geranylgeranyl-pyrophosphate (GGPP) associated to the activation of caspase-1 and IL-1beta release.	Mevalonic Acid	18-28	caspase 1	Homo sapiens	278-287
20418539-3	2010	We propose a rapid and versatile reverse phase-HPLC method for assaying HMGR activity capable of monitoring the levels of both substrates (HMG-CoA and NADPH) and products (CoA, mevalonate, and NADP(+)) in a single 20 min run with no pretreatment required.	Mevalonic Acid	177-187	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	72-76
20594936-3	2010	K-ras modulation has become a promising concept for new therapies, mostly by interference with the mevalonate pathway and subsequently by the prenylation of k-ras.	Mevalonic Acid	99-109	KRAS proto-oncogene, GTPase	Homo sapiens	0-5
20594936-4	2010	Clinical data of agents interfering with the mevalonate pathway and the prenylation of ras are summarized and suggest that these agents might be effective when administered in combination with anticancer drugs that target k-ras.	Mevalonic Acid	45-55	KRAS proto-oncogene, GTPase	Homo sapiens	222-227
20179743-7	2010	Our results, although preliminary, showed that the inhibition of the mevalonate pathway led to a hyper-expression of NALP3, suggesting a possible involvement of NALP3-inflammasome in the activation of caspase-1 consequent to GGPP decrement.	Mevalonic Acid	69-79	NLR family pyrin domain containing 3	Homo sapiens	117-122
20179743-7	2010	Our results, although preliminary, showed that the inhibition of the mevalonate pathway led to a hyper-expression of NALP3, suggesting a possible involvement of NALP3-inflammasome in the activation of caspase-1 consequent to GGPP decrement.	Mevalonic Acid	69-79	NLR family pyrin domain containing 3	Homo sapiens	161-166
20179743-7	2010	Our results, although preliminary, showed that the inhibition of the mevalonate pathway led to a hyper-expression of NALP3, suggesting a possible involvement of NALP3-inflammasome in the activation of caspase-1 consequent to GGPP decrement.	Mevalonic Acid	69-79	caspase 1	Homo sapiens	201-210
20395302-3	2010	Here, we show that farnesyl pyrophosphate (FPP), an intermediate metabolite in the mevalonate pathway, specifically activates TRPV3 among six thermoTRPs using Ca(2+) imaging and electrophysiology with cultured keratinocytes and TRPV3-overexpressing cells.	Mevalonic Acid	83-93	transient receptor potential cation channel subfamily V member 3	Homo sapiens	126-131
20045866-5	2010	Concomitant treatment with mevalonate or geranylgeranyl pyrophosphate completely reversed the inhibitory effect of pitavastatin, suggesting that geranylgeranylated proteins are involved in the inhibition of EL expression by statins.	Mevalonic Acid	27-37	lipase G, endothelial type	Homo sapiens	207-209
20179743-0	2010	The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency.	Mevalonic Acid	18-28	NLR family pyrin domain containing 3	Homo sapiens	61-66
20179743-2	2010	The shortage of mevalonate-derived intermediates, and in particular of geranylgeranyl pyrophosphate (GGPP), has been linked with the activation of caspase-1 and thereby with the production of IL-1beta, but the true concatenation of these two events has not been clarified yet.	Mevalonic Acid	16-26	caspase 1	Homo sapiens	147-156
20179743-2	2010	The shortage of mevalonate-derived intermediates, and in particular of geranylgeranyl pyrophosphate (GGPP), has been linked with the activation of caspase-1 and thereby with the production of IL-1beta, but the true concatenation of these two events has not been clarified yet.	Mevalonic Acid	16-26	interleukin 1 beta	Homo sapiens	192-200
20304105-1	2010	The inhibition of mevalonate pathway through genetic defects (mevalonate kinase deficiency, MKD) or pharmacologic drugs (aminobisphosphonates) causes a shortage of intermediate compounds and, in particular, of geranylgeranyl-pyrophosphate (GGPP) associated to the activation of caspase-1 and IL-1beta release.	Mevalonic Acid	18-28	interleukin 1 beta	Homo sapiens	292-300
20484369-3	2010	FKP1 is a single-copy gene in the Arabidopsis genome and encodes 3-hydroxy-3-methylglutaryl-coenzyme A synthase (HMG-CoA synthase), an enzyme of the mevalonate (MVA) pathway involved in biosynthesis of isoprenoids such as sterols.	Mevalonic Acid	149-159	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	0-4
20484369-3	2010	FKP1 is a single-copy gene in the Arabidopsis genome and encodes 3-hydroxy-3-methylglutaryl-coenzyme A synthase (HMG-CoA synthase), an enzyme of the mevalonate (MVA) pathway involved in biosynthesis of isoprenoids such as sterols.	Mevalonic Acid	149-159	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	113-129
20641992-1	2004	These phosphonates tend to accumulate in osteoclasts at areas of increased bone metabolism by inhibiting the farnesyl diphosphate synthase, an important enzyme of the mevalonate pathway in the cell (1), as described by Drake et.	Mevalonic Acid	167-177	farnesyl diphosphate synthetase	Mus musculus	109-138
20298756-5	2010	The present results suggest that FPPS plays an important role in apoptotic cell death of cancer cells by blocking the JNK signaling cascade and activating mevalonate metabolism in paclitaxel-treated glioblastoma cells.	Mevalonic Acid	155-165	farnesyl diphosphate synthase	Homo sapiens	33-37
20155363-8	2010	Mevalonate completely reversed VEGF-induced VEGFR2 phosphorylation, but only partially reversed the phosphorylation of p44/42 MAP kinase and MLC.	Mevalonic Acid	0-10	vascular endothelial growth factor A	Homo sapiens	31-35
20155363-8	2010	Mevalonate completely reversed VEGF-induced VEGFR2 phosphorylation, but only partially reversed the phosphorylation of p44/42 MAP kinase and MLC.	Mevalonic Acid	0-10	kinase insert domain receptor	Homo sapiens	44-50
20155363-8	2010	Mevalonate completely reversed VEGF-induced VEGFR2 phosphorylation, but only partially reversed the phosphorylation of p44/42 MAP kinase and MLC.	Mevalonic Acid	0-10	modulator of VRAC current 1	Homo sapiens	141-144
19946014-6	2010	The statin effect was reversed by mevalonate and geranylgeranyl-pyrophosphate and mimicked by the Rho inhibitor C3 transferase, indicating the involvement of Rho in the signal transduction pathway leading to COX-2 expression.	Mevalonic Acid	34-44	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	208-213
20155363-5	2010	Involvement of the mevalonate pathway in VEGF-induced signaling was also examined.	Mevalonic Acid	19-29	vascular endothelial growth factor A	Homo sapiens	41-45
20019585-2	2010	Statins work by inhibiting HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, thus stopping the conversion of HMG-CoA to mevalonate, which is found in the cholesterol synthesis cascade.	Mevalonic Acid	129-139	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	36-84
20136831-7	2010	Co-incubation of mevalonate and geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, reversed the inhibitory effects of statins on MCP-1 expression.	Mevalonic Acid	17-27	C-C motif chemokine ligand 2	Homo sapiens	140-145
19819230-1	2010	Increasing evidence is accumulating that zoledronic acid (ZOL), a nitrogen-containing bisphosphonate (N-BP), is able to affect tumor cells by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway (MVP).	Mevalonic Acid	210-220	farnesyl diphosphate synthase	Homo sapiens	164-195
19819230-1	2010	Increasing evidence is accumulating that zoledronic acid (ZOL), a nitrogen-containing bisphosphonate (N-BP), is able to affect tumor cells by inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway (MVP).	Mevalonic Acid	210-220	farnesyl diphosphate synthase	Homo sapiens	197-201
19800872-1	2010	Farnesyl pyrophosphate synthase (FPPS), an essential enzyme in the mevalonate pathway, was reported to be upregulated in young spontaneously hypertensive rats (SHR) when compared with Wistar-Kyoto (WKY) rats, and this was accompanied by development of left ventricular hypertrophy.	Mevalonic Acid	67-77	farnesyl diphosphate synthase	Rattus norvegicus	0-31
20067528-4	2010	Therefore, we investigated whether these strains possessed the 3-hydroxyl-3-methylglutaryl coenzyme A reductase (hmgr) gene, which indicates the presence of the mevalonate pathway.	Mevalonic Acid	161-171	high mobility group AT-hook 1	Homo sapiens	113-117
19937728-9	2010	ATV treatment induced a decrease of F-actin content and Thr18/Ser19 dual phosphorylation of myosin regulatory light chain (MRLC), which was rescued by 2ME or mevalonate.	Mevalonic Acid	158-168	myosin heavy chain 14	Homo sapiens	92-98
19800872-1	2010	Farnesyl pyrophosphate synthase (FPPS), an essential enzyme in the mevalonate pathway, was reported to be upregulated in young spontaneously hypertensive rats (SHR) when compared with Wistar-Kyoto (WKY) rats, and this was accompanied by development of left ventricular hypertrophy.	Mevalonic Acid	67-77	farnesyl diphosphate synthase	Rattus norvegicus	33-37
19919573-6	2010	Identification of the function of the MEF11 protein in site-specific mitochondrial RNA editing suggests indirect effects of retrograde signalling from mitochondria to the cytoplasm to evoke alteration of the mevalonate pathway.	Mevalonic Acid	208-218	Pentatricopeptide repeat (PPR) superfamily protein	Arabidopsis thaliana	38-43
19932975-9	2010	Mevalonate and GGPP partially prevented simvastatin-induced sensitization to LSEC death mediated by Jo2 and TNF-alpha, but not Jo2 alone.	Mevalonic Acid	0-10	tumor necrosis factor	Homo sapiens	108-117
19595352-3	2010	Mevalonate (200 microM) reversed the inhibition of ox-PAPC-stimulated mRNA and protein levels by lovastatin, indicating the inhibitory effect of lovastatin was due to inhibition of mevalonate synthesis.	Mevalonic Acid	0-10	protocadherin 8	Homo sapiens	54-58
19595352-3	2010	Mevalonate (200 microM) reversed the inhibition of ox-PAPC-stimulated mRNA and protein levels by lovastatin, indicating the inhibitory effect of lovastatin was due to inhibition of mevalonate synthesis.	Mevalonic Acid	181-191	protocadherin 8	Homo sapiens	54-58
19699819-14	2009	This mechanism and the inhibition of protein prenylation, both outcomes of FPPS inhibition in mevalonate pathway, seem to act in concert in ZOL-induced apoptosis in cancer cells.	Mevalonic Acid	94-104	farnesyl diphosphate synthase	Homo sapiens	75-79
20722615-5	2010	The enzyme target of these drugs, FPP synthase, is at a branch point in the mevalonate pathway.	Mevalonic Acid	76-86	farnesyl diphosphate synthase	Homo sapiens	34-46
20016680-2	2010	Statin drugs act as inhibitors of the 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase enzyme early in the mevalonate pathway, thereby reducing the endogenous cholesterol synthesis.	Mevalonic Acid	115-125	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	38-94
19846523-1	2010	MicroRNA 122 (miR-122) promotes hepatitis C virus (HCV) RNA abundance through a direct interaction with the viral RNA and stimulates the mevalonate pathway in the animal liver.	Mevalonic Acid	137-147	microRNA 122	Homo sapiens	14-21
20037483-5	2010	The rate-limiting enzyme of the mevalonate pathway, 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase showed differential expression in the myocardium in response to I/R and PC in mice on normal diet but not in cholesterol-fed animals.	Mevalonic Acid	32-42	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	52-109
20642002-1	2004	The NBPs tend to accumulate in osteoclasts at areas of increased bone metabolism by inhibiting the farnesyl diphosphate synthase, an important enzyme of the mevalonate pathway in the cell (2).	Mevalonic Acid	157-167	farnesyl diphosphate synthase	Rattus norvegicus	99-128
20642004-1	2004	The NBPs tend to accumulate in osteoclasts at areas of increased bone metabolism by inhibiting the farnesyl diphosphate synthase, an important enzyme of the mevalonate pathway in the cell (2).	Mevalonic Acid	157-167	farnesyl diphosphate synthase	Rattus norvegicus	99-128
19571257-1	2009	Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, a rate-limiting step of the mevalonate pathway.	Mevalonic Acid	115-125	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	38-85
19500062-5	2009	Statins are lipid lowering drugs, which reduce cholesterol production by inhibiting HMG-CoA reductase, the rate limiting enzyme of the mevalonate pathway.	Mevalonic Acid	135-145	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	84-101
19672814-4	2009	Growing evidence suggests that BMP-2 expression is regulated by the mevalonate pathway and Rho-associated protein kinase (ROK) activity.	Mevalonic Acid	68-78	bone morphogenetic protein 2	Mus musculus	31-36
19672814-10	2009	These findings suggest that BMP-2 mRNA expression was upregulated by PTH in MC3T3-E1 cells mediated by mevalonate pathway suppression followed by ROK inhibition.	Mevalonic Acid	103-113	bone morphogenetic protein 2	Mus musculus	28-33
19672814-11	2009	We have now demonstrated for the first time that PTH stimulated BMP-2 mRNA expression via the mevalonate pathway and ROK in osteoblastic MC3T3-E1 cells.	Mevalonic Acid	94-104	bone morphogenetic protein 2	Mus musculus	64-69
19771520-8	2009	Intracellular levels of 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase, an ER-transmembrane enzyme catalyzing the synthesis of mevalonate, decreased following gamma-tocotrienol treatment, but combined treatment with mevalonate did not reverse gamma-tocotrienol-induced apoptosis, suggesting that a decrease in HMGCoA reductase activity is not required for gamma-tocotrienol induced apoptosis.	Mevalonic Acid	137-147	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	24-80
19771520-8	2009	Intracellular levels of 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase, an ER-transmembrane enzyme catalyzing the synthesis of mevalonate, decreased following gamma-tocotrienol treatment, but combined treatment with mevalonate did not reverse gamma-tocotrienol-induced apoptosis, suggesting that a decrease in HMGCoA reductase activity is not required for gamma-tocotrienol induced apoptosis.	Mevalonic Acid	137-147	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	320-336
19665003-5	2009	Mevalonate abolishes the activation of CAC gene expression by statins; the inhibitor of the PKA pathway H89 suppresses the stimulation of CAC gene expression by forskolin.	Mevalonic Acid	0-10	solute carrier family 25 member 20	Homo sapiens	39-42
19660469-11	2009	The beneficial effects of pitavastatin were reversed by intermediate products of the mevalonate pathway that are required for the activation of Rac1, and Rac1 inhibitor exhibited cardioprotective effects comparable to those of pitavastatin.	Mevalonic Acid	85-95	Rac family small GTPase 1	Mus musculus	144-148
19665949-1	2009	Nitrogen-containing bisphosphonates (N-BPs) are shown to inhibit a key enzyme of intracellular mevalonate pathway, FPP synthase, leading to intracellular accumulation of pathway metabolites isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP).	Mevalonic Acid	95-105	farnesyl diphosphate synthase	Homo sapiens	115-127
19777282-3	2009	Treatment with 8 microM simvastatin inhibited cell growth and isoprenylation of Rap1A and Rab6, and supplementation with 2 microM mevalonate reversed these effects.	Mevalonic Acid	130-140	RAP1A, member of RAS oncogene family	Homo sapiens	80-85
19777282-3	2009	Treatment with 8 microM simvastatin inhibited cell growth and isoprenylation of Rap1A and Rab6, and supplementation with 2 microM mevalonate reversed these effects.	Mevalonic Acid	130-140	RAB6A, member RAS oncogene family	Homo sapiens	90-94
19741129-5	2009	The protective effects of stains were inhibited by mevalonate, a PI3K inhibitor, and tyrphostin AG538, suggesting roles for cholesterol and insulin/IGF-1 signaling in the neurotoxic response.	Mevalonic Acid	51-61	insulin like growth factor 1	Homo sapiens	148-153
19834579-0	2009	Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway.	Mevalonic Acid	83-93	vascular endothelial growth factor A	Mus musculus	21-25
19834579-5	2009	Bisphosphonates are known to inhibit the mevalonate intracellular signaling pathway used by VEGF.	Mevalonic Acid	41-51	vascular endothelial growth factor A	Mus musculus	92-96
19834579-6	2009	Addition of the mevalonate pathway intermediates farnesol (FOH) and geranylgeraniol (GGOH) interacted with the low concentration of alendronate to further decrease secreted VEGF protein whereas FOH partially restored VEGF protein secretion when combined with the high alendronate.	Mevalonic Acid	16-26	vascular endothelial growth factor A	Mus musculus	173-177
19834579-6	2009	Addition of the mevalonate pathway intermediates farnesol (FOH) and geranylgeraniol (GGOH) interacted with the low concentration of alendronate to further decrease secreted VEGF protein whereas FOH partially restored VEGF protein secretion when combined with the high alendronate.	Mevalonic Acid	16-26	vascular endothelial growth factor A	Mus musculus	217-221
19834579-9	2009	Thus, the bisphophonate alendronate impairs growth plate chondrocyte turnover by down-regulating the secreted forms of VEGF mRNA and protein by inhibiting the mevalonate pathway.	Mevalonic Acid	159-169	vascular endothelial growth factor A	Mus musculus	119-123
19289970-12	2009	Co-administration of mevalonate abolished protective effects of simvastatin on endotoxin-provoked increases in ALT, AST, and hepatocellular apoptosis as well as leukocyte recruitment.	Mevalonic Acid	21-31	glutamic pyruvic transaminase, soluble	Mus musculus	111-114
19592534-2	2009	In the yeast Saccharomyces cerevisiae, GGOH is synthesized from the end products of the mevalonate pathway through the sequential reactions of farnesyl diphosphate synthetase (encoded by the ERG20 gene), geranylgeranyl diphosphate synthase (the BTS1 gene), and some endogenous phosphatases.	Mevalonic Acid	88-98	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	191-196
19592534-2	2009	In the yeast Saccharomyces cerevisiae, GGOH is synthesized from the end products of the mevalonate pathway through the sequential reactions of farnesyl diphosphate synthetase (encoded by the ERG20 gene), geranylgeranyl diphosphate synthase (the BTS1 gene), and some endogenous phosphatases.	Mevalonic Acid	88-98	farnesyltranstransferase	Saccharomyces cerevisiae S288C	245-249
19592534-5	2009	Overexpression of the hydroxymethylglutaryl-coenzyme A reductase (HMG1) gene, which encodes the major rate-limiting enzyme of the mevalonate pathway, resulted in overproduction of squalene (191.9 mg liter(-1)) rather than GGOH (0.2 mg liter(-1)) in test tube cultures.	Mevalonic Acid	130-140	hydroxymethylglutaryl-CoA reductase (NADPH) HMG1	Saccharomyces cerevisiae S288C	66-70
19563533-8	2009	Moreover, conditional medium, supplemented with mevalonic acid in order to nullify a possible contamination by statins, significantly triggered caspase 8 activity.	Mevalonic Acid	48-62	caspase 8	Homo sapiens	144-153
19384817-0	2009	Inhibition of the mevalonate pathway rescues the dexamethasone-induced suppression of the mineralization in osteoblasts via enhancing bone morphogenetic protein-2 signal.	Mevalonic Acid	18-28	bone morphogenetic protein 2	Mus musculus	134-162
19384817-4	2009	These findings suggest that the mevalonate pathway was involved in glucocorticoid-induced osteoblast dysfunction, and that its inhibition might promote bone formation through BMP-2 and alleviate glucocorticoid-induced osteoporosis.	Mevalonic Acid	32-42	bone morphogenetic protein 2	Mus musculus	175-180
19464995-3	2009	AKR1B10 efficiently reduced long-chain aliphatic aldehydes including farnesal and geranylgeranial, which are generated from degradation of prenylated proteins and metabolism of farnesol and geranylgeraniol derived from the mevalonate pathway.	Mevalonic Acid	223-233	aldo-keto reductase family 1 member B10	Homo sapiens	0-7
19494338-0	2009	Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells.	Mevalonic Acid	26-36	farnesyl diphosphate synthase	Homo sapiens	52-83
19151402-8	2009	Supplementation with mevalonate or geranylgeranyl pyrophosphate prevented, whereas inhibition of geranylgeranyl transferase mimicked, the effects of lovastatin on RhoA and RhoB accumulation.	Mevalonic Acid	21-31	ras homolog family member A	Homo sapiens	163-167
19151402-8	2009	Supplementation with mevalonate or geranylgeranyl pyrophosphate prevented, whereas inhibition of geranylgeranyl transferase mimicked, the effects of lovastatin on RhoA and RhoB accumulation.	Mevalonic Acid	21-31	ras homolog family member B	Homo sapiens	172-176
20396700-1	2009	We studied the effects of cholesterol, its oxidized derivatives mevalonate, and nuclear receptor agonists LXR, RXR, and FXR on the production of transforming growth factor-beta1 (TGF- beta1) by macrophages.	Mevalonic Acid	64-74	transforming growth factor beta 1	Homo sapiens	145-177
20396700-1	2009	We studied the effects of cholesterol, its oxidized derivatives mevalonate, and nuclear receptor agonists LXR, RXR, and FXR on the production of transforming growth factor-beta1 (TGF- beta1) by macrophages.	Mevalonic Acid	64-74	transforming growth factor beta 1	Homo sapiens	179-189
20396700-6	2009	Under conditions of inflammation, hypercholesterolemia can be a factor of fibrogenesis due to TGF-beta1 induction in macrophages, which depends on the products of mevalonate biochemical chain.	Mevalonic Acid	163-173	transforming growth factor beta 1	Homo sapiens	94-103
19825518-6	2009	In this review, we discuss recent reports demonstrating that in vitro inhibition of the mevalonate pathway by statins specifically increases the production, by activated monocytes, of cytokines of the IL-1 family, by enhancing caspase-1 activity, the enzyme responsible for IL-1beta and IL-18 maturation.	Mevalonic Acid	88-98	caspase 1	Homo sapiens	227-236
19825518-6	2009	In this review, we discuss recent reports demonstrating that in vitro inhibition of the mevalonate pathway by statins specifically increases the production, by activated monocytes, of cytokines of the IL-1 family, by enhancing caspase-1 activity, the enzyme responsible for IL-1beta and IL-18 maturation.	Mevalonic Acid	88-98	interleukin 1 beta	Homo sapiens	274-282
19825518-6	2009	In this review, we discuss recent reports demonstrating that in vitro inhibition of the mevalonate pathway by statins specifically increases the production, by activated monocytes, of cytokines of the IL-1 family, by enhancing caspase-1 activity, the enzyme responsible for IL-1beta and IL-18 maturation.	Mevalonic Acid	88-98	interleukin 18	Homo sapiens	287-292
19825520-0	2009	Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes.	Mevalonic Acid	34-44	interleukin 1 alpha	Homo sapiens	66-70
19825520-0	2009	Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes.	Mevalonic Acid	34-44	interleukin 1 alpha	Homo sapiens	86-90
19825520-2	2009	HMGR is implicated in the mevalonate pathway, directly upstream of cholesterol biosynthesis.	Mevalonic Acid	26-36	high mobility group AT-hook 1	Homo sapiens	0-4
19825520-7	2009	RESULTS: Pharmacological inhibition of the mevalonate pathway specifically enhanced the release of IL-1alpha, IL-1beta and IL-18 and inhibited IL-1ra production by LPS-activated PBMCs and THP-1 cells.	Mevalonic Acid	43-53	interleukin 1 alpha	Homo sapiens	99-108
19825520-7	2009	RESULTS: Pharmacological inhibition of the mevalonate pathway specifically enhanced the release of IL-1alpha, IL-1beta and IL-18 and inhibited IL-1ra production by LPS-activated PBMCs and THP-1 cells.	Mevalonic Acid	43-53	interleukin 1 beta	Homo sapiens	110-118
19825520-7	2009	RESULTS: Pharmacological inhibition of the mevalonate pathway specifically enhanced the release of IL-1alpha, IL-1beta and IL-18 and inhibited IL-1ra production by LPS-activated PBMCs and THP-1 cells.	Mevalonic Acid	43-53	interleukin 18	Homo sapiens	123-128
19825520-7	2009	RESULTS: Pharmacological inhibition of the mevalonate pathway specifically enhanced the release of IL-1alpha, IL-1beta and IL-18 and inhibited IL-1ra production by LPS-activated PBMCs and THP-1 cells.	Mevalonic Acid	43-53	interleukin 1 receptor antagonist	Homo sapiens	143-149
19825520-11	2009	CONCLUSION: Pharmacological inhibition of the mevalonate pathway by statins highlighted the specific induction of the proinflammatory cytokines of the IL-1 family whose maturation is either directly (i.e. IL-1beta and IL-18), or indirectly (i.e. IL-1alpha) dependant on caspase-1.	Mevalonic Acid	46-56	interleukin 1 alpha	Homo sapiens	151-155
19825520-11	2009	CONCLUSION: Pharmacological inhibition of the mevalonate pathway by statins highlighted the specific induction of the proinflammatory cytokines of the IL-1 family whose maturation is either directly (i.e. IL-1beta and IL-18), or indirectly (i.e. IL-1alpha) dependant on caspase-1.	Mevalonic Acid	46-56	interleukin 1 beta	Homo sapiens	205-213
19825520-11	2009	CONCLUSION: Pharmacological inhibition of the mevalonate pathway by statins highlighted the specific induction of the proinflammatory cytokines of the IL-1 family whose maturation is either directly (i.e. IL-1beta and IL-18), or indirectly (i.e. IL-1alpha) dependant on caspase-1.	Mevalonic Acid	46-56	interleukin 18	Homo sapiens	218-223
19825520-11	2009	CONCLUSION: Pharmacological inhibition of the mevalonate pathway by statins highlighted the specific induction of the proinflammatory cytokines of the IL-1 family whose maturation is either directly (i.e. IL-1beta and IL-18), or indirectly (i.e. IL-1alpha) dependant on caspase-1.	Mevalonic Acid	46-56	interleukin 1 alpha	Homo sapiens	246-255
19825520-11	2009	CONCLUSION: Pharmacological inhibition of the mevalonate pathway by statins highlighted the specific induction of the proinflammatory cytokines of the IL-1 family whose maturation is either directly (i.e. IL-1beta and IL-18), or indirectly (i.e. IL-1alpha) dependant on caspase-1.	Mevalonic Acid	46-56	caspase 1	Homo sapiens	270-279
19380384-1	2009	Recent studies have suggested that statins, the inhibitors for 3-hydroxy-3-methyglutaryl (HMG)-CoA reductase in the mevalonate pathway, exhibit anti-inflammatory effects.	Mevalonic Acid	116-126	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	63-108
19289970-12	2009	Co-administration of mevalonate abolished protective effects of simvastatin on endotoxin-provoked increases in ALT, AST, and hepatocellular apoptosis as well as leukocyte recruitment.	Mevalonic Acid	21-31	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	116-119
19323650-9	2009	Strikingly, cells selected to grow in the continuous presence of statins showed increased expression of caspase 7 mRNA and protein, which was maintained in the absence of statins for several weeks, suggesting that high expression of this caspase might participate in adaptation to blunting of the mevalonate pathway in this model.	Mevalonic Acid	297-307	caspase 7	Homo sapiens	104-113
19254925-7	2009	Addition of mevalonate or geranylgeranyl pyrophosphate (GGPP), a mevalonate metabolite, abolished simvastatin-induced inhibition of leptin expression in 3T3-L1 cells.	Mevalonic Acid	12-22	leptin	Mus musculus	132-138
19323650-10	2009	Taken together, our results show that caspase 7, as an SREBP-1/2 target, can be induced under mevalonate-restricting conditions, which might help overcome its shortage.	Mevalonic Acid	94-104	caspase 7	Homo sapiens	38-47
19323650-10	2009	Taken together, our results show that caspase 7, as an SREBP-1/2 target, can be induced under mevalonate-restricting conditions, which might help overcome its shortage.	Mevalonic Acid	94-104	sterol regulatory element binding transcription factor 1	Homo sapiens	55-64
23572922-4	2009	Mevalonate synthesis, which is the first step in isoprenoid biosynthesis, is catalyzed by the enzyme 3-hydroxy-3-methylglutarylcoenzyme A reductase 1 (hmgr1).	Mevalonic Acid	0-10	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	151-156
19254730-0	2009	Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells.	Mevalonic Acid	81-95	insulin like growth factor 1	Homo sapiens	23-28
19254730-7	2009	Mevalonic acid prevented fluvastatin inhibition of IGF-1-induced MEK1/2 and ERK1/2 phosphorylation, cyclin D1 expression, and MC proliferation.	Mevalonic Acid	0-14	insulin like growth factor 1	Homo sapiens	51-56
19254730-7	2009	Mevalonic acid prevented fluvastatin inhibition of IGF-1-induced MEK1/2 and ERK1/2 phosphorylation, cyclin D1 expression, and MC proliferation.	Mevalonic Acid	0-14	mitogen-activated protein kinase kinase 1	Homo sapiens	65-71
19254730-7	2009	Mevalonic acid prevented fluvastatin inhibition of IGF-1-induced MEK1/2 and ERK1/2 phosphorylation, cyclin D1 expression, and MC proliferation.	Mevalonic Acid	0-14	mitogen-activated protein kinase 3	Homo sapiens	76-82
19254730-7	2009	Mevalonic acid prevented fluvastatin inhibition of IGF-1-induced MEK1/2 and ERK1/2 phosphorylation, cyclin D1 expression, and MC proliferation.	Mevalonic Acid	0-14	cyclin D1	Homo sapiens	100-109
19254730-8	2009	SIGNIFICANCE: Fluvastatin inhibits IGF-1-induced activation of the MAP kinase pathway and MC proliferation by mevalonic acid depletion, and might have renoprotective effects by inhibiting IGF-1-mediated MC proliferation.	Mevalonic Acid	110-124	insulin like growth factor 1	Homo sapiens	35-40
19589242-4	2009	Mevalonate, but not GW9662, reversed the simvastatin-induced down-regulation of OX40 and OX40L expression, indicating that these effects were mediated through the mevalonate pathway.	Mevalonic Acid	0-10	TNF receptor superfamily member 4	Homo sapiens	80-84
19589242-4	2009	Mevalonate, but not GW9662, reversed the simvastatin-induced down-regulation of OX40 and OX40L expression, indicating that these effects were mediated through the mevalonate pathway.	Mevalonic Acid	0-10	TNF superfamily member 4	Homo sapiens	89-94
19473519-8	2009	SP600125 and JNK small interfering RNA (siRNA) completely attenuated the resistin protein expression induced by TNF-alpha and mevalonate.	Mevalonic Acid	126-136	mitogen-activated protein kinase 8	Homo sapiens	13-16
19416104-2	2009	FPP formed from mevalonate in a reaction catalyzed by FPP synthase (Erg20p).	Mevalonic Acid	16-26	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	68-74
19346993-1	2009	OBJECTIVE: The rate-limiting activity of the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, provides intermediates essential for growth.	Mevalonic Acid	45-55	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	65-122
19346993-11	2009	CONCLUSIONS: Suppression of mevalonate pathway activities, be it by modulators of HMG CoA reductase (statins, tocotrienols, and farnesol), farnesyl transferase (farnesyl transferase inhibitors), and/or mevalonate pyrophosphate decarboxylase (phenylacetate) activity, may have a potential in pancreatic cancer chemotherapy.	Mevalonic Acid	28-38	mevalonate diphosphate decarboxylase	Homo sapiens	202-240
18798562-1	2009	Phosphomevalonate kinase (PMK) catalyzes an essential step in the mevalonate pathway, which is the only pathway for synthesis of isoprenoids and steroids in humans.	Mevalonic Acid	7-17	phosphomevalonate kinase	Homo sapiens	26-29
19001547-1	2009	AMP-activated protein kinase (AMPK) and Rho kinase (ROK) are known to modulate the mevalonate pathway.	Mevalonic Acid	83-93	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	40-50
18692592-12	2009	CONCLUSION: This study demonstrates that high glucose induced significant alterations in endothelial cell growth by inhibition of the mevalonate pathway, which subsequently mediates the increase in TGFbeta(1) and inhibition of Ras prenylation.	Mevalonic Acid	134-144	transforming growth factor, beta 1	Rattus norvegicus	198-208
18982375-8	2009	The observed results were reversed when mevalonate was added to THP-1 macrophages.	Mevalonic Acid	40-50	GLI family zinc finger 2	Homo sapiens	64-69
19149867-5	2009	RESULTS: Transcriptome profiling of Huh-7 cells treated with 25-HC gave 47 downregulated genes, 16 of which are clearly related to the mevalonate pathway.	Mevalonic Acid	135-145	MIR7-3 host gene	Homo sapiens	36-41
19149867-11	2009	CONCLUSION: Treatment of Huh-7 cells bearing HCV replicons with 25-HC leads to the downregulation of many key genes involved in the mevalonate pathway leading to an antiviral state within the host cell.	Mevalonic Acid	132-142	MIR7-3 host gene	Homo sapiens	25-30
19001547-11	2009	These findings suggest that the AMPK activator and the ROK inhibitor are able to stimulate the mineralization of osteoblasts through modulating the mevalonate pathway.	Mevalonic Acid	148-158	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	55-58
19110480-8	2009	Several metabolic derangements in peroxisome-deficient PEX2-/- liver are likely to trigger ER stress, including perturbed flux of mevalonate metabolites, altered bile acid homeostasis, changes in fatty acid levels and composition, and oxidative stress.	Mevalonic Acid	130-140	peroxisomal biogenesis factor 2	Mus musculus	55-59
19001547-1	2009	AMP-activated protein kinase (AMPK) and Rho kinase (ROK) are known to modulate the mevalonate pathway.	Mevalonic Acid	83-93	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	52-55
18787804-4	2008	Simvastatin triggered nuclear translocation of Nrf2 in rat liver and in primary rat hepatocytes in a mevalonate-dependent and cholesterol-independent way.	Mevalonic Acid	101-111	NFE2 like bZIP transcription factor 2	Rattus norvegicus	47-51
19026553-1	2009	Efficient drugs such as statins or mevinic acids are inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGR), an enzyme responsible for the double reduction of 3-hydroxy-3-methyl-glutaryl coenzyme A into mevalonic acid.	Mevalonic Acid	272-286	high mobility group AT-hook 1	Homo sapiens	171-175
18929563-8	2009	The toxic effect of simvastatin could be rescued by the product of HMG-CoA reductase mevalonate but not low-density lipoprotein (LDL).	Mevalonic Acid	85-95	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	67-84
19041104-1	2009	3-Hydroxy-3-methylglutaryl-CoA reductase (HMGR, EC 1.1.1.34) catalyzes the major rate-limiting step in the mevalonate (MVA) pathway for isoprenoid biosynthesis.	Mevalonic Acid	107-117	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	0-40
19041104-1	2009	3-Hydroxy-3-methylglutaryl-CoA reductase (HMGR, EC 1.1.1.34) catalyzes the major rate-limiting step in the mevalonate (MVA) pathway for isoprenoid biosynthesis.	Mevalonic Acid	107-117	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	42-46
18782552-10	2008	However, incubation of the cells with pamidronate, an inhibitor of farnesyl pyrophosphate synthase, resulted in increased levels of mevalonate, isopentenyl pyrophosphate/dimethylallyl pyrophosphate, and geranyl pyrophosphate.	Mevalonic Acid	132-142	farnesyl diphosphate synthase	Homo sapiens	67-98
19132091-1	2009	The isoprenoid biosynthetic pathway leading from the production of mevalonate by HMGCoA reductase (Hmgcr) to the geranylation of the G protein subunit, Ggamma1, plays an important role in cardiac development in the fly.	Mevalonic Acid	67-77	HMG Coenzyme A reductase	Drosophila melanogaster	81-97
19132091-1	2009	The isoprenoid biosynthetic pathway leading from the production of mevalonate by HMGCoA reductase (Hmgcr) to the geranylation of the G protein subunit, Ggamma1, plays an important role in cardiac development in the fly.	Mevalonic Acid	67-77	HMG Coenzyme A reductase	Drosophila melanogaster	99-104
19132091-1	2009	The isoprenoid biosynthetic pathway leading from the production of mevalonate by HMGCoA reductase (Hmgcr) to the geranylation of the G protein subunit, Ggamma1, plays an important role in cardiac development in the fly.	Mevalonic Acid	67-77	G protein gamma 1	Drosophila melanogaster	152-159
32688858-9	2008	The obtained results are in agreement with the involvement of AACT2 in catalysing the first step of the mevalonate pathway.	Mevalonic Acid	104-114	acetoacetyl-CoA thiolase 2	Arabidopsis thaliana	62-67
19053857-8	2008	While mevalonate, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), restored proliferation in LV-treated cells, it failed to do so in RYR-treated cells.	Mevalonic Acid	6-16	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	83-88
18757369-10	2008	We showed that mevalonate or geranylgeranylpyrophosphate treatment prevented the statin-induced reduction in JNK phosphorylation, MMP2 activity, and cell invasion.	Mevalonic Acid	15-25	mitogen-activated protein kinase 8	Homo sapiens	109-112
18757369-10	2008	We showed that mevalonate or geranylgeranylpyrophosphate treatment prevented the statin-induced reduction in JNK phosphorylation, MMP2 activity, and cell invasion.	Mevalonic Acid	15-25	matrix metallopeptidase 2	Homo sapiens	130-134
18787804-6	2008	In ST2 cells stably transfected with constructs bearing Nrf2-binding site (antioxidant responsive element), simvastatin enhanced Nrf2-mediated transcriptional activity in a mevalonate-dependent and cholesterol-independent fashion.	Mevalonic Acid	173-183	NFE2 like bZIP transcription factor 2	Rattus norvegicus	56-60
18787804-6	2008	In ST2 cells stably transfected with constructs bearing Nrf2-binding site (antioxidant responsive element), simvastatin enhanced Nrf2-mediated transcriptional activity in a mevalonate-dependent and cholesterol-independent fashion.	Mevalonic Acid	173-183	NFE2 like bZIP transcription factor 2	Rattus norvegicus	129-133
18625202-1	2008	Simvastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway required for the biosynthesis of cholesterol and higher isoprenoids such as geranylgeranyl pyrophosphate (GGPP).	Mevalonic Acid	93-103	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-59
18771750-0	2008	Rsp5p ubiquitin ligase and the transcriptional activators Spt23p and Mga2p are involved in co-regulation of biosynthesis of end products of the mevalonate pathway and triacylglycerol in yeast Saccharomyces cerevisiae.	Mevalonic Acid	144-154	NEDD4 family E3 ubiquitin-protein ligase	Saccharomyces cerevisiae S288C	0-5
18771750-0	2008	Rsp5p ubiquitin ligase and the transcriptional activators Spt23p and Mga2p are involved in co-regulation of biosynthesis of end products of the mevalonate pathway and triacylglycerol in yeast Saccharomyces cerevisiae.	Mevalonic Acid	144-154	Spt23p	Saccharomyces cerevisiae S288C	58-64
18771750-0	2008	Rsp5p ubiquitin ligase and the transcriptional activators Spt23p and Mga2p are involved in co-regulation of biosynthesis of end products of the mevalonate pathway and triacylglycerol in yeast Saccharomyces cerevisiae.	Mevalonic Acid	144-154	Mga2p	Saccharomyces cerevisiae S288C	69-74
18771750-2	2008	Here we show that the conditional mutant rsp5-19 produces decreased levels of the end products of mevalonate pathway, such as ergosterol, ubiquinone and of dolichols, especially those with 19-24 isoprene units.	Mevalonic Acid	98-108	NEDD4 family E3 ubiquitin-protein ligase	Saccharomyces cerevisiae S288C	41-45
18581203-9	2008	The effects of simvastatin on ERK1/2, PKC, and AKT activation and DNA synthesis could be reversed by mevalonate.	Mevalonic Acid	101-111	mitogen activated protein kinase 3	Rattus norvegicus	30-36
18581203-9	2008	The effects of simvastatin on ERK1/2, PKC, and AKT activation and DNA synthesis could be reversed by mevalonate.	Mevalonic Acid	101-111	AKT serine/threonine kinase 1	Rattus norvegicus	47-50
18556704-4	2008	GRP78 induction was abolished by co-treatment with mevalonate and 1,2-bis(o-aminophenoxy)ethane-N, N, N",N"-tetraacetic acid, indicating the involvement of both 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase-dependent and -independent mechanisms.	Mevalonic Acid	51-61	heat shock protein family A (Hsp70) member 5	Homo sapiens	0-5
18556704-4	2008	GRP78 induction was abolished by co-treatment with mevalonate and 1,2-bis(o-aminophenoxy)ethane-N, N, N",N"-tetraacetic acid, indicating the involvement of both 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase-dependent and -independent mechanisms.	Mevalonic Acid	51-61	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	161-219
18624305-0	2008	Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR gamma delta cells.	Mevalonic Acid	26-36	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	94-97
18685105-1	2008	Mice deficient in cholesterol 24-hydroxylase exhibit reduced rates of cholesterol synthesis and other non-sterol isoprenoids that arise from the mevalonate pathway.	Mevalonic Acid	145-155	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	18-44
18624305-4	2008	Here, we show that, during the initial phases of infections with Escherichia coli and Staphylococcus aureus, TCR gammadelta cells are activated by endogenous mevalonate metabolites.	Mevalonic Acid	158-168	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	109-112
18624305-5	2008	Infections with low bacteria inocula up-regulate the production and accumulation of host-derived TCR gammadelta stimulatory antigens within 1 h, which is followed by a peak of TCR gammadelta cell activation at 5 h. Infections induce the accumulation and dephosphorylation of the hydroxymethylglutaryl-coenzyme A reductase, the rate-limiting enzyme of the mevalonate pathway, resulting in increased activity of this enzyme and in increased synthesis of intermediate metabolites.	Mevalonic Acid	355-365	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	97-100
18624305-5	2008	Infections with low bacteria inocula up-regulate the production and accumulation of host-derived TCR gammadelta stimulatory antigens within 1 h, which is followed by a peak of TCR gammadelta cell activation at 5 h. Infections induce the accumulation and dephosphorylation of the hydroxymethylglutaryl-coenzyme A reductase, the rate-limiting enzyme of the mevalonate pathway, resulting in increased activity of this enzyme and in increased synthesis of intermediate metabolites.	Mevalonic Acid	355-365	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	176-179
18453621-7	2008	This effect was reversed by mevalonic acid, a downstream metabolite of 3-hydroxy-3-methylglutaryl CoA reductase, confirming that simvastatin"s specific effect is through the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase.	Mevalonic Acid	28-42	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	71-111
18504457-1	2008	3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase produces mevalonate, an important intermediate in the synthesis of cholesterol and essential nonsterol isoprenoids.	Mevalonic Acid	67-77	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
18214569-8	2008	FPPS is a key enzyme in the mevalonate pathway, which generates isoprenoid lipids utilized for the post-translational modification of small GTP-binding proteins that are essential for osteoclast function.	Mevalonic Acid	28-38	farnesyl diphosphate synthase	Homo sapiens	0-4
18325729-3	2008	Nitrogen-containing bisphosphonates directly inhibit farnesyl diphosphate (FPP) synthase activity (mevalonate pathway) and reduce protein prenylation leading to osteoclast cell death.	Mevalonic Acid	99-109	farnesyl diphosphate synthase	Rattus norvegicus	53-88
18489904-3	2008	Dolichyl phosphate is a nonsterol isoprenoid derivative in the mevalonate pathway that affects the expression of the Insulin-like growth factor 1 receptor (IGF-1R).	Mevalonic Acid	63-73	insulin like growth factor 1 receptor	Homo sapiens	117-154
18489904-3	2008	Dolichyl phosphate is a nonsterol isoprenoid derivative in the mevalonate pathway that affects the expression of the Insulin-like growth factor 1 receptor (IGF-1R).	Mevalonic Acid	63-73	insulin like growth factor 1 receptor	Homo sapiens	156-162
18628692-14	2008	CONCLUSION: Simvastatin drives a mechanism for promoting chondrogenesis of IVD cells partially mediated by upregulated BMP-2 through the inhibition of mevalonate pathway.	Mevalonic Acid	151-161	bone morphogenetic protein 2	Rattus norvegicus	119-124
18515953-3	2008	N-BPs suppress bone resorption by inhibiting farnesyl diphosphate synthase in mevalonate pathway, reducing protein-prenylation, consequently disrupting the membrance structure in osteoclasts.	Mevalonic Acid	78-88	farnesyl diphosphate synthase	Homo sapiens	45-74
18390541-8	2008	The observed inhibitory effects of simvastatin on keratinocyte VEGF expression and proliferation could be reversed by mevalonate, the product of HMGR enzymatic activity.	Mevalonic Acid	118-128	vascular endothelial growth factor A	Mus musculus	63-67
18787645-5	2008	Statin, 3-hydroxy-3- methyl-glutaryl (HMG)-CoA reductase inhibitor therapy inhibits conversion of HMG-CoA to mevalonate and lowers plasma CoQ(10) concentrations.	Mevalonic Acid	109-119	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	8-56
18454049-4	2008	Recently, we reported that nitrogen-containing bisphosphonates (N-BPs) induce formation of a novel ATP analog (ApppI) as a consequence of the inhibition of farnesyl diphosphate synthase in the mevalonate pathway.	Mevalonic Acid	193-203	farnesyl diphosphate synthase	Homo sapiens	156-185
18037402-5	2008	Our results showed that the amino-bisphosphonates down-regulate hTERT gene expression and that combined treatment with geranylgeraniol and zoledronate was able to revert only partially the effects on viability; on the contrary, hTERT gene down-regulation was not affected by the restoration of the mevalonate pathway.	Mevalonic Acid	298-308	telomerase reverse transcriptase	Homo sapiens	228-233
18319397-6	2008	IPP isomerase activity in the cytosol was confirmed by uniform labeling of IPP- and DMAPP-derived units of the cytoplasmic isoprenoid product, sitosterol, when labeled mevalonate was administered.	Mevalonic Acid	168-178	isopentenyl diphosphate isomerase 1	Arabidopsis thaliana	0-13
18356691-4	2008	METHODS AND RESULTS: Simvastatin induced mRNA expression and protein secretion of VEGF in endothelial cells that were reversed by pretreatment with mevalonate and geranylgeranylpyrophosphate but not by farnesylpyrophosphate.	Mevalonic Acid	148-158	vascular endothelial growth factor A	Homo sapiens	82-86
18365690-4	2008	Furthermore, exogenously applied mevalonate or geranylgeranylpyrophosphate in combination with simvastatin completely prevented the inhibitory effects of simvastatin on ROS generation and monocyte-endothelial cell adhesion by TNFalpha and Ang II.	Mevalonic Acid	33-43	tumor necrosis factor	Homo sapiens	226-234
17936042-9	2008	Mevalonate and geranylgeranylpyrophosphate blocked the stimulatory effects of pitavastatin on iNOS and IL-1RI induction.	Mevalonic Acid	0-10	nitric oxide synthase 2	Homo sapiens	94-98
17936042-9	2008	Mevalonate and geranylgeranylpyrophosphate blocked the stimulatory effects of pitavastatin on iNOS and IL-1RI induction.	Mevalonic Acid	0-10	interleukin 1 receptor type 1	Homo sapiens	103-109
17333335-5	2008	The FXR activator farnesol, a mevalonate pathway intermediate, exerts a mitogenic effect on MCF-7 cells.	Mevalonic Acid	30-40	nuclear receptor subfamily 1 group H member 4	Homo sapiens	4-7
17764839-7	2008	Intrathecal injection of mevalonate increased the amount of geranylgeranylated RhoA in the spinal cord, which was completely blocked by intrathecal pretreatment with GGTI-2133.	Mevalonic Acid	25-35	ras homolog family member A	Mus musculus	79-83
17764839-8	2008	Intrathecal injection of mevalonate also produced RhoA translocation from cytosol to plasma membrane.	Mevalonic Acid	25-35	ras homolog family member A	Mus musculus	50-54
17764839-9	2008	This mevalonate-induced RhoA translocation was also blocked by intrathecal pretreatment with GGTI-2133, indicating that the RhoA translocation is triggered by RhoA geranylgeranylation.	Mevalonic Acid	5-15	ras homolog family member A	Mus musculus	24-28
17764839-9	2008	This mevalonate-induced RhoA translocation was also blocked by intrathecal pretreatment with GGTI-2133, indicating that the RhoA translocation is triggered by RhoA geranylgeranylation.	Mevalonic Acid	5-15	ras homolog family member A	Mus musculus	124-128
17764839-9	2008	This mevalonate-induced RhoA translocation was also blocked by intrathecal pretreatment with GGTI-2133, indicating that the RhoA translocation is triggered by RhoA geranylgeranylation.	Mevalonic Acid	5-15	ras homolog family member A	Mus musculus	124-128
17764839-11	2008	Our present results suggest that mevalonate sensitizes the spinal nociceptive transmission, which is mediated by the activation of ROCK following the RhoA geranylgeranylation.	Mevalonic Acid	33-43	ras homolog family member A	Mus musculus	150-154
18504409-1	2008	BACKGROUND: Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a key rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	121-131	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	28-85
18406365-2	2008	Vgamma9Vdelta2 T cells use their TCR as a pattern recognition receptor to sense the presence of infection through specific recognition of intermediates of the microbial non-mevalonate pathway of isoprenoid biosynthesis.	Mevalonic Acid	173-183	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	33-36
18057884-0	2008	Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products.	Mevalonic Acid	108-118	C-reactive protein	Homo sapiens	21-39
18057884-2	2008	We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products.	Mevalonic Acid	124-134	C-reactive protein	Homo sapiens	52-55
19024283-4	2008	Risedronate has moderate mineral binding and has a higher inhibition of a key branch-point enzyme famesyl pyrophosphate synthase (FPPS) in the mevalonate pathway.	Mevalonic Acid	143-153	farnesyl diphosphate synthase	Homo sapiens	98-128
18792797-5	2008	These findings demonstrate that the Rho family, such as Rho, Rac and Cdc42, occurring downstream of geranylgeranyl pyrophosphate in the mevalonic acid pathway, was involved in the simvastatin-mediated blockage of myotube formation.	Mevalonic Acid	136-150	thymoma viral proto-oncogene 1	Mus musculus	61-64
18792797-5	2008	These findings demonstrate that the Rho family, such as Rho, Rac and Cdc42, occurring downstream of geranylgeranyl pyrophosphate in the mevalonic acid pathway, was involved in the simvastatin-mediated blockage of myotube formation.	Mevalonic Acid	136-150	cell division cycle 42	Mus musculus	69-74
19024283-4	2008	Risedronate has moderate mineral binding and has a higher inhibition of a key branch-point enzyme famesyl pyrophosphate synthase (FPPS) in the mevalonate pathway.	Mevalonic Acid	143-153	farnesyl diphosphate synthase	Homo sapiens	130-134
17714440-3	2007	We generated transgenic spike lavender plants expressing the Arabidopsis thaliana HMG1 cDNA, encoding the catalytic domain of 3-hydroxy-3-methylglutaryl CoA reductase (HMGR1S), a key enzyme of the mevalonic acid (MVA) pathway.	Mevalonic Acid	197-211	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	82-86
18390205-8	2008	(3) The inhibition effect of simvastatin on ET-1 mRNA and ET-1 expression of endothelial cells could be prevented by mevalonate with concentration of 100 micromol/L.	Mevalonic Acid	117-127	endothelin 1	Homo sapiens	44-48
18390205-8	2008	(3) The inhibition effect of simvastatin on ET-1 mRNA and ET-1 expression of endothelial cells could be prevented by mevalonate with concentration of 100 micromol/L.	Mevalonic Acid	117-127	endothelin 1	Homo sapiens	58-62
18056045-5	2007	The inhibitory effects of the nitrogen-containing BPs (including alendronate, risedronate, ibandronate, and zoledronate) on osteoclasts appear to result from their inhibition of farnesyl pyrophosphate synthase (FPPS), a key branch-point enzyme in the mevalonate pathway.	Mevalonic Acid	251-261	farnesyl diphosphate synthase	Homo sapiens	178-209
17964869-1	2007	Mevalonate kinase is one of ATP-dependent enzymes in the mevalonate pathway and catalyzes the phosphorylation of mevalonate to form mevalonate 5-phosphate.	Mevalonic Acid	57-67	mevalonate kinase	Rattus norvegicus	0-17
17964869-1	2007	Mevalonate kinase is one of ATP-dependent enzymes in the mevalonate pathway and catalyzes the phosphorylation of mevalonate to form mevalonate 5-phosphate.	Mevalonic Acid	113-123	mevalonate kinase	Rattus norvegicus	0-17
18269829-4	2007	RESULTS: Simvastatin (0 - 10 micromol/L) decreased in a concentration-dependent manner the expression of VCAM-1 induced by CD40L and this effect could be blocked by cotreatment with mevalonic acid.	Mevalonic Acid	182-196	vascular cell adhesion molecule 1	Homo sapiens	105-111
18269829-4	2007	RESULTS: Simvastatin (0 - 10 micromol/L) decreased in a concentration-dependent manner the expression of VCAM-1 induced by CD40L and this effect could be blocked by cotreatment with mevalonic acid.	Mevalonic Acid	182-196	CD40 ligand	Homo sapiens	123-128
17714440-3	2007	We generated transgenic spike lavender plants expressing the Arabidopsis thaliana HMG1 cDNA, encoding the catalytic domain of 3-hydroxy-3-methylglutaryl CoA reductase (HMGR1S), a key enzyme of the mevalonic acid (MVA) pathway.	Mevalonic Acid	197-211	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	126-166
17622571-1	2007	Statins are a class of drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMGcoA) reductase, a critical enzyme in the mevalonate pathway.	Mevalonic Acid	125-135	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-98
17902708-1	2007	Phosphomevalonate kinase (PMK) catalyzes the cation-dependent reaction of mevalonate 5-phosphate with ATP to form mevalonate 5-diphosphate and ADP, a key step in the mevalonate pathway for isoprenoid/sterol biosynthesis.	Mevalonic Acid	7-17	phosphomevalonate kinase	Homo sapiens	26-29
17622571-8	2007	Atorvastatin"s effects on MYC were specific to the inhibition of HMGcoA reductase, as treatment with mevalonate, the product of HMG-CoA reductase activity, abrogated these effects and inhibited the ability of atorvastatin to reverse or suppress tumorigenesis.	Mevalonic Acid	101-111	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	26-29
17622571-8	2007	Atorvastatin"s effects on MYC were specific to the inhibition of HMGcoA reductase, as treatment with mevalonate, the product of HMG-CoA reductase activity, abrogated these effects and inhibited the ability of atorvastatin to reverse or suppress tumorigenesis.	Mevalonic Acid	101-111	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	65-81
17850825-4	2007	However, our studies revealed that N-BPs induce formation of a novel pro-apoptotic ATP analog (ApppI), as a consequence of the inhibition of FPP synthase in the mevalonate pathway, and the subsequent accumulation of isopentenyl pyrophosphate (IPP) in vitro.	Mevalonic Acid	161-171	farnesyl diphosphate synthetase	Mus musculus	141-153
17640631-8	2007	Geranylgeranyl pyrophosphate, an end-product of the mevalonate pathway, reversed the accumulation of unprenylated Rap1A but not phosphorylation of p38.	Mevalonic Acid	52-62	RAP1A, member of RAS oncogene family	Homo sapiens	114-119
17601486-1	2007	Previously we demonstrated that secondary products of plant mevalonate metabolism called isoprenoids attenuate 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA translational efficiency and cause tumor cell death.	Mevalonic Acid	60-70	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	111-158
17586475-5	2007	Mevalonate depletion inhibits the formation of the highly glycosylated mature form of EpoR without affecting the other form.	Mevalonic Acid	0-10	erythropoietin receptor	Homo sapiens	86-90
17586475-6	2007	Treatment of cells with lovastatin, a selective inhibitor of the rate-limiting enzyme in the mevalonate pathway leads to inhibition of cell surface EpoR that is induced by Epo starvation.	Mevalonic Acid	93-103	erythropoietin receptor	Homo sapiens	148-152
17586475-6	2007	Treatment of cells with lovastatin, a selective inhibitor of the rate-limiting enzyme in the mevalonate pathway leads to inhibition of cell surface EpoR that is induced by Epo starvation.	Mevalonic Acid	93-103	erythropoietin	Homo sapiens	148-151
17586475-13	2007	These results indicate that mevalonate derivatives are required for normal EpoR expression on the cell surface through two pathways, glycosylation and geranylgeranylation.	Mevalonic Acid	28-38	erythropoietin receptor	Homo sapiens	75-79
17491006-3	2007	1-deoxy-D-xylulose-5-phosphate reductoisomerase catalyzes the second step of this non-mevalonate pathway, which involves an NADPH-dependent rearrangement and reduction of 1-deoxy-D-xylulose 5-phosphate to form 2-C-methyl-D-erythritol 4-phosphate.	Mevalonic Acid	86-96	2,4-dienoyl-CoA reductase 1	Homo sapiens	124-129
17592071-5	2007	The inhibitory effect of statins on CTGF upregulation was reversed by mevalonate and geranylgeranylpyrophosphate, suggesting that RhoA inhibition could be involved in this process.	Mevalonic Acid	70-80	cellular communication network factor 2	Rattus norvegicus	36-40
17592071-5	2007	The inhibitory effect of statins on CTGF upregulation was reversed by mevalonate and geranylgeranylpyrophosphate, suggesting that RhoA inhibition could be involved in this process.	Mevalonic Acid	70-80	ras homolog family member A	Rattus norvegicus	130-134
17922340-9	2007	Mevalonate partially reversed this inhibitory effect of atorvastatin on TSP-1, whereas the presence of FPP and GGPP did not alter TSP-1.	Mevalonic Acid	0-10	thrombospondin 1	Homo sapiens	72-77
17483544-5	2007	Here we demonstrate that in prostate cancer cells SQS expression is enhanced by androgens, channeling intermediates of the mevalonate/isoprenoid pathway toward cholesterol synthesis.	Mevalonic Acid	123-133	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	50-53
17922340-11	2007	In conclusion, atorvastatin inhibits TSP-1 expression in endothelial cells via the mevalonate pathway.	Mevalonic Acid	83-93	thrombospondin 1	Homo sapiens	37-42
17412884-1	2007	Apomine, a 1,1-bisphosphonate-ester with antitumor activity, has previously been reported to strongly down-regulate 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in the mevalonate pathway responsible for the prenylation of proteins.	Mevalonic Acid	217-227	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	116-163
17322126-4	2007	Furthermore, crocidolite, similarly to mevastatin, inhibited the synthesis of cholesterol and ubiquinone and the prenylation of RhoA: these effects were prevented in the presence of mevalonic acid.	Mevalonic Acid	182-196	ras homolog family member A	Homo sapiens	128-132
17272831-3	2007	Mevalonic acid, the product of HMG-CoA reductase, was converted to mevalonolactone (MVL) in an incubation mixture, extracted by a salting-out procedure, derivatized into the mevalonyl-(2-pyrrolidin-1-yl-ethyl)-amide, and then purified using a disposable silica cartridge.	Mevalonic Acid	0-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	31-48
17317725-5	2007	Mevalonate, the direct metabolite of HMG CoA reductase, and farnesyl pyrophosphate and geranylgeranyl-pyrophosphate, intermediates of the mevalonate pathway, significantly reversed the inhibitory effect of statins on COX-2.	Mevalonic Acid	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	217-222
17317725-5	2007	Mevalonate, the direct metabolite of HMG CoA reductase, and farnesyl pyrophosphate and geranylgeranyl-pyrophosphate, intermediates of the mevalonate pathway, significantly reversed the inhibitory effect of statins on COX-2.	Mevalonic Acid	138-148	prostaglandin-endoperoxide synthase 2	Homo sapiens	217-222
17303772-5	2007	Mevalonate, and the isoprenoid derivative geranylgeraniol, precursors of geranylgeranylated proteins, completely prevent the inhibitory effect of simvastatin on MMP1.	Mevalonic Acid	0-10	matrix metallopeptidase 1	Homo sapiens	161-165
17185615-8	2007	Mevalonic acid but not LDL reversed the observed changes in lipid content and prothrombinase activity induced by atorvastatin.	Mevalonic Acid	0-14	coagulation factor X	Homo sapiens	78-92
17390058-4	2007	Subsequently, luciferase assay revealed that pitavastatin (1 microM) inhibited the transcriptional activity of the NF-kappaB promoter, which was clearly related to the HMG-CoA reductase activity because addition of mevalonic acid (MEV) could elevate the NF-kappaB activity.	Mevalonic Acid	215-229	nuclear factor kappa B subunit 1	Homo sapiens	115-124
17300749-1	2007	Mevalonate kinase (MVK) catalyses an early step in cholesterol biosynthesis converting mevalonate to phosphomevalonate.	Mevalonic Acid	87-97	mevalonate kinase	Mus musculus	0-17
17300749-1	2007	Mevalonate kinase (MVK) catalyses an early step in cholesterol biosynthesis converting mevalonate to phosphomevalonate.	Mevalonic Acid	87-97	mevalonate kinase	Mus musculus	19-22
17392488-1	2007	3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase is the rate-limiting enzyme in the mevalonate pathway that provides essential intermediates for the membrane anchorage and biologic functions of growth-related proteins.	Mevalonic Acid	93-103	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	0-57
17182966-7	2007	Mevalonate, the immediate downstream product of HMG-CoA reductase, partially reversed the effect of lipophilic statins on cytotoxicity and CD107a expression.	Mevalonic Acid	0-10	lysosomal associated membrane protein 1	Homo sapiens	139-145
17218607-8	2007	Prolonged shear stress also attenuated the bradykinin-induced activation of Ras and extracellular signal-regulated kinase 1/2, a phenomenon that was comparable to the effects of cerivastatin and that was reversed by mevalonate and thus attributed to HCR inhibition.	Mevalonic Acid	216-226	mitogen-activated protein kinase 3	Mus musculus	84-125
17218607-8	2007	Prolonged shear stress also attenuated the bradykinin-induced activation of Ras and extracellular signal-regulated kinase 1/2, a phenomenon that was comparable to the effects of cerivastatin and that was reversed by mevalonate and thus attributed to HCR inhibition.	Mevalonic Acid	216-226	eukaryotic translation initiation factor 2 alpha kinase 1	Mus musculus	250-253
17245169-15	2007	These lovastatin-induced changes in tPA and PAI-1 production were significantly reversed by the addition of MVA, GGPP, and FPP.	Mevalonic Acid	108-111	serpin family E member 1	Homo sapiens	44-49
17178381-7	2007	Various statins (mevalonate-synthesis inhibitors) suppressed the alendronate-induced HDC inductions, while mevalonate itself augmented such inductions.	Mevalonic Acid	17-27	histidine decarboxylase	Mus musculus	85-88
16820231-7	2007	The in vitro effect of atorvastatin and mevalonate (MVA) on TF production in adipocytes was observed.	Mevalonic Acid	40-50	tissue factor	Oryctolagus cuniculus	60-62
16820231-12	2007	It also indicated that mevalonate pathway may play an important role in TF expression in adipocyte.	Mevalonic Acid	23-33	tissue factor	Oryctolagus cuniculus	72-74
17277961-15	2007	The more active nitrogen containing bisphosphonates inhibit mevalonate metabolism due to the specific inhibition of farnesyl pyrophosphate synthase.	Mevalonic Acid	60-70	farnesyl diphosphate synthase	Homo sapiens	116-147
17070781-10	2007	The effect of statins on TNF-alpha-induced OPG production was reversed by mevalonate and geranyl-geranyl pyrophosphate at the level of protein production and at the level of mRNA expression, suggesting that it was brought about by inhibition of the mevalonic acid pathway and protein prenylation.	Mevalonic Acid	74-84	tumor necrosis factor	Homo sapiens	25-34
16952276-5	2007	The effects of lovastatin on the Ras/ERK1/2/CREB pathway were time- and concentration-dependent and fully prevented by mevalonate.	Mevalonic Acid	119-129	mitogen activated protein kinase 3	Rattus norvegicus	37-43
16952276-5	2007	The effects of lovastatin on the Ras/ERK1/2/CREB pathway were time- and concentration-dependent and fully prevented by mevalonate.	Mevalonic Acid	119-129	cAMP responsive element binding protein 1	Rattus norvegicus	44-48
17114179-8	2007	Mevalonate reversed the NF-kappaB inhibitory effect of gamma-tocotrienol, indicating the role of hydroxymethylglutaryl-CoA reductase.	Mevalonic Acid	0-10	nuclear factor kappa B subunit 1	Homo sapiens	24-33
17303974-10	2007	The favorable effect of rosuvastatin is probably related to the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, because mevalonate treatment reversed the favorable effects of rosuvastatin.	Mevalonic Acid	145-155	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	78-135
17070781-10	2007	The effect of statins on TNF-alpha-induced OPG production was reversed by mevalonate and geranyl-geranyl pyrophosphate at the level of protein production and at the level of mRNA expression, suggesting that it was brought about by inhibition of the mevalonic acid pathway and protein prenylation.	Mevalonic Acid	74-84	TNF receptor superfamily member 11b	Homo sapiens	43-46
17070781-10	2007	The effect of statins on TNF-alpha-induced OPG production was reversed by mevalonate and geranyl-geranyl pyrophosphate at the level of protein production and at the level of mRNA expression, suggesting that it was brought about by inhibition of the mevalonic acid pathway and protein prenylation.	Mevalonic Acid	249-263	tumor necrosis factor	Homo sapiens	25-34
17070781-10	2007	The effect of statins on TNF-alpha-induced OPG production was reversed by mevalonate and geranyl-geranyl pyrophosphate at the level of protein production and at the level of mRNA expression, suggesting that it was brought about by inhibition of the mevalonic acid pathway and protein prenylation.	Mevalonic Acid	249-263	TNF receptor superfamily member 11b	Homo sapiens	43-46
17120136-9	2007	Analysis of gene co-expression clusters in Arabidopsis suggests a role for peroxisomal KAT2 in beta-oxidation, while KAT5 co-expresses with genes of the flavonoid biosynthesis pathway and cytosolic ACAT2 clearly co-expresses with genes of the cytosolic mevalonate biosynthesis pathway.	Mevalonic Acid	253-263	peroxisomal 3-keto-acyl-CoA thiolase 2	Arabidopsis thaliana	117-121
17691952-4	2007	ZOL inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.	Mevalonic Acid	66-76	farnesyl diphosphate synthase	Homo sapiens	13-44
17560160-11	2007	Mevalonate cycle inhibiting fluvastatin and 25-hydroxycholesterol decreased cholesterol production in leptin-stimulated monocytes.	Mevalonic Acid	0-10	leptin	Homo sapiens	102-108
17206841-1	2007	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) catalyzes the formation of mevalonate.	Mevalonic Acid	82-92	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-47
17206841-1	2007	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) catalyzes the formation of mevalonate.	Mevalonic Acid	82-92	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	49-53
17120136-9	2007	Analysis of gene co-expression clusters in Arabidopsis suggests a role for peroxisomal KAT2 in beta-oxidation, while KAT5 co-expresses with genes of the flavonoid biosynthesis pathway and cytosolic ACAT2 clearly co-expresses with genes of the cytosolic mevalonate biosynthesis pathway.	Mevalonic Acid	253-263	acetoacetyl-CoA thiolase 2	Arabidopsis thaliana	198-203
18078012-2	2007	However, because mevalonic acid (MVA), the product of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase reaction, is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, the inhibition of HMG-CoA reductase may result in pleiotropic effects, independent of their hypocholesterolemic properties.	Mevalonic Acid	17-31	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	54-114
18078012-2	2007	However, because mevalonic acid (MVA), the product of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase reaction, is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, the inhibition of HMG-CoA reductase may result in pleiotropic effects, independent of their hypocholesterolemic properties.	Mevalonic Acid	33-36	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	54-114
16774905-1	2006	The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors exert modulatory effects on a number of cell signaling cascades by preventing the synthesis of various isoprenoids derived from the mevalonate pathway.	Mevalonic Acid	205-215	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-61
16774905-8	2006	Our data also indicate that simvastatin, via mevalonate depletion, reverses VEGF-induced ECM accumulation by preventing RhoA activation.	Mevalonic Acid	45-55	vascular endothelial growth factor A	Homo sapiens	76-80
16774905-8	2006	Our data also indicate that simvastatin, via mevalonate depletion, reverses VEGF-induced ECM accumulation by preventing RhoA activation.	Mevalonic Acid	45-55	ras homolog family member A	Homo sapiens	120-124
16944474-1	2006	Statin, a HMG-CoA reductase inhibitor, was shown to increase BMP-2 gene expression for bone formation, by blocking the mevalonate pathway in cholesterol production.	Mevalonic Acid	119-129	bone morphogenetic protein 2	Rattus norvegicus	61-66
17075828-3	2006	The goal of our study was to determine whether a temporary shortage of certain isoprenoid end products and/or the accumulation of mevalonic acid is the cause of interleukin-1beta (IL-1beta) secretion in MKD.	Mevalonic Acid	130-144	interleukin 1 beta	Homo sapiens	161-178
17075828-3	2006	The goal of our study was to determine whether a temporary shortage of certain isoprenoid end products and/or the accumulation of mevalonic acid is the cause of interleukin-1beta (IL-1beta) secretion in MKD.	Mevalonic Acid	130-144	interleukin 1 beta	Homo sapiens	180-188
17075828-6	2006	Furthermore, the increased IL-1beta secretion by PBMCs of patients with MKD was reversed by supplementation with GGPP as well as with mevalonic acid.	Mevalonic Acid	134-148	interleukin 1 beta	Homo sapiens	27-35
17075828-7	2006	IL-1beta secretion was increased only when control PBMCs were incubated with excessive amounts of mevalonic acid.	Mevalonic Acid	98-112	interleukin 1 beta	Homo sapiens	0-8
17046548-6	2006	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin inhibited TNF-alpha-induced PAI-1 production by 59%, which was reversed by coincubation with mevalonic acid.	Mevalonic Acid	168-182	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-51
17046548-6	2006	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin inhibited TNF-alpha-induced PAI-1 production by 59%, which was reversed by coincubation with mevalonic acid.	Mevalonic Acid	168-182	tumor necrosis factor	Homo sapiens	85-94
17046548-6	2006	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin inhibited TNF-alpha-induced PAI-1 production by 59%, which was reversed by coincubation with mevalonic acid.	Mevalonic Acid	168-182	serpin family E member 1	Homo sapiens	103-108
17049599-2	2006	In our recent studies, we aimed at elucidating whether Ang II and leptin, affecting the intensity of the mevalonate cycle, are able to increase endogenous cholesterol synthesis.	Mevalonic Acid	105-115	angiotensinogen	Homo sapiens	55-61
16973154-6	2006	Simvastatin also significantly reduced the adhesion of monocytes to interleukin-1beta (IL-1beta)-activated endothelium to 80% after preincubation for 24 h. This effect was completely reversed by coincubation with MVA and GGPP, and partially with FPP.	Mevalonic Acid	213-216	interleukin 1 beta	Homo sapiens	68-85
16973154-6	2006	Simvastatin also significantly reduced the adhesion of monocytes to interleukin-1beta (IL-1beta)-activated endothelium to 80% after preincubation for 24 h. This effect was completely reversed by coincubation with MVA and GGPP, and partially with FPP.	Mevalonic Acid	213-216	interleukin 1 beta	Homo sapiens	87-95
17062705-5	2006	RESULTS: Nitrogen-containing bisphosphonates act intracellularly by inhibiting farnesyl diphosphate synthase, an enzyme of the mevalonate pathway, thereby preventing prenylation of small GTPase signaling proteins required for normal cellular function.	Mevalonic Acid	127-137	farnesyl diphosphate synthase	Homo sapiens	79-108
16825673-6	2006	Increases in cholesterol supply induced by LDL or mevalonate stimulate ABCA1 expression, whereas inhibiting cholesterol synthesis with statins or cholesterol sulfate decreases ABCA1 expression in CHKs.	Mevalonic Acid	50-60	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	71-76
16872642-1	2006	Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme-A reductase and the downstream mevalonate pathway is in part responsible for the beneficial effects that statins exert on the cardiovascular system.	Mevalonic Acid	85-95	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	18-65
16741291-1	2006	Squalene synthase (SS) is the first committed enzyme for cholesterol biosynthesis, located at a branch point in the mevalonate pathway.	Mevalonic Acid	116-126	farnesyl diphosphate farnesyl transferase 1	Mus musculus	0-17
16741291-1	2006	Squalene synthase (SS) is the first committed enzyme for cholesterol biosynthesis, located at a branch point in the mevalonate pathway.	Mevalonic Acid	116-126	farnesyl diphosphate farnesyl transferase 1	Mus musculus	19-21
16571871-3	2006	Actions of statins may be related to decreased availability of cholesterol as well as intermediate metabolites of the mevalonate pathway downstream of HMGCR.	Mevalonic Acid	118-128	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	151-156
16698791-2	2006	The synthesis of these isoprenoids proceeds in mammals through the mevalonate pathway, and the final steps in the synthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase and geranylgeranyl pyrophosphate synthase.	Mevalonic Acid	67-77	farnesyl diphosphate synthase	Homo sapiens	161-192
16698791-2	2006	The synthesis of these isoprenoids proceeds in mammals through the mevalonate pathway, and the final steps in the synthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase and geranylgeranyl pyrophosphate synthase.	Mevalonic Acid	67-77	geranylgeranyl diphosphate synthase 1	Homo sapiens	197-234
16507303-8	2006	The effect of atorvastatin and mevalonate (MVA) on PAI-1 production in adipocytes in vitro was observed.	Mevalonic Acid	31-41	plasminogen activator inhibitor 1	Oryctolagus cuniculus	51-56
16507303-13	2006	We also suggest that the mevalonate pathway may play an important role in PAI-1 expression in adipocyte.	Mevalonic Acid	25-35	plasminogen activator inhibitor 1	Oryctolagus cuniculus	74-79
16735695-4	2006	The addition of mevalonate abolished the IL-18 production induced by pravastatin, fluvastatin, and simvastatin, indicating that the IL-18 production might be a result of the inhibition of HMG-CoA reductase.	Mevalonic Acid	16-26	interleukin 18	Homo sapiens	41-46
16735695-4	2006	The addition of mevalonate abolished the IL-18 production induced by pravastatin, fluvastatin, and simvastatin, indicating that the IL-18 production might be a result of the inhibition of HMG-CoA reductase.	Mevalonic Acid	16-26	interleukin 18	Homo sapiens	132-137
16857822-0	2006	Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.	Mevalonic Acid	72-82	epidermal growth factor	Homo sapiens	22-45
16857822-1	2006	Mevalonate metabolites play an essential role in transducing epidermal growth factor (EGF) receptor (EGFR)-mediated signaling, as several of these metabolites are required for the function of this receptor and the components of its signaling cascades.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	61-99
16857822-1	2006	Mevalonate metabolites play an essential role in transducing epidermal growth factor (EGF) receptor (EGFR)-mediated signaling, as several of these metabolites are required for the function of this receptor and the components of its signaling cascades.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	101-105
16857822-2	2006	Thus, the depletion of mevalonate metabolites may have a significant effect on EGFR function.	Mevalonic Acid	23-33	epidermal growth factor receptor	Homo sapiens	79-83
16857822-3	2006	Lovastatin is a specific and potent inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway.	Mevalonic Acid	123-133	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	49-89
16650801-2	2006	Although several years ago the molecular target of the potent nitrogen-containing BPs (N-BPs) was identified as farnesyl diphosphate synthase, an enzyme in the mevalonate pathway, recent data have shed new light on the precise mechanism of inhibition and demonstrated that the acute-phase reaction, an adverse effect of N-BPs, is also caused by inhibition of this enzyme.	Mevalonic Acid	160-170	farnesyl diphosphate synthase	Homo sapiens	112-141
16450390-6	2006	All statins" effects were reverted by mevalonic acid, thus suggesting that they were mediated by the inhibition of HMGCoA reductase and were likely to be subsequent to the reduced availability of precursor molecules for RhoA prenylation.	Mevalonic Acid	38-52	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	115-131
16450390-6	2006	All statins" effects were reverted by mevalonic acid, thus suggesting that they were mediated by the inhibition of HMGCoA reductase and were likely to be subsequent to the reduced availability of precursor molecules for RhoA prenylation.	Mevalonic Acid	38-52	ras homolog family member A	Homo sapiens	220-224
16613876-3	2006	These actions of AMPK appear to be mediated through multiple mechanisms including regulation of the cell cycle and inhibition of protein synthesis, de novo fatty acid synthesis, specifically the generation of mevalonate as well as other products downstream of mevalonate in the cholesterol synthesis pathway.	Mevalonic Acid	209-219	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	17-21
16613876-3	2006	These actions of AMPK appear to be mediated through multiple mechanisms including regulation of the cell cycle and inhibition of protein synthesis, de novo fatty acid synthesis, specifically the generation of mevalonate as well as other products downstream of mevalonate in the cholesterol synthesis pathway.	Mevalonic Acid	260-270	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	17-21
16740997-6	2006	In addition, these inhibitory effects of cerivastatin on ET-1 release and prepro ET-1 mRNA expression were completely abolished by simultaneous treatment with 200 microM mevalonate.	Mevalonic Acid	170-180	endothelin 1	Homo sapiens	57-61
16740997-6	2006	In addition, these inhibitory effects of cerivastatin on ET-1 release and prepro ET-1 mRNA expression were completely abolished by simultaneous treatment with 200 microM mevalonate.	Mevalonic Acid	170-180	endothelin 1	Homo sapiens	81-85
16019130-9	2006	These above results indicate that the decrease in AP-N expression elicited by bisphosphonate is related to the inhibition of the mevalonate pathway.	Mevalonic Acid	129-139	alanyl aminopeptidase, membrane	Homo sapiens	50-54
16595893-5	2006	Subsequently, luciferase assay revealed that pitavastatin suppressed the transcriptional activity of the NF-kappaB promoter, which was clearly related to the HMG-CoA reductase activity because the addition of mevalonic acid (MEV) elevated the TNF-alpha activity.	Mevalonic Acid	209-223	nuclear factor kappa B subunit 1	Homo sapiens	105-114
16684881-3	2006	FPPS, a key branchpoint of the mevalonate pathway, catalyzes the successive condensation of isopentenyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate.	Mevalonic Acid	31-41	farnesyl diphosphate synthase	Homo sapiens	0-4
16595893-5	2006	Subsequently, luciferase assay revealed that pitavastatin suppressed the transcriptional activity of the NF-kappaB promoter, which was clearly related to the HMG-CoA reductase activity because the addition of mevalonic acid (MEV) elevated the TNF-alpha activity.	Mevalonic Acid	209-223	tumor necrosis factor	Homo sapiens	243-252
16932286-2	2006	When embedded in bone matrix, bisphosphonates are taken up by osteoclasts engaged in bone resorption, leading--mainly by inhibition of farnesyl diphosphate synthase, a key enzyme of the mevalonate pathway--to osteoclast apoptosis.	Mevalonic Acid	186-196	farnesyl diphosphate synthase	Homo sapiens	135-164
16476765-1	2006	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is a critical enzyme in the mevalonate pathway that regulates the biosynthesis of cholesterol as well as isoprenoids that mediate the membrane association of certain GTPases.	Mevalonic Acid	86-96	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
16505352-2	2006	In the brain, a fraction of cholesterol is metabolized in neurons by the enzyme cholesterol 24-hydroxylase, and this depletion activates the mevalonate pathway.	Mevalonic Acid	141-151	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	80-106
16436135-1	2006	BACKGROUND: Statins are inhibitors of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase, a key enzyme in mevalonic acid (MVA)-dependent signaling.	Mevalonic Acid	108-122	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	38-90
16436135-1	2006	BACKGROUND: Statins are inhibitors of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase, a key enzyme in mevalonic acid (MVA)-dependent signaling.	Mevalonic Acid	124-127	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	38-90
16511915-9	2006	These effects of simvastatin on IL-6 and IL-8 production and cell proliferation were reversed in the presence of mevalonic acid or geranylgeranyl-pyrophosphate, but not with farnesyl-pyrophosphate.	Mevalonic Acid	113-127	interleukin 6	Homo sapiens	32-36
16511915-9	2006	These effects of simvastatin on IL-6 and IL-8 production and cell proliferation were reversed in the presence of mevalonic acid or geranylgeranyl-pyrophosphate, but not with farnesyl-pyrophosphate.	Mevalonic Acid	113-127	C-X-C motif chemokine ligand 8	Homo sapiens	41-45
16165408-0	2006	Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.	Mevalonic Acid	90-100	retinoic acid receptor, alpha	Mus musculus	139-161
16873994-7	2006	The decreased levels of activated RhoA and Rac1 in both the cytoplasmic and membrane fractions of the cells were reversed by geranylgeranyl pyrophosphate and mevalonate, and thus attributable to the inhibition of isoprenylation of RhoGTPases by statins.	Mevalonic Acid	158-168	ras homolog family member A	Homo sapiens	34-38
16405649-10	2006	Although the effect of AMPK activation was partially reversed by mevalonate, this was not associated with altered subcellular localization of Rho GTPases.	Mevalonic Acid	65-75	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	23-27
16179378-2	2006	However, we have shown recently that N-BPs indirectly activate Vgamma9Vdelta2 T cells as a consequence of inhibition of farnesyl diphosphate synthase (a key enzyme of the mevalonate pathway) and the intracellular accumulation of IPP.	Mevalonic Acid	171-181	farnesyl diphosphate synthase	Homo sapiens	120-149
16873994-7	2006	The decreased levels of activated RhoA and Rac1 in both the cytoplasmic and membrane fractions of the cells were reversed by geranylgeranyl pyrophosphate and mevalonate, and thus attributable to the inhibition of isoprenylation of RhoGTPases by statins.	Mevalonic Acid	158-168	Rac family small GTPase 1	Homo sapiens	43-47
16165089-5	2005	The effects on eNOS expression mediated through rosuvastatin could be reversed by treatment with mevalonate indicating inhibition of HMG-CoA reductase as the underlying mechanism.	Mevalonic Acid	97-107	nitric oxide synthase 3	Homo sapiens	15-19
16152630-8	2005	Treatment of hOB with substrates of cholesterol biosynthesis that are downstream of the HMG-CoA reductase reaction (mevalonate, geranylgeranyl pyrophosphate) reversed atorvastatin-induced enhancement of OPG production.	Mevalonic Acid	116-126	TNF receptor superfamily member 11b	Homo sapiens	203-206
16203826-5	2006	Using two different Epo-responsive cell lines, we found that depletion of mevalonate and its isoprenoid derivatives using the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin impairs Epo signaling as assessed by phosphorylation of cellular substrates and inhibition of apoptosis.	Mevalonic Acid	74-84	erythropoietin	Mus musculus	20-23
16203826-5	2006	Using two different Epo-responsive cell lines, we found that depletion of mevalonate and its isoprenoid derivatives using the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin impairs Epo signaling as assessed by phosphorylation of cellular substrates and inhibition of apoptosis.	Mevalonic Acid	74-84	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	126-172
16203826-5	2006	Using two different Epo-responsive cell lines, we found that depletion of mevalonate and its isoprenoid derivatives using the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin impairs Epo signaling as assessed by phosphorylation of cellular substrates and inhibition of apoptosis.	Mevalonic Acid	74-84	erythropoietin	Mus musculus	202-205
16162862-3	2006	Here we look within the domain Bacteria at lateral acquisition of HMGR, whether as a single gene or as part of a mevalonate pathway cluster.	Mevalonic Acid	113-123	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	66-70
16263716-11	2005	The addition of mevalonate, which has been shown to compete for LHR mRNA binding to LRBP, also reduced the extent of translation inhibition by LRBP.	Mevalonic Acid	16-26	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	64-67
16263716-11	2005	The addition of mevalonate, which has been shown to compete for LHR mRNA binding to LRBP, also reduced the extent of translation inhibition by LRBP.	Mevalonic Acid	16-26	mevalonate kinase	Rattus norvegicus	84-88
16263716-11	2005	The addition of mevalonate, which has been shown to compete for LHR mRNA binding to LRBP, also reduced the extent of translation inhibition by LRBP.	Mevalonic Acid	16-26	mevalonate kinase	Rattus norvegicus	143-147
16221687-9	2005	Mevalonate depletion increased fatty acid synthase (FAS) mRNA by transcriptional mechanisms, without increasing gene expression of other enzymes involved in fatty acid biosynthesis or of SREBP-1c.	Mevalonic Acid	0-10	fatty acid synthase	Homo sapiens	31-50
16221687-9	2005	Mevalonate depletion increased fatty acid synthase (FAS) mRNA by transcriptional mechanisms, without increasing gene expression of other enzymes involved in fatty acid biosynthesis or of SREBP-1c.	Mevalonic Acid	0-10	fatty acid synthase	Homo sapiens	52-55
16221687-10	2005	The abundance of mature SREBP-2 but not SREBP-1 was increased following mevalonate depletion.	Mevalonic Acid	72-82	sterol regulatory element binding transcription factor 2	Homo sapiens	24-31
16221687-11	2005	FPP prevented the increase in FAS mRNA in mevalonate-depleted cells without altering SREBP-2 activation.	Mevalonic Acid	42-52	fatty acid synthase	Homo sapiens	30-33
16098957-12	2005	Mevalonate restored the preventive effect of cerivasatain on stretch-induced Rho A membrane accumulation.	Mevalonic Acid	0-10	ras homolog family member A	Homo sapiens	77-82
16286544-1	2005	BACKGROUND: Statin drugs (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) reduce the level of cholesterol by inhibiting the synthesis of mevalonate, an intermediary in the cholesterol biosynthetic pathway.	Mevalonic Acid	149-159	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	26-73
16256738-1	2005	Drosophila HMGCoA reductase (hmgcr) catalyzes the biosynthesis of a mevalonate precursor for isoprenoids and has been implicated in the production of a signal by the somatic gonadal precursor cells (SGPs) that attracts migrating germ cells.	Mevalonic Acid	68-78	HMG Coenzyme A reductase	Drosophila melanogaster	11-27
16256738-1	2005	Drosophila HMGCoA reductase (hmgcr) catalyzes the biosynthesis of a mevalonate precursor for isoprenoids and has been implicated in the production of a signal by the somatic gonadal precursor cells (SGPs) that attracts migrating germ cells.	Mevalonic Acid	68-78	HMG Coenzyme A reductase	Drosophila melanogaster	29-34
16052215-3	2005	The pharmacologic activities of fluvastatin are prevented by administration of mevalonic acid, suggesting that the shown inhibition of geranyl-geranylation and farnesylation of cellular proteins, including p21rhoA and p21ras, plays a major role in its anticancer effect.	Mevalonic Acid	79-93	HRas proto-oncogene, GTPase	Homo sapiens	218-224
16075407-5	2005	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in cholesterol synthesis from mevalonate and its inhibitors, or statins, can therefore interfere with the above-mentioned consequences of hyperlipidemia.	Mevalonic Acid	116-126	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
16160062-2	2005	However, because statins are potent inhibitors of the mevalonate, which governs diverse cell signaling pathways, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may also result in pleiotropic effects.	Mevalonic Acid	54-64	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	127-174
16061942-2	2005	cPLA(2)gamma contains a C-terminal CaaX sequence and is radiolabeled by mevalonic acid when expressed in cPLA(2)alpha-deficient immortalized lung fibroblasts (IMLF(-/-)).	Mevalonic Acid	72-86	phospholipase A2 group IVC	Homo sapiens	0-12
15914674-10	2005	Consecutive activation of caspase 9 and 3 execute apoptotic cell death that was in part reversed by the coadministration of mevalonic acid.	Mevalonic Acid	124-138	caspase 9	Homo sapiens	26-35
15878865-5	2005	KLF2 induction was observed within 8 h after drug treatment and remained elevated for at least 24 h. This statin effect on KLF2 expression was reversed by addition of mevalonate and its downstream metabolite geranygeranyl pyrophosphate.	Mevalonic Acid	167-177	Kruppel like factor 2	Homo sapiens	0-4
15770484-1	2005	3-Hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) synthase (HMGS; EC 2.3.3.10) synthesizes HMG-CoA, a substrate for mevalonate biosynthesis in the isoprenoid pathway.	Mevalonic Acid	114-124	hydroxymethylglutaryl-CoA synthase-like	Nicotiana tabacum	0-56
15878865-5	2005	KLF2 induction was observed within 8 h after drug treatment and remained elevated for at least 24 h. This statin effect on KLF2 expression was reversed by addition of mevalonate and its downstream metabolite geranygeranyl pyrophosphate.	Mevalonic Acid	167-177	Kruppel like factor 2	Homo sapiens	123-127
15605420-4	2005	The induction of MMP-12 in mouse macrophages by statins is specific for HMG CoA reductase inhibition, rescued by mevalonate and not observed after inhibition of subsequent steps in the cholesterol biosynthetic pathway.	Mevalonic Acid	113-123	matrix metallopeptidase 12	Mus musculus	17-23
15665062-12	2005	Pravastatin is endowed with cardiac antihypertropic properties that are independent of its hemodynamic and hypolipidemic effects and appear to be related to their capacity to decrease cardiac ET-1 levels, which is linked to mevalonate metabolism.	Mevalonic Acid	224-234	endothelin 1	Rattus norvegicus	192-196
15817453-6	2005	Addition of mevalonate, GGPP or farnesyl pyrophosphate completely blocked the statin-induced increase in ABCA1 expression and apoAI-mediated cholesterol efflux.	Mevalonic Acid	12-22	ATP binding cassette subfamily A member 1	Homo sapiens	105-110
15822054-1	2005	Statins are lipid-lowering agents that specifically, competitively, and reversibly inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in the formation of cholesterol.	Mevalonic Acid	205-219	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	91-148
15949312-7	2005	However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively.	Mevalonic Acid	43-53	high mobility group AT-hook 1	Homo sapiens	73-77
15949312-7	2005	However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively.	Mevalonic Acid	43-53	caspase 3	Homo sapiens	385-394
15949312-7	2005	However, Co-incubation of simvastatin with mevalonate (the production of HMGR) completely reversed the activity of simvastatin on EOS apoptosis even when the highest simvastatin (20 micromol/L) dose was used; the rates of EOSs undergoing apoptosis in the control, mevalonate plus simvastatin and simvastatin alone were (24 +/- 3)%, (52 +/- 4)% and (25 +/- 3)%, respectively; while the caspase-3 levels were (8 +/- 3) microg/L, (23 +/- 5) microg/L and (9 +/- 3) microg/L, respectively.	Mevalonic Acid	264-274	high mobility group AT-hook 1	Homo sapiens	73-77
15670755-7	2005	The inhibition of RANKL mRNA expression was reversed when geranylgeranyl pyrophosphate (GGPP), an intermediate in the mevalonate pathway, was used in combination.	Mevalonic Acid	118-128	TNF superfamily member 11	Homo sapiens	18-23
15788691-0	2005	Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.	Mevalonic Acid	14-24	epidermal growth factor receptor	Homo sapiens	62-94
15677697-1	2005	Statins are widely used hypocholesterolemic drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of the mevalonate pathway whose biosynthetic end product is cholesterol.	Mevalonic Acid	152-162	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	63-120
15670755-11	2005	This indicates that YM529/ONO-5920 inhibits GGPP biosynthesis in the mevalonate pathway and then signal transduction in the Ras-mitogen-activated protein kinase pathway, thereby inhibiting RANKL expression on ST2 cells.	Mevalonic Acid	69-79	TNF superfamily member 11	Homo sapiens	189-194
15710425-10	2005	We speculate that lovastatin regulates PECAM-1 expression in HUVECs through the mevalonate-GGPP pathway by inhibiting of Rho small GTPase.	Mevalonic Acid	80-90	platelet and endothelial cell adhesion molecule 1	Homo sapiens	39-46
15486036-14	2005	The results of the present study suggest that the antihypertropic and electrocardiographic effects of simvastatin at a clinical therapeutic dose are mediated through inhibition of tissue endothelin-1 expression, which is linked to mevalonate metabolism, and result in an amelioration of cardiomyocyte hypertrophy development by an atherogenic diet.	Mevalonic Acid	231-241	endothelin-1	Oryctolagus cuniculus	187-199
15788691-4	2005	Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	69-73
15788691-4	2005	Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	131-135
15788691-4	2005	Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies.	Mevalonic Acid	86-96	epidermal growth factor receptor	Homo sapiens	69-73
15788691-4	2005	Mevalonate metabolites play significant roles in the function of the EGFR; therefore, mevalonate pathway inhibitors may potentiate EGFR-targeted therapies.	Mevalonic Acid	86-96	epidermal growth factor receptor	Homo sapiens	131-135
15788691-8	2005	RESULTS: Lovastatin treatment inhibited EGF-induced EGFR autophosphorylation by 24 hours that was reversed by the coadministration of mevalonate.	Mevalonic Acid	134-144	epidermal growth factor receptor	Homo sapiens	52-56
15788691-12	2005	CONCLUSIONS: Taken together, these results show that targeting the mevalonate pathway can inhibit EGFR function.	Mevalonic Acid	67-77	epidermal growth factor receptor	Homo sapiens	98-102
15617098-1	2005	A role for mevalonate in cancer development has long been suggested by findings that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity is elevated in malignant cells.	Mevalonic Acid	11-21	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	85-142
15974856-12	2005	Moreover this statin-enhanced ALP activity was abolished by mevalonate.	Mevalonic Acid	60-70	alkaline phosphatase, placental	Homo sapiens	30-33
15606619-5	2005	We show that by inhibiting the mevalonate pathway, nBPs induce rapid and copious production of TNFalpha and IL6 by peripheral blood gammadelta T cells.	Mevalonic Acid	31-41	tumor necrosis factor	Homo sapiens	95-103
15581604-3	2005	Substitution of [(14)C]mevalonate for [(14)C]acetate in McARH7777 hepatoma cells expressing SPF reduced the 1.8-fold increase in cholesterol synthesis by half, suggesting that SPF acted on or prior to mevalonate synthesis.	Mevalonic Acid	23-33	SEC14-like lipid binding 2	Rattus norvegicus	92-95
15585595-8	2005	We also discuss the "succinate mechanism," which hypothesizes that insulin secretagogues produce both NADPH and mevalonate.	Mevalonic Acid	112-122	insulin	Homo sapiens	67-74
15606619-5	2005	We show that by inhibiting the mevalonate pathway, nBPs induce rapid and copious production of TNFalpha and IL6 by peripheral blood gammadelta T cells.	Mevalonic Acid	31-41	interleukin 6	Homo sapiens	108-111
18248212-2	2005	Hydroxymethylglutaryl-Coenzyme A reductase (HMGCoAR) catalyzes the rate-limiting step in the mevalonate pathway that produces isoprenoids and cholesterol.	Mevalonic Acid	93-103	HMG Coenzyme A reductase	Drosophila melanogaster	44-51
15857307-3	2005	HMG-CoA reductase inhibitors (HMGRI) effectively lower LDL-C by inhibiting the mevalonate pathway and enhancing the activity of the LDL receptor (LDL-R).	Mevalonic Acid	79-89	component of oligomeric golgi complex 2	Homo sapiens	55-60
15857307-8	2005	Other therapeutic strategies examined in experimental animals are the inhibition of squalene synthase, the first enzyme of the mevalonate pathway, which is specifically committed to cholesterol biosynthesis, and the direct up-regulation of LDL receptor activity.	Mevalonic Acid	127-137	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	84-101
16048353-2	2005	Statins target several tissues, depending upon their lipophilicity, where they competitively inhibit HMG-CoA reductase, the rate-limiting enzyme for mevalonic acid synthesis and subsequently cholesterol biosynthesis.	Mevalonic Acid	149-163	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	101-118
16020917-7	2005	With the addition of mevalonate (10 microM, 3 days), LPL activity weakened significantly.	Mevalonic Acid	21-31	lipoprotein lipase	Mus musculus	53-56
17168896-1	2005	The genetic manipulation of both the mevalonic acid (MVA) and methylerythritol-4-phosphate (MEP) pathways, leading to the formation of isopentenyl diphosphate (IPP), has been achieved in tomato using 3-hydroxymethylglutaryl CoA (hmgr-1) and 1-deoxy-d-xylulose-5-phosphate synthase (dxs) genes, respectively.	Mevalonic Acid	37-51	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	229-235
15648011-6	2005	In addition, studies in animals have shown that the mevalonate pathway also may be involved in the regulation of the renin-angiotensin system, providing the rationale for the use of statins in combination with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor antagonists, 2 classes of drugs that have evidenced beneficial effects in different forms of renal diseases.	Mevalonic Acid	52-62	renin	Homo sapiens	117-122
18248212-2	2005	Hydroxymethylglutaryl-Coenzyme A reductase (HMGCoAR) catalyzes the rate-limiting step in the mevalonate pathway that produces isoprenoids and cholesterol.	Mevalonic Acid	93-103	HMG Coenzyme A reductase	Drosophila melanogaster	0-42
18248212-4	2005	These effects were completely blocked by prior injection of mevalonate, the product of HMGCoAR activity, or the prenylation precursors farnesol and geranylgeraniol.	Mevalonic Acid	60-70	HMG Coenzyme A reductase	Drosophila melanogaster	87-94
15571826-13	2004	The activity of the mevalonate pathway in the liver may be related to the metabolism of CRP.	Mevalonic Acid	20-30	C-reactive protein	Homo sapiens	88-91
15324309-7	2004	ZOL effect on BSP expression occurred through an interference with the mevalonate pathway since it was reversed by either mevalonate pathway intermediates or a Rho GTPase activator.	Mevalonic Acid	71-81	integrin binding sialoprotein	Homo sapiens	14-17
15324309-7	2004	ZOL effect on BSP expression occurred through an interference with the mevalonate pathway since it was reversed by either mevalonate pathway intermediates or a Rho GTPase activator.	Mevalonic Acid	122-132	integrin binding sialoprotein	Homo sapiens	14-17
15530865-4	2004	Effects of statins on the activation of COX-2 promoter, induction of COX-2 protein, and PGE(2) production were all prevented by mevalonate and prenylated metabolites, FPP and GGPP.	Mevalonic Acid	128-138	cytochrome c oxidase II, mitochondrial	Mus musculus	40-45
15530865-4	2004	Effects of statins on the activation of COX-2 promoter, induction of COX-2 protein, and PGE(2) production were all prevented by mevalonate and prenylated metabolites, FPP and GGPP.	Mevalonic Acid	128-138	cytochrome c oxidase II, mitochondrial	Mus musculus	69-74
15474503-4	2004	The induction of apoA-I by statins disappeared with addition of mevalonate, which indicates that the effect is HMG-CoA reductase inhibition-dependent.	Mevalonic Acid	64-74	apolipoprotein A1	Homo sapiens	17-23
15389884-5	2004	Mevalonate and geranylgeranylpyrophosphate reversed the inhibitory effect of cerivastatin on ALP expression in HVSMCs, while farnesylpyrophosphate showed no effect on the ALP activities inhibited by this drug, suggesting that inhibition of Rho and its downstream target, Rho kinase may mediate the inhibitory effect of cerivastatin.	Mevalonic Acid	0-10	alkaline phosphatase, placental	Homo sapiens	93-96
15364922-3	2004	This question takes on added significance given the potential use of statins, drugs that block the rate-limiting step (3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase)) in mevalonate and cholesterol synthesis, in AD treatment.	Mevalonic Acid	191-201	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	119-166
15247258-0	2004	Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways.	Mevalonic Acid	73-87	insulin-like growth factor 1	Mus musculus	14-42
15861311-3	2004	However, because mevalonic acid is the precursor not only of cholesterol but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may result in pleiotropic effects.	Mevalonic Acid	17-31	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	139-186
15210833-4	2004	The inhibition was due to the decreased mevalonic acid production because addition of exogenous mevalonic acid restored ABCA1 mRNA levels.	Mevalonic Acid	40-54	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	120-125
15210833-4	2004	The inhibition was due to the decreased mevalonic acid production because addition of exogenous mevalonic acid restored ABCA1 mRNA levels.	Mevalonic Acid	96-110	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	120-125
15450939-1	2004	3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyzes the formation of mevalonate, a precursor of cholesterol that is also required for cell proliferation.	Mevalonic Acid	85-95	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
15450939-2	2004	Mevalonate depletion results in a G1 phase cell cycle arrest that is mediated in part by impaired activity of cyclin-dependent kinase (CDK) 2, and decreased expression of positive regulators of G1 to S phase progression.	Mevalonic Acid	0-10	cyclin dependent kinase 2	Homo sapiens	110-141
15381079-7	2004	The endothelial death and beta4 integrin upregulation by ATV could be reversed by intermediate metabilites of the HMG-CoA reductase pathway mevalonate or GGPP, but not by FPP, suggesting that these effects were results of specific inhibition of the pathway.	Mevalonic Acid	140-150	tubulin beta 3 class III	Homo sapiens	26-31
15381079-7	2004	The endothelial death and beta4 integrin upregulation by ATV could be reversed by intermediate metabilites of the HMG-CoA reductase pathway mevalonate or GGPP, but not by FPP, suggesting that these effects were results of specific inhibition of the pathway.	Mevalonic Acid	140-150	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	114-131
15598886-1	2004	Geranylgeranyl diphosphate synthase (GGPS) is a branch point enzyme in the mevalonate pathway that catalyzes the synthesis of geranylgeranyl diphosphate used for the geranylgeranylation of Rho, Rac and Rab proteins.	Mevalonic Acid	75-85	AKT serine/threonine kinase 1	Homo sapiens	194-197
15333031-11	2004	Mevalonate (100 micro m) completely abrogated the inhibitory effects of fluvastatin on TF expression induced by aPL.	Mevalonic Acid	0-10	coagulation factor III, tissue factor	Homo sapiens	87-89
15358158-4	2004	In both basal and ABCA1 expressing cells pitavastatin 0.1-50microM induced a dose-dependent increase in cholesterol efflux to apoA-I; this effect was reversed by mevalonate or geranyl geraniol.	Mevalonic Acid	162-172	ATP binding cassette subfamily A member 1	Rattus norvegicus	18-23
15352124-0	2004	Proto oncogene/eukaryotic translation initiation factor (eIF) 4E attenuates mevalonate-mediated regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase synthesis.	Mevalonic Acid	76-86	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	110-167
15352124-1	2004	The rate-limiting enzyme for mevalonate synthesis in mammalian cells is 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.	Mevalonic Acid	29-39	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	72-129
15385088-7	2004	RESULTS: HMG-CoA reductase activity was decreased in livers, mammary glands, and colons of mice given mevalonate via mini-osmotic pumps.	Mevalonic Acid	102-112	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	9-26
15358158-4	2004	In both basal and ABCA1 expressing cells pitavastatin 0.1-50microM induced a dose-dependent increase in cholesterol efflux to apoA-I; this effect was reversed by mevalonate or geranyl geraniol.	Mevalonic Acid	162-172	apolipoprotein A1	Rattus norvegicus	126-132
15274361-3	2004	In the present study we analysed the effect of mevastatin--a novel inhibitor of HMG-COA reductase, the rate-limiting enzyme of the mevalonate pathway--on U266 human myeloma cells.	Mevalonic Acid	131-141	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	80-97
15234191-6	2004	Pitavastatin-induced changes in THP-1 cells were reversed by treatment with 10 microM of mevalonate, the intermediate of cholesterol biosynthesis.	Mevalonic Acid	89-99	GLI family zinc finger 2	Homo sapiens	32-37
15173604-8	2004	Hence, mevalonate or putrescine partially reverted the effects of NCX 6550 and their combination was fully effective.	Mevalonic Acid	7-17	solute carrier family 8 member A1	Rattus norvegicus	66-69
15155733-0	2004	Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity.	Mevalonic Acid	0-10	cyclin dependent kinase 2	Homo sapiens	133-158
15155733-1	2004	Malignant cells are known to have elevated rates of mevalonate synthesis because of increased levels and catalytic efficiency of 3-hydroxy-3-methylglutaryl-CoA reductase.	Mevalonic Acid	52-62	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	129-169
15178557-6	2004	We found that NARC-1 expression was strongly induced by statins in a dose-dependent manner and that this induction was efficiently reversed by mevalonate.	Mevalonic Acid	143-153	proprotein convertase subtilisin/kexin type 9	Homo sapiens	14-20
15213258-6	2004	Addition of mevalonate (200 microM) or geranylgeranyl pyrophosphate (5 microM) reversed the inhibitory effect of SMV on p27 protein expression, suggesting that the effect of SMV is geranylgeranyl dependent.	Mevalonic Acid	12-22	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	120-123
15102959-5	2004	Ro 48-8071-inducible CYP3A mRNA expression was restored when pravastatin-treated cultures were incubated with medium containing mevalonate.	Mevalonic Acid	128-138	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	21-26
15021918-9	2004	Therefore, the tumour suppressor activities of WT1 may be achieved by repressing the mevalonate pathway, thereby controlling cellular proliferation and promoting terminal differentiation.	Mevalonic Acid	85-95	WT1 transcription factor	Homo sapiens	47-50
15049129-7	2004	In addition, the expression of endothelial nitric oxide synthase was strongly induced by Pitavastatin, and was suppressed by mevalonic acid and geranylgeranyl pyrophosphate by Western blot analysis.	Mevalonic Acid	125-139	nitric oxide synthase 3	Homo sapiens	31-64
14985133-1	2004	We have reported that geranylgeranyl pyrophosphate (GGPP), one of the isoprenoids in the mevalonate pathway, plays an essential role for cell growth through the geranylgeranylation of Rho small GTPases, which control the degradation of P27Kip1 at G1/S transition in rat thyroid FRTL-5 cells.	Mevalonic Acid	89-99	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	236-243
15076215-6	2004	Mevalonate reduced the amount of VEGF secretion by simvastatin in vitro.	Mevalonic Acid	0-10	vascular endothelial growth factor A	Homo sapiens	33-37
14749336-8	2004	Inhibition of LHR mRNA binding activity of mevalonate kinase in the presence of ATP and mevalonate indicates that the RNA recognition site of mevalonate kinase might involve the ATP/mevalonate binding region of the protein.	Mevalonic Acid	43-53	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	14-17
14749336-8	2004	Inhibition of LHR mRNA binding activity of mevalonate kinase in the presence of ATP and mevalonate indicates that the RNA recognition site of mevalonate kinase might involve the ATP/mevalonate binding region of the protein.	Mevalonic Acid	43-53	mevalonate kinase	Homo sapiens	142-159
14749336-8	2004	Inhibition of LHR mRNA binding activity of mevalonate kinase in the presence of ATP and mevalonate indicates that the RNA recognition site of mevalonate kinase might involve the ATP/mevalonate binding region of the protein.	Mevalonic Acid	88-98	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	14-17
14749336-8	2004	Inhibition of LHR mRNA binding activity of mevalonate kinase in the presence of ATP and mevalonate indicates that the RNA recognition site of mevalonate kinase might involve the ATP/mevalonate binding region of the protein.	Mevalonic Acid	88-98	mevalonate kinase	Homo sapiens	43-60
14749336-8	2004	Inhibition of LHR mRNA binding activity of mevalonate kinase in the presence of ATP and mevalonate indicates that the RNA recognition site of mevalonate kinase might involve the ATP/mevalonate binding region of the protein.	Mevalonic Acid	88-98	mevalonate kinase	Homo sapiens	142-159
14749336-9	2004	Treatment of 293 cells with mevastatin to deplete cellular mevalonate resulted in an increase in LHR mRNA binding activity of mevalonate kinase.	Mevalonic Acid	59-69	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	97-100
14749336-9	2004	Treatment of 293 cells with mevastatin to deplete cellular mevalonate resulted in an increase in LHR mRNA binding activity of mevalonate kinase.	Mevalonic Acid	59-69	mevalonate kinase	Homo sapiens	126-143
14996812-8	2004	The dxs gene was interrupted with a synthetic operon containing the Saccharomyces cerevisiae genes erg8, erg12, and erg19 allowing for the conversion of mevalonic acid to IPP by the mevalonate pathway.	Mevalonic Acid	153-167	phosphomevalonate kinase	Saccharomyces cerevisiae S288C	99-103
14996812-8	2004	The dxs gene was interrupted with a synthetic operon containing the Saccharomyces cerevisiae genes erg8, erg12, and erg19 allowing for the conversion of mevalonic acid to IPP by the mevalonate pathway.	Mevalonic Acid	153-167	mevalonate kinase	Saccharomyces cerevisiae S288C	105-110
14996812-8	2004	The dxs gene was interrupted with a synthetic operon containing the Saccharomyces cerevisiae genes erg8, erg12, and erg19 allowing for the conversion of mevalonic acid to IPP by the mevalonate pathway.	Mevalonic Acid	153-167	diphosphomevalonate decarboxylase MVD1	Saccharomyces cerevisiae S288C	116-121
14996812-8	2004	The dxs gene was interrupted with a synthetic operon containing the Saccharomyces cerevisiae genes erg8, erg12, and erg19 allowing for the conversion of mevalonic acid to IPP by the mevalonate pathway.	Mevalonic Acid	182-192	phosphomevalonate kinase	Saccharomyces cerevisiae S288C	99-103
14996812-8	2004	The dxs gene was interrupted with a synthetic operon containing the Saccharomyces cerevisiae genes erg8, erg12, and erg19 allowing for the conversion of mevalonic acid to IPP by the mevalonate pathway.	Mevalonic Acid	182-192	mevalonate kinase	Saccharomyces cerevisiae S288C	105-110
14996812-8	2004	The dxs gene was interrupted with a synthetic operon containing the Saccharomyces cerevisiae genes erg8, erg12, and erg19 allowing for the conversion of mevalonic acid to IPP by the mevalonate pathway.	Mevalonic Acid	182-192	diphosphomevalonate decarboxylase MVD1	Saccharomyces cerevisiae S288C	116-121
14757118-6	2004	Interleukin-1 beta-induced nitrite production was twofold increased by 0.05 microM cerivastatin, and this effect could be reversed by addition of 100 microM mevalonate.	Mevalonic Acid	157-167	interleukin 1 beta	Rattus norvegicus	0-18
14627708-8	2004	This Apomine-enhanced activation of sterol-regulatory element-binding protein-2 was prevented by sterols or mevalonate.	Mevalonic Acid	108-118	sterol regulatory element binding transcription factor 2	Rattus norvegicus	36-79
14627708-2	2004	Here we show that Apomine reduced the levels of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the rate-limiting enzyme in the mevalonate pathway, both in rat liver and in cultured cells.	Mevalonic Acid	136-146	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	48-95
14627708-2	2004	Here we show that Apomine reduced the levels of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the rate-limiting enzyme in the mevalonate pathway, both in rat liver and in cultured cells.	Mevalonic Acid	136-146	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	97-101
14711309-7	2004	Since bisphosphonates are known to be potent, nanomolar inhibitors of the mevalonate/isoprene pathway enzyme farnesyl pyrophosphate synthase (FPPS), we also compared the pharmacophores for gammadelta T cell activation with those for FPPS inhibition, using the Catalyst program.	Mevalonic Acid	74-84	farnesyl diphosphate synthase	Homo sapiens	142-146
14969398-6	2004	However, because N-BPs are potent inhibitors of farnesyl diphosphate (FPP) synthase, they could cause indirect activation of gamma,delta-T-cells owing to the accumulation of intermediates upstream of FPP synthase in the mevalonate pathway, such as isopentenyl diphosphate/dimethylallyl diphosphate, which are known gamma,delta-T-cell agonists.	Mevalonic Acid	220-230	farnesyl diphosphate synthase	Homo sapiens	200-212
14706631-1	2004	Leukaemia inhibitory factor (LIF) or Oncostatin M (OSM), both mitogens for Swiss mouse 3T3 cells, triggers initiation of DNA synthesis without the requirement for mevalonic acid.	Mevalonic Acid	163-177	leukemia inhibitory factor	Mus musculus	29-32
14706631-1	2004	Leukaemia inhibitory factor (LIF) or Oncostatin M (OSM), both mitogens for Swiss mouse 3T3 cells, triggers initiation of DNA synthesis without the requirement for mevalonic acid.	Mevalonic Acid	163-177	oncostatin M	Mus musculus	37-49
15459425-4	2004	N-BPs exert their effects on osteoclasts and tumor cells by inhibiting a key enzyme in the mevalonate pathway, farnesyl diphosphate synthase, thus preventing protein prenylation and activation of intracellular signaling proteins such as Ras.	Mevalonic Acid	91-101	farnesyl diphosphate synthase	Homo sapiens	111-140
15563400-8	2004	Interruption of the mevalonate pathway was in part responsible for lovastatin"s action, as the downstream metabolite mevalonate partially reversed the effect of lovastatin on actin fragmentation.	Mevalonic Acid	117-127	actin, beta	Gallus gallus	175-180
15576975-1	2004	Statins are cholesterol-lowering drugs by inhibiting HMG-CoA reductase, which is a rate limiting enzyme in the mevalonate pathway.	Mevalonic Acid	111-121	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	53-70
15134389-3	2004	Inhibitors of hydroxymethylglutaryl CoA (HMGCoA) reductase might increase experimentally new bone formation through a mevalonate-dependent effect.	Mevalonic Acid	118-128	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	14-58
15655579-3	2004	In the present study we analysed the effect of mevastatin -- a novel inhibitor of HMG-COA reductase, the rate-limiting enzyme of the mevalonate pathway -- on U266 human myeloma cells.	Mevalonic Acid	133-143	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	82-99
14644448-3	2003	This effect is specific for SOCS-3 and could be blocked by mevalonate, farnesyl pyrophosphate and geranylgeranyl pyrophosphate, while it was not affected by inhibitors of protein kinase C and A, mitogen-activated protein/extracellular signal-regulated kinase kinase, p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, Src, Raf and Rho kinase.	Mevalonic Acid	59-69	suppressor of cytokine signaling 3	Homo sapiens	28-34
14663504-7	2003	We conclude that the decrease in HMG-CoA reductase activity evoked by ethanol treatment on Hep G2 cells would not be the cause but the consequence of the impairment in cellular growth, since this impairment could not be reverted by the addition of mevalonate to the culture medium.	Mevalonic Acid	248-258	DNL-type zinc finger	Homo sapiens	91-94
14672267-1	2003	BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a key rate-limiting enzyme in the mevalonate pathway, which generates precursors both for cholesterol biosynthesis and for the production of nonsteroidal mevalonate derivatives that are involved in a number of growth-regulatory processes.	Mevalonic Acid	107-117	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	12-69
14563711-4	2003	Cerivastatin exerted most potent effect on modulation of Th1/Th2 development, and the effect was completely abrogated by an addition of mevalonate.	Mevalonic Acid	136-146	negative elongation factor complex member C/D, Th1l	Mus musculus	57-60
14563711-4	2003	Cerivastatin exerted most potent effect on modulation of Th1/Th2 development, and the effect was completely abrogated by an addition of mevalonate.	Mevalonic Acid	136-146	heart and neural crest derivatives expressed 2	Mus musculus	61-64
14500290-6	2003	Simvastatin increased nuclear factors, notably sterol regulatory element-binding protein-2, capable of binding to the paraoxonase promoter; this was also blocked by mevalonate.	Mevalonic Acid	165-175	sterol regulatory element binding transcription factor 2	Homo sapiens	47-90
14672267-1	2003	BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a key rate-limiting enzyme in the mevalonate pathway, which generates precursors both for cholesterol biosynthesis and for the production of nonsteroidal mevalonate derivatives that are involved in a number of growth-regulatory processes.	Mevalonic Acid	227-237	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	12-69
14629460-7	2003	RESULTS: Pretreatment with simvastatin, fluvastatin or pravastatin potentiated the TNF-alpha and LPS-induced expression of E-selectin and VCAM-1, and mevalonate reversed the potentiating effect of these statins.	Mevalonic Acid	150-160	tumor necrosis factor	Homo sapiens	83-92
12942316-11	2003	Mevalonate metabolites may regulate EGFR function, suggesting that lovastatin may inhibit the activity of this receptor.	Mevalonic Acid	0-10	epidermal growth factor receptor	Homo sapiens	36-40
12955403-2	2003	However, inhibition of HMG-CoA reductase, a key enzyme in the mevalonate pathway, was shown to increase the level of endothelial NO-synthase (eNOS) mRNA.	Mevalonic Acid	62-72	nitric oxide synthase 3	Rattus norvegicus	117-140
14520514-2	2003	They achieve this through their ability to limit the production of mevalonate via blockade of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase.	Mevalonic Acid	67-77	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	94-152
12963986-1	2003	Statins, which have been introduced to the clinic for the treatment of hypercholesterolemia, are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the major rate-limiting enzyme that controls the conversion of HMG-CoA to mevalonic acid (MA).	Mevalonic Acid	256-270	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	123-180
12941308-6	2003	This up-regulation is prevented by mevalonic acid, farnesol, and geranylgeraniol, suggesting a G-protein mediated signal transduction mechanism in the regulation of hIPS gene expression.	Mevalonic Acid	35-49	inositol-3-phosphate synthase 1	Homo sapiens	165-169
12955403-2	2003	However, inhibition of HMG-CoA reductase, a key enzyme in the mevalonate pathway, was shown to increase the level of endothelial NO-synthase (eNOS) mRNA.	Mevalonic Acid	62-72	nitric oxide synthase 3	Rattus norvegicus	142-146
12771135-2	2003	This enzyme catalyzes phosphorylation of the 2-hydroxyl group of CDP-ME, the fourth step of the non-mevalonate pathway, which is essential for isoprenoid biosynthesis in several pathogenic microorganisms.	Mevalonic Acid	100-110	cut like homeobox 1	Homo sapiens	65-68
12960612-4	2003	The increase in endothelial TM conferred by statin was prevented by the addition of mevalonic acid, geranylgeranyl-pyrophosphate, and nitric oxide scavenger, and was mimicked by the addition of a specific inhibitor of geranylgeranyl transferase, as well as by nitric oxide donors.	Mevalonic Acid	84-98	thrombomodulin	Homo sapiens	28-30
12933658-7	2003	However, administration of mevalonate or geranylgeraniol, but not farnesol, dose-dependently prevented lovastatin-induced poly (ADP-ribose) polymerase degradation and the occurrence of apoptosis, but treatment with geranylgeranyl transferase inhibitor, GGTI-298, which blocks the geranylgeranylation, induced an increase in the percentage of the apoptotic cells.	Mevalonic Acid	27-37	protein geranylgeranyltransferase type I subunit beta	Homo sapiens	253-257
12933658-10	2003	Moreover, the lovastatin-induced translocation inhibitions in RhoA and Rac1 were prevented by mevalonate and geranylgeraniol but not farnesol.	Mevalonic Acid	94-104	ras homolog family member A	Homo sapiens	62-66
12933658-10	2003	Moreover, the lovastatin-induced translocation inhibitions in RhoA and Rac1 were prevented by mevalonate and geranylgeraniol but not farnesol.	Mevalonic Acid	94-104	Rac family small GTPase 1	Homo sapiens	71-75
12953163-5	2003	The inhibitory effect on IL-6 mRNA was prevented by the intermediates of the cholesterol synthesis pathway, mevalonate and geranyl-geranyl-phyrophosphate (GGPP) but not by farnesyl-pyrophosphate.	Mevalonic Acid	108-118	interleukin 6	Homo sapiens	25-29
12736259-2	2003	The key enzyme of the cytoplasmic mevalonic acid (MVA) pathway is 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR).	Mevalonic Acid	34-48	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Nicotiana tabacum	66-113
12736259-2	2003	The key enzyme of the cytoplasmic mevalonic acid (MVA) pathway is 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR).	Mevalonic Acid	34-48	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Nicotiana tabacum	115-119
12736259-2	2003	The key enzyme of the cytoplasmic mevalonic acid (MVA) pathway is 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR).	Mevalonic Acid	50-53	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Nicotiana tabacum	115-119
12736259-2	2003	The key enzyme of the cytoplasmic mevalonic acid (MVA) pathway is 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR).	Mevalonic Acid	50-53	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Nicotiana tabacum	66-113
12792788-4	2003	By depletion of cellular mevalonate pools, p21ras proteins can be rendered non-functional as a result of deficient post-translational protein farnesylation.	Mevalonic Acid	25-35	HRas proto-oncogene, GTPase	Homo sapiens	43-49
12805493-9	2003	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin inhibited the PTHrP(1-36) induction of both NF-kappaB activity and MCP-1 overexpression, and this was reversed by mevalonate.	Mevalonic Acid	188-198	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-51
12805493-9	2003	The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin inhibited the PTHrP(1-36) induction of both NF-kappaB activity and MCP-1 overexpression, and this was reversed by mevalonate.	Mevalonic Acid	188-198	parathyroid hormone like hormone	Homo sapiens	88-93
12506040-2	2003	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	91-101	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
12753293-13	2003	The effects of simvastatin on t-PA, PAI-1 and tissue factor expression were prevented by mevalonate and geranylgeraniol (GG), suggesting the involvement of geranylgeranyl-modified intermediates in simvastatin"s mode of action.	Mevalonic Acid	89-99	coagulation factor III, tissue factor	Homo sapiens	46-59
12702011-4	2003	CLA1 encodes 1-deoxy-d-xylulose 5-phosphate synthase, which catalyses the first step of the non-mevalonate isoprenoid biosynthetic pathway.	Mevalonic Acid	96-106	Deoxyxylulose-5-phosphate synthase	Arabidopsis thaliana	0-4
12659988-2	2003	Experimental studies have shown that lipoproteins or mevalonate regulate matrix metalloproteinase (MMP)-9, tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1) expression, providing nonlipid mechanism.	Mevalonic Acid	53-63	matrix metallopeptidase 9	Homo sapiens	73-105
12654603-9	2003	Interestingly, COX-2/mPGES inhibition by simvastatin was completely reversed by mevalonate in vitro.	Mevalonic Acid	80-90	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	15-20
12654603-9	2003	Interestingly, COX-2/mPGES inhibition by simvastatin was completely reversed by mevalonate in vitro.	Mevalonic Acid	80-90	prostaglandin E synthase	Mus musculus	21-26
12841361-1	2003	The aim of the present study was to examine hypothesis that the enhanced cholesterologenesis, found in rats with experimental chronic renal failure (CRF) resulted from the increased gene expression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase--the rate limiting enzyme in the cholesterologenesis pathway, responsible for mevalonate synthesis.	Mevalonic Acid	337-347	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	201-258
12615663-9	2003	The inhibitory effect of PON1 on macrophage cholesterol biosynthesis was shown to be downstream to mevalonate, probably at the lanosterol metabolic point.	Mevalonic Acid	99-109	paraoxonase 1	Mus musculus	25-29
12659988-2	2003	Experimental studies have shown that lipoproteins or mevalonate regulate matrix metalloproteinase (MMP)-9, tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1) expression, providing nonlipid mechanism.	Mevalonic Acid	53-63	coagulation factor III, tissue factor	Homo sapiens	107-120
12659988-2	2003	Experimental studies have shown that lipoproteins or mevalonate regulate matrix metalloproteinase (MMP)-9, tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1) expression, providing nonlipid mechanism.	Mevalonic Acid	53-63	coagulation factor III, tissue factor	Homo sapiens	122-124
12659988-2	2003	Experimental studies have shown that lipoproteins or mevalonate regulate matrix metalloproteinase (MMP)-9, tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1) expression, providing nonlipid mechanism.	Mevalonic Acid	53-63	serpin family E member 1	Homo sapiens	127-160
12659988-2	2003	Experimental studies have shown that lipoproteins or mevalonate regulate matrix metalloproteinase (MMP)-9, tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1) expression, providing nonlipid mechanism.	Mevalonic Acid	53-63	serpin family E member 1	Homo sapiens	162-167
12477733-8	2003	HMGR activity in MA cells was down-regulated also by addition of its product mevalonate to the culture medium.	Mevalonic Acid	77-87	high mobility group AT-hook 1	Homo sapiens	0-4
12477733-9	2003	Thus, it appears that the elevation of mevalonate levels, which are high in MA patients and moderate in HIDS patients, allows the cells to compensate for the depressed MK activity.	Mevalonic Acid	39-49	mevalonate kinase	Homo sapiens	168-170
12477733-11	2003	Our results indicate that MK-deficient cells maintain the flux through the isoprenoid/cholesterol biosynthesis pathway by elevating intracellular mevalonate levels.	Mevalonic Acid	146-156	mevalonate kinase	Homo sapiens	26-28
12548094-8	2003	Mevalonate or GGPP restored the TNF-alpha-induced adhesive potential.	Mevalonic Acid	0-10	tumor necrosis factor	Homo sapiens	32-41
12591091-5	2003	Mevalonate completely abrogated the inhibitory effect on serum-induced MCM6 and MCM7 expression, demonstrating that biosynthesis of isoprenoids was likely the specific pathway blocked by atorvastatin.	Mevalonic Acid	0-10	minichromosome maintenance complex component 6	Rattus norvegicus	71-75
12591091-5	2003	Mevalonate completely abrogated the inhibitory effect on serum-induced MCM6 and MCM7 expression, demonstrating that biosynthesis of isoprenoids was likely the specific pathway blocked by atorvastatin.	Mevalonic Acid	0-10	minichromosome maintenance complex component 7	Rattus norvegicus	80-84
12500026-4	2003	Flow cytometry revealed an increased expression of alpha2- and beta1-integrins after treatment with atorvastatin (0.1 microM ) at 24 and 48 h. Atorvastatin increased levels of beta1-integrin mRNA after 12- and 24-h treatment in HSMCs, which was inhibited by mevalonate.	Mevalonic Acid	258-268	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	51-68
12504097-1	2003	We have examined the effects of tumor necrosis factor alpha (TNF alpha) and its second messenger, ceramide, on HMGCoA reductase, the rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	161-171	tumor necrosis factor	Homo sapiens	61-70
12504097-1	2003	We have examined the effects of tumor necrosis factor alpha (TNF alpha) and its second messenger, ceramide, on HMGCoA reductase, the rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	161-171	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	111-127
12504097-3	2003	Maturation of p21(ras) was also inhibited in a mevalonate-dependent fashion.	Mevalonic Acid	47-57	H3 histone pseudogene 16	Homo sapiens	14-17
12504097-4	2003	The addition of mevalonate to both U-937 and HL-60 cells could also partially prevent TNF alpha and ceramide-induced apoptosis.	Mevalonic Acid	16-26	tumor necrosis factor	Homo sapiens	86-95
12621163-9	2003	Mevalonate and farnesylpyrophosphate reduced the inhibition of ERK1/2 phosphorylation by pitavastatin.	Mevalonic Acid	0-10	mitogen activated protein kinase 3	Rattus norvegicus	63-69
12621163-10	2003	These studies demonstrate that pitavastatin may inhibit lysoPC-induced VSMC proliferation, at least in part, by inactivating ERK1/2, which is linked to mevalonate metabolism.	Mevalonic Acid	152-162	mitogen activated protein kinase 3	Rattus norvegicus	125-131
12538631-10	2003	Pretreating MC3T3-E1 cells with mevalonate or geranylgeranyl pyrophosphate, a mevalonate metabolite, abolished simvastatin-induced VEGF mRNA expression; manumycin A, a protein prenylation inhibitor, mimicked statin effects on VEGF expression.	Mevalonic Acid	32-42	vascular endothelial growth factor A	Mus musculus	131-135
12538631-10	2003	Pretreating MC3T3-E1 cells with mevalonate or geranylgeranyl pyrophosphate, a mevalonate metabolite, abolished simvastatin-induced VEGF mRNA expression; manumycin A, a protein prenylation inhibitor, mimicked statin effects on VEGF expression.	Mevalonic Acid	32-42	vascular endothelial growth factor A	Mus musculus	226-230
12526919-1	2003	The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-limiting enzyme in the mevalonate biochemical pathway and HMG-CoA reductase inhibitors (statins) show toxicity for certain tumors, including acute myeloid leukemia (AML).	Mevalonic Acid	95-105	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-61
12538656-3	2003	In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells.	Mevalonic Acid	105-115	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	28-64
12538656-3	2003	In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells.	Mevalonic Acid	105-115	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	66-70
12538656-3	2003	In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells.	Mevalonic Acid	155-165	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	28-64
12538656-3	2003	In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate metabolites and recognition by TCR-gammadelta cells.	Mevalonic Acid	155-165	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	66-70
12492458-7	2003	The IL-12p35/IL-10 ratio correlated significantly with plasma mevalonic acid concentrations but not with serum LDL concentrations.	Mevalonic Acid	62-76	interleukin 10	Homo sapiens	13-18
12510809-1	2003	Statins, which are inhibitors of 3-hydroxy-3-glutaryl-coenzyme A (HMG-CoA) reductase, decrease the hepatic biosynthesis of cholesterol by blocking the mevalonate pathway.	Mevalonic Acid	151-161	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	30-84
12514264-1	2003	The rate-limiting enzyme for mevalonate and cholesterol synthesis in mammalian cells is 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase.	Mevalonic Acid	29-39	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	88-138
12518023-7	2003	The level and activity of HMGR mRNA are reduced in clofibrate-treated AH-130 cells and apoptosis can be partially prevented by addition of mevalonate.	Mevalonic Acid	139-149	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	26-30
12514264-3	2003	End products of plant mevalonate metabolism, i.e., plant-derived isoprenoids, also suppress mammalian HMG-CoA reductase.	Mevalonic Acid	22-32	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	102-119
12514264-5	2003	We tested the hypothesis that plant-derived isoprenoids also regulate mammalian HMG-CoA reductase synthesis at a post-transcriptional level by incubating lovastatin-treated C100 cells with mevalonate or a plant-derived isoprenoid (the monoterpenes, limonene, perillyl alcohol or geraniol) either alone or combined with the oxysterol, 25-hydroxycholesterol (25-OH C).	Mevalonic Acid	189-199	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	80-97
12514264-6	2003	Mevalonate decreased HMG-CoA reductase synthesis and mRNA levels by 65 and 66%, respectively (P < 0.05).	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	21-38
12514264-9	2003	A combination of 25-OH C and either mevalonate or any three monoterpenes reduced HMG-CoA reductase mRNA levels (P < 0.05) compared with lovastatin-only treated cells.	Mevalonic Acid	36-46	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	81-98
12514264-10	2003	However, the dual combination of 25-OH C and either mevalonate or a monoterpene resulted in a greater decrease in HMG-CoA reductase synthesis than in mRNA levels.	Mevalonic Acid	52-62	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	114-131
12514264-12	2003	Mevalonate enhanced HMG-CoA reductase degradation, but no such effect was observed for the monoterpenes.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	20-37
12467639-2	2003	Statins inhibit HMG CoA reductase, a rate limiting enzyme which catalyses conversion of HMG CoA to mevalonic acid.	Mevalonic Acid	99-113	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	16-33
12472772-18	2003	This effect was independent of mevalonate, but involved inhibition of ERK activation during TNF-alpha priming.	Mevalonic Acid	31-41	tumor necrosis factor	Homo sapiens	92-101
12509999-1	2003	Mevalonate kinase catalyzes the phosphorylation of mevalonic acid to form mevalonate 5-phosphate, which plays a key role in regulating cholesterol biosynthesis in animal cells.	Mevalonic Acid	51-65	mevalonate kinase	Rattus norvegicus	0-17
12514251-6	2002	Application of mevalonate or zeatin dramatically restored the decrease in starch deposition, and restored AgpS mRNA accumulation.	Mevalonic Acid	15-25	glucose-1-phosphate adenylyltransferase small subunit, chloroplastic/amyloplastic-like	Nicotiana tabacum	106-110
12468034-7	2002	ApoE secretion could also be suppressed by inhibiting synthesis of mevalonate, the precursor to both types of protein prenylation, using hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors (statins).	Mevalonic Acid	67-77	apolipoprotein E	Homo sapiens	0-4
12468034-10	2002	In this model, statin-mediated inhibition of mevalonate synthesis, an essential reaction in forming geranylgeranyl lipid, would lower extracellular levels of parenchymal apoE.	Mevalonic Acid	45-55	apolipoprotein E	Homo sapiens	170-174
14755972-1	2003	3-Hydroxy-3-methyl-coenzyme A reductase (HMG-CoA reductase) which transforms 3-hydroxy-3-methylglutaril-coenzyme A (HMG-CoA) in mevalonate, is the rate limiting enzyme in cholesterol biosynthesis.	Mevalonic Acid	128-138	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	41-58
12384510-1	2002	A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway.	Mevalonic Acid	72-82	ras homolog family member B	Homo sapiens	49-53
12562045-8	2002	As a result of these biochemical effects on the mevalonate pathway, bisphosphonates appear to modulate the expression of bcl-2 leading to caspase-dependent apoptosis, inhibit matrix metalloproteinases, downregulate alphavbeta3 and alphavbeta5 integrins, and increase expression of osteoprotegerin, thereby antagonizing osteoclastogenesis.	Mevalonic Acid	48-58	BCL2 apoptosis regulator	Homo sapiens	121-126
12562045-8	2002	As a result of these biochemical effects on the mevalonate pathway, bisphosphonates appear to modulate the expression of bcl-2 leading to caspase-dependent apoptosis, inhibit matrix metalloproteinases, downregulate alphavbeta3 and alphavbeta5 integrins, and increase expression of osteoprotegerin, thereby antagonizing osteoclastogenesis.	Mevalonic Acid	48-58	TNF receptor superfamily member 11b	Homo sapiens	281-296
12454262-2	2002	HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step of eukaryotic isoprenoid biosynthesis, and is the main target of cholesterol-lowering drugs.	Mevalonic Acid	65-75	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
12454262-2	2002	HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step of eukaryotic isoprenoid biosynthesis, and is the main target of cholesterol-lowering drugs.	Mevalonic Acid	65-75	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	19-24
12454262-4	2002	However, during the last years several lines of evidence pointed to the existence of a second isoform of HMGCR localized in peroxisomes, where mevalonate is converted further to farnesyl diphosphate.	Mevalonic Acid	143-153	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	105-110
12417261-4	2002	In these cells, simvastatin (S), an HMG-CoA reductase inhibitor, blocked, in a mevalonate-dependent way, oxidative stress-induced membrane translocation of Rac(1).	Mevalonic Acid	79-89	Rac family small GTPase 1	Homo sapiens	156-162
12427032-2	2002	We have previously shown that this mevalonate depletion also leads to the upregulation of Ras, Rap1a, RhoA, and RhoB.	Mevalonic Acid	35-45	RAP1A, member of RAS oncogene family	Homo sapiens	95-100
12427032-2	2002	We have previously shown that this mevalonate depletion also leads to the upregulation of Ras, Rap1a, RhoA, and RhoB.	Mevalonic Acid	35-45	ras homolog family member A	Homo sapiens	102-106
12427032-2	2002	We have previously shown that this mevalonate depletion also leads to the upregulation of Ras, Rap1a, RhoA, and RhoB.	Mevalonic Acid	35-45	ras homolog family member B	Homo sapiens	112-116
12208470-7	2002	The effect of fluvastatin on IL-8 production was completely reversed in the presence of mevalonate or geranylgeranyl-pyrophosphate, but not in the presence of squalene or farnesyl-pyrophosphate.	Mevalonic Acid	88-98	C-X-C motif chemokine ligand 8	Homo sapiens	29-33
12426205-4	2002	In contrast, mevalonic acid prevented the inhibitory effect of atorvastatin on cytokine-stimulated vascular cell adhesion molecule-1 expression and subsequent adhesion of THP-1 monocytes to the cultured endothelial cells.	Mevalonic Acid	13-27	vascular cell adhesion molecule 1	Homo sapiens	99-132
12426205-4	2002	In contrast, mevalonic acid prevented the inhibitory effect of atorvastatin on cytokine-stimulated vascular cell adhesion molecule-1 expression and subsequent adhesion of THP-1 monocytes to the cultured endothelial cells.	Mevalonic Acid	13-27	GLI family zinc finger 2	Homo sapiens	171-176
12398901-4	2002	Exogenous mevalonate completely prevented the inhibitory effect of cerivastatin on [14C]phenylalanine incorporation, ANP release and cell size.	Mevalonic Acid	10-20	natriuretic peptide A	Rattus norvegicus	117-120
12371961-9	2002	The effects of simvastatin were prevented in the presence of mevalonate and geranylgeraniol, suggesting that the effect of simvastatin on t-PA and PAI-1 synthesis is mediated through geranylgeranyl-modified intermediates.	Mevalonic Acid	61-71	plasminogen activator, tissue type	Homo sapiens	138-142
12371961-9	2002	The effects of simvastatin were prevented in the presence of mevalonate and geranylgeraniol, suggesting that the effect of simvastatin on t-PA and PAI-1 synthesis is mediated through geranylgeranyl-modified intermediates.	Mevalonic Acid	61-71	serpin family E member 1	Homo sapiens	147-152
12208479-6	2002	Female FH patients exhibited a diurnal pattern in plasma mevalonate levels similar to that previously reported in controls with peak values occurring at night.	Mevalonic Acid	57-67	low density lipoprotein receptor	Homo sapiens	7-9
12384940-10	2002	The effect of lovastatin on IL-1beta secretion was reduced by mevalonate, FOH, and GGOH.	Mevalonic Acid	62-72	interleukin 1 beta	Homo sapiens	28-36
12656204-1	2002	We have previously shown that alpha-tocotrienol (alpha-T3), a vitamin E analogue and HMG CoA reductase (HMGR) inhibitor, markedly inhibited monocyte-endothelial cell adhesion, a process that was reversed with the addition of mevalonate intermediates involved in protein prenylation.	Mevalonic Acid	225-235	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	85-102
12523826-0	2002	Detection of the mevalonate pathway in Streptomyces species using the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene.	Mevalonic Acid	17-27	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	70-117
12656204-1	2002	We have previously shown that alpha-tocotrienol (alpha-T3), a vitamin E analogue and HMG CoA reductase (HMGR) inhibitor, markedly inhibited monocyte-endothelial cell adhesion, a process that was reversed with the addition of mevalonate intermediates involved in protein prenylation.	Mevalonic Acid	225-235	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	104-108
12204108-1	2002	In experimental animals and humans, the concentration of serum mevalonate (MVA), a direct product of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is considered to reflect the activity of whole-body sterol synthesis.	Mevalonic Acid	63-73	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	101-158
12702274-5	2002	In this context the role of the Yta7 protein, belonging to the AAA ATPase family, in the regulation of FPP flux to the dolichol branch of the mevalonate pathway is discussed, and the effect of FPP and/or derived molecules on the transcription of genes encoding the first enzyme committed to dolichol biosynthesis, i.e. cis-prenyl transferase.	Mevalonic Acid	142-152	Yta7p	Saccharomyces cerevisiae S288C	32-36
12147302-10	2002	The results suggested that endothelin receptors and the mevalonate pathway were involved in bFGF-induced SMC proliferation.	Mevalonic Acid	56-66	fibroblast growth factor 2	Rattus norvegicus	92-96
12193060-5	2002	Furthermore, we suggest that the mevalonate metabolism would interfere with PPAR-alpha activity.	Mevalonic Acid	33-43	peroxisome proliferator activated receptor alpha	Bos taurus	76-86
12039487-12	2002	The mevalonate pathway plays a role in the regulation of TGF-beta(1) expression in human monocytes.	Mevalonic Acid	4-14	transforming growth factor beta 1	Homo sapiens	57-68
12131557-7	2002	In contrast, cerivastatin dose-dependently activated the phosphorylation of both c-jun NH2-terminal protein kinase and activating transcription factor-2, and these activations were abolished by the addition of mevalonate.	Mevalonic Acid	210-220	activating transcription factor 2	Rattus norvegicus	119-152
12131557-8	2002	The levels of phosphorylated Akt and p70 S6 kinase as well as those of Bcl-2 were dose-dependently reduced by cerivastatin, and these reductions were abolished by the addition of mevalonate.	Mevalonic Acid	179-189	AKT serine/threonine kinase 1	Rattus norvegicus	29-32
12131557-8	2002	The levels of phosphorylated Akt and p70 S6 kinase as well as those of Bcl-2 were dose-dependently reduced by cerivastatin, and these reductions were abolished by the addition of mevalonate.	Mevalonic Acid	179-189	BCL2, apoptosis regulator	Rattus norvegicus	71-76
12082550-1	2002	We recently identified 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of the head and neck squamous cell carcinomas (HNSCC) and cervical carcinomas (CC).	Mevalonic Acid	114-124	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	23-80
12090904-6	2002	The effects of fluvastatin on IL-6 expression were completely reversed in the presence of mevalonate or geranylgeranyl-pyrophosphate, but not squalene.	Mevalonic Acid	90-100	interleukin 6	Homo sapiens	30-34
11877411-1	2002	Mevalonate kinase catalyzes the ATP-dependent phosphorylation of mevalonic acid to form mevalonate 5-phosphate, a key intermediate in the pathways of isoprenoids and sterols.	Mevalonic Acid	65-79	mevalonate kinase	Homo sapiens	0-17
11976279-4	2002	Pre-treatment with 1 - 10 microM atorvastatin, cerivastatin or pravastatin decreased TNFalpha plus IFNgamma stimulated iNOS expression in the endothelium irrespective of the presence of the HMG-CoA reductase product mevalonate (400 microM).	Mevalonic Acid	216-226	tumor necrosis factor	Homo sapiens	85-93
11960327-1	2002	The statin family of drugs target HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, and have been used successfully in the treatment of hypercholesterolemia for the past 15 years.	Mevalonic Acid	85-95	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	34-51
11788600-4	2002	In these studies we have shown that depletion of mevalonate results in increased total levels of Ras, Rap1a, RhoA, and RhoB in K562 cells.	Mevalonic Acid	49-59	RAP1A, member of RAS oncogene family	Homo sapiens	102-107
11788600-4	2002	In these studies we have shown that depletion of mevalonate results in increased total levels of Ras, Rap1a, RhoA, and RhoB in K562 cells.	Mevalonic Acid	49-59	ras homolog family member A	Homo sapiens	109-113
11788600-4	2002	In these studies we have shown that depletion of mevalonate results in increased total levels of Ras, Rap1a, RhoA, and RhoB in K562 cells.	Mevalonic Acid	49-59	ras homolog family member B	Homo sapiens	119-123
11788600-5	2002	Cycloheximide and [(35)S]methionine pulse/pulse-chase experiments reveal that mevalonate depletion increases the de novo synthesis of Ras and RhoA and decreases the degradation of existing Ras and RhoA protein.	Mevalonic Acid	78-88	ras homolog family member A	Homo sapiens	142-146
11788600-5	2002	Cycloheximide and [(35)S]methionine pulse/pulse-chase experiments reveal that mevalonate depletion increases the de novo synthesis of Ras and RhoA and decreases the degradation of existing Ras and RhoA protein.	Mevalonic Acid	78-88	ras homolog family member A	Homo sapiens	197-201
11785983-1	2002	We and others have recently shown that the major molecular target of nitrogen-containing bisphosphonate drugs is farnesyl diphosphate synthase, an enzyme in the mevalonate pathway.	Mevalonic Acid	161-171	farnesyl diphosphate synthase	Homo sapiens	113-142
12002344-6	2002	Inhibition of hFOB cell proliferation by Ara-CBP and zoledronate was partially reversed by mevalonate pathway intermediates, and stimulation of hFOB cell mineralization was completely reversed by mevalonate pathway intermediates.	Mevalonic Acid	91-101	CREB binding protein	Homo sapiens	45-48
12002344-7	2002	These results suggest that zoledronate and Ara-CBP act, at least in part, via inhibition of the mevalonate pathway in hFOB cells.	Mevalonic Acid	96-106	CREB binding protein	Homo sapiens	47-50
12002344-10	2002	In summary, these data suggest that zoledronate and Ara-CBP induce human osteoblast differentiation via inhibition of the mevalonate pathway.	Mevalonic Acid	122-132	CREB binding protein	Homo sapiens	56-59
11832446-1	2002	BACKGROUND & AIMS: Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase blocks the mevalonate metabolic pathway, which is necessary for the isoprenylation of a number of small guanosine triphosphatases.	Mevalonic Acid	106-116	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	37-94
15562337-1	2002	Statins are very potent inhibitors of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis at the mevalonate level.	Mevalonic Acid	117-127	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	38-55
11773414-5	2002	Results revealed that G4 interacts with farnesyl pyrophosphate synthetase (FPPS), a protein involved in the mevalonate/squalene pathway and in synthesis of FPP, a substrate required for prenylation of Ras.	Mevalonic Acid	108-118	farnesyl diphosphate synthase	Homo sapiens	40-73
11773414-5	2002	Results revealed that G4 interacts with farnesyl pyrophosphate synthetase (FPPS), a protein involved in the mevalonate/squalene pathway and in synthesis of FPP, a substrate required for prenylation of Ras.	Mevalonic Acid	108-118	farnesyl diphosphate synthase	Homo sapiens	75-79
11908910-2	2002	Treatment of cells with lovastatin, a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, depletes cells of mevalonic acid and thus blocks the isoprenylation of proteins in the RAS superfamily.	Mevalonic Acid	120-134	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	38-90
11779144-6	2002	In addition, the cerivastatin-induced transcriptional activation of PPARalpha/RXRalpha was decreased by addition of mevalonate, farnesol, geranylgeraniol, or cholesterol and by co-transfection with sterol regulatory element-binding protein-1 (SREBP-1).	Mevalonic Acid	116-126	peroxisome proliferator activated receptor alpha	Homo sapiens	68-77
11779144-6	2002	In addition, the cerivastatin-induced transcriptional activation of PPARalpha/RXRalpha was decreased by addition of mevalonate, farnesol, geranylgeraniol, or cholesterol and by co-transfection with sterol regulatory element-binding protein-1 (SREBP-1).	Mevalonic Acid	116-126	retinoid X receptor alpha	Homo sapiens	78-86
11742861-9	2001	Taken together, statins downregulate AT(1)-R expression through a mevalonate-dependent, geranylgeranyl pyrophosphate-dependent, and Rho A-dependent manner and attenuate the biological function of Ang II.	Mevalonic Acid	66-76	angiotensin II receptor type 1	Homo sapiens	37-44
11792566-1	2002	Nitrogen-containing bisphosphonates (NBps) are taken up by osteoclasts and inhibit farnesyl pyrophosphate synthase, an enzyme of the mevalonate pathway.	Mevalonic Acid	133-143	farnesyl diphosphate synthetase	Mus musculus	83-114
11641412-3	2001	In searching for potential modulators of ABCA1 expression, we have studied the effects of various mevalonate metabolites on the expression of ABCA1 in two human cell lines, THP-1 and Caco-2 cells.	Mevalonic Acid	98-108	ATP binding cassette subfamily A member 1	Homo sapiens	142-147
11448925-1	2001	The statin family of drugs inhibits 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway, and is used clinically as a safe and effective approach in the control of hypercholesterolemia.	Mevalonic Acid	120-130	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	36-86
11698677-6	2001	All three enzymes responsible for synthesis of isopentenyl diphosphate from mevalonate (mevalonate kinase, phosphomevalonate kinase, and MDD) share the same fold, catalyze phosphorylation of chemically similar substrates (MDD decarboxylation involves phosphorylation of mevalonate diphosphate), and seem to have evolved from a common ancestor.	Mevalonic Acid	76-86	mevalonate kinase	Homo sapiens	88-105
11487529-5	2001	The inhibition of CTGF expression was prevented when the cells were incubated with mevalonate or geranylgeranylpyrophosphate (GGPP) but not by farnesylpyrophosphate (FPP).	Mevalonic Acid	83-93	cellular communication network factor 2	Homo sapiens	18-22
11742861-6	2001	Coincubation of VSMCs with mevalonate or geranylgeranyl pyrophosphate but not with farnesyl pyrophosphate reversed the cerivastatin-induced AT(1)-R downregulation.	Mevalonic Acid	27-37	angiotensin II receptor type 1	Homo sapiens	140-147
11696371-3	2001	Lovastatin had no effect on cell cholesterol levels, but its effects were reversed by mevalonate, demonstrating that inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes.	Mevalonic Acid	86-96	insulin	Homo sapiens	162-169
11339822-7	2001	In addition, depletion of cellular cholesterol by mevalonate and methyl-beta-cyclodextrin leads to the shift of PGI2 synthase and caveolin-1 to higher density fractions of the gradient.	Mevalonic Acid	50-60	caveolin 1	Homo sapiens	130-140
11479731-6	2001	Whereas wild-type cDNA of the HMGCS2 gene reverted the auxotrophy for mevalonate, the cDNAs of the mutants did not.	Mevalonic Acid	70-80	3-hydroxy-3-methylglutaryl-CoA synthase 2	Homo sapiens	30-36
11406567-1	2001	3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors prevent the conversion of HMG-CoA to mevalonate and thereby inhibit the synthesis of other products derived from this metabolite.	Mevalonic Acid	106-116	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
11397700-5	2001	The inhibition of phospholipase D and PKC was reversed by 100 micromol/L mevalonate, its isoprenoid derivative, farnesol, and geranylgeraniol but not by 10 micromol/L squalene.	Mevalonic Acid	73-83	proline rich transmembrane protein 2	Homo sapiens	38-41
11390424-4	2001	Treatment with statins increased apoA-I mRNA levels in human HepG2 hepatoma cells, and this effect was reversed by the addition of mevalonate, implicating HMG-CoA reductase as the relevant target of these drugs.	Mevalonic Acid	131-141	apolipoprotein A1	Homo sapiens	33-39
11403422-5	2001	The expression of p42/44 mitogen-activated protein kinase (MAPK) was clearly reduced, but could be restored by addition of mevalonate, while the phosphorylation of p44 was mildly suppressed and the phosphorylation of p42 MAPK was reduced to non-detectable levels.	Mevalonic Acid	123-133	cyclin dependent kinase 20	Homo sapiens	18-21
11403422-5	2001	The expression of p42/44 mitogen-activated protein kinase (MAPK) was clearly reduced, but could be restored by addition of mevalonate, while the phosphorylation of p44 was mildly suppressed and the phosphorylation of p42 MAPK was reduced to non-detectable levels.	Mevalonic Acid	123-133	mitogen-activated protein kinase 3	Homo sapiens	59-63
11403422-6	2001	While the phosphorylation of p44 MAPK could partially be restored by addition of mevalonate, the reduced phosphorylation of p42 MAPK could not be restored by addition of excessive doses of mevalonate or stimulation of the cells with basic fibroblast growth factor.	Mevalonic Acid	81-91	mitogen-activated protein kinase 3	Homo sapiens	29-37
11111075-1	2000	Mevalonate kinase (MK) is an essential enzyme in the mevalonate pathway which produces numerous cellular isoprenoids.	Mevalonic Acid	53-63	mevalonate kinase	Homo sapiens	0-17
11518463-4	2001	It is not known at present whether constitutively high intracellular levels of cyclin D1 might interfere with the cytostatic actions of mevalonate/protein prenylation inhibitors.	Mevalonic Acid	136-146	cyclin D1	Homo sapiens	79-88
11518463-7	2001	In addition, D1-overexpressing embryo fibroblasts were also found to be responsive to the cell cycle effects of mevalonate/protein prenylation pathway blockade, further suggesting that high intracellular levels of cyclin D1 do not prevent the cytostatic actions of compounds targeting this metabolic pathway.	Mevalonic Acid	112-122	cyclin D1	Homo sapiens	214-223
11322384-3	2001	The present study shows that lovastatin inhibits bFGF-stimulated DNA synthesis in cSMC, and that this inhibition is reversed by mevalonate (50 micromol/l) and by geranylgeranyl-pyrophosphate (1-5 micromol/l).	Mevalonic Acid	128-138	fibroblast growth factor 2	Homo sapiens	49-53
11370859-5	2001	Functional expression in a HMG-CoA reductase-deficient mutant yeast showed that Cm-HMGR products mediate the synthesis of mevalonate.	Mevalonic Acid	122-132	3-hydroxy-3-methylglutaryl-coenzyme A reductase 1	Solanum lycopersicum	83-87
11325797-6	2001	The inhibitory effect of NK-104 was almost completely reversed by mevalonate, suggesting that mevalonate or its metabolites play important roles in the regulation of osteopontin expression.	Mevalonic Acid	66-76	secreted phosphoprotein 1	Rattus norvegicus	166-177
11325797-6	2001	The inhibitory effect of NK-104 was almost completely reversed by mevalonate, suggesting that mevalonate or its metabolites play important roles in the regulation of osteopontin expression.	Mevalonic Acid	94-104	secreted phosphoprotein 1	Rattus norvegicus	166-177
18429123-2	2001	The two prenoid groups that have been found attached to proteins--farnesyl (C15) and geranylgeranyl (C20)--are both derived from intermediates in the isoprenoid biosynthetic pathway that utilizes mevalonic acid.	Mevalonic Acid	196-210	placenta associated 8	Homo sapiens	76-79
11275002-6	2001	All the reported effects of simvastatin were inhibited by the product of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, mevalonate (10(-3) M).	Mevalonic Acid	132-142	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	73-130
11243736-1	2001	Phosphomevalonate kinase (PMK; EC 2.7.4.2) catalyzes the phosphorylation of 5-phosphomevalonate into 5-diphosphomevalonate, an essential step in isoprenoid biosynthesis via the mevalonate pathway.	Mevalonic Acid	7-17	phosphomevalonate kinase	Homo sapiens	26-29
11171976-4	2001	Levels of SREBP-1c mRNA are restored by mevalonate, the product of the HMG CoA reductase reaction, and by ligands for the nuclear hormone receptor LXR, including 22(R)-hydroxycholesterol and T0901317.	Mevalonic Acid	40-50	sterol regulatory element binding transcription factor 1	Rattus norvegicus	10-18
11160563-7	2001	Tocotrienols have beneficial effects in cardiovascular diseases both by inhibiting LDL oxidation and by down-regulating 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG CoA) reductase, a key enzyme of the mevalonate pathway.	Mevalonic Acid	200-210	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	120-178
11205904-1	2001	3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase is the rate-limiting enzyme of the mevalonate pathway, the diverse array of end products of which are vital for a variety of cellular functions, including cholesterol synthesis and cell cycle progression.	Mevalonic Acid	86-96	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-50
11111075-1	2000	Mevalonate kinase (MK) is an essential enzyme in the mevalonate pathway which produces numerous cellular isoprenoids.	Mevalonic Acid	53-63	mevalonate kinase	Homo sapiens	19-21
11426618-1	2000	We recently identified HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of various retinoic acid responsive cancers.	Mevalonic Acid	74-84	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	23-40
11079678-12	2000	Mevalonate abrogated the effects of cerivastatin on Cdk2 and Rb but only partially rescued the 3H-thymidine incorporation (from 164 +/- 11% to 211 +/- 13%, n = 4, p < 0.01).	Mevalonic Acid	0-10	cyclin dependent kinase 2	Homo sapiens	52-56
10964918-1	2000	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the key regulatory enzyme in the mevalonate (MVA) pathway, is rapidly degraded in mammalian cells supplemented with sterols or MVA.	Mevalonic Acid	89-99	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-47
10964918-1	2000	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), the key regulatory enzyme in the mevalonate (MVA) pathway, is rapidly degraded in mammalian cells supplemented with sterols or MVA.	Mevalonic Acid	89-99	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	49-53
11079678-13	2000	CONCLUSIONS: In humans, SVEC inhibition of HMG-CoA/mevalonate pathway contributes to the enhanced eNOS expression and NO release by cerivastatin, whereas in SMC, inhibition of this pathway only partially explains cerivastatin-induced cell growth arrest.	Mevalonic Acid	51-61	nitric oxide synthase 3	Homo sapiens	98-102
10988259-6	2000	The effect of fluvastatin on MMP-1 expression was completely reversed in the presence of mevalonate or geranylgeranyl-pyrophosphate, but not in the presence of squalene.	Mevalonic Acid	89-99	matrix metallopeptidase 1	Homo sapiens	29-34
11009568-5	2000	Transfection studies with the preproendothelin-1 gene promoter showed that mevalonate (100 micromol/L) was able to prevent the inhibitory effect mediated by simvastatin.	Mevalonic Acid	75-85	endothelin 1	Bos taurus	30-48
10946069-1	2000	OBJECTIVES: HMG CoA reductase inhibitors reduce cellular availability of mevalonate, a precursor in cholesterol synthesis.	Mevalonic Acid	73-83	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	12-29
10946846-4	2000	Moreover, the mRNA levels of p22phox, a 22-kD subunit and the protein levels of p47phox, a 47-kD subunit of nicotine adenine dinucleotide phosphate (NADPH) oxidase, was decreased by treatment with either simvastatin, fluvastatin or cerivastatin, and this effect was reversed by mevalonate, geranylgeraniol, farnesol, and cholesterol.	Mevalonic Acid	278-288	cytochrome b-245 alpha chain	Homo sapiens	29-36
10953355-15	2000	Lovastatin acts through isoprenoid depletion, because supplementation of the media with 50-100 microM mevalonate restored all tau eta epsilon effects.	Mevalonic Acid	102-112	endothelin receptor type A	Homo sapiens	130-133
10946846-4	2000	Moreover, the mRNA levels of p22phox, a 22-kD subunit and the protein levels of p47phox, a 47-kD subunit of nicotine adenine dinucleotide phosphate (NADPH) oxidase, was decreased by treatment with either simvastatin, fluvastatin or cerivastatin, and this effect was reversed by mevalonate, geranylgeraniol, farnesol, and cholesterol.	Mevalonic Acid	278-288	neutrophil cytosolic factor 1	Homo sapiens	80-87
10774794-1	2000	Statins competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity reducing mevalonate synthesis.	Mevalonic Acid	106-116	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	30-87
10947201-5	2000	Downregulation of HMG-CoA reductase activity in SLOS was supported by measuring plasma levels of mevalonic acid, the immediate product of HMG-CoA reductase.	Mevalonic Acid	97-111	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	18-35
10947201-5	2000	Downregulation of HMG-CoA reductase activity in SLOS was supported by measuring plasma levels of mevalonic acid, the immediate product of HMG-CoA reductase.	Mevalonic Acid	97-111	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	138-155
10751437-0	2000	Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.	Mevalonic Acid	47-57	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	169-209
10751437-1	2000	We investigated the role of the intrinsic mevalonate cascade in the neuronal cell death (NCD) induced by the inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase in rat primary cortical neurons cultured from the brains of 17-d-old fetal SD rats.	Mevalonic Acid	42-52	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	123-173
10751437-9	2000	These data indicated that (1) the inhibition of the intrinsic mevalonate cascade induces the apoptotic NCD with the induction of p53 followed by that of Bax, (2) the inhibition of HMG-CoA reductase concomitantly causes blockage of the translocation or redistribution of Rho small GTPase families, not Ras small GTPase, to membrane, and (3) GGPP, not FPP, is one of the essential metabolites in the mevalonate cascade for protecting neurons from H-NCD.	Mevalonic Acid	62-72	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	129-132
10751437-9	2000	These data indicated that (1) the inhibition of the intrinsic mevalonate cascade induces the apoptotic NCD with the induction of p53 followed by that of Bax, (2) the inhibition of HMG-CoA reductase concomitantly causes blockage of the translocation or redistribution of Rho small GTPase families, not Ras small GTPase, to membrane, and (3) GGPP, not FPP, is one of the essential metabolites in the mevalonate cascade for protecting neurons from H-NCD.	Mevalonic Acid	62-72	BCL2 associated X, apoptosis regulator	Rattus norvegicus	153-156
10751437-9	2000	These data indicated that (1) the inhibition of the intrinsic mevalonate cascade induces the apoptotic NCD with the induction of p53 followed by that of Bax, (2) the inhibition of HMG-CoA reductase concomitantly causes blockage of the translocation or redistribution of Rho small GTPase families, not Ras small GTPase, to membrane, and (3) GGPP, not FPP, is one of the essential metabolites in the mevalonate cascade for protecting neurons from H-NCD.	Mevalonic Acid	398-408	BCL2 associated X, apoptosis regulator	Rattus norvegicus	153-156
10928471-5	2000	Mevalonate (100 microM), a precursor of isoprenoids, added to cells simultaneously with fluvastatin, suppressed the effect of the drug on PAI-1 both in unstimulated and stimulated cells as well as on t-PA antigen.	Mevalonic Acid	0-10	serpin family E member 1	Homo sapiens	138-143
10928471-5	2000	Mevalonate (100 microM), a precursor of isoprenoids, added to cells simultaneously with fluvastatin, suppressed the effect of the drug on PAI-1 both in unstimulated and stimulated cells as well as on t-PA antigen.	Mevalonic Acid	0-10	plasminogen activator, tissue type	Homo sapiens	200-204
10917872-1	2000	Does inhibition of the mevalonate pathway lower interleukin-8 levels in the vessel wall?	Mevalonic Acid	23-33	C-X-C motif chemokine ligand 8	Homo sapiens	48-61
10905355-4	2000	The products of ERG10 and GPI1, respectively, catalyze mevalonate and glycosyl phosphatidylinositol anchor synthesis, while VPS18 and VPS11 genes belong to the class C VPS (Vacuolar Protein Sorting) genes, and the VPS34 gene is classified as a class D VPS.	Mevalonic Acid	55-65	acetyl-CoA C-acetyltransferase	Saccharomyces cerevisiae S288C	16-21
10905355-4	2000	The products of ERG10 and GPI1, respectively, catalyze mevalonate and glycosyl phosphatidylinositol anchor synthesis, while VPS18 and VPS11 genes belong to the class C VPS (Vacuolar Protein Sorting) genes, and the VPS34 gene is classified as a class D VPS.	Mevalonic Acid	55-65	phosphatidylinositol N-acetylglucosaminyltransferase	Saccharomyces cerevisiae S288C	26-30
10814523-7	2000	The statin-mediated activation of BMP-2 promoter was completely inhibited by the downstream metabolite of HMG-CoA reductase, mevalonate, indicating that the activation was a result of the inhibition of the enzyme.	Mevalonic Acid	125-135	bone morphogenetic protein 2	Homo sapiens	34-39
10753223-2	2000	Uptake of serum low density lipoprotein cholesterol by tissues leads to down-regulation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate limiting enzyme in cholesterol biosynthesis that catalyzes the formation of mevalonate.	Mevalonic Acid	228-238	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	91-141
10681320-1	2000	We previously showed that the mouse inorganic phosphate transporter Npt1 operates in the hepatic sinusoidal membrane transport of anionic drugs such as benzylpenicillin and mevalonic acid.	Mevalonic Acid	173-187	solute carrier family 17 (sodium phosphate), member 1	Mus musculus	68-72
10704442-1	2000	The integral ER membrane protein HMG-CoA reductase (HMGR) is a key enzyme of the mevalonate pathway from which sterols and other essential molecules are produced.	Mevalonic Acid	81-91	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	33-50
10704442-1	2000	The integral ER membrane protein HMG-CoA reductase (HMGR) is a key enzyme of the mevalonate pathway from which sterols and other essential molecules are produced.	Mevalonic Acid	81-91	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	52-56
10704442-2	2000	HMGR degradation occurs in the ER and is regulated by mevalonate-derived signals.	Mevalonic Acid	54-64	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-4
10731415-8	2000	These data suggest that the induction of ubiquinone biosynthesis after administration of peroxisome proliferators is dependent on the PPARalpha through regulation of some of the mevalonate pathway enzymes.	Mevalonic Acid	178-188	peroxisome proliferator activated receptor alpha	Mus musculus	134-143
10688662-3	2000	GGPP synthase catalyzes the synthesis of all-trans-geranylgeranyl diphosphate (GGPP), an isoprenoid used for protein isoprenylation in animal cells, and is a branch point enzyme in the mevalonic acid pathway.	Mevalonic Acid	185-199	geranylgeranyl diphosphate synthase 1	Mus musculus	0-13
10698924-1	2000	3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the formation of mevalonate, the committed step in the biosynthesis of sterols and isoprenoids.	Mevalonic Acid	75-85	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-40
10698924-1	2000	3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the formation of mevalonate, the committed step in the biosynthesis of sterols and isoprenoids.	Mevalonic Acid	75-85	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-46
10698924-2	2000	The activity of HMGR is controlled through synthesis, degradation and phosphorylation to maintain the concentration of mevalonate-derived products.	Mevalonic Acid	119-129	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	16-20
11154978-1	2000	Lovastatin reduces the isoprenylation of p21ras via suppression of mevalonic acid generation.	Mevalonic Acid	67-81	HRas proto-oncogene, GTPase	Homo sapiens	41-47
10651982-3	2000	Mevalonic acid is an intermediate after the rate-limiting step in cholesterol biosynthesis, which is catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A reductase.	Mevalonic Acid	0-14	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	114-161
10651982-9	2000	In the skin of mice topically administered with mevalonic acid, stimulation of cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A reductase activity were both observed, whereas none was seen with stimulation by equimolar cholesterol.	Mevalonic Acid	48-62	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	105-152
10743676-1	2000	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors decrease mevalonate and subsequently cholesterol synthesis competitively.	Mevalonic Acid	78-88	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-57
11043510-1	2000	We determined the genomic structure of the human gene encoding 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate and is the rate-limiting and major regulatory enzyme in sterol biosynthesis.	Mevalonic Acid	167-177	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	63-120
10620343-9	2000	These findings (i) identify farnesyl diphosphate synthase as the selective target of alendronate in the mevalonate pathway, (ii) show that this enzyme is inhibited by other N-containing bisphosphonates, such as risendronate, but not by clodronate, supporting a different mechanism of action for different bisphosphonates, and (iii) document in purified osteoclasts alendronate inhibition of prenylation and sterol biosynthesis.	Mevalonic Acid	104-114	farnesyl diphosphate synthase	Homo sapiens	28-57
10506194-2	1999	L-90 cells massively accumulate HMGR, a result of >10-fold amplification of the gene and 40-fold rise in mRNA, and also overexpress other enzymes of the mevalonate pathway.	Mevalonic Acid	156-166	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	32-36
10794536-1	2000	Mevalonate kinase (MVK), the enzyme that catalyzes the phosphorylation of mevalonate to produce mevalonate 5-phosphate, is considered as a potential regulatory enzyme of the isoprenoid biosynthetic pathway.	Mevalonic Acid	74-84	mevalonate kinase	Arabidopsis thaliana	0-17
10794536-1	2000	Mevalonate kinase (MVK), the enzyme that catalyzes the phosphorylation of mevalonate to produce mevalonate 5-phosphate, is considered as a potential regulatory enzyme of the isoprenoid biosynthetic pathway.	Mevalonic Acid	74-84	mevalonate kinase	Arabidopsis thaliana	19-22
10665838-2	1999	However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects.	Mevalonic Acid	17-31	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	140-187
10531376-1	1999	Sterol synthesis by the mevalonate pathway is modulated, in part, through feedback-regulated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR).	Mevalonic Acid	24-34	high mobility group AT-hook 1	Homo sapiens	157-161
10601643-4	1999	The incubation of FAO rat hepatoma cells with 25-OH cholesterol and mevalonate led to a three-fold increase of apo E mRNA, demonstrating a direct role of cholesterol on apo E expression.	Mevalonic Acid	68-78	apolipoprotein E	Rattus norvegicus	111-116
10601643-4	1999	The incubation of FAO rat hepatoma cells with 25-OH cholesterol and mevalonate led to a three-fold increase of apo E mRNA, demonstrating a direct role of cholesterol on apo E expression.	Mevalonic Acid	68-78	apolipoprotein E	Rattus norvegicus	169-174
10601643-6	1999	Immunoblot and immunofluorescence analysis revealed that 25-OH cholesterol/mevalonate strongly increased also apo E protein synthesis and secretion in FAO cells.	Mevalonic Acid	75-85	apolipoprotein E	Rattus norvegicus	110-115
10563217-1	1999	BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) is a key rate-limiting enzyme in the mevalonate pathway, which generates precursors for cholesterol biosynthesis and the production of non-steroidal mevalonate derivatives that are involved in a number of growth-regulatory processes.	Mevalonic Acid	117-127	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	12-78
10563217-1	1999	BACKGROUND: 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) is a key rate-limiting enzyme in the mevalonate pathway, which generates precursors for cholesterol biosynthesis and the production of non-steroidal mevalonate derivatives that are involved in a number of growth-regulatory processes.	Mevalonic Acid	229-239	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	12-78
10216221-0	1999	IPP isomerase, an enzyme of mevalonate pathway, is preferentially expressed in postnatal cortical neurons and induced after nerve transection.	Mevalonic Acid	28-38	intracisternal A particle-promoted polypeptide	Rattus norvegicus	0-3
10580331-0	1999	Regulation of mevalonate synthesis in low density lipoprotein receptor knockout mice fed n-3 or n-6 polyunsaturated fatty acids.	Mevalonic Acid	14-24	low density lipoprotein receptor	Mus musculus	38-70
10580331-1	1999	3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, catalyzes the formation of mevalonate which is also required for cell proliferation.	Mevalonic Acid	129-139	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	0-46
10460692-1	1999	Pure and mixed isoprenoid end products of plant mevalonate metabolism trigger actions that suppress 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity.	Mevalonic Acid	48-58	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	100-157
10430507-5	1999	), an inhibitor of the mevalonate pathway, inhibits the expression of iNOS and proinflammatory cytokines in rat primary glial cells (astroglia and microglia) and macrophages.	Mevalonic Acid	23-33	nitric oxide synthase 2	Rattus norvegicus	70-74
10412745-3	1999	Inhibition of 3-hydro-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibits the production of mevalonate and has been shown to suppress proliferation in many cell types, including mesangial cells in vitro.	Mevalonic Acid	97-107	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	14-69
10569199-3	1999	Further, Receptor-Ck dependent signalling, known to control the mevalonate pathway, had a direct effect upon the p27 gene expression.	Mevalonic Acid	64-74	interferon alpha inducible protein 27	Homo sapiens	113-116
10399961-2	1999	We have previously shown that blocking the mevalonate pathway with lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, inhibits medulloblastoma proliferation and induces apoptosis in vitro.	Mevalonic Acid	43-53	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	106-163
10440099-6	1999	Mevalonate (10(-4) M) overcame the inhibitory effects of lovastatin and simvastatin on angiotensin II-induced increases in these parameters.	Mevalonic Acid	0-10	angiotensinogen	Rattus norvegicus	87-101
10440099-9	1999	These studies demonstrate that a lipid-soluble HMG-CoA reductase inhibitor, lovastatin, may prevent angiotensin II-induced cardiac hypertrophy, at least in part, through p21ras/MAP kinase pathway, which is linked to mevalonate metabolism.	Mevalonic Acid	216-226	angiotensinogen	Rattus norvegicus	100-114
10440099-9	1999	These studies demonstrate that a lipid-soluble HMG-CoA reductase inhibitor, lovastatin, may prevent angiotensin II-induced cardiac hypertrophy, at least in part, through p21ras/MAP kinase pathway, which is linked to mevalonate metabolism.	Mevalonic Acid	216-226	HRas proto-oncogene, GTPase	Rattus norvegicus	170-176
10205288-7	1999	Concomitant addition of mevalonate, farnesylpyrophosphate and geranylgeranylpyrophosphate prevented the effects of HMG-CoA reductase inhibition resulting in rescued expression of c-Jun and c-Fos.	Mevalonic Acid	24-34	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	179-184
10205288-7	1999	Concomitant addition of mevalonate, farnesylpyrophosphate and geranylgeranylpyrophosphate prevented the effects of HMG-CoA reductase inhibition resulting in rescued expression of c-Jun and c-Fos.	Mevalonic Acid	24-34	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	189-194
10216221-2	1999	Among these genes, we focused on pyrophosphate (isopentenyl diphosphate, dimethylallyl diphosphate: IPP) isomerase gene, the product of which is known as an enzyme of the mevalonate pathway.	Mevalonic Acid	171-181	intracisternal A particle-promoted polypeptide	Rattus norvegicus	100-103
10216221-3	1999	Rat IPP isomerase was recently cloned and the gene expression was shown to be dependent on the activation of the mevalonate pathway.	Mevalonic Acid	113-123	intracisternal A particle-promoted polypeptide	Rattus norvegicus	4-7
9927639-5	1999	Furthermore, results from feeding studies with 13C-labeled mevalonic acid and compactin show that the defective step is specifically the Delta7 sterol C-5 desaturation, suggesting that dwf7 is an allele of the previously cloned STEROL1 (STE1) gene.	Mevalonic Acid	59-73	sterol 1	Arabidopsis thaliana	185-189
10374838-3	1999	However, while the addition of mevalonate, the product of HMG-CoA-reductase, circumvented the inhibition by lovastatin it had no reversing effect on the inhibition by L-ascorbic acid.	Mevalonic Acid	31-41	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	58-75
10353467-12	1999	The inhibition of monocyte adhesion was reversed by mevalonate but not LDL in vitro, indicating that isoprenoid precursors are crucial for adhesiveness of Mac-1.	Mevalonic Acid	52-62	integrin subunit beta 2	Homo sapiens	155-160
10360679-7	1999	Mevalonate and squalene, which are metabolites of the cholesterol synthesis pathway, protected neuronal cells from apoE4-induced cell death.	Mevalonic Acid	0-10	apolipoprotein E	Homo sapiens	115-120
9882513-0	1999	Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing"s sarcoma cells.	Mevalonic Acid	19-29	EWS RNA binding protein 1	Homo sapiens	96-99
9882513-0	1999	Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing"s sarcoma cells.	Mevalonic Acid	19-29	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	100-105
10075142-1	1999	BACKGROUND: The 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors competitively inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation.	Mevalonic Acid	123-133	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	16-73
9756921-7	1998	In contrast, mevalonate and its metabolite, geranylgeranylpyrophosphate (GGPP) but not farnesylpyrophosphate (FPP), reversed the inhibitory effects of pravastatin on cyclin E expression and Cdk2 activation and allowed G1/S transition.	Mevalonic Acid	13-23	cyclin E1	Rattus norvegicus	166-174
9869647-0	1999	HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells.	Mevalonic Acid	137-147	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
9869647-0	1999	HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells.	Mevalonic Acid	137-147	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	78-97
9869647-1	1999	The activity of HMG-CoA reductase (HMGR) is tightly regulated, in part through post-transcriptional mechanisms that are mediated by nonsterol products of mevalonate metabolism.	Mevalonic Acid	154-164	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	16-33
9869647-1	1999	The activity of HMG-CoA reductase (HMGR) is tightly regulated, in part through post-transcriptional mechanisms that are mediated by nonsterol products of mevalonate metabolism.	Mevalonic Acid	154-164	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	35-39
9811854-2	1998	A dramatic overall reduction of protein prenylation was found in v-K-ras-transformed cells in comparison with the parent FRTL-5 cells, as shown by labeling cells with [3H]mevalonic acid.	Mevalonic Acid	171-185	KRAS proto-oncogene, GTPase	Rattus norvegicus	67-72
9799804-9	1998	In addition, we have also recently demonstrated that the UT2 cells express a 90 kDa HMG-CoA reductase protein that is localized exclusively in peroxisomes, and is up-regulated when the cells are grown in the absence of added mevalonate.	Mevalonic Acid	225-235	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	84-101
12532841-1	1999	In eukaryotes, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a key enzyme that catalyses the synthesis of a precusor of cholesterol as well as non-sterol isoprenoids, mevalonate.	Mevalonic Acid	182-192	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	15-72
9756921-7	1998	In contrast, mevalonate and its metabolite, geranylgeranylpyrophosphate (GGPP) but not farnesylpyrophosphate (FPP), reversed the inhibitory effects of pravastatin on cyclin E expression and Cdk2 activation and allowed G1/S transition.	Mevalonic Acid	13-23	cyclin dependent kinase 2	Rattus norvegicus	190-194
9703948-2	1998	The ability of rab proteins to carry out their role in intracellular membrane traffic requires the post-translational attachment to their C-terminus of a geranylgeranyl group, an isoprenoid lipid moiety derived from mevalonate.	Mevalonic Acid	216-226	RAB7A, member RAS oncogene family	Rattus norvegicus	15-18
9778150-6	1998	The addition of intermediate metabolites of the cholesterol biosynthetic pathway, including mevalonate and squalene, rescued neuronal cells incubated with apoE4 and beta-VLDL, in the presence of compactin.	Mevalonic Acid	92-102	apolipoprotein E	Homo sapiens	155-160
9758637-10	1998	The effects of HRI were reversed by mevalonate and geranylgeranyl pyrophosphate, but not by LDL cholesterol and farnesyl pyrophosphate, and were not induced by alpha-hydroxyfarnesyl phosphonic acid, an inhibitor of protein farnesyl transferase.	Mevalonic Acid	36-46	eukaryotic translation initiation factor 2 alpha kinase 1	Rattus norvegicus	15-18
9703948-3	1998	Here we report that depletion of intracellular mevalonate by lovastatin in FRTL-5 thyroid cells specifically resulted in a four-fold increase of Rab5 and Rab7 protein levels.	Mevalonic Acid	47-57	RAB7A, member RAS oncogene family	Rattus norvegicus	154-158
9802623-1	1998	Lovastatin, a fungal antibiotic used in the treatment of hypercholesterolemia, is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the key regulatory enzyme in the mevalonate pathway of cholesterol synthesis.	Mevalonic Acid	180-190	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	98-145
9523093-1	1998	PURPOSE: Mevalonic aciduria in humans results from a genetic deficiency of mevalonate kinase and is characterized by very high plasma mevalonic acid levels, developmental malformations and cataracts.	Mevalonic Acid	134-148	mevalonate kinase	Homo sapiens	75-92
9610772-8	1998	The study was extended by examining plasma levels of mevalonic acid and lathosterol, both markers of cholesterol biosynthesis, in response to cholestyramine, a bile acid sequestrant that is known to up-regulate HRase.	Mevalonic Acid	53-67	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	211-216
9562250-1	1998	The present study was addressed to understand the interrelationship between Receptor-Ck activation, mevalonate pathway and primary response genes such as c-fos, c-myc and cyclin "D" involved in the cell cycle.	Mevalonic Acid	100-110	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	154-159
9562250-1	1998	The present study was addressed to understand the interrelationship between Receptor-Ck activation, mevalonate pathway and primary response genes such as c-fos, c-myc and cyclin "D" involved in the cell cycle.	Mevalonic Acid	100-110	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	161-166
9562250-1	1998	The present study was addressed to understand the interrelationship between Receptor-Ck activation, mevalonate pathway and primary response genes such as c-fos, c-myc and cyclin "D" involved in the cell cycle.	Mevalonic Acid	100-110	proliferating cell nuclear antigen	Homo sapiens	171-177
9500571-5	1998	Similar results were obtained in cells in which ACAT activity was induced by preincubation either with 25-hydroxycholesterol and mevalonic acid or with CEase and bile salt mixed-micelles containing 100 micromol/L cholesterol.	Mevalonic Acid	129-143	carboxylesterase 1	Homo sapiens	48-52
9445257-7	1998	The inhibition of the stimulatory effect of BP II on cholesterol production by genistein in hyperapoB cells may be mediated through 3-hydroxy 3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme of cholesterol biosynthesis, since the rate of incorporation of [14C]acetate, but not [3H]mevalonate, into unesterified cholesterol was decreased by genistein in the hyperapoB cells.	Mevalonic Acid	296-306	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	132-179
9389730-7	1997	This study delineates a novel role of the mevalonate pathway in controlling the expression of iNOS and different cytokines in rat astrocytes, microglia, and macrophages that may be important in developing therapeutics against cytokine- and NO-mediated neurodegenerative diseases.	Mevalonic Acid	42-52	nitric oxide synthase 2	Rattus norvegicus	94-98
9430371-0	1997	Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells.	Mevalonic Acid	0-10	insulin like growth factor 1	Homo sapiens	31-36
9430371-0	1997	Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells.	Mevalonic Acid	0-10	insulin	Homo sapiens	37-44
9389730-1	1997	This study explores the role of mevalonate inhibitors in the activation of NF-kbeta and the induction of inducible nitric oxide synthase (iNOS) and cytokines (TNF-alpha, IL-1beta, and IL-6) in rat primary astrocytes, microglia, and macrophages.	Mevalonic Acid	32-42	nitric oxide synthase 2	Rattus norvegicus	105-136
9426061-8	1998	Caspase-7, but not caspase-3, underwent proteolytic activation during lovastatin-induced apoptosis, an effect prevented by mevalonate.	Mevalonic Acid	123-133	caspase 7	Homo sapiens	0-9
9371780-6	1997	Furthermore, Hmg2p ubiquitination was regulated by the mevalonate pathway in a manner consistent with regulation of Hmg2p stability.	Mevalonic Acid	55-65	hydroxymethylglutaryl-CoA reductase (NADPH) HMG2	Saccharomyces cerevisiae S288C	13-18
9389730-1	1997	This study explores the role of mevalonate inhibitors in the activation of NF-kbeta and the induction of inducible nitric oxide synthase (iNOS) and cytokines (TNF-alpha, IL-1beta, and IL-6) in rat primary astrocytes, microglia, and macrophages.	Mevalonic Acid	32-42	nitric oxide synthase 2	Rattus norvegicus	138-142
9389730-1	1997	This study explores the role of mevalonate inhibitors in the activation of NF-kbeta and the induction of inducible nitric oxide synthase (iNOS) and cytokines (TNF-alpha, IL-1beta, and IL-6) in rat primary astrocytes, microglia, and macrophages.	Mevalonic Acid	32-42	tumor necrosis factor	Rattus norvegicus	159-168
9389730-1	1997	This study explores the role of mevalonate inhibitors in the activation of NF-kbeta and the induction of inducible nitric oxide synthase (iNOS) and cytokines (TNF-alpha, IL-1beta, and IL-6) in rat primary astrocytes, microglia, and macrophages.	Mevalonic Acid	32-42	interleukin 6	Rattus norvegicus	184-188
9389730-3	1997	Reversal of the inhibitory effect of lovastatin on LPS-induced iNOS expression by mevalonate and farnesyl pyrophosphate and reversal of the inhibitory effect of NaPA on LPS-induced iNOS expression by farnesyl pyrophosphate, however, suggests a role of farnesylation in the LPS-mediated induction of iNOS.	Mevalonic Acid	82-92	nitric oxide synthase 2	Rattus norvegicus	63-67
9371780-6	1997	Furthermore, Hmg2p ubiquitination was regulated by the mevalonate pathway in a manner consistent with regulation of Hmg2p stability.	Mevalonic Acid	55-65	hydroxymethylglutaryl-CoA reductase (NADPH) HMG2	Saccharomyces cerevisiae S288C	116-121
9409246-8	1997	The increase in LDL receptor activity induced by pravastatin was abolished by concomitant administration of mevalonic acid, 770 mumol/L.	Mevalonic Acid	108-122	low density lipoprotein receptor	Homo sapiens	16-28
9395276-0	1997	Direct association between the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 and plasma mevalonic acid and lathosterol concentrations in man.	Mevalonic Acid	113-127	apolipoprotein B	Homo sapiens	81-101
9316434-5	1997	The change in hepatic VLDL apoB secretion was significantly and independently correlated with changes in plasma mevalonic acid and lathosterol concentrations and the lathosterol-to-cholesterol ratio.	Mevalonic Acid	112-126	apolipoprotein B	Homo sapiens	27-31
9380679-0	1997	The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism.	Mevalonic Acid	100-110	nuclear receptor subfamily 1 group H member 3	Homo sapiens	28-36
9380679-3	1997	The use of metabolic inhibitors revealed that mevalonic acid biosynthesis is required for LXRalpha activity.	Mevalonic Acid	46-60	nuclear receptor subfamily 1 group H member 3	Homo sapiens	90-98
9380679-6	1997	Inhibition of LXRalpha could be reversed by addition of mevalonic acid and certain oxysterols but not by other products of mevalonic acid metabolism.	Mevalonic Acid	56-70	nuclear receptor subfamily 1 group H member 3	Homo sapiens	14-22
9380679-7	1997	Surprisingly, the constitutive activity of LXRalpha was inhibited by geranylgeraniol, a metabolite of mevalonic acid.	Mevalonic Acid	102-116	nuclear receptor subfamily 1 group H member 3	Homo sapiens	43-51
9380679-8	1997	These findings suggest that LXRalpha may represent a central component of a signaling pathway that is both positively and negatively regulated by multiple products of mevalonate metabolism.	Mevalonic Acid	167-177	nuclear receptor subfamily 1 group H member 3	Homo sapiens	28-36
9350917-8	1997	Coincubation with mevalonate, but not with low density lipoprotein (LDL), reversed the effects of lovastatin, suggesting that early cholesterol precursors, but not cholesterol, are crucial for adhesiveness of CD11b.	Mevalonic Acid	18-28	integrin subunit alpha M	Homo sapiens	209-214
9334262-15	1997	Our results indicate that the bacterial expression system for human MKase will provide a useful model system in which to analyze inherited mutations and identify the first active site residue in MKase associated with stabilization of mevalonate binding.	Mevalonic Acid	234-244	mevalonate kinase	Homo sapiens	68-73
9334262-15	1997	Our results indicate that the bacterial expression system for human MKase will provide a useful model system in which to analyze inherited mutations and identify the first active site residue in MKase associated with stabilization of mevalonate binding.	Mevalonic Acid	234-244	mevalonate kinase	Homo sapiens	195-200
9305924-8	1997	The UT2 cells grown in the absence of mevalonate containing the up-regulated peroxisomal HMG-CoA reductase are designated UT2*.	Mevalonic Acid	38-48	solute carrier family 14 member 2	Homo sapiens	4-7
9305924-8	1997	The UT2 cells grown in the absence of mevalonate containing the up-regulated peroxisomal HMG-CoA reductase are designated UT2*.	Mevalonic Acid	38-48	solute carrier family 14 member 2	Homo sapiens	122-125
9235998-9	1997	Third, inhibition of Galphai and Gbeta expression in cholesterol-enriched cells was overcome by mevalonate, the immediate product of HMG-CoA reductase.	Mevalonic Acid	96-106	succinate-CoA ligase GDP-forming subunit beta	Homo sapiens	33-38
9288773-4	1997	In comparison to the n-6 diet, the n-3 diet significantly reduced the activity and levels of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase in mammary glands, thereby suppressing the formation of mevalonate.	Mevalonic Acid	200-210	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	93-143
9244250-6	1997	Furthermore, during the course of this study, we observed that a high level of expression of the wild-type ERG19 gene led to a lower sterol steady-state accumulation compared to that of a wild-type strain, suggesting that this enzyme may be a key enzyme in mevalonate pathway regulation.	Mevalonic Acid	257-267	diphosphomevalonate decarboxylase MVD1	Saccharomyces cerevisiae S288C	107-112
9254045-0	1997	Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc.	Mevalonic Acid	0-10	insulin like growth factor 1 receptor	Homo sapiens	104-141
9237866-0	1997	Posttranscriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in lens epithelial cells by mevalonate-derived nonsterols.	Mevalonic Acid	110-120	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	34-81
9237866-4	1997	Mevalonate derived nonsterols were additionally restricted by inhibition of HMGR activity with lovastatin.	Mevalonic Acid	0-10	high mobility group AT-hook 1	Homo sapiens	76-80
9237866-7	1997	The additional restriction of mevalonate derived nonsterols increased HMGR protein levels to about 400-fold.	Mevalonic Acid	30-40	high mobility group AT-hook 1	Homo sapiens	70-74
9237866-9	1997	The capacity of the nonsterol regulators to promote enzyme degradation appeared independent of sterols, since mevalonate restored rapid degradation of HMGR protein when 2,3-oxidosqualene cyclase activity was simultaneously blocked.	Mevalonic Acid	110-120	high mobility group AT-hook 1	Homo sapiens	151-155
9254045-0	1997	Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc.	Mevalonic Acid	0-10	insulin like growth factor 1 receptor	Homo sapiens	143-149
9254045-0	1997	Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc.	Mevalonic Acid	0-10	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	202-207
9254045-2	1997	Conceivable mevalonate-dependent mechanisms involved in growth control are farnesylation of Ras proteins, regulation of c-myc expression, and N-linked glycosylation of the IGF-1 receptor.	Mevalonic Acid	12-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	120-125
9254045-2	1997	Conceivable mevalonate-dependent mechanisms involved in growth control are farnesylation of Ras proteins, regulation of c-myc expression, and N-linked glycosylation of the IGF-1 receptor.	Mevalonic Acid	12-22	insulin like growth factor 1	Homo sapiens	172-177
9254045-5	1997	We found that mevalonate depletion due to treatment with 3 microM lovastatin for 24 h, which efficiently growth-arrested the cells, hardly at all affected the expression of c-myc, and although Ras prenylation was inhibited by 50%, the most pronounced effect of lovastatin was seen on N-linked glycosylation of IGF-1 receptors, which was inhibited by more than 95%.	Mevalonic Acid	14-24	insulin like growth factor 1	Homo sapiens	310-315
9250604-3	1997	In the monocytic cells THP-1, the biosynthesis of LC-PUFA is also enhanced by treatment with the HMGCoA reductase inhibitor simvastatin (S), an effect which is reverted by mevalonate and other intermediates of cholesterol synthesis.	Mevalonic Acid	172-182	GLI family zinc finger 2	Homo sapiens	23-28
9250604-3	1997	In the monocytic cells THP-1, the biosynthesis of LC-PUFA is also enhanced by treatment with the HMGCoA reductase inhibitor simvastatin (S), an effect which is reverted by mevalonate and other intermediates of cholesterol synthesis.	Mevalonic Acid	172-182	pumilio RNA binding family member 3	Homo sapiens	53-57
9250604-3	1997	In the monocytic cells THP-1, the biosynthesis of LC-PUFA is also enhanced by treatment with the HMGCoA reductase inhibitor simvastatin (S), an effect which is reverted by mevalonate and other intermediates of cholesterol synthesis.	Mevalonic Acid	172-182	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	97-113
9191394-0	1997	Lipids derived from the mevalonate pathway in HL-60 cells modulate the interactions of beta 2 integrins with their ligands.	Mevalonic Acid	24-34	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	87-93
9221828-3	1997	Myotoxicity was determined to be directly related to inhibition of HMG CoA reductase, since mevalonate, the immediate product of HMG CoA reductase metabolism, abrogated the drug-induced changes.	Mevalonic Acid	92-102	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	67-84
9221828-3	1997	Myotoxicity was determined to be directly related to inhibition of HMG CoA reductase, since mevalonate, the immediate product of HMG CoA reductase metabolism, abrogated the drug-induced changes.	Mevalonic Acid	92-102	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	129-146
8995216-4	1997	Mevalonate and its metabolite, geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, restore the inhibitory effect of pravastatin on the degradation of p27 and allow Cdk2 activation.	Mevalonic Acid	0-10	cyclin dependent kinase 2	Rattus norvegicus	174-178
9087171-1	1997	Although UT-2 cells, a mutant clone of Chinese hamster ovary cells, have been shown to require mevalonate for growth due to a deficiency in 3-hydroxy-3-methylglutaryl-CoA reductase, the precise mevalonate-derived product(s) essential for proliferation has not been identified.	Mevalonic Acid	95-105	solute carrier family 14 member 2	Homo sapiens	9-13
9087171-1	1997	Although UT-2 cells, a mutant clone of Chinese hamster ovary cells, have been shown to require mevalonate for growth due to a deficiency in 3-hydroxy-3-methylglutaryl-CoA reductase, the precise mevalonate-derived product(s) essential for proliferation has not been identified.	Mevalonic Acid	95-105	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	140-180
9087171-2	1997	These studies show that UT-2 cells proliferate in the presence of free geranylgeraniol (GG-OH), as well as mevalonate.	Mevalonic Acid	107-117	solute carrier family 14 member 2	Homo sapiens	24-28
9107038-2	1997	As the first committed step in the pathway, the conversion of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) to mevalonic acid by HMG CoA reductase and the regulation of the genes encoding this enzyme have been implicated in the network that controls isoprenoid biosynthesis in higher plants.	Mevalonic Acid	113-127	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	131-148
9081680-6	1997	The inhibitory effect of fluvastatin on TF activity and antigen was fully reversible by coincubation with 100 mumol/L mevalonate or 10 mumol/L all-trans-geranylgeraniol but not with dolichol, farnesol, or geraniol.	Mevalonic Acid	118-128	coagulation factor III, tissue factor	Homo sapiens	40-42
9081680-7	1997	Suppression of TF antigen and activity was accompanied by a diminution in TF mRNA levels, which was completely prevented by mevalonate.	Mevalonic Acid	124-134	coagulation factor III, tissue factor	Homo sapiens	15-17
9081680-7	1997	Suppression of TF antigen and activity was accompanied by a diminution in TF mRNA levels, which was completely prevented by mevalonate.	Mevalonic Acid	124-134	coagulation factor III, tissue factor	Homo sapiens	74-76
9081680-9	1997	We conclude that lipophilic vastatins inhibit TF expression in macrophages, and because this effect is prevented by mevalonate and geranylgeraniol, a geranylgeranylated protein plays a crucial role in the regulation of TF biosynthesis.	Mevalonic Acid	116-126	coagulation factor III, tissue factor	Homo sapiens	219-221
9016820-0	1997	Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level.	Mevalonic Acid	66-76	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	101-148
8995216-4	1997	Mevalonate and its metabolite, geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, restore the inhibitory effect of pravastatin on the degradation of p27 and allow Cdk2 activation.	Mevalonic Acid	0-10	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	160-163
8995216-7	1997	These results indicate (i) among mevalonate metabolites, geranylgeranyl pyrophosphate is absolutely required for the elimination of p27 followed by Cdk2 activation; (ii) geranylgeranylated Rho small GTPase(s) promote the degradation of p27 during G1/S transition in FRTL-5 cells.	Mevalonic Acid	33-43	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	132-135
8995216-7	1997	These results indicate (i) among mevalonate metabolites, geranylgeranyl pyrophosphate is absolutely required for the elimination of p27 followed by Cdk2 activation; (ii) geranylgeranylated Rho small GTPase(s) promote the degradation of p27 during G1/S transition in FRTL-5 cells.	Mevalonic Acid	33-43	cyclin dependent kinase 2	Rattus norvegicus	148-152
8995216-7	1997	These results indicate (i) among mevalonate metabolites, geranylgeranyl pyrophosphate is absolutely required for the elimination of p27 followed by Cdk2 activation; (ii) geranylgeranylated Rho small GTPase(s) promote the degradation of p27 during G1/S transition in FRTL-5 cells.	Mevalonic Acid	33-43	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	236-239
10684438-2	1997	It prevents mevalonate synthesis, reducing endogenous cholesterol production, and reduces cholesterol content in the liver, thus resulting in a down-regulation of low-density lipoprotein receptor production.	Mevalonic Acid	12-22	low density lipoprotein receptor	Homo sapiens	163-195
8970163-3	1996	The degradation of HMG-R is regulated as part of feedback control of the mevalonate pathway.	Mevalonic Acid	73-83	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	19-24
9034205-8	1997	To determine whether the increase in transcriptional activity of the LDL-R gene was secondary to changes in the cholesterol regulatory pool we performed experiments in which the cell cholesterol content was modified by the addition of either 25-hydroxycholesterol and mevalonate or inhibitors of ACAT activity (SA-58035 and progesterone).	Mevalonic Acid	268-278	low density lipoprotein receptor	Homo sapiens	69-74
9605009-1	1997	Mevalonate pathway inhibitor lovastatin inhibited proliferation of human multidrug-resistant promyelocytic leukemia HL-60/ADR cells in vitro, with MRP-gene coded p190 mediated drug resistance, to a markedly lesser extent than that of the parental drug sensitive HL-60 cells and also that of the other human multidrug resistant (MDR-1, P-glycoprotein) myeloid leukemia cell line HL-60/VCR.	Mevalonic Acid	0-10	ATP binding cassette subfamily C member 1	Homo sapiens	147-150
9605009-1	1997	Mevalonate pathway inhibitor lovastatin inhibited proliferation of human multidrug-resistant promyelocytic leukemia HL-60/ADR cells in vitro, with MRP-gene coded p190 mediated drug resistance, to a markedly lesser extent than that of the parental drug sensitive HL-60 cells and also that of the other human multidrug resistant (MDR-1, P-glycoprotein) myeloid leukemia cell line HL-60/VCR.	Mevalonic Acid	0-10	contactin associated protein 1	Homo sapiens	162-166
9605009-1	1997	Mevalonate pathway inhibitor lovastatin inhibited proliferation of human multidrug-resistant promyelocytic leukemia HL-60/ADR cells in vitro, with MRP-gene coded p190 mediated drug resistance, to a markedly lesser extent than that of the parental drug sensitive HL-60 cells and also that of the other human multidrug resistant (MDR-1, P-glycoprotein) myeloid leukemia cell line HL-60/VCR.	Mevalonic Acid	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	328-333
9501689-3	1997	HMG-CoA reductase catalyses the reduction of HMG-CoA o mevalonate and is rate-limiting step in cholesterol biosynthesis pathway.	Mevalonic Acid	55-65	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
8810339-1	1996	The endoplasmic reticulum (ER) membrane protein 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is subject to regulated degradation when cells are presented with an excess of sterols or mevalonate.	Mevalonic Acid	196-206	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	48-105
8908154-1	1996	Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, inhibits the synthesis of mevalonic acid and is widely used as an anti-atherosclerotic drug.	Mevalonic Acid	113-127	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	28-85
8671958-8	1996	In the presence of either mevalonate or the mevalonate metabolite farnesyl pyrophosphate, the lovastatin inhibition of NF-kappaB activation was substantially reversed, supporting a role for mevalonate metabolites in LPS-induced mesangial cell NF-kappaB activation.	Mevalonic Acid	26-36	nuclear factor kappa B subunit 1	Homo sapiens	119-128
8630089-12	1996	Such results are consistent with inhibition of the mevalonate pathway at, and not before, SQS.	Mevalonic Acid	51-61	farnesyl diphosphate farnesyl transferase 1	Rattus norvegicus	90-93
8807496-3	1996	Since the different products from the biosynthesis pathway utilizing mevalonate have several important cellular functions, ranging from cholesterol synthesis to growth control, we here investigate the possible role for the mevalonate pathway in IFN-gamma-driven parasite proliferation.	Mevalonic Acid	223-233	interferon gamma	Rattus norvegicus	245-254
8807496-11	1996	Addition of mevalonate to this concentration of IFN-gamma gave a threefold increase in parasite proliferation.	Mevalonic Acid	12-22	interferon gamma	Rattus norvegicus	48-57
8807496-12	1996	Our data suggest that a low concentration of IFN-gamma induces parasite growth, a high concentration has the opposite effect, and both these events are regulated by activity or inactivity of the mevalonate pathway.	Mevalonic Acid	195-205	interferon gamma	Rattus norvegicus	45-54
8663239-0	1996	Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface.	Mevalonic Acid	0-14	insulin like growth factor 1 receptor	Homo sapiens	79-116
8663239-2	1996	Depletion of mevalonic acid (MVA), obtained by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase using lovastatin, depressed the biosynthesis of dolichyl-phosphate and the rate of N-linked glycosylation and caused growth arrest in the melanoma cell line SK-MEL-2.	Mevalonic Acid	13-27	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	61-118
8671958-8	1996	In the presence of either mevalonate or the mevalonate metabolite farnesyl pyrophosphate, the lovastatin inhibition of NF-kappaB activation was substantially reversed, supporting a role for mevalonate metabolites in LPS-induced mesangial cell NF-kappaB activation.	Mevalonic Acid	26-36	nuclear factor kappa B subunit 1	Homo sapiens	243-252
8671958-8	1996	In the presence of either mevalonate or the mevalonate metabolite farnesyl pyrophosphate, the lovastatin inhibition of NF-kappaB activation was substantially reversed, supporting a role for mevalonate metabolites in LPS-induced mesangial cell NF-kappaB activation.	Mevalonic Acid	44-54	nuclear factor kappa B subunit 1	Homo sapiens	119-128
8671958-8	1996	In the presence of either mevalonate or the mevalonate metabolite farnesyl pyrophosphate, the lovastatin inhibition of NF-kappaB activation was substantially reversed, supporting a role for mevalonate metabolites in LPS-induced mesangial cell NF-kappaB activation.	Mevalonic Acid	44-54	nuclear factor kappa B subunit 1	Homo sapiens	243-252
8671958-8	1996	In the presence of either mevalonate or the mevalonate metabolite farnesyl pyrophosphate, the lovastatin inhibition of NF-kappaB activation was substantially reversed, supporting a role for mevalonate metabolites in LPS-induced mesangial cell NF-kappaB activation.	Mevalonic Acid	44-54	nuclear factor kappa B subunit 1	Homo sapiens	119-128
8671958-8	1996	In the presence of either mevalonate or the mevalonate metabolite farnesyl pyrophosphate, the lovastatin inhibition of NF-kappaB activation was substantially reversed, supporting a role for mevalonate metabolites in LPS-induced mesangial cell NF-kappaB activation.	Mevalonic Acid	44-54	nuclear factor kappa B subunit 1	Homo sapiens	243-252
8773465-1	1996	Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, inhibits the synthesis of mevalonic acid.	Mevalonic Acid	99-113	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	14-61
8835365-5	1995	All elevated biochemical changes and morphological alterations were prevented or reversed by coadministration of mevalonate, the product of the HMG-CoA reductase.	Mevalonic Acid	113-123	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	144-161
8621648-2	1996	The enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonic acid, considered the rate-limiting step in isoprenoid biosynthesis.	Mevalonic Acid	121-135	3-hydroxy-3-methylglutaryl-coenzyme A reductase 1	Solanum lycopersicum	11-51
8621648-2	1996	The enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonic acid, considered the rate-limiting step in isoprenoid biosynthesis.	Mevalonic Acid	121-135	3-hydroxy-3-methylglutaryl-coenzyme A reductase 1	Solanum lycopersicum	53-57
8626470-0	1996	Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo.	Mevalonic Acid	91-101	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	14-61
8626470-1	1996	We have previously reported that degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in the isoprenoid pathway leading to cholesterol production, can be accelerated in cultured cells by the addition of farnesyl compounds, which are thought to mimic a natural, nonsterol mevalonate metabolite(s).	Mevalonic Acid	307-317	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	48-95
8645011-1	1996	A recent report, in which cultured tumor cells were used, identified farnesol as the nonsterol mevalonate-derived metabolite required for the accelerated degradation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (C. C. Correll, L. Ng, and P. A. Edwards, 1994, J. Biol.	Mevalonic Acid	95-105	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	169-226
8742338-2	1996	As one step toward understanding the role that light plays in the regulation of the mevalonate pathway in plants, we characterized the suppression of HMG1 gene expression in response to illumination wavelength, duration, and fluence rate.	Mevalonic Acid	84-94	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	150-154
7641798-1	1995	Cells treated with compactin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the rate-limiting step of the mevalonate pathway, are arrested prior to the DNA synthesis (S) phase of the cell cycle.	Mevalonic Acid	162-172	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	46-103
7670949-1	1995	We previously reported that mevalonate starvation elicited by hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors reduced cholesterol accumulation promoted in murine macrophages by acetylated LDL (AcLDL).	Mevalonic Acid	28-38	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	62-115
7589883-4	1995	There was a positive correlation between VLDL apoB secretion rate and (i) fasting C-peptide (r = 0.84, p = 0.04) and (ii) mevalonic acid concentration (r = 0.83, p < 0.05) in the diabetic patients but not in the non-diabetic subjects.	Mevalonic Acid	122-136	apolipoprotein B	Homo sapiens	46-50
7564103-5	1995	The inhibitory effects of lovastatin in the presence of exogenous cholesterol were reversed by mevalonate, suggesting a role for isoprenoid intermediates of the mevalonate pathway and/or isoprenylated proteins in mesangial cell MCP-1 regulation.	Mevalonic Acid	95-105	C-C motif chemokine ligand 2	Homo sapiens	228-233
8562480-7	1995	When endogenous and transfected reductase activity was bypassed by the addition of mevalonate and compactin, a competitive inhibitor, the filamentous actin distribution in HMG-CoA reductase-transfected cells became very similar to that of control cells, demonstrating the role of exogenous HMG-CoA reductase activity in this process.	Mevalonic Acid	83-93	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	172-189
8562480-7	1995	When endogenous and transfected reductase activity was bypassed by the addition of mevalonate and compactin, a competitive inhibitor, the filamentous actin distribution in HMG-CoA reductase-transfected cells became very similar to that of control cells, demonstrating the role of exogenous HMG-CoA reductase activity in this process.	Mevalonic Acid	83-93	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	290-307
7559642-6	1995	The lovastatin-induced declines in CFTR function were corrected by the simultaneous addition of mevalonate or the isoprenyl lipids geranylgeranyl and farnesyl but not cholesterol.	Mevalonic Acid	96-106	CF transmembrane conductance regulator	Homo sapiens	35-39
7559642-8	1995	Mevalonate or isoprenyl lipids protected CFTR levels from the actions of lovastatin.	Mevalonic Acid	0-10	CF transmembrane conductance regulator	Homo sapiens	41-45
7773308-1	1995	In eukaryotes, all isoprenoid compounds share a common precursor, mevalonic acid, whose synthesis is catalyzed by the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase.	Mevalonic Acid	66-80	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	125-182
7720643-7	1995	The AVP-induced [Ca2+]i mobilization and MAP kinase activation were totally restored when cells were preexposed to a mixture of mevalonate and simvastatin.	Mevalonic Acid	128-138	arginine vasopressin	Rattus norvegicus	4-7
7482033-0	1995	Mevalonate regulates polysome distribution and blocks translation-dependent suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA: relationship to translational control.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	91-138
8538683-5	1995	In addition, antibodies to human p21ras immunoprecipitated mevalonate-labelled species of approx.	Mevalonic Acid	59-69	HRas proto-oncogene, GTPase	Homo sapiens	33-39
7773308-7	1995	Taken together, these data suggest that HMG CoA reductase expression is regulated at multiple levels in plants as well as animals, and they provide a foundation for elucidating the molecular mechanisms for mevalonate regulation in A. thaliana.	Mevalonic Acid	206-216	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	40-57
7482033-1	1995	We reported previously that 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis is regulated at the translational level by mevalonate.	Mevalonic Acid	129-139	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	28-75
7872789-5	1995	Mevalonate does partially regulate the expression of both the artificial promoter construct pTK-Kx3-CAT, containing three copies of the sterol regulatory element, SRE-1, and the full-length LDL receptor promoter construct, pLDLRCAT-6500 as well as the expression of functional LDL receptors.	Mevalonic Acid	0-10	low-density lipoprotein receptor	Cricetulus griseus	190-202
7747441-4	1995	Our results suggest that the enhanced and inappropriate expression of Mk may lead to increased metabolism of mevalonate and phosphorylation of hitherto unknown cellular proteins.	Mevalonic Acid	109-119	mevalonate kinase	Homo sapiens	70-72
7712482-5	1995	In contrast, ongoing IL-3-independent proliferation of Fmev-blocked RasDC cells was not completely restored by providing exogenous cholesterol and preventing the accumulation of inhibitory mevalonate product(s).	Mevalonic Acid	189-199	interleukin 3	Mus musculus	21-25
7872789-10	1995	In contrast, sterol regulators derived from exogenous mevalonate appear to be capable of downregulating the LDL receptor promoter.	Mevalonic Acid	54-64	low-density lipoprotein receptor	Cricetulus griseus	108-120
7723897-3	1995	Mevalonate is the direct product of the rate-limiting step in cholesterol synthesis which is catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A reductase.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	106-153
7723786-1	1995	Activity of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the key enzyme in the biosynthesis of steroids and polyisoprenoids in mammalian cells, has been detected in both the bloodstream form and the culture-adapted procyclic form of Trypanosoma brucei (3.7 +/- 0.6 and 12.7 +/- 1.8 pmol mevalonate produced min-1 (mg cell protein)-1, respectively).	Mevalonic Acid	296-306	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	12-64
7749195-4	1995	Depletion of intracellular mevalonate resulted in decreased steady-state levels of Ras1p and Ras2p, an effect that was mediated at the level of mRNA accumulation.	Mevalonic Acid	27-37	Ras family GTPase RAS1	Saccharomyces cerevisiae S288C	83-88
7749195-4	1995	Depletion of intracellular mevalonate resulted in decreased steady-state levels of Ras1p and Ras2p, an effect that was mediated at the level of mRNA accumulation.	Mevalonic Acid	27-37	Ras family GTPase RAS2	Saccharomyces cerevisiae S288C	93-98
7749195-5	1995	The sequences controlling the response of RAS2 mRNA level to mevalonate availability, mapped to the coding region of the RAS2 gene.	Mevalonic Acid	61-71	Ras family GTPase RAS2	Saccharomyces cerevisiae S288C	42-46
7749195-5	1995	The sequences controlling the response of RAS2 mRNA level to mevalonate availability, mapped to the coding region of the RAS2 gene.	Mevalonic Acid	61-71	Ras family GTPase RAS2	Saccharomyces cerevisiae S288C	121-125
7814446-10	1995	These findings strongly suggest that either EGF or PGF2 alpha stimulations generate early cell cycle signals which induce mevalonate formation, N" glycoprotein synthesis, and proliferation.	Mevalonic Acid	122-132	epidermal growth factor	Mus musculus	44-47
7955120-3	1994	We here report that exposure of HT-29 SF human colonic adenocarcinoma cells to DHEAS inhibited the incorporation of [3H]mevalonate into cellular proteins in a dose-dependent manner when endogenous mevalonate synthesis was blocked by lovastatin.	Mevalonic Acid	120-130	sulfotransferase family 2A member 1	Homo sapiens	79-84
7989303-1	1994	Two recessive alleles of ERG10 and three temperature-sensitive recessive alleles of HMG1 (3-hydroxy-3-methyl-glutaryl-CoA reductase isoenzyme 1) were isolated in a screen for mevalonate auxotrophs in Saccharomyces cerevisiae.	Mevalonic Acid	175-185	hydroxymethylglutaryl-CoA reductase (NADPH) HMG1	Saccharomyces cerevisiae S288C	84-88
7955441-12	1994	The reduction in mevalonic acid is consistent with up-regulation of hepatic LDL receptors caused by GH and this may explain the fall in LDL cholesterol and apolipoprotein B concentrations.	Mevalonic Acid	17-31	apolipoprotein B	Homo sapiens	156-172
7888300-6	1994	Addition of mevalonate to lovastatin-treated cells completely reversed the inhibition of PAF- and FMLP-stimulated Ca(2+)-mobilization.	Mevalonic Acid	12-22	PCNA clamp associated factor	Homo sapiens	89-93
7888300-6	1994	Addition of mevalonate to lovastatin-treated cells completely reversed the inhibition of PAF- and FMLP-stimulated Ca(2+)-mobilization.	Mevalonic Acid	12-22	formyl peptide receptor 1	Homo sapiens	98-102
8021239-0	1994	Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.	Mevalonic Acid	59-73	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	118-165
7844177-11	1994	CHO cells transfected with DNA encoding HM-Gal were exposed to mevalonic acid, which enhances the rate of HMG CoA reductase degradation several fold, and leads to the reduction of the steady state levels of HM-Gal by 80-90%.	Mevalonic Acid	63-77	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	106-123
7974251-1	1994	Mevalonic acid is a product of the enzyme HMG-CoA reductase which is essential for cholesterol biosynthesis.	Mevalonic Acid	0-14	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	42-59
7964176-2	1994	The mevalonate pathway, which starts with the synthesis of mevalonate by HMGR, has more branch pathways in plants than in most other organisms, leading to a tremendous variety of isoprenoid products.	Mevalonic Acid	4-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	73-77
7964176-2	1994	The mevalonate pathway, which starts with the synthesis of mevalonate by HMGR, has more branch pathways in plants than in most other organisms, leading to a tremendous variety of isoprenoid products.	Mevalonic Acid	59-69	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	73-77
8276863-0	1994	Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo and in vitro.	Mevalonic Acid	0-14	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	40-87
7949422-7	1994	Furthermore, regulation of Hmg1p synthesis was keyed to the level of a nonsterol product of the mevalonate pathway.	Mevalonic Acid	96-106	hydroxymethylglutaryl-CoA reductase (NADPH) HMG1	Saccharomyces cerevisiae S288C	27-32
7949422-8	1994	Manipulations of endogenous levels of several isoprenoid intermediates, either pharmacologically or genetically, suggested that mevalonate levels may control the synthesis of Hmg1p through effects on translation.	Mevalonic Acid	128-138	hydroxymethylglutaryl-CoA reductase (NADPH) HMG1	Saccharomyces cerevisiae S288C	175-180
8163547-7	1994	Hmg2p stability was strongly affected by modulation of the mevalonate pathway through pharmacological or genetic means.	Mevalonic Acid	59-69	hydroxymethylglutaryl-CoA reductase (NADPH) HMG2	Saccharomyces cerevisiae S288C	0-5
8163547-8	1994	Decreased mevalonate pathway flux resulted in decreased degradation of Hmg2p.	Mevalonic Acid	10-20	hydroxymethylglutaryl-CoA reductase (NADPH) HMG2	Saccharomyces cerevisiae S288C	71-76
8163547-9	1994	One signal for degradation of Hmg2p was a nonsterol, mevalonate-derived molecule produced before the synthesis of squalene.	Mevalonic Acid	53-63	hydroxymethylglutaryl-CoA reductase (NADPH) HMG2	Saccharomyces cerevisiae S288C	30-35
8307022-10	1994	Administration of radiolabelled mevalonic acid to cotyledons and isolation of glyoxysomes yielded labelled Dnaj protein which remained membrane bound during the purification of glyoxysomal membranes by floatation in a density gradient.	Mevalonic Acid	32-46	dnaJ protein homolog	Cucumis sativus	107-111
8195701-0	1994	Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells.	Mevalonic Acid	12-22	C-X-C motif chemokine ligand 8	Homo sapiens	58-62
8195701-6	1994	Coincubation of reductase inhibitor-treated cells with mevalonate prevented the attenuation of IL-8 production by reductase inhibitors.	Mevalonic Acid	55-65	C-X-C motif chemokine ligand 8	Homo sapiens	95-99
8195701-9	1994	We conclude that isoprenoid generation through the mevalonate pathway is a requirement for IL-8 induction by activated monocytic cells in vitro.	Mevalonic Acid	51-61	C-X-C motif chemokine ligand 8	Homo sapiens	91-95
12232220-6	1994	Determination of the activities of all five enzymes of the pathway involved in the sequence from mevalonic acid to phytoene revealed that the only enzyme activity stimulated by light was isopentenyl pyrophosphate isomerase.	Mevalonic Acid	97-111	Isopentenyl-diphosphate Delta-isomerase I	Zea mays	187-222
8198025-6	1994	The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors inhibit biosynthesis of mevalonate, a precursor of non-sterol compounds involved in cell proliferation, and thus may control the neointimal response, which forms the kernel of restenosis.	Mevalonic Acid	97-107	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-61
8302869-10	1994	Our results suggest that the endoplasmic reticulum is the only cell compartment for the targeting of HMGR in Arabidopsis and support the hypothesis that in higher plants the formation of mevalonate occurs solely in the cytosol.	Mevalonic Acid	187-197	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	101-105
8276863-5	1994	In the current study, inhibitors of the isoprene biosynthetic pathway were used to define further this mevalonic acid derivative involved in the accelerated degradation of HMG-CoA reductase.	Mevalonic Acid	103-117	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	172-189
7902394-8	1993	Treatment of cells with lovastatin, an inhibitor of ras-encoded p21ras post-translational processing via the mevalonate pathway, markedly decreased the yield of micronuclei formation in cells transfected with ras; the drug had no effect on radiation-induced micronuclei formation in parental cells.	Mevalonic Acid	109-119	HRas proto-oncogene, GTPase	Homo sapiens	64-70
7710260-0	1994	The effects of insulin on plasma mevalonate concentrations in man.	Mevalonic Acid	33-43	insulin	Homo sapiens	15-22
7710260-6	1994	In conclusion, hyperinsulinemia in the presence of euglycemia acutely decreases the circulating levels of mevalonic acid, the immediate product of HMG CoA reductase in the cholesterol pathway.	Mevalonic Acid	106-120	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	147-164
8302606-5	1994	MK phosphorylates mevalonate, a major intermediate in the branched cholesterol/isoprenoid biosynthetic pathway.	Mevalonic Acid	18-28	mevalonate kinase	Homo sapiens	0-2
8406993-0	1993	Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.	Mevalonic Acid	14-24	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	60-77
8406993-1	1993	HMG-CoA reductase catalyzes the synthesis of mevalonate, a crucial intermediate in the biosynthesis of cholesterol and non-sterol isoprenoid compounds essential for cell growth.	Mevalonic Acid	45-55	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
8482726-1	1993	Blockade of mevalonate synthesis by the 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor mevinolin (lovastatin) causes FRTL-5 thyroid cells to undergo significant morphological changes; these include a transition from a flat, polygonal to a round shape, the development of cytoplasmic arborizations, and the loss of contact between neighboring cells.	Mevalonic Acid	12-22	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	40-87
8216498-0	1993	Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.	Mevalonic Acid	21-31	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	112-129
12231959-5	1993	The rapid increase in rubber formation may result from exposing the plants to low temperatures of 5 to 7[deg]C. The activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) was 21.1 nmol mevalonic acid (MVA) h-1 g-1 fresh weight in the bark of the lower stems in June during seedling growth and decreased to 5.1 nmol MVA h-1g-1 fresh weight in July and 2.9 nmol MVA h-1 g-1 fresh weight in September.	Mevalonic Acid	190-204	3-hydroxy-3-methylglutaryl-coenzyme A reductase 1	Solanum lycopersicum	170-174
8352528-6	1993	Following a 25-hydroxycholesterol treatment as short as 4 h, the onset of DNA synthesis was delayed, indicating that a certain level of HMG CoA reductase activity (= mevalonate synthesis) in the early and mid stage of the prereplicative phase is required for the transduction of the signal leading to initiation of DNA synthesis.	Mevalonic Acid	166-176	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	136-153
8352528-7	1993	In concurrence with these data, it was also demonstrated that giving an exogenous supply of mevalonate to the insulin-stimulated HMEC results in a faster initiation of DNA synthesis.	Mevalonic Acid	92-102	insulin	Homo sapiens	110-117
8097083-5	1993	These observations suggest that the initial phase of mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity was governed primarily by post-translational processes.	Mevalonic Acid	53-63	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	88-135
8446927-1	1993	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (EC 1.1.1.34) is the rate limiting step in the mevalonate pathway that produces isoprenoids and cholesterol.	Mevalonic Acid	105-115	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-57
8491805-3	1993	Simple regression analysis revealed significant correlations between the plasma level of mevalonate and the hepatic activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (EC 1.1.1.34) (r = 0.83, P < 0.01) and between the plasma level of free 7 alpha-hydroxycholesterol and the hepatic activity of cholesterol 7 alpha-hydroxylase (EC 1.14.13.7) (r = 0.76, P < 0.05).	Mevalonic Acid	89-99	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	306-337
8446927-10	1993	The wide embryonic and extraembryonic distribution and abundance of HMG-CoA reductase mRNA may reflect developmental requirements for products of the mevalonate pathway, e.g., isoprenoids for post-translational farnesylation of p21ras.	Mevalonic Acid	150-160	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	68-85
8446927-10	1993	The wide embryonic and extraembryonic distribution and abundance of HMG-CoA reductase mRNA may reflect developmental requirements for products of the mevalonate pathway, e.g., isoprenoids for post-translational farnesylation of p21ras.	Mevalonic Acid	150-160	HRas proto-oncogene, GTPase	Rattus norvegicus	228-234
8476209-3	1993	Following addition of mevalonate to cells arrested by HMG CoA reductase inhibitors, the depression of N-linked glycosylation was overcome and the cells initiated DNA synthesis.	Mevalonic Acid	22-32	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	54-71
8425769-4	1993	Interestingly, treatment of the ras-transformed cells with lovastatin, an inhibitor of p21ras post-translational processing via the mevalonate pathway, markedly decreased their radioresistance.	Mevalonic Acid	132-142	HRas proto-oncogene, GTPase	Homo sapiens	87-93
8424783-0	1993	Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT-T15 cells.	Mevalonic Acid	12-22	insulin	Mesocricetus auratus	117-124
16653244-1	1992	De novo synthesis of mevalonic acid, which is catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A reductase, is the first committed step in the formation of isoprenoid compounds.	Mevalonic Acid	21-35	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Nicotiana tabacum	59-106
8502754-10	1993	Diminished low density lipoprotein (LDL) receptor (LDL-R) activity is a significant alteration in a metabolic pathway with such fundamental ties to cellular growth and activation (via mevalonate effects on isoprenylation of G-proteins for example), that it is selected for in the development of certain tumors--among them human colonic carcinomas.	Mevalonic Acid	184-194	low density lipoprotein receptor	Homo sapiens	11-49
8502754-10	1993	Diminished low density lipoprotein (LDL) receptor (LDL-R) activity is a significant alteration in a metabolic pathway with such fundamental ties to cellular growth and activation (via mevalonate effects on isoprenylation of G-proteins for example), that it is selected for in the development of certain tumors--among them human colonic carcinomas.	Mevalonic Acid	184-194	low density lipoprotein receptor	Homo sapiens	51-56
1487489-5	1992	They also responded to mevinolin (an HMG CoA reductase inhibitor) by a similar G1-block, indicating that a mevalonate-derived product is involved in the G1-located cell cycle control of HDF.	Mevalonic Acid	107-117	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	37-54
8097863-5	1993	In contrast, acetoacetyl-CoA thiolase and HMG-CoA reductase, the enzymes also responsible for mevalonate synthesis in the pathway, did not show any significant change in activity.	Mevalonic Acid	94-104	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	42-59
1471162-7	1992	The 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase (the rate-limiting reaction in cholesterol biosynthesis) is the enzyme which catalyzes the conversion of HMGCoA to mevalonic acid.	Mevalonic Acid	169-183	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-53
16653244-2	1992	Various studies have shown that mevalonic acid-derived compounds are required for growth of plant and animal cells, a conclusion supported by the observation that cells treated with lovastatin (a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase) cease growth.	Mevalonic Acid	32-46	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Nicotiana tabacum	216-263
1503903-2	1992	The effect of ONC alone and in combination with lovastatin (LVT), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of mevalonate (MVA) and cholesterol synthesis pathway, in three human tumour cell lines ASPC-1 pancreatic, A-549 lung, and HT-520 lung carcinomas, has been presently studied.	Mevalonic Acid	167-177	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	82-139
1524429-5	1992	Thus, modulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity was coupled to physiological changes in mevalonate/nonsterol isopentenoid availability.	Mevalonic Acid	117-127	HMG Coenzyme A reductase	Drosophila melanogaster	20-67
1636694-0	1992	Role of GH in regulating nocturnal rates of lipolysis and plasma mevalonate levels in normal and diabetic humans.	Mevalonic Acid	65-75	growth hormone 1	Homo sapiens	8-10
1618856-2	1992	Using Chinese hamster ovary cells transfected with a plasmid encoding HMGal, a chimeric protein containing the membrane domain of HMG-CoA reductase coupled to beta-galactosidase, we have demonstrated mevalonate and sterol-stimulated loss of beta-galactosidase activity.	Mevalonic Acid	200-210	beta-galactosidase	Cricetulus griseus	159-177
1580550-1	1992	The proliferative rate as well as the activity of 3-hydroxy-3-methylglutaryl CoA (HMG CoA) reductase, which regulates de novo synthesis of mevalonate, was comparable in the two human breast cancer cell lines Hs578T and MDA-231 when cultured in the presence of serum.	Mevalonic Acid	139-149	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	50-100
1399833-1	1992	The developmental expression of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting reaction of mevalonate formation, was investigated in rat testes.	Mevalonic Acid	147-157	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	32-89
1586169-5	1992	C18 radio-HPLC tryptic digest profiles for delipidized, [3H]mevalonate-labeled (a) insect (Drosophila and Spodoptera frugiperda) and mammalian (Chinese hamster ovary met 18-2b) cells, (b) Kc cell nuclear lamin, and (c) a 23.5-kDa purified Kc cell GTP-binding protein were compared and analyzed.	Mevalonic Acid	60-70	l(3)C18	Drosophila melanogaster	0-3
1533625-1	1992	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) is located in the endoplasmic reticulum (ER) and responds to rapid degradation which is regulated by mevalonate or sterols.	Mevalonic Acid	169-179	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	0-66
1619360-2	1992	Regulation of cholesterol 7 alpha-hydroxylase by taurocholate and mevalonate.	Mevalonic Acid	66-76	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	14-45
1312092-5	1992	Mevalonate kinase is believed to be a cytosolic enzyme and catalyzes the phosphorylation of mevalonate to form mevalonate 5-phosphate.	Mevalonic Acid	92-102	mevalonate kinase	Rattus norvegicus	0-17
1349377-4	1992	In-vivo and cell-culture experiments have shown that lowering the plasma cholesterol concentration or intervening in the mevalonate pathway with 3-hydroxy-3-methylglutaryl (HMG) CoA reductase inhibitors decreases tumour growth.	Mevalonic Acid	121-131	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	145-191
1546367-0	1992	Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis in Syrian hamster C100 cells by mevinolin, 25-hydroxycholesterol, and mevalonate: the role of posttranscriptional control.	Mevalonic Acid	142-152	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	14-61
1311272-5	1992	In fact, when used at high concentrations, mevalonate activates Cyp1a-1 transcription.	Mevalonic Acid	43-53	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	64-71
1740442-9	1992	This change in rab protein localization is reversed by providing cells with mevalonate.	Mevalonic Acid	76-86	ArfGAP with FG repeats 1	Homo sapiens	15-18
1346397-6	1992	Surprisingly, the addition of A23187 to THP-1 cells incubated in the presence of 25-hydroxycholesterol and mevalonic acid also led to significant increases in the mRNA levels for HMG-CoA reductase and HMG-CoA synthase.	Mevalonic Acid	107-121	GLI family zinc finger 2	Homo sapiens	40-45
1346397-6	1992	Surprisingly, the addition of A23187 to THP-1 cells incubated in the presence of 25-hydroxycholesterol and mevalonic acid also led to significant increases in the mRNA levels for HMG-CoA reductase and HMG-CoA synthase.	Mevalonic Acid	107-121	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	179-196
1346397-6	1992	Surprisingly, the addition of A23187 to THP-1 cells incubated in the presence of 25-hydroxycholesterol and mevalonic acid also led to significant increases in the mRNA levels for HMG-CoA reductase and HMG-CoA synthase.	Mevalonic Acid	107-121	3-hydroxy-3-methylglutaryl-CoA synthase 2	Homo sapiens	201-217
1546367-2	1992	In this study the effects of the oxysterol 25-hydroxycholesterol and mevalonate on the mRNA level and rate of synthesis for HMG-CoA reductase were evaluated in C100 cells treated with mevinolin, a competitive inhibitor of HMG-CoA reductase.	Mevalonic Acid	69-79	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	124-141
1546367-6	1992	Degradation of HMG-CoA reductase was rapid in the presence (t1/2 = 1.34 h) or absence (t1/2 = 1.17 h) of mevinolin and was not changed significantly by adding either 25-hydroxycholesterol, alone (t1/2 = 1.30 h) or both 25-hydroxycholesterol and mevalonate (t1/2 = 1.30 h) to mevinolin-treated cells.	Mevalonic Acid	245-255	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	15-32
1546367-7	1992	This study demonstrates that mevalonate and 25-hydroxycholesterol act synergistically in the presence of mevinolin to achieve a greater degree of suppression in the rate of HMG-CoA reductase synthesis than can be accounted for by their individual effects on HMG-CoA reductase mRNA.	Mevalonic Acid	29-39	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	173-190
1546367-7	1992	This study demonstrates that mevalonate and 25-hydroxycholesterol act synergistically in the presence of mevinolin to achieve a greater degree of suppression in the rate of HMG-CoA reductase synthesis than can be accounted for by their individual effects on HMG-CoA reductase mRNA.	Mevalonic Acid	29-39	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	258-275
1546367-8	1992	In addition, the data suggest that mevalonate affects the synthesis of HMG-CoA reductase at a yet unidentified posttranscriptional control site.	Mevalonic Acid	35-45	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	71-88
1953779-4	1991	These results suggest the involvement of product(s) of mevalonate metabolism (e.g., prenylated proteins such as p21ras or G proteins) in the signal transduction of EGF, insulin and IGF-I.	Mevalonic Acid	55-65	HRas proto-oncogene, GTPase	Homo sapiens	112-118
1953779-4	1991	These results suggest the involvement of product(s) of mevalonate metabolism (e.g., prenylated proteins such as p21ras or G proteins) in the signal transduction of EGF, insulin and IGF-I.	Mevalonic Acid	55-65	epidermal growth factor	Homo sapiens	164-167
1953779-4	1991	These results suggest the involvement of product(s) of mevalonate metabolism (e.g., prenylated proteins such as p21ras or G proteins) in the signal transduction of EGF, insulin and IGF-I.	Mevalonic Acid	55-65	insulin	Homo sapiens	169-176
1953779-4	1991	These results suggest the involvement of product(s) of mevalonate metabolism (e.g., prenylated proteins such as p21ras or G proteins) in the signal transduction of EGF, insulin and IGF-I.	Mevalonic Acid	55-65	insulin like growth factor 1	Homo sapiens	181-186
1918164-1	1991	We have used compactin, an inhibitor of mevalonate biosynthesis, to block p21ras posttranslational modification and membrane association in PC12 cells.	Mevalonic Acid	40-50	HRas proto-oncogene, GTPase	Rattus norvegicus	74-80
1666129-2	1991	We found that CNP, like these other proteins, is modified posttranslationally by an isoprenoid derived from mevalonic acid.	Mevalonic Acid	108-122	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	14-17
1666129-4	1991	Inhibition of isoprenoid synthesis by Lovastatin blocks the binding of newly synthesized CNP to cell membranes; binding is restored upon addition of mevalonate to the culture medium.	Mevalonic Acid	149-159	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	89-92
1657912-7	1991	Mevalonate, at concentrations that did not decrease HMGR activity, was able to restore the inhibiting effect of SKF 104976 on HMGR activity.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	126-130
1657912-9	1991	These findings suggest that upon inhibition of 14 alpha DM by SKF 104976, a mevalonate-derived precursor regulates HMGR activity, even when the sterol synthetic rate is considerably reduced and when HMGR protein levels are very high.	Mevalonic Acid	76-86	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	115-119
1657912-9	1991	These findings suggest that upon inhibition of 14 alpha DM by SKF 104976, a mevalonate-derived precursor regulates HMGR activity, even when the sterol synthetic rate is considerably reduced and when HMGR protein levels are very high.	Mevalonic Acid	76-86	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	199-203
1673788-8	1991	Because mevalonate is essential for the posttranslational modification (isoprenylation) of p21ras, which in turn allows this protein to become attached to the cell membrane, the data suggest that the LOV-induced G1 arrest may be a consequence of the loss of the signal transduction capacity of p21ras.	Mevalonic Acid	8-18	HRas proto-oncogene, GTPase	Homo sapiens	91-97
1894647-2	1991	Given the recent discovery of the post-translational modification of p21ras and other cell growth-associated proteins by intermediates in the mevalonic acid pathway, and the common biochemical origins of limonene and these isoprene products, we investigated the effect of limonene on protein isoprenylation.	Mevalonic Acid	142-156	HRas proto-oncogene, GTPase	Homo sapiens	69-75
1908464-1	1991	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in the biosynthesis of cholesterol and isoprenoids, is subject to rapid degradation which is regulated by mevalonate (MVA)-derived metabolic products.	Mevalonic Acid	200-210	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-47
1908464-1	1991	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in the biosynthesis of cholesterol and isoprenoids, is subject to rapid degradation which is regulated by mevalonate (MVA)-derived metabolic products.	Mevalonic Acid	212-215	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-47
1712015-11	1991	In mAb is associated with PKC-dependent induction of HMG-CoA reductase which, in turn, leads to the generation of mevalonic acid and its metabolites, one or more of which play a requisite role in cell cycle progression.	Mevalonic Acid	114-128	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	53-70
1943491-2	1991	3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is the enzyme which catalyzes mevalonic acid synthesis.	Mevalonic Acid	88-102	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
1827487-5	1991	Receptor-mediated Ca2+ mobilization, secretion, and ruffling are all restored by 0.5- to 4-h incubation of lovastatin-treated cells with mevalonic acid, the product of HMG CoA reductase and the first committed intermediate of the isoprenoid biosynthetic pathway.	Mevalonic Acid	137-151	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	168-185
1673788-8	1991	Because mevalonate is essential for the posttranslational modification (isoprenylation) of p21ras, which in turn allows this protein to become attached to the cell membrane, the data suggest that the LOV-induced G1 arrest may be a consequence of the loss of the signal transduction capacity of p21ras.	Mevalonic Acid	8-18	HRas proto-oncogene, GTPase	Homo sapiens	294-300
2007618-2	1991	We have shown previously that in rabbit reticulocyte lysates the cysteine residue of the CaaX motif of chicken lamin B2 is necessary for incorporation of a derivative of mevalonic acid, the precursor of isoprenoids.	Mevalonic Acid	170-184	lamin B2	Gallus gallus	111-119
1713501-1	1991	Mevalonate-activating enzymes from chick brain and liver were stable when 105,000 x g supernatants were stored at -4 degrees C for 168 h. Mevalonate kinase and mevalonate 5-phosphate kinase retained their activities for 72 h at 4 degrees C while mevalonate 5-pyrophosphate decarboxylase activity significantly decreased after 24-48 h of storage at 4 degrees C. Direct addition of 2.5 mM phenylpyruvate to the reaction mixture produced a significant inhibition of decarboxylase activity in brain and liver.	Mevalonic Acid	0-10	mevalonate kinase	Gallus gallus	138-155
1847705-6	1991	Urinary excretion of mevalonate, which correlates with rates of whole body cholesterol synthesis, decreased from 3.8 +/- 0.42 (+/- SEM) mu,ol/24 h at baseline to 2.75 +/- 0.56 on simvastatin; no significant changes were seen in the urinary mevalonate levels before and after simvastatin therapy during ACTH stimulation.	Mevalonic Acid	21-31	proopiomelanocortin	Homo sapiens	302-306
1900292-4	1991	This anti-rap2 antiserum was used for two-dimensional immunoblotting analysis and immunoprecipitation of mevalonate-labeled rap2 from platelets and HEL cells.	Mevalonic Acid	105-115	RAP2A, member of RAS oncogene family	Homo sapiens	10-14
1900292-4	1991	This anti-rap2 antiserum was used for two-dimensional immunoblotting analysis and immunoprecipitation of mevalonate-labeled rap2 from platelets and HEL cells.	Mevalonic Acid	105-115	RAP2A, member of RAS oncogene family	Homo sapiens	124-128
1993065-1	1991	Human liver alcohol dehydrogenase (ADH) catalyzes the oxidation of 3,3-dimethylallyl alcohol, the intermediary alcohol of the shunt pathway of mevalonate metabolism.	Mevalonic Acid	143-153	aldo-keto reductase family 1 member A1	Homo sapiens	12-33
1993065-1	1991	Human liver alcohol dehydrogenase (ADH) catalyzes the oxidation of 3,3-dimethylallyl alcohol, the intermediary alcohol of the shunt pathway of mevalonate metabolism.	Mevalonic Acid	143-153	aldo-keto reductase family 1 member A1	Homo sapiens	35-38
2176219-5	1990	Addition of 1 mM mevalonic acid to normal or mevinolin-treated cells raised the cellular cholesterol content and decreased the amount of secreted H-TGL activity to levels below control values.	Mevalonic Acid	17-31	lipase C, hepatic type	Homo sapiens	146-151
16296004-7	1991	Deprivation of isoprenyl precursors by the addition of lovastatin, a drug that blocks the synthesis of mevalonate, also abolished the ability of activated K-ras(B) to induce meiosis, although this inhibition could be overcome by the addition of exogenous mevalonate.	Mevalonic Acid	255-265	kirsten rat sarcoma viral oncogene homolog L homeolog	Xenopus laevis	155-163
1846516-4	1991	In addition, an enhancement of the synthesis ratio (UQ-10/UQ-9) was observed when the rats were treated with isoproterenol to increase the activity of 3-hydroxymethylglutaryl-CoA (HMG-CoA) reductase, a rate-limiting enzyme which forms mevalonate.	Mevalonic Acid	235-245	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	151-198
16296004-7	1991	Deprivation of isoprenyl precursors by the addition of lovastatin, a drug that blocks the synthesis of mevalonate, also abolished the ability of activated K-ras(B) to induce meiosis, although this inhibition could be overcome by the addition of exogenous mevalonate.	Mevalonic Acid	103-113	kirsten rat sarcoma viral oncogene homolog L homeolog	Xenopus laevis	155-163
2176219-6	1990	Mevalonic acid also prevented mevinolin-induction of H-TGL and HMG-CoA reductase mRNA, suggesting a common regulatory step for H-TGL and HMG-CoA reductase.	Mevalonic Acid	0-14	lipase C, hepatic type	Homo sapiens	53-58
2176219-6	1990	Mevalonic acid also prevented mevinolin-induction of H-TGL and HMG-CoA reductase mRNA, suggesting a common regulatory step for H-TGL and HMG-CoA reductase.	Mevalonic Acid	0-14	lipase C, hepatic type	Homo sapiens	127-132
2086705-10	1990	By contrast, the oxygenated sterol, 25-hydroxycholesterol, and mevalonate, the precursor of endogenously synthesized sterols, down-regulated LDL receptor mRNA levels comparably in mitogen-stimulated and control PBMC.	Mevalonic Acid	63-73	low density lipoprotein receptor	Homo sapiens	141-153
2246324-2	1990	Earlier, we reported that treatment of NK cells with an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase such as compactin or lovastatin significantly abrogates the in vitro killing of a susceptible human erythroleukemic cell line and that this inhibition can be completely reversed by 2 hr of exposure to mevalonate (J.	Mevalonic Acid	328-338	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	69-126
2079605-5	1990	Mevalonic acid reversed the effect of lovastatin on 125I-labeled HDL3 binding.	Mevalonic Acid	0-14	HDL3	Homo sapiens	65-69
2247467-2	1990	It functions by inhibiting the enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (EC 1.1.1.34), that is required for the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonic acid.	Mevalonic Acid	182-196	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	39-86
2285988-9	1990	These results indicate that when catalase activity of liver peroxisomes is suppressed by aminotriazole treatment, biosynthesis of bile acid from exogenous cholesterol is not inhibited, but a step in the pathway of biosynthesis of endogenous cholesterol from mevalonate is inhibited.	Mevalonic Acid	258-268	catalase	Rattus norvegicus	33-41
2217184-3	1990	Inhibition of mevalonate synthesis reverts the abnormal phenotypes induced by the mutant RAS2Val-19 gene in Saccharomyces cerevisiae and blocks the maturation of Xenopus oocytes induced by an oncogenic Ras p21 protein of human origin.	Mevalonic Acid	14-24	cyclin-dependent kinase inhibitor 1A L homeolog	Xenopus laevis	206-209
2197592-0	1990	The Ha-ras protein, p21, is modified by a derivative of mevalonate and methyl-esterified when expressed in the insect/baculovirus system.	Mevalonic Acid	56-66	H3 histone pseudogene 16	Homo sapiens	20-23
2115642-0	1990	Mevalonate deprivation alters the induction of fos and myc by growth factors.	Mevalonic Acid	0-10	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	47-50
2197592-3	1990	It is highly likely that the insect expression system recognizes the C-terminal CAAX Motif in p21, incorporates the mevalonate into the recently described polyisoprenylation modification and carboxyl-methylates the protein.	Mevalonic Acid	116-126	H3 histone pseudogene 16	Homo sapiens	94-97
2115642-0	1990	Mevalonate deprivation alters the induction of fos and myc by growth factors.	Mevalonic Acid	0-10	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	55-58
2115642-5	1990	This effect of mevalonate deprivation appears to be on the transcriptional regulation of fos and does not depend upon the nature of the initial events of signal transduction, since the same phenomenon was observed following EGF and TPA stimulation.	Mevalonic Acid	15-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	89-92
2180959-1	1990	It has recently been reported that a precursor of p21ras (pro-p21ras) becomes modified by a metabolite of mevalonic acid prior to conversion to mature p21ras.	Mevalonic Acid	106-120	HRas proto-oncogene, GTPase	Homo sapiens	50-56
2112479-7	1990	Our results indicate that the potent hypocholesterolaemic effects of simvastatin are accompanied by increases in high-affinity LDL receptor-mediated degradation of LDL and a compensatory increase in cholesterol biosynthesis in freshly isolated mononuclear leucocytes but that rates of mevalonic acid excretion in the urine decrease.	Mevalonic Acid	285-299	low density lipoprotein receptor	Homo sapiens	127-139
2335559-4	1990	Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin (lovastatin) specifically depletes endogenous isoprenoid pools and inhibits the conversion of prelamin A to lamin A. Prelamin A processing is also blocked by mevalonate starvation of Mev-1, a CHO cell line auxotrophic for mevalonate.	Mevalonic Acid	233-243	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	14-61
2335559-4	1990	Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin (lovastatin) specifically depletes endogenous isoprenoid pools and inhibits the conversion of prelamin A to lamin A. Prelamin A processing is also blocked by mevalonate starvation of Mev-1, a CHO cell line auxotrophic for mevalonate.	Mevalonic Acid	297-307	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	14-61
2362431-2	1990	3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase could have a key function in controlling uterine mitosis through its control of mevalonic acid and cholesterol synthesis as the rate-limiting enzyme in their synthetic pathways.	Mevalonic Acid	138-152	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-57
2158094-1	1990	Mevalonate kinase [ATP:(R)-mevalonate 5-phosphotransferase, EC 2.7.1.36] may be a regulatory site in the cholesterol biosynthetic pathway, and a mutation in the gene coding for this enzyme is thought to cause the genetic disease mevalonic aciduria.	Mevalonic Acid	23-37	mevalonate kinase	Rattus norvegicus	0-17
2180959-1	1990	It has recently been reported that a precursor of p21ras (pro-p21ras) becomes modified by a metabolite of mevalonic acid prior to conversion to mature p21ras.	Mevalonic Acid	106-120	HRas proto-oncogene, GTPase	Homo sapiens	62-68
2180959-1	1990	It has recently been reported that a precursor of p21ras (pro-p21ras) becomes modified by a metabolite of mevalonic acid prior to conversion to mature p21ras.	Mevalonic Acid	106-120	HRas proto-oncogene, GTPase	Homo sapiens	62-68
2180959-3	1990	Fluoromevalonate, which inhibits the conversion of pyrophosphomevalonate to isopentenyl pyrophosphate, blocks the incorporation of radioactive mevalonate into pro-p21ras, demonstrating the mevalonate must be converted to an isoprenoid prior to such incorporation.	Mevalonic Acid	6-16	HRas proto-oncogene, GTPase	Homo sapiens	163-169
2180959-5	1990	The precursor, accumulated due to either of these treatments, is converted through an intermediate form to the mature p21ras by incubation of cells with mevalonate.	Mevalonic Acid	153-163	HRas proto-oncogene, GTPase	Homo sapiens	118-124
33032653-9	2020	RESULTS: We demonstrated the capacity of the combined approach to target CSC compartment by a novel molecular mechanism based on the inhibition of YAP oncogene via concurrent modulation of mevalonate pathway and AMPK.	Mevalonic Acid	189-199	yes-associated protein 1	Mus musculus	147-150
2313206-13	1990	When a bolus dose of mevinolinic acid was coupled with a continuous infusion of mevalonate, the product of the reaction catalyzed by HMG-CoA reductase, the mevinolinic acid-induced decrease in cholesterol 7 alpha-hydroxylase activity and bile acid synthesis was prevented.	Mevalonic Acid	80-90	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	133-150
2313206-13	1990	When a bolus dose of mevinolinic acid was coupled with a continuous infusion of mevalonate, the product of the reaction catalyzed by HMG-CoA reductase, the mevinolinic acid-induced decrease in cholesterol 7 alpha-hydroxylase activity and bile acid synthesis was prevented.	Mevalonic Acid	80-90	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	193-224
33825684-4	2021	Both spatial retention of HMGCRs and increased mevalonate pathway flux during AGR is dependent on NVJ tether Nvj1.	Mevalonic Acid	47-57	Nvj1p	Saccharomyces cerevisiae S288C	109-113
33825684-6	2021	Loss of Nvj1-mediated HMGCR partitioning can be bypassed by artificially multimerizing HMGCRs, indicating NVJ compartmentalization enhances mevalonate pathway flux by promoting the association of HMGCRs in high molecular weight assemblies.	Mevalonic Acid	140-150	Nvj1p	Saccharomyces cerevisiae S288C	8-12
16857902-0	2006	The mevalonate pathway controls heart formation in Drosophila by isoprenylation of Ggamma1.	Mevalonic Acid	4-14	G protein gamma 1	Drosophila melanogaster	83-90
21702715-1	2011	INTRODUCTION: Farnesyl pyrophosphate synthase (FPPS, also known as farnesyl diphosphate synthase (FDPS)) is one of the key enzymes involved in the mevalonate pathway and as such is widely expressed.	Mevalonic Acid	147-157	farnesyl diphosphate synthase	Homo sapiens	14-45
21702715-1	2011	INTRODUCTION: Farnesyl pyrophosphate synthase (FPPS, also known as farnesyl diphosphate synthase (FDPS)) is one of the key enzymes involved in the mevalonate pathway and as such is widely expressed.	Mevalonic Acid	147-157	farnesyl diphosphate synthase	Homo sapiens	47-51
21702715-1	2011	INTRODUCTION: Farnesyl pyrophosphate synthase (FPPS, also known as farnesyl diphosphate synthase (FDPS)) is one of the key enzymes involved in the mevalonate pathway and as such is widely expressed.	Mevalonic Acid	147-157	farnesyl diphosphate synthase	Homo sapiens	67-96
21702715-1	2011	INTRODUCTION: Farnesyl pyrophosphate synthase (FPPS, also known as farnesyl diphosphate synthase (FDPS)) is one of the key enzymes involved in the mevalonate pathway and as such is widely expressed.	Mevalonic Acid	147-157	farnesyl diphosphate synthase	Homo sapiens	98-102
16857902-3	2006	This phenotype resulted from mutations in the genes encoding HMG-CoA reductase, downstream enzymes in the mevalonate pathway, and G protein Ggamma1, which is geranylgeranylated, thus representing an end point of isoprenoid biosynthesis.	Mevalonic Acid	106-116	HMG Coenzyme A reductase	Drosophila melanogaster	61-78
16857902-4	2006	Our findings reveal a cardial cell-autonomous requirement of Ggamma1 geranylgeranylation for heart formation and suggest the involvement of the mevalonate pathway in congenital heart disease.	Mevalonic Acid	144-154	G protein gamma 1	Drosophila melanogaster	61-68
34351398-0	2021	Engineering acetyl-CoA supply and ERG9 repression to enhance mevalonate production in Saccharomyces cerevisiae.	Mevalonic Acid	61-71	bifunctional farnesyl-diphosphate farnesyltransferase/squalene synthase	Saccharomyces cerevisiae S288C	34-38
34883342-7	2022	Treatment of IL-33-activated mast cells with mevalonic acid or isoprenoids reduced fluvastatin effects, suggesting fluvastatin acts at least partly by reducing isoprenoid production.	Mevalonic Acid	45-59	interleukin 33	Homo sapiens	13-18
34893975-9	2022	IPPF inhibits cholesterol intestinal absorption by modulating the cholesterol transporters expression and reduces hepatic cholesterol synthesis by inhibiting the SREBP2-regulated mevalonate pathway.	Mevalonic Acid	179-189	sterol regulatory element binding transcription factor 2	Homo sapiens	162-168
34794035-8	2021	Metabolic flux analysis around the mevalonate node, also revealed that significant amounts of acetoacetate are being produced from BCAA derived carbon, which could be at the source of lipid synthesis.	Mevalonic Acid	35-45	AT-rich interaction domain 4B	Homo sapiens	131-135
34950147-1	2021	Mevalonic aciduria (MA) is the most severe clinical subtype of mevalonate kinase deficiency (MKD) caused by an inherited defect in the mevalonate pathway.	Mevalonic Acid	135-145	mevalonate kinase	Homo sapiens	63-80
34700228-0	2021	Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.	Mevalonic Acid	50-60	polo like kinase 1	Homo sapiens	11-15
34700228-0	2021	Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.	Mevalonic Acid	50-60	AXL receptor tyrosine kinase	Homo sapiens	79-82
34700228-0	2021	Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.	Mevalonic Acid	50-60	twist family bHLH transcription factor 1	Homo sapiens	83-88
34885764-3	2021	The deletion of alcohol dehydrogenase (adhE) and acetate kinase (ackA) genes, along with the supplementation with betaine, improved the co-production of lactate and isoprene from the substrates of glucose and mevalonate.	Mevalonic Acid	209-219	Alcohol dehydrogenase	Escherichia coli	16-37
34885764-3	2021	The deletion of alcohol dehydrogenase (adhE) and acetate kinase (ackA) genes, along with the supplementation with betaine, improved the co-production of lactate and isoprene from the substrates of glucose and mevalonate.	Mevalonic Acid	209-219	Alcohol dehydrogenase	Escherichia coli	39-43
34885721-2	2021	In our previous studies, including an in silico inverse virtual screening, NMR experiments and in vitro enzymatic assays, we demonstrated that i6A targeted farnesyl pyrophosphate synthase (FPPS), a key enzyme involved in the mevalonate (MVA) pathway and prenylation of downstream proteins, which are aberrant in several cancers.	Mevalonic Acid	225-235	farnesyl diphosphate synthase	Homo sapiens	156-187
34885721-2	2021	In our previous studies, including an in silico inverse virtual screening, NMR experiments and in vitro enzymatic assays, we demonstrated that i6A targeted farnesyl pyrophosphate synthase (FPPS), a key enzyme involved in the mevalonate (MVA) pathway and prenylation of downstream proteins, which are aberrant in several cancers.	Mevalonic Acid	225-235	farnesyl diphosphate synthase	Homo sapiens	189-193
34391805-5	2021	Additionally, the mevalonate pathway was intensified by introducing a truncated HMG1 gene coding for HMG-CoA reductase and ERG10 encoding acetyl-CoA thiolase.	Mevalonic Acid	18-28	hydroxymethylglutaryl-CoA reductase (NADPH) HMG1	Saccharomyces cerevisiae S288C	80-84
34884489-8	2021	NRF3 also promotes mevalonate biosynthesis by inducing SREBP2 and HMGCR gene expression, and reduces the intracellular levels of neural fatty acids by inducing GGPS1 gene expression.	Mevalonic Acid	19-29	NFE2 like bZIP transcription factor 3	Homo sapiens	0-4
34884489-8	2021	NRF3 also promotes mevalonate biosynthesis by inducing SREBP2 and HMGCR gene expression, and reduces the intracellular levels of neural fatty acids by inducing GGPS1 gene expression.	Mevalonic Acid	19-29	sterol regulatory element binding transcription factor 2	Homo sapiens	55-61
34884489-8	2021	NRF3 also promotes mevalonate biosynthesis by inducing SREBP2 and HMGCR gene expression, and reduces the intracellular levels of neural fatty acids by inducing GGPS1 gene expression.	Mevalonic Acid	19-29	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	66-71
34391805-5	2021	Additionally, the mevalonate pathway was intensified by introducing a truncated HMG1 gene coding for HMG-CoA reductase and ERG10 encoding acetyl-CoA thiolase.	Mevalonic Acid	18-28	acetyl-CoA C-acetyltransferase	Saccharomyces cerevisiae S288C	123-128
34711640-3	2022	ETP-ALLs showed increased biosynthesis of phospholipids and sphingolipids, and were specifically sensitive to inhibition of 3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	206-216	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	124-164
34711640-3	2022	ETP-ALLs showed increased biosynthesis of phospholipids and sphingolipids, and were specifically sensitive to inhibition of 3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	206-216	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	166-171
34706244-4	2021	To identify metabolic vulnerabilities that enhance this phenotype, we utilized a CRISPR/Cas9 loss-of-function screen and identified HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway and target of statin therapies, as a top-scoring sensitizer to ABL inhibition.	Mevalonic Acid	183-193	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	265-268
34687147-3	2022	We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9).	Mevalonic Acid	13-23	galectin 9	Homo sapiens	259-265
34687147-3	2022	We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9).	Mevalonic Acid	13-23	galectin 9	Homo sapiens	267-277
34687147-0	2022	Inhibition of mevalonate metabolism by statins augments the immunoregulatory phenotype of vascular endothelial cells and inhibits the costimulation of CD4+ T cells.	Mevalonic Acid	14-24	CD4 molecule	Homo sapiens	151-154
34687147-3	2022	We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9).	Mevalonic Acid	13-23	TNF superfamily member 4	Homo sapiens	134-140
34687147-3	2022	We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9).	Mevalonic Acid	13-23	TNF superfamily member 4	Homo sapiens	142-148
34687147-3	2022	We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9).	Mevalonic Acid	13-23	TNF superfamily member 18	Homo sapiens	154-161
34687147-3	2022	We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9).	Mevalonic Acid	13-23	TNF receptor superfamily member 18	Homo sapiens	163-167
34687147-3	2022	We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9).	Mevalonic Acid	13-23	galectin 3	Homo sapiens	235-241
34687147-3	2022	We find that mevalonate-dependent gene regulation includes a reduction in the expression of multiple pro-inflammatory genes including TNFSF4 (OX40-L) and TNFSF18 (GITR-L) and a co-incident induction of immunoregulatory genes including LGALS3 (Galectin-3) and LGALS9 (Galectin-9).	Mevalonic Acid	13-23	galectin 3	Homo sapiens	243-253
34687147-4	2022	In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC.	Mevalonic Acid	69-79	protein tyrosine phosphatase receptor type C	Homo sapiens	154-160
34687147-4	2022	In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC.	Mevalonic Acid	69-79	CD4 molecule	Homo sapiens	162-165
34687147-4	2022	In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC.	Mevalonic Acid	69-79	interleukin 2	Homo sapiens	199-203
34687147-4	2022	In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC.	Mevalonic Acid	69-79	interferon gamma	Homo sapiens	205-213
34687147-4	2022	In functional assays, pretreatment of EC with simvastatin to inhibit mevalonate metabolism resulted in a dose-dependent reduction in the costimulation of CD45RO+ CD4+ T cell proliferation as well as IL-2, IFNgamma and IL-6 production vs. vehicle-treated EC.	Mevalonic Acid	69-79	interleukin 6	Homo sapiens	218-222
34671620-5	2021	In cancer cells with GOF Mutp53, statins can induce CHIP-mediated degradation of Mutp53 within the mevalonate pathway by blocking the interaction between mutp53 and DNAJA1.	Mevalonic Acid	99-109	DnaJ heat shock protein family (Hsp40) member A1	Homo sapiens	165-171
34627266-7	2021	Further experiments showed that SIM could inhibit the expression of HMGCR to downregulate the mevalonate (MVA) pathway and glutathione peroxidase 4 (GPX4), thereby inducing cancer cell ferroptosis.	Mevalonic Acid	94-104	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	68-73
34627383-15	2021	Mevalonate administration partially reversed these reductions in the expression of YAP and YAP target genes.	Mevalonic Acid	0-10	Yes1 associated transcriptional regulator	Homo sapiens	83-86
34627383-15	2021	Mevalonate administration partially reversed these reductions in the expression of YAP and YAP target genes.	Mevalonic Acid	0-10	Yes1 associated transcriptional regulator	Homo sapiens	91-94
34627383-17	2021	CONCLUSIONS: These results suggest that the mevalonate pathway activates RhoA, which in turn activates YAP and promotes OS cell resistance to MPPa-PDT therapy.	Mevalonic Acid	44-54	ras homolog family member A	Homo sapiens	73-77
34627383-17	2021	CONCLUSIONS: These results suggest that the mevalonate pathway activates RhoA, which in turn activates YAP and promotes OS cell resistance to MPPa-PDT therapy.	Mevalonic Acid	44-54	Yes1 associated transcriptional regulator	Homo sapiens	103-106
34671620-7	2021	In this review, we summarize recent advances with Wee1 inhibitors, statins, and mevalonate pathway inhibitors in cancers with p53 mutations.	Mevalonic Acid	80-90	tumor protein p53	Homo sapiens	126-129
34103960-6	2021	Differential expression of LDLR due to mevalonate pathway inhibition suggests variations in the regulation of cholesterol uptake between primary and metastatic cancer cells.	Mevalonic Acid	39-49	low density lipoprotein receptor	Homo sapiens	27-31
34680069-5	2021	According to this perspective, the squalene synthase inhibitor Lapaquistat (TAK-475), originally developed as a cholesterol-lowering drug, might find a new indication in MKD, by modulating the mevalonate cholesterol pathway, increasing the availability of anti-inflammatory isoprenoid intermediates.	Mevalonic Acid	193-203	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	35-52
34667945-0	2021	NRF3 upregulates gene expression in SREBP2-dependent mevalonate pathway with cholesterol uptake and lipogenesis inhibition.	Mevalonic Acid	53-63	NFE2 like bZIP transcription factor 3	Homo sapiens	0-4
34667945-0	2021	NRF3 upregulates gene expression in SREBP2-dependent mevalonate pathway with cholesterol uptake and lipogenesis inhibition.	Mevalonic Acid	53-63	sterol regulatory element binding transcription factor 2	Homo sapiens	36-42
34667945-4	2021	Here, we show that NRF3 upregulates gene expression in SREBP2-dependent mevalonate pathway.	Mevalonic Acid	72-82	NFE2 like bZIP transcription factor 3	Homo sapiens	19-23
34667945-4	2021	Here, we show that NRF3 upregulates gene expression in SREBP2-dependent mevalonate pathway.	Mevalonic Acid	72-82	sterol regulatory element binding transcription factor 2	Homo sapiens	55-61
34667945-8	2021	These results reveal the potential roles of NRF3 in the SREBP2-dependent mevalonate pathway for cholesterol uptake through macropinocytosis induction and for lipogenesis inhibition through GGPP production.	Mevalonic Acid	73-83	NFE2 like bZIP transcription factor 3	Homo sapiens	44-48
34667945-8	2021	These results reveal the potential roles of NRF3 in the SREBP2-dependent mevalonate pathway for cholesterol uptake through macropinocytosis induction and for lipogenesis inhibition through GGPP production.	Mevalonic Acid	73-83	sterol regulatory element binding transcription factor 2	Homo sapiens	56-62
34266895-0	2021	Mevalonate blockade in cancer cells triggers CLEC9A+ dendritic cell-mediated antitumor immunity.	Mevalonic Acid	0-10	C-type lectin domain family 9, member a	Mus musculus	45-51
34451823-7	2021	Mevalonic acid, cholesterol and the MEK1/2 inhibitor U0126 reversed this Pitavastatin-mediated ERK1/2 activation and apoptosis of T cells.	Mevalonic Acid	0-14	mitogen-activated protein kinase 3	Homo sapiens	95-101
34572136-2	2021	In multiple mouse cancer models, de novo synthesis of mevalonate and cholesterol inhibitors was found to synergize with anti-PD-1 antibody therapy.	Mevalonic Acid	54-64	programmed cell death 1	Mus musculus	125-129
34111424-7	2021	Simvastatin impaired the phosphorylation of the insulin receptor (IR beta), Akt ser473 and S6rp, and increased phosphorylation of AMPK thr172 in both myotubes and myoblasts, which was prevented by insulin and mevalonate.	Mevalonic Acid	209-219	insulin receptor	Homo sapiens	48-64
34111424-7	2021	Simvastatin impaired the phosphorylation of the insulin receptor (IR beta), Akt ser473 and S6rp, and increased phosphorylation of AMPK thr172 in both myotubes and myoblasts, which was prevented by insulin and mevalonate.	Mevalonic Acid	209-219	AKT serine/threonine kinase 1	Homo sapiens	76-79
34111424-7	2021	Simvastatin impaired the phosphorylation of the insulin receptor (IR beta), Akt ser473 and S6rp, and increased phosphorylation of AMPK thr172 in both myotubes and myoblasts, which was prevented by insulin and mevalonate.	Mevalonic Acid	209-219	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	130-134
34452303-6	2021	Fluvastatin, which inhibits 3-hydroxy 3-methyl glutaryl CoA reductase in the mevalonic acid pathway, disrupts these NS4 interactions.	Mevalonic Acid	77-91	SOS Ras/Rac guanine nucleotide exchange factor 1	Homo sapiens	116-119
34137822-0	2021	Zoledronate extends healthspan and survival via the mevalonate pathway in a FOXO-dependent manner.	Mevalonic Acid	52-62	forkhead box, sub-group O	Drosophila melanogaster	76-80
34137822-3	2021	Zoledronate is a nitrogen containing bisphosphonate, which inhibits the farnesyl pyrophosphate synthase (FPPS) enzyme, central to the mevalonate pathway.	Mevalonic Acid	134-144	Farnesyl pyrophosphate synthase	Drosophila melanogaster	72-103
34137822-3	2021	Zoledronate is a nitrogen containing bisphosphonate, which inhibits the farnesyl pyrophosphate synthase (FPPS) enzyme, central to the mevalonate pathway.	Mevalonic Acid	134-144	Farnesyl pyrophosphate synthase	Drosophila melanogaster	105-109
34137822-8	2021	Moreover, Zoledronate was associated with inhibition of pAKT in the mTOR pathway downstream of the mevalonate pathway and required dFOXO for its action, both molecules associated with increased longevity.	Mevalonic Acid	99-109	Akt1	Drosophila melanogaster	56-60
35391801-9	2022	This minireview covers the role of p53 in the mevalonate pathway and how bioactive phytochemicals target the mevalonate pathway and promote p53-dependent anticancer activities.	Mevalonic Acid	46-56	tumor protein p53	Homo sapiens	35-38
35619540-0	2022	KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma.	Mevalonic Acid	35-45	kinesin family member 11	Homo sapiens	0-5
35619540-0	2022	KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma.	Mevalonic Acid	35-45	sterol regulatory element binding transcription factor 2	Homo sapiens	18-24
35619540-8	2022	Gene set enrichment analysis (GSEA) revealed that KIF11 correlated intensively with the mevalonate (MVA) metabolic pathway.	Mevalonic Acid	88-98	kinesin family member 11	Homo sapiens	50-55
35619540-8	2022	Gene set enrichment analysis (GSEA) revealed that KIF11 correlated intensively with the mevalonate (MVA) metabolic pathway.	Mevalonic Acid	100-103	kinesin family member 11	Homo sapiens	50-55
35625883-6	2022	Indeed, these compounds inhibit the farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, reducing isoprenoid formation of farnesyl pyrophosphate and geranylgeranyl pyrophosphate.	Mevalonic Acid	89-99	farnesyl diphosphate synthase	Homo sapiens	36-67
35538051-2	2022	Statins inhibit HMG-CoA reductase (HMGCR), which converts the metabolite HMG-CoA into mevalonate.	Mevalonic Acid	86-96	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	16-33
35538051-2	2022	Statins inhibit HMG-CoA reductase (HMGCR), which converts the metabolite HMG-CoA into mevalonate.	Mevalonic Acid	86-96	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	35-40
35565457-0	2022	Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins.	Mevalonic Acid	20-30	EWS RNA binding protein 1	Homo sapiens	47-52
35565457-0	2022	Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins.	Mevalonic Acid	20-30	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	53-57
35565457-0	2022	Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins.	Mevalonic Acid	20-30	early growth response 2	Homo sapiens	58-62
35565457-2	2022	We show that EGR2, an Ewing-susceptibility gene and an essential direct target of EWSR1-FLI1, directly regulates the transcription of genes encoding key enzymes of the mevalonate (MVA) pathway.	Mevalonic Acid	168-178	early growth response 2	Homo sapiens	13-17
35565457-2	2022	We show that EGR2, an Ewing-susceptibility gene and an essential direct target of EWSR1-FLI1, directly regulates the transcription of genes encoding key enzymes of the mevalonate (MVA) pathway.	Mevalonic Acid	168-178	EWS RNA binding protein 1	Homo sapiens	82-87
35565457-2	2022	We show that EGR2, an Ewing-susceptibility gene and an essential direct target of EWSR1-FLI1, directly regulates the transcription of genes encoding key enzymes of the mevalonate (MVA) pathway.	Mevalonic Acid	168-178	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	88-92
35600875-3	2022	Nitrogen-containing bisphosphonates suppress osteoclastic resorption by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway, leading to deficiency of the substrate for GTPase prenylation.	Mevalonic Acid	122-132	farnesyl diphosphate synthase	Homo sapiens	83-114
34093831-3	2021	While mechanisms associated with sterol regulatory element-binding protein 2 (SREBP-2)/mevalonate, the low-density lipoprotein receptor (LDL-R) and liver X receptor (LXR) have been linked with tumor growth; metabolites derived from cholesterol-oxidation, such as oxysterols and epoxy-cholesterols, also have been described as tumor processes-inducers.	Mevalonic Acid	87-97	sterol regulatory element binding transcription factor 2	Homo sapiens	33-76
34093831-3	2021	While mechanisms associated with sterol regulatory element-binding protein 2 (SREBP-2)/mevalonate, the low-density lipoprotein receptor (LDL-R) and liver X receptor (LXR) have been linked with tumor growth; metabolites derived from cholesterol-oxidation, such as oxysterols and epoxy-cholesterols, also have been described as tumor processes-inducers.	Mevalonic Acid	87-97	sterol regulatory element binding transcription factor 2	Homo sapiens	78-85
35562083-2	2022	Previously, it has been shown that HMG-CoA-Reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway, can be phosphorylated and inactivated by the metabolic stress sensor AMP-activated protein kinase (AMPK).	Mevalonic Acid	94-104	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	35-52
35562083-2	2022	Previously, it has been shown that HMG-CoA-Reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway, can be phosphorylated and inactivated by the metabolic stress sensor AMP-activated protein kinase (AMPK).	Mevalonic Acid	94-104	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	54-59
35321818-3	2022	Although the primary target of statins is the inhibition of HMG-CoA reductase (HMGR), the rate-limiting enzyme in cholesterol biosynthesis, statins exhibit many pleiotropic effects downstream of the mevalonate pathway.	Mevalonic Acid	199-209	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	60-77
35321818-3	2022	Although the primary target of statins is the inhibition of HMG-CoA reductase (HMGR), the rate-limiting enzyme in cholesterol biosynthesis, statins exhibit many pleiotropic effects downstream of the mevalonate pathway.	Mevalonic Acid	199-209	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	79-83
35189552-4	2022	Furthermore, MSH6 promotes sterol biosynthesis via the mevalonate pathway in a MPTAC- and ATAC-dependent manner.	Mevalonic Acid	55-65	mutS homolog 6	Homo sapiens	13-17
35470784-1	2022	Human 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; EC 1.1.1.34) catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, which has been defined as the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus playing a critical role in cellular cholesterol homeostasis.	Mevalonic Acid	150-164	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	6-53
35470784-1	2022	Human 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; EC 1.1.1.34) catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, which has been defined as the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus playing a critical role in cellular cholesterol homeostasis.	Mevalonic Acid	150-164	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	55-60
35395704-5	2022	RSV intervened in metabolic mevalonate pathway to disturb the redox homeostasis regulated by CoQ/FSP1 axis, thereby overcoming ferroptosis resistance.	Mevalonic Acid	28-38	atlastin GTPase 1	Homo sapiens	97-101
35391801-9	2022	This minireview covers the role of p53 in the mevalonate pathway and how bioactive phytochemicals target the mevalonate pathway and promote p53-dependent anticancer activities.	Mevalonic Acid	109-119	tumor protein p53	Homo sapiens	140-143
35359411-9	2022	Interestingly, the expression of some genes of the mevalonate and cholesterol synthesis such as HMGS1, HMGCR, IDI1, SQLE, MSMO1, SREBF1, and SOAT1 was up-regulated by CDPs exposure.	Mevalonic Acid	51-61	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	103-108
35359411-9	2022	Interestingly, the expression of some genes of the mevalonate and cholesterol synthesis such as HMGS1, HMGCR, IDI1, SQLE, MSMO1, SREBF1, and SOAT1 was up-regulated by CDPs exposure.	Mevalonic Acid	51-61	isopentenyl-diphosphate delta isomerase 1	Homo sapiens	110-114
35359411-9	2022	Interestingly, the expression of some genes of the mevalonate and cholesterol synthesis such as HMGS1, HMGCR, IDI1, SQLE, MSMO1, SREBF1, and SOAT1 was up-regulated by CDPs exposure.	Mevalonic Acid	51-61	squalene epoxidase	Homo sapiens	116-120
35359411-9	2022	Interestingly, the expression of some genes of the mevalonate and cholesterol synthesis such as HMGS1, HMGCR, IDI1, SQLE, MSMO1, SREBF1, and SOAT1 was up-regulated by CDPs exposure.	Mevalonic Acid	51-61	methylsterol monooxygenase 1	Homo sapiens	122-127
35359411-9	2022	Interestingly, the expression of some genes of the mevalonate and cholesterol synthesis such as HMGS1, HMGCR, IDI1, SQLE, MSMO1, SREBF1, and SOAT1 was up-regulated by CDPs exposure.	Mevalonic Acid	51-61	sterol regulatory element binding transcription factor 1	Homo sapiens	129-135
35359411-9	2022	Interestingly, the expression of some genes of the mevalonate and cholesterol synthesis such as HMGS1, HMGCR, IDI1, SQLE, MSMO1, SREBF1, and SOAT1 was up-regulated by CDPs exposure.	Mevalonic Acid	51-61	sterol O-acyltransferase 1	Homo sapiens	141-146
34995578-0	2022	Mevalonate pathway orchestrates insulin signaling via RAB14 geranylgeranylation-mediated phosphorylation of AKT to regulate hepatic glucose metabolism.	Mevalonic Acid	0-10	insulin	Homo sapiens	32-39
34995578-0	2022	Mevalonate pathway orchestrates insulin signaling via RAB14 geranylgeranylation-mediated phosphorylation of AKT to regulate hepatic glucose metabolism.	Mevalonic Acid	0-10	RAB14, member RAS oncogene family	Homo sapiens	54-59
34995578-0	2022	Mevalonate pathway orchestrates insulin signaling via RAB14 geranylgeranylation-mediated phosphorylation of AKT to regulate hepatic glucose metabolism.	Mevalonic Acid	0-10	AKT serine/threonine kinase 1	Homo sapiens	108-111
34995578-8	2022	In conclusion, our data indicate that statins-targeted mevalonate pathway regulates hepatic insulin signaling and glucose metabolism via geranylgeranylation of RAB14.	Mevalonic Acid	55-65	RAB14, member RAS oncogene family	Homo sapiens	160-165
35193687-10	2022	RPPA analysis and carbon-13 tracing analysis in these melanoma cells showed that IACS treatment decreased metabolic fuel utilization for fatty acid metabolism, but increased substrate availability for activation of the mevalonate pathway by HMGCR, creating a dependence on this pathway.	Mevalonic Acid	219-229	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	241-246
35168393-5	2022	Moreover, lovastatin suppressed important genes and proteins related to the canonical Wnt/beta-catenin and alternative Wnt-YAP/TAZ signaling pathways in RKO and SW480 cells, and these effects were rescued by mevalonic acid (MVA), as confirmed through a series of Western blotting, RT-PCR, and reporter assays.	Mevalonic Acid	208-222	catenin beta 1	Homo sapiens	90-102
35064110-6	2022	The data demonstrate that the plasma membrane associated P2K1 directly impacts plant cellular metabolism by phosphorylation of MVK, a key enzyme in the mevalonate pathway.	Mevalonic Acid	152-162	mevalonate kinase	Arabidopsis thaliana	127-130
35163971-1	2022	The non-mevalonate or also called MEP pathway is an essential route for the biosynthesis of isoprenoid precursors in most bacteria and in microorganisms belonging to the Apicomplexa phylum, such as the parasite responsible for malaria.	Mevalonic Acid	8-18	neurolysin	Homo sapiens	34-37
35168393-5	2022	Moreover, lovastatin suppressed important genes and proteins related to the canonical Wnt/beta-catenin and alternative Wnt-YAP/TAZ signaling pathways in RKO and SW480 cells, and these effects were rescued by mevalonic acid (MVA), as confirmed through a series of Western blotting, RT-PCR, and reporter assays.	Mevalonic Acid	208-222	Yes1 associated transcriptional regulator	Homo sapiens	123-126
35168393-5	2022	Moreover, lovastatin suppressed important genes and proteins related to the canonical Wnt/beta-catenin and alternative Wnt-YAP/TAZ signaling pathways in RKO and SW480 cells, and these effects were rescued by mevalonic acid (MVA), as confirmed through a series of Western blotting, RT-PCR, and reporter assays.	Mevalonic Acid	208-222	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	127-130
2795368-10	1989	The finding of HMG-CoA reductase provides an enzymatic mechanism for the intermediate conversion of HMG-CoA to mevalonic acid that would be needed for acetate-dependent isoprenoid lipid synthesis by adult H. diminuta.	Mevalonic Acid	111-125	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	15-32
2568358-2	1989	Addition of either delipidized serum and mevinolin or low density lipoprotein, 25-hydroxycholesterol, or mevalonic acid to HepG2 cells resulted in rapid changes both in the levels of the mRNAs and in the rates of synthesis of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase, HMG-CoA reductase, and farnesyl pyrophosphate synthetase (prenyltranferase).	Mevalonic Acid	105-119	3-hydroxy-3-methylglutaryl-CoA synthase 2	Homo sapiens	226-282
2568358-2	1989	Addition of either delipidized serum and mevinolin or low density lipoprotein, 25-hydroxycholesterol, or mevalonic acid to HepG2 cells resulted in rapid changes both in the levels of the mRNAs and in the rates of synthesis of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase, HMG-CoA reductase, and farnesyl pyrophosphate synthetase (prenyltranferase).	Mevalonic Acid	105-119	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	284-301
2569235-4	1989	Studies of yeast mutants blocked in sterol biosynthesis demonstrated that the membrane association and biological activation of the yeast Ras2 protein require mevalonate, a precursor of sterols and other isoprenes such as farnesyl pyrophosphate.	Mevalonic Acid	159-169	Ras family GTPase RAS2	Saccharomyces cerevisiae S288C	138-142
2567731-2	1989	In this paper, we assess the relative degree of regulation of the rate-limiting enzyme of isoprenoid biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, by sterol and nonsterol products of mevalonate by utilizing cultured Chinese hamster ovary cells blocked in sterol synthesis.	Mevalonic Acid	210-220	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	115-172
2649893-1	1989	We have isolated the Arabidopsis thaliana gene (HMG1) encoding 3-hydroxy-3-methylglutaryl-CoA reductase [HMG-CoA reductase; (S)-mevalonate:NAD+ oxido-reductase (CoA-acylating), EC 1.1.1.88], the catalyst of the first committed step in isoprenoid biosynthesis.	Mevalonic Acid	124-138	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	48-52
2725293-2	1989	The mean rates of urinary mevalonate excretion of 28 FH patients were initially higher (2.95 +/- 0.29 (+/- SEM) mumols/d) than in 17 control subjects (1.82 +/- 0.12 mumols/d).	Mevalonic Acid	26-36	low density lipoprotein receptor	Homo sapiens	53-55
2725293-6	1989	Similar decreases in urinary mevalonate excretions were observed when patients with FH were treated directly with 40 mg (20 mg twice daily) or 80 mg (40 mg twice daily) mg of lovastatin daily.	Mevalonic Acid	29-39	low density lipoprotein receptor	Homo sapiens	84-86
2649893-1	1989	We have isolated the Arabidopsis thaliana gene (HMG1) encoding 3-hydroxy-3-methylglutaryl-CoA reductase [HMG-CoA reductase; (S)-mevalonate:NAD+ oxido-reductase (CoA-acylating), EC 1.1.1.88], the catalyst of the first committed step in isoprenoid biosynthesis.	Mevalonic Acid	124-138	oxidoreductase	Arabidopsis thaliana	144-159
2918466-6	1989	All histopathological and serum biochemical changes induced by lovastatin were completely prevented by coadministration of mevalonate, the product of the inhibited HMG-CoA reductase enzyme.	Mevalonic Acid	123-133	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	164-181
2799859-1	1989	Labeled 4,4-dimethyl-5 alpha -cholesta-8,24-dien-3 beta-ol (4,4-dimethylzymosterol) was prepared by incubating labeled mevalonate with rat liver extracts in the presence of arsenite and lanosterol.	Mevalonic Acid	119-129	integrin subunit beta 1	Rattus norvegicus	51-58
2904178-1	1988	Two enzymes of mammalian cellular mevalonate biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase and HMG-CoA reductase, have been shown to be regulated by exogenous sterols.	Mevalonic Acid	34-44	3-hydroxy-3-methylglutaryl-CoA synthase 2	Homo sapiens	59-115
2535541-2	1989	The HMGR reaction makes mevalonate, a necessary component in the synthesis of all isoprene containing compounds, such as sterols and carotenoids.	Mevalonic Acid	24-34	3-hydroxy-3-methylglutaryl-coenzyme A reductase 2	Solanum lycopersicum	4-8
16666457-8	1988	A reexamination of the data pertaining to the transient induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity (EC 1.1.1.34) in elicitor-treated cells suggested that, while the reductase activity was necessary for sesquiterpenoid biosynthesis, it functioned more to maintain a sufficient level of intermediates between mevalonate and farnesyl diphosphate rather than as a rate limiting step controlling the synthesis rate of any one class of isoprenoids.	Mevalonic Acid	334-344	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Nicotiana tabacum	69-116
2904178-1	1988	Two enzymes of mammalian cellular mevalonate biosynthesis, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase and HMG-CoA reductase, have been shown to be regulated by exogenous sterols.	Mevalonic Acid	34-44	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	120-137
2848511-0	1988	Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites.	Mevalonic Acid	127-137	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	14-54
3113763-1	1987	HMG-CoA reductase catalyzes the conversion of hydroxymethylglutarate to mevalonate, an important early rate-limiting step in the cholesterol biosynthesis pathway.	Mevalonic Acid	72-82	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
3361487-3	1988	Serum progesterone concentrations were measured at 4-day intervals and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity was estimated by the conversion of HMG to mevalonate in microsomes from corpora lutea removed on Days 4, 8, 12, 16 and 20 of pseudopregnancy (4 rabbits/day).	Mevalonic Acid	180-190	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	71-128
2892200-0	1987	Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: search for the enzyme"s repressor derived from mevalonate.	Mevalonic Acid	110-120	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	14-61
2892200-10	1987	It is argued that the suppressor of HMG-CoA reductase, derived from mevalonate, is a sterol and not a non-steroidal product of mevalonate metabolism.	Mevalonic Acid	68-78	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	36-53
2892200-10	1987	It is argued that the suppressor of HMG-CoA reductase, derived from mevalonate, is a sterol and not a non-steroidal product of mevalonate metabolism.	Mevalonic Acid	127-137	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	36-53
3267015-3	1988	Each type of growth inhibition was correlated to a depression of the activity of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase, an enzyme that regulates the biosynthesis of cholesterol and isoprenoid derivatives (e.g. dolichol) by catalysing the reduction of HMG CoA (which is derived from acetyl-CoA) into mevalonate.	Mevalonic Acid	320-330	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	81-139
3267015-6	1988	Addition of epidermal growth factor (EGF) to the cell cultures, whose proliferation was inhibited due to serum depletion, restored DNA synthesis completely, and these effects were related to a normalization of the activity of HMG CoA reductase and of the incorporation of mevalonate into dolichol.	Mevalonic Acid	272-282	epidermal growth factor	Mus musculus	12-35
3267015-6	1988	Addition of epidermal growth factor (EGF) to the cell cultures, whose proliferation was inhibited due to serum depletion, restored DNA synthesis completely, and these effects were related to a normalization of the activity of HMG CoA reductase and of the incorporation of mevalonate into dolichol.	Mevalonic Acid	272-282	epidermal growth factor	Mus musculus	37-40
3150971-4	1988	Like others (Volpe & Goldberg, 1983), we found that tunicamycin inhibited the activity of 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA), which constitutes the ratelimiting step in the biosynthesis of cholesterol and isoprenoid derivatives, by catalysing the reduction of HMG-CoA to mevalonate, and it has been suggested that it plays a role in the control of cell proliferation and in tumour transformation.	Mevalonic Acid	298-308	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	94-141
3150971-4	1988	Like others (Volpe & Goldberg, 1983), we found that tunicamycin inhibited the activity of 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA), which constitutes the ratelimiting step in the biosynthesis of cholesterol and isoprenoid derivatives, by catalysing the reduction of HMG-CoA to mevalonate, and it has been suggested that it plays a role in the control of cell proliferation and in tumour transformation.	Mevalonic Acid	298-308	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	143-150
3150971-6	1988	By adding exogenous mevalonate, the rate-limiting step at which HMG-CoA reductase converts HMG-CoA to mevalonate can be bypassed.	Mevalonic Acid	20-30	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	64-71
3150971-6	1988	By adding exogenous mevalonate, the rate-limiting step at which HMG-CoA reductase converts HMG-CoA to mevalonate can be bypassed.	Mevalonic Acid	20-30	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	91-98
3150971-6	1988	By adding exogenous mevalonate, the rate-limiting step at which HMG-CoA reductase converts HMG-CoA to mevalonate can be bypassed.	Mevalonic Acid	102-112	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	64-71
3150971-6	1988	By adding exogenous mevalonate, the rate-limiting step at which HMG-CoA reductase converts HMG-CoA to mevalonate can be bypassed.	Mevalonic Acid	102-112	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	91-98
3278736-10	1988	Both mevalonate and cholesterol auxotrophs have been isolated with the BUdR technique and have proven useful for elucidation of the early steps in cholesterol biosynthesis, particularly for the ratelimiting enzyme HMG-CoA reductase.	Mevalonic Acid	5-15	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	214-231
2836685-1	1987	In vivo regulation of hepatic HMG-CoA reductase (HMGR) (mevalonate:NADP+ oxidoreductase [acylating CoA]; EC 1.1.1.34] by phosphorylation/dephosphorylation has not been demonstrated.	Mevalonic Acid	56-66	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	30-47
2836685-1	1987	In vivo regulation of hepatic HMG-CoA reductase (HMGR) (mevalonate:NADP+ oxidoreductase [acylating CoA]; EC 1.1.1.34] by phosphorylation/dephosphorylation has not been demonstrated.	Mevalonic Acid	56-66	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	49-53
3670308-2	1987	The level of CR39 mRNA was increased seven- to ninefold over normal levels by dietary cholestyramine and mevinolin and decreased about fourfold compared with normal levels by cholesterol feeding or administration of mevalonate.	Mevalonic Acid	216-226	farnesyl diphosphate synthase	Rattus norvegicus	13-17
3033149-6	1987	Simultaneous addition of mevalonate (20 mM) prevented the inhibition of the induction of CNP by mevinolin.	Mevalonic Acid	25-35	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	89-92
3827206-1	1987	Cholesterol 7 alpha-hydroxylase activity was determined in parallel with the rate of cholesterogenesis from acetate and mevalonate in the liver of hamsters fed diets enriched with pectins (5%) and/or cholesterol (0.1%).	Mevalonic Acid	120-130	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	0-31
3569277-8	1987	These observations demonstrate two defects in CR200 cells: decreased levels of LDL receptor and a defective regulation of HMG-CoA reductase by one or more products derived from mevalonate.	Mevalonic Acid	177-187	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	122-139
4055772-4	1985	Although mevalonate caused a rapid, reversible suppression of reductase activity, fluoro- and homomevalonate increased activity; fluoromevalonate was more effective than homomevalonate.	Mevalonic Acid	9-19	Pyrroline 5-carboyxlate reductase	Drosophila melanogaster	62-71
3131638-4	1987	The addition of mevalonate, the product of HMG CoA reductase, prevented the inhibition of DNA synthesis by compactin, suggesting that the supply of a sufficient amount of sterol is an essential prerequisite for IL-2 action.	Mevalonic Acid	16-26	interleukin 2	Mus musculus	211-215
3084536-6	1986	Finally, a positive correlation was found between mevalonate oxidation and serum PTH levels.	Mevalonic Acid	50-60	parathyroid hormone	Homo sapiens	81-84
3707903-7	1986	The activation of ACAT by mevalonate is prevented by adding a specific squalene oxide cyclase inhibitor to cells, indicating the requirement for endogenous sterol synthesis to mediate the mevalonate effect.	Mevalonic Acid	26-36	sterol O-acyltransferase 1	Cricetulus griseus	18-22
3707903-7	1986	The activation of ACAT by mevalonate is prevented by adding a specific squalene oxide cyclase inhibitor to cells, indicating the requirement for endogenous sterol synthesis to mediate the mevalonate effect.	Mevalonic Acid	188-198	sterol O-acyltransferase 1	Cricetulus griseus	18-22
3742535-0	1986	Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevalonate and cholesterol in isolated rat hepatocytes during perinatal development.	Mevalonic Acid	65-75	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	14-61
3733706-1	1986	Possible regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by shunted mevalonate carbon.	Mevalonic Acid	91-101	HMG Coenzyme A reductase	Drosophila melanogaster	23-70
4065145-0	1985	The effect of mevalonate on 3-hydroxy-3-methylglutaryl-CoA reductase activity and the absolute rate of cholesterol biosynthesis in human monocyte-derived macrophages.	Mevalonic Acid	14-24	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	28-68
4055772-5	1985	Mevalonate, added simultaneously with fluoromevalonate, blocked the analogue"s effect on Kc cell reductase activity.	Mevalonic Acid	0-10	Pyrroline 5-carboyxlate reductase	Drosophila melanogaster	97-106
4055772-11	1985	We have concluded that mevalonate, fluoromevalonate, homomevalonate, and compactin (mevinolin) modulated HMG-CoA reductase activity because they altered isoprenoid carbon flow to a post-isopentenyl 1-pyrophosphate regulatory, signal molecule.	Mevalonic Acid	23-33	Pyrroline 5-carboyxlate reductase	Drosophila melanogaster	113-122
3850904-1	1985	3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase catalyzes the formation of mevalonate, an essential precursor for isoprenoid compounds in mammalian cells.	Mevalonic Acid	85-95	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
4019518-2	1985	A somatic cell mutant (Mev-1) auxotrophic for mevalonate by virtue of a complete lack of detectable 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase activity has been shown to demonstrate a requirement for a non-sterol mevalonate-derived product for regulation of synthesis of HMG-CoA reductase.	Mevalonic Acid	46-56	3-hydroxy-3-methylglutaryl-CoA synthase 2	Homo sapiens	100-156
2411835-0	1985	Role of mevalonate in regulation of cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured cells and their cytoplasts.	Mevalonic Acid	8-18	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	62-109
4019479-9	1985	Addition of mevalonate to cells growing on glucose was followed by a rapid and biphasic induction of HMG-CoA reductase activity.	Mevalonic Acid	12-22	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	101-118
6565710-1	1984	Measurement of mevalonic acid (MVA) concentrations in plasma or 24-h urine samples is shown to be useful in studies of the regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and cholesterol synthesis.	Mevalonic Acid	15-29	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	137-194
3838796-1	1985	A recombinant plasmid containing a full-length cDNA for hamster 3-hydroxy-3-methylglutaryl coenzyme A reductase was introduced by calcium phosphate-mediated transfection into UT-2 cells, a mutant line of Chinese hamster ovary cells that lack 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and thus require low density lipoprotein-cholesterol and mevalonate for growth.	Mevalonic Acid	356-366	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	64-111
6397554-2	1984	Mevalonic acid, the product of HMG-CoA reductase, the rate-limiting enzyme of cholesterogenesis, is now known to serve at least two functions in the cell cycle.	Mevalonic Acid	0-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	31-48
6594693-9	1984	These combined effects favor an increase in the steady-state level of the phosphorylated forms of both HMG-CoA reductase and reductase kinase, resulting in a net reduction in the enzymic activity of HMG-CoA reductase and mevalonate formation.	Mevalonic Acid	221-231	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	103-120
7132293-1	1982	With an aim to study the cholesterol biosynthetic capacity of the leprosy patients, the enzyme Beta hydroxy methyl glutaryl CoA reductase (HMG CoA) has been indirectly determined in the sera of leprosy patients and their family members by assaying the circulating levels of HMG CoA and mevalonate and finding out the ratio between two.	Mevalonic Acid	286-296	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	100-137
6147036-2	1984	It is emphasized that the mevalonate synthesis with participation of acetyl-CoA-carboxylase and hydroxymethylglutaryl-CoA-reductase not bound with the endoplasmic reticulum membranes results in formation of the pool of mevalonic acid and other precursors necessary mainly for the organism supply with bile acids under conditions of cholesterol synthesis inhibition.	Mevalonic Acid	26-36	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	96-131
6147036-2	1984	It is emphasized that the mevalonate synthesis with participation of acetyl-CoA-carboxylase and hydroxymethylglutaryl-CoA-reductase not bound with the endoplasmic reticulum membranes results in formation of the pool of mevalonic acid and other precursors necessary mainly for the organism supply with bile acids under conditions of cholesterol synthesis inhibition.	Mevalonic Acid	219-233	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	96-131
6643457-1	1983	3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) converts HMG-CoA to mevalonate, a key intermediate in the formation of cholesterol and several nonsterol isoprenoid compounds.	Mevalonic Acid	88-98	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	0-47
6643457-1	1983	3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) converts HMG-CoA to mevalonate, a key intermediate in the formation of cholesterol and several nonsterol isoprenoid compounds.	Mevalonic Acid	88-98	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	49-66
6139093-3	1983	Permanently repressed levels of both HMG CoA synthase and HMG CoA reductase activities are observed in another CHO mutant, phenotypically a mevalonate auxotroph.	Mevalonic Acid	140-150	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	58-75
6863299-6	1983	However, mevalonate caused a rapid strong suppression of Kc HMG-CoA reductase activity; 18 microM R-mevalonate produced 50% suppression of the enzyme within 24 h. Compactin, a competitive inhibitor, decreased HMG-CoA reductase activity in Drosophila embryo cell-free extracts with an apparent Ki of 1.0 nM.	Mevalonic Acid	9-19	HMG Coenzyme A reductase	Drosophila melanogaster	60-77
6863299-6	1983	However, mevalonate caused a rapid strong suppression of Kc HMG-CoA reductase activity; 18 microM R-mevalonate produced 50% suppression of the enzyme within 24 h. Compactin, a competitive inhibitor, decreased HMG-CoA reductase activity in Drosophila embryo cell-free extracts with an apparent Ki of 1.0 nM.	Mevalonic Acid	98-110	HMG Coenzyme A reductase	Drosophila melanogaster	209-226
6863299-10	1983	The signal for modulation of HMG-CoA reductase activity may be mevalonate and/or its magnitude conversion to a nonsterol isopentenoid precursor and/or end product.	Mevalonic Acid	63-73	HMG Coenzyme A reductase	Drosophila melanogaster	29-46
6831033-1	1983	ML-236B is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the key regulatory enzyme in the sequence that catalyzes the conversion of acetate to mevalonic acid in cholesterol biosynthesis.	Mevalonic Acid	183-197	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	38-95
6572913-1	1983	We describe a cell line, designated C100, that displays a 100-fold increase in the major regulatory enzyme of the cholesterol biosynthetic pathway, 3-hydroxy-3-methylglutaryl-coenzyme A reductase [HMG-CoA; mevalonate:NADP(+) oxido-reductase (CoA-acylating), EC 1.1.1.34].	Mevalonic Acid	206-216	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	148-195
6286363-13	1982	Regulation of HMG-CoA reductase by mevalonolactone is of major importance in cellular metabolism because mevalonate serves as precursor for four separate metabolic pathways, including the formation of cholesterol, ubiquinone, dolichols, and isopentenyl tRNA.	Mevalonic Acid	105-115	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	14-31
7085625-0	1982	Analysis of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in a somatic cell mutant auxotrophic for mevalonate.	Mevalonic Acid	115-125	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	26-73
7132293-1	1982	With an aim to study the cholesterol biosynthetic capacity of the leprosy patients, the enzyme Beta hydroxy methyl glutaryl CoA reductase (HMG CoA) has been indirectly determined in the sera of leprosy patients and their family members by assaying the circulating levels of HMG CoA and mevalonate and finding out the ratio between two.	Mevalonic Acid	286-296	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	139-146
6089762-5	1984	Addition of either mevalonate or LDL prevented the compactin-induced rise in activities of both HMG-CoA reductase and LDL receptor in a comparable manner.	Mevalonic Acid	19-29	low density lipoprotein receptor	Homo sapiens	118-130
6089762-6	1984	It is concluded that in this human hepatoma cell line, as in non-transformed cells, both endogenous mevalonate or mevalonate-derived products and exogenous cholesterol are able to modulate the HMG-CoA reductase activity as well as the LDL-receptor activity.	Mevalonic Acid	100-110	low density lipoprotein receptor	Homo sapiens	235-247
6089762-6	1984	It is concluded that in this human hepatoma cell line, as in non-transformed cells, both endogenous mevalonate or mevalonate-derived products and exogenous cholesterol are able to modulate the HMG-CoA reductase activity as well as the LDL-receptor activity.	Mevalonic Acid	114-124	low density lipoprotein receptor	Homo sapiens	235-247
6671216-3	1983	The LDL-induced inhibition was LDL-dose dependent and was reversed by the addition of mevalonate, a product of the reaction of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (mevalonate: NADP+ oxidoreductase (CoA-acylating), EC 1.1.1.34).	Mevalonic Acid	86-96	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	127-184
6603842-3	1983	The inclusion of 30 mM EDTA and 10 mM mevalonic acid in assays of 3-hydroxy-3-methylglutaryl CoA reductase inactivation in vitro eliminated artifacts generated by the presence of mevalonate kinase.	Mevalonic Acid	38-52	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	66-106
6886611-0	1983	Mevalonate reverses the developmental arrest of preimplantation mouse embryos by Compactin, an inhibitor of HMG Co A reductase.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	108-126
6886611-1	1983	Hydroxymethyl glutaryl Co A reductase (HMG Co A reductase) is the key regulatory enzyme in the conversion of acetate to mevalonate.	Mevalonic Acid	120-130	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	39-57
6830849-4	1983	The reversal effect by mevalonate was most evident with compactin, a well known competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.	Mevalonic Acid	23-33	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	105-152
6617952-1	1983	The optimal conditions for identification of mevalonic acid as the product of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase are described, as well as the effect of different buffer constituents on the enzyme activity.	Mevalonic Acid	45-59	3-hydroxy-3-methylglutaryl-CoA reductase	Gallus gallus	78-128
6113851-0	1981	[Activities of 3-hydroxy-3-methylglutaryl-CoA reductase and acetyl-CoA carboxylase and rate of biosynthesis of mevalonic acid, squalene, sterols and fatty acids from [1-14C]acetyl-CoA and [2-14C]malonyl-CoA in rat liver: changes induced by daily rhythm].	Mevalonic Acid	111-125	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	15-55
6948302-0	1982	In vivo regulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase: immunotitration of the enzyme after short-term mevalonate or cholesterol feeding.	Mevalonic Acid	128-138	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	32-79
7287864-2	1981	The mean specific activity was 0.58 +/- 0.18 nmol mevalonate formed min-1 mg-1 protein.	Mevalonic Acid	50-60	CD59 molecule (CD59 blood group)	Homo sapiens	68-78
6113851-1	1981	The activity of 3-hydrosy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) and the rate of mevalonic acid (MVA) synthesis from [I-14C]acetyl-CoA and [2-14C]malonyl-CoA in the soluble (X140000 g) and microsomal fractions of rat liver and in a reconstituted system containing the soluble and microsomal fractions were studied.	Mevalonic Acid	93-107	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	58-75
7438103-0	1980	Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid.	Mevalonic Acid	126-140	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	14-61
7193053-1	1980	Intact, but sham-operated female rats had 2- to 3-fold higher levels of hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity than their male counterparts (15--21.5 vs. 6.7--8.7 nmol mevalonate/mg protein per h).	Mevalonic Acid	187-197	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	80-120
7438103-2	1980	injection of mevalonate on the activity of microsomal 3-hydroxy-3-methylglutaryl Coenzyme A reductase was studied in livers from non-tumor-bearing rats and in host liver and hepatomas from rats bearing transplantable Morris hepatoma 7800.	Mevalonic Acid	13-23	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	54-101
7438103-3	1980	We confirmed that a single bolus injection of 100 mg of mevalonate in non-tumor-bearing male rats caused a 90% inhibition of hepatic 3-hydroxy-3-methylglutaryl Coenzyme A reductase activity within 2 hr.	Mevalonic Acid	56-66	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	133-180
687657-3	1978	The administration of mevalonic acid to rats by stomach tube resulted in an increase in the activity of cholesterol 7alpha-hydroxylase and of acyl-coenzyme A:cholesterol acyltransferase and in the concentration of cholesterol esters in the liver microsomal fraction, while there was a considerable decrease in the activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.	Mevalonic Acid	22-36	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	104-134
6903572-8	1980	Despite the abundant amount of cholesterol that was already present in the livers of the mevinolin-treated, cholesterol-fed animals, their elevated HMG CoA reductase could be rapidly suppressed by the subcutaneous injection of small amounts of mevalonate, the product of HMG CoA reductase.	Mevalonic Acid	244-254	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	148-165
6903572-8	1980	Despite the abundant amount of cholesterol that was already present in the livers of the mevinolin-treated, cholesterol-fed animals, their elevated HMG CoA reductase could be rapidly suppressed by the subcutaneous injection of small amounts of mevalonate, the product of HMG CoA reductase.	Mevalonic Acid	244-254	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	271-288
6903572-9	1980	These data are compatible with the existence in mouse liver of a multivalent feedback regulatory mechanism for HMG CoA reductase in which suppression of the enzyme requires both a sterol and a nonsterol substance derived from mevalonate.	Mevalonic Acid	226-236	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	111-128
6903572-11	1980	The ability to suppress the elevated HMG CoA reductase with mevalonate may prove useful in potentiating the effectiveness of mevinolin as a hypocholesterolemic agent.	Mevalonic Acid	60-70	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	37-54
6995544-1	1980	The availability of compactin (ML-236B), a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl Coenzyme A reductase, has permitted the demonstration of a hitherto unsuspected aspect of mevalonate metabolism and isoprenoid synthesis in cultured mammalian cells.	Mevalonic Acid	192-202	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	75-122
6995544-2	1980	3-Hydroxy-3-methylglutaryl Coenzyme A reductase, the enzyme that synthesizes mevalonate, appears to be regulated through a multivalent feedback mechanism.	Mevalonic Acid	77-87	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-47
6995544-5	1980	The multivalent feedback regulation of 3-hydroxy-3-methylglutaryl Coenzyme A reductase, together with secondary regulatory changes in other enzymes of the sterol synthetic pathway, coordinates the branched pathway of mevalonate metabolism so as to assure a constant supply of cholesterol and nonsterol products.	Mevalonic Acid	217-227	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	39-86
687657-1	1978	The administration of mevalonic acid to rats by intravenous injection resulted in a dose- and time-dependent increase in the activity of cholesterol 7alpha-hydroxylase in the liver microsomal fraction, a decrease in the microsomal activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and no significant change in the activity of acyl-coenzyme A:cholesterol acyltransferase or in the concentration of free and of esterified cholesterol in the liver microsomal fraction.	Mevalonic Acid	22-36	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	137-167
687657-1	1978	The administration of mevalonic acid to rats by intravenous injection resulted in a dose- and time-dependent increase in the activity of cholesterol 7alpha-hydroxylase in the liver microsomal fraction, a decrease in the microsomal activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and no significant change in the activity of acyl-coenzyme A:cholesterol acyltransferase or in the concentration of free and of esterified cholesterol in the liver microsomal fraction.	Mevalonic Acid	22-36	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	243-290
687657-2	1978	However, the increased hepatic cholesterogenesis that follows the injection of mevalonic acid resulted in an increase of the size of the intracellular pool of cholesterol that is in the environment of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and acts as substrate for cholesterol 7alpha-hydroxylase.	Mevalonic Acid	79-93	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	201-248
7190032-4	1980	According to the function of the brain and the kidney in the sterol and nonsterol pathways in the metabolism of mevalonic acid during neonatal development of chick, an important role for the mevalonate kinase during myelination can be suggested.	Mevalonic Acid	112-126	mevalonate kinase	Gallus gallus	191-208
291922-5	1979	Finally, the compactin-induced inhibition of DNA synthesis could be completely reversed within minutes by the addition of mevalonate, the product of the HMG CoA reductase reaction.	Mevalonic Acid	122-132	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	153-170
291922-7	1979	These data demonstrate that HMG CoA reductase activity, and therefore the production of mevalonate, plays an essential role in the synthesis of DNA specifically during the S phase of the cell cycle.	Mevalonic Acid	88-98	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	28-45
291971-1	1979	The activity of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase [HMG-CoA reductase; mevalonate:NADP(+) oxidoreductase (CoA-acylating), EC 1.1.1.34] can be modulated in vitro by a phosphorylation-dephosphorylation reaction sequence.	Mevalonic Acid	94-104	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	26-73
226078-12	1979	Of the three mevalonate-metabolizing enzymes, mevalonate pyrophosphate decarboxylase has the lowest specific activity and is probably the rate-determining step in this part of the pathway.	Mevalonic Acid	13-23	mevalonate diphosphate decarboxylase	Rattus norvegicus	46-84
278983-1	1978	The activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) [mevalonate:NADP+ oxidoreductase (CoA-acylating); EC 1.1.1.34] was inhibited by ATP+Mg2+.	Mevalonic Acid	96-106	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	27-74
278983-1	1978	The activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) [mevalonate:NADP+ oxidoreductase (CoA-acylating); EC 1.1.1.34] was inhibited by ATP+Mg2+.	Mevalonic Acid	96-106	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	76-93
687657-2	1978	However, the increased hepatic cholesterogenesis that follows the injection of mevalonic acid resulted in an increase of the size of the intracellular pool of cholesterol that is in the environment of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and acts as substrate for cholesterol 7alpha-hydroxylase.	Mevalonic Acid	79-93	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	275-305
687657-3	1978	The administration of mevalonic acid to rats by stomach tube resulted in an increase in the activity of cholesterol 7alpha-hydroxylase and of acyl-coenzyme A:cholesterol acyltransferase and in the concentration of cholesterol esters in the liver microsomal fraction, while there was a considerable decrease in the activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.	Mevalonic Acid	22-36	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	326-373
900481-0	1977	A simplified procedure for the concentration, desalting, and thin-layer chromatography of mevalonic acid from reaction mixtures used to assay 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity.	Mevalonic Acid	90-104	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	142-189
1066664-2	1976	In the current studies, reduction of the plasma cholesterol level by 90% in rats through the administration of aminopyrazolopyrimidine was found to be associated with a 5- to 30-fold increase in the activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase [mevalonate:NADP+ oxidoreductase (CoA-acylating), EC1.1.1.34] in kidney and lung.	Mevalonic Acid	260-270	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	211-258
187533-1	1976	HMG CoA reductase, which catalyzes the reaction, HMG CoA + 2 NADAPH2 leads to mevalonate + CoA-SH + 2 NADP, is considered to be the rate-limiting enzyme on cholesterol biosynthetic pathway.	Mevalonic Acid	78-88	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	0-17
175882-7	1976	Specific activity of the mevalonate synthesizing enzyme, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) was greatest at 11 DIV, threefold greater than at 6 and 30 DIV.	Mevalonic Acid	25-35	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	57-123
1112830-1	1975	C-5 of mevalonate appears as C0-2 in the breath of rats and men almost immediately after administration either by injection or by mouth.	Mevalonic Acid	7-17	complement C5	Rattus norvegicus	0-3
241330-4	1975	Advantage was taken of the specific action of alk-3-ynoyl-CoA esters on acetoacetyl-CoA thiolase to show that in a postmitochondrial fraction from rat liver they are effective inhibitors of cholesterol synthesis from sodium [2-14C]acetate under conditions when mevalonate conversion into cholesterol and fatty acid synthesis are unafffected.	Mevalonic Acid	261-271	bone morphogenetic protein receptor type 1A	Rattus norvegicus	46-51
1112830-1	1975	C-5 of mevalonate appears as C0-2 in the breath of rats and men almost immediately after administration either by injection or by mouth.	Mevalonic Acid	7-17	complement C2	Rattus norvegicus	29-33
14410081-0	1959	The biosynthesis of mevalonic acid from 1-C14-acetate by a rat liver enzyme system.	Mevalonic Acid	20-34	anti-Mullerian hormone receptor type 2	Rattus norvegicus	42-45
5164097-2	1971	These are a simple synthesis of the substrate precursor HMG-3-(14)C anhydride and a double-label ((14)C and (3)H) method for determining the amount of mevalonate-3-(14)C that is formed from the substrate.	Mevalonic Acid	151-161	high mobility group box 1	Homo sapiens	56-61
14006050-2	1962	Inhibition of cholesterol biosynthesis from acetate-1-C14 and mevalonate-2-C14 by lactose or succinylsulfathiazole-feeding in the rat.	Mevalonic Acid	62-72	anti-Mullerian hormone receptor type 2	Rattus norvegicus	75-78
33930349-9	2021	Supplementation of mevalonate, geranylgeranyl pyrophosphate, or farnesyl pyrophosphate prevented the reduction in IL-1beta release, suggesting a crucial role of protein prenylation, but not cholesterol synthesis.	Mevalonic Acid	19-29	interleukin 1 alpha	Mus musculus	114-122
33744759-6	2021	Proteomic analysis identified farnesyl-diphosphate farnesyltransferase 1 (FDFT1) as a novel substrate of USP32 that is an enzyme in the mevalonate pathway, essentially associated with cell proliferation and stemness.	Mevalonic Acid	136-146	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	30-72
33992804-3	2021	Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis.	Mevalonic Acid	125-128	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	31-71
33992804-3	2021	Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis.	Mevalonic Acid	125-128	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	73-78
33992804-3	2021	Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis.	Mevalonic Acid	113-123	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	31-71
33992804-3	2021	Simvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway for the cholesterol biosynthesis.	Mevalonic Acid	113-123	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	73-78
33744759-6	2021	Proteomic analysis identified farnesyl-diphosphate farnesyltransferase 1 (FDFT1) as a novel substrate of USP32 that is an enzyme in the mevalonate pathway, essentially associated with cell proliferation and stemness.	Mevalonic Acid	136-146	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	74-79
33744759-6	2021	Proteomic analysis identified farnesyl-diphosphate farnesyltransferase 1 (FDFT1) as a novel substrate of USP32 that is an enzyme in the mevalonate pathway, essentially associated with cell proliferation and stemness.	Mevalonic Acid	136-146	ubiquitin specific peptidase 32	Homo sapiens	105-110
33744759-8	2021	Inhibition of USP32, FDFT1, or mevalonate pathway considerably suppressed tumor sphere formation, which was restored by adding squalene, a downstream product of FDFT1.	Mevalonic Acid	31-41	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	161-166
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Mevalonic Acid	241-251	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	307-339
33601148-1	2021	Hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) is a key enzyme in the mevalonate pathway of cholesterol synthesis.	Mevalonic Acid	72-82	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	41-47
33592328-3	2021	The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute-phase response associated with the administration of nitrogen containing BPs (N-BPs), with the stimulus of pro-inflammatory cytokines, through the mevalonate pathway, activation of T-cells and the decrease in the cytotoxic T-lymphocyte antigen-4 (CTLA-4).	Mevalonic Acid	241-251	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	341-347
33174245-6	2021	The mTOR signaling pathway was downregulated, and this was associated with a reduction in key proteins involved in the mevalonate pathway.	Mevalonic Acid	119-129	mechanistic target of rapamycin kinase	Homo sapiens	4-8
33511728-2	2021	They inhibit beta-hydroxy beta-methylglutaryl-coenzyme A reductase, i.e. the rate-limiting enzyme in mevalonate pathway, reduce endogenous cholesterol synthesis, and increase low-density lipoprotein clearance by promoting low-density lipoprotein receptor expression mainly in the hepatocytes.	Mevalonic Acid	101-111	low density lipoprotein receptor	Homo sapiens	222-254
34049800-4	2021	GGPP is synthesized by geranylgeranyl pyrophosphate synthase (GGPPS) in the mevalonate pathway.	Mevalonic Acid	76-86	geranylgeranyl diphosphate synthase 1	Mus musculus	23-60
34049800-4	2021	GGPP is synthesized by geranylgeranyl pyrophosphate synthase (GGPPS) in the mevalonate pathway.	Mevalonic Acid	76-86	geranylgeranyl diphosphate synthase 1	Mus musculus	62-67
33932349-0	2021	The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability.	Mevalonic Acid	21-31	zinc finger MYND-type containing 8	Homo sapiens	4-10
33932349-0	2021	The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability.	Mevalonic Acid	21-31	Yes1 associated transcriptional regulator	Homo sapiens	47-50
33686046-10	2021	Besides, mevalonate completely reversed the effect of atorvastatin on PPARgamma, PGC-1alpha, HNF-4alpha, FXR, and CYP7A1.	Mevalonic Acid	9-19	peroxisome proliferator activated receptor gamma	Homo sapiens	70-79
33686046-10	2021	Besides, mevalonate completely reversed the effect of atorvastatin on PPARgamma, PGC-1alpha, HNF-4alpha, FXR, and CYP7A1.	Mevalonic Acid	9-19	PPARG coactivator 1 alpha	Homo sapiens	81-91
33686046-10	2021	Besides, mevalonate completely reversed the effect of atorvastatin on PPARgamma, PGC-1alpha, HNF-4alpha, FXR, and CYP7A1.	Mevalonic Acid	9-19	hepatocyte nuclear factor 4 alpha	Homo sapiens	93-103
33686046-10	2021	Besides, mevalonate completely reversed the effect of atorvastatin on PPARgamma, PGC-1alpha, HNF-4alpha, FXR, and CYP7A1.	Mevalonic Acid	9-19	nuclear receptor subfamily 1 group H member 4	Homo sapiens	105-108
33686046-10	2021	Besides, mevalonate completely reversed the effect of atorvastatin on PPARgamma, PGC-1alpha, HNF-4alpha, FXR, and CYP7A1.	Mevalonic Acid	9-19	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	114-120
33070276-6	2021	The c-Myc expression and the progression of cell division cycle were restored upon the addition of mevalonate to the culture media containing statins.	Mevalonic Acid	99-109	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	4-9
33608672-4	2021	In this study we investigated the effect of a combination of 2-deoxy-D-glucose with lovastatin (a known inhibitor of mevalonate pathway and oxidative phosphorylation) on growth of KRAS-mutant human colorectal cancer cell lines HCT116 and LoVo.	Mevalonic Acid	117-127	KRAS proto-oncogene, GTPase	Homo sapiens	180-184
33307558-1	2021	3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway, which generates cholesterol and non-sterol compounds such as isoprenoid, which are involved in key steps of tumorigenesis such as cell growth and proliferation.	Mevalonic Acid	91-101	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-47
33307558-1	2021	3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway, which generates cholesterol and non-sterol compounds such as isoprenoid, which are involved in key steps of tumorigenesis such as cell growth and proliferation.	Mevalonic Acid	91-101	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	49-54
33538531-9	2021	In this review, we focus on the function of several critical enzymes, including hydroxymethylglutaryl coenzyme A reductase, FPP synthase, farnesyltransferase, and geranylgeranyltransferase in the mevalonate pathway which are involved in regulating the generation of isoprenoids and isoprenylation of small GTPases, and their pathophysiological role in the cardiovascular system.	Mevalonic Acid	196-206	farnesyl diphosphate synthase	Homo sapiens	124-136
33627871-9	2021	Second, Treg cells in tumours show enhanced expression of the PD-1 gene, through a process that depends on SREBP activity and signals via mevalonate metabolism to protein geranylgeranylation.	Mevalonic Acid	138-148	programmed cell death 1	Homo sapiens	62-66
33361684-2	2021	Here, we found that inhibition of mevalonate pathway by pitavastatin, a widely used cholesterol-lowering drug, drastically destabilized the haploid state in HAP1 cells.	Mevalonic Acid	34-44	huntingtin associated protein 1	Homo sapiens	157-161
33070276-8	2021	Together, these data demonstrate that statins inhibit the mevalonate pathway which is tightly coupled to oxidative branch of the pentose phosphate pathway, c-Myc expression, cell division cycle progression, and cellular senescence.	Mevalonic Acid	58-68	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	156-161
33109681-1	2020	HMG-CoA Reductase (Hmgcr) is the rate-limiting enzyme in the mevalonate pathway and is inhibited by statins.	Mevalonic Acid	61-71	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
33452755-10	2021	Mevalonate and geranylgeranyl-pyrophosphate (GGPP), but not cholesterol, counteracted the negative effect of statins on IFN-beta and ISG expression and phosphorylation of IRF3 and STAT1.	Mevalonic Acid	0-10	interferon alpha	Mus musculus	120-128
33452755-10	2021	Mevalonate and geranylgeranyl-pyrophosphate (GGPP), but not cholesterol, counteracted the negative effect of statins on IFN-beta and ISG expression and phosphorylation of IRF3 and STAT1.	Mevalonic Acid	0-10	interferon regulatory factor 3	Mus musculus	171-175
33452755-10	2021	Mevalonate and geranylgeranyl-pyrophosphate (GGPP), but not cholesterol, counteracted the negative effect of statins on IFN-beta and ISG expression and phosphorylation of IRF3 and STAT1.	Mevalonic Acid	0-10	signal transducer and activator of transcription 1	Mus musculus	180-185
33525735-2	2021	Although it is recognized that the lack of protein prenylation consequent to mevalonate pathway blockade drives IL1beta hypersecretion, and hence autoinflammation, MKD pathogenesis and the molecular mechanisms underlaying most of its clinical manifestations are still largely unknown.	Mevalonic Acid	77-87	interleukin 1 alpha	Homo sapiens	112-119
33410495-8	2021	The persistence of urinary excretion of mevalonic acid after SCT, probably related to the ubiquitous expression of MVK enzyme, suggests that these patients should be carefully monitored after SCT to exclude MKD clinical recurrence.	Mevalonic Acid	40-54	mevalonate kinase	Homo sapiens	115-118
33191463-3	2020	To further increase D-limonene formation, the metabolic flux of the mevalonate (MVA) pathway was enhanced by overexpressing the key genes tHMGR1, ERG12, IDI1, and IDI1WWW, respectively, or co-overexpressing.	Mevalonic Acid	68-78	mevalonate kinase	Saccharomyces cerevisiae S288C	146-151
33191463-3	2020	To further increase D-limonene formation, the metabolic flux of the mevalonate (MVA) pathway was enhanced by overexpressing the key genes tHMGR1, ERG12, IDI1, and IDI1WWW, respectively, or co-overexpressing.	Mevalonic Acid	68-78	isopentenyl-diphosphate delta-isomerase IDI1	Saccharomyces cerevisiae S288C	153-157
33191463-3	2020	To further increase D-limonene formation, the metabolic flux of the mevalonate (MVA) pathway was enhanced by overexpressing the key genes tHMGR1, ERG12, IDI1, and IDI1WWW, respectively, or co-overexpressing.	Mevalonic Acid	68-78	isopentenyl-diphosphate delta-isomerase IDI1	Saccharomyces cerevisiae S288C	163-167
33191463-3	2020	To further increase D-limonene formation, the metabolic flux of the mevalonate (MVA) pathway was enhanced by overexpressing the key genes tHMGR1, ERG12, IDI1, and IDI1WWW, respectively, or co-overexpressing.	Mevalonic Acid	80-83	mevalonate kinase	Saccharomyces cerevisiae S288C	146-151
33191463-3	2020	To further increase D-limonene formation, the metabolic flux of the mevalonate (MVA) pathway was enhanced by overexpressing the key genes tHMGR1, ERG12, IDI1, and IDI1WWW, respectively, or co-overexpressing.	Mevalonic Acid	80-83	isopentenyl-diphosphate delta-isomerase IDI1	Saccharomyces cerevisiae S288C	153-157
33191463-3	2020	To further increase D-limonene formation, the metabolic flux of the mevalonate (MVA) pathway was enhanced by overexpressing the key genes tHMGR1, ERG12, IDI1, and IDI1WWW, respectively, or co-overexpressing.	Mevalonic Acid	80-83	isopentenyl-diphosphate delta-isomerase IDI1	Saccharomyces cerevisiae S288C	163-167
33109681-1	2020	HMG-CoA Reductase (Hmgcr) is the rate-limiting enzyme in the mevalonate pathway and is inhibited by statins.	Mevalonic Acid	61-71	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	19-24
33292612-2	2020	This study aimed to assess statin-induced changes of the intratumoral levels of cholesterol and the expression of the low-density lipoprotein receptor (LDLR) to enhance our understanding of the role of the mevalonate pathway in cancer cholesterol metabolism.	Mevalonic Acid	206-216	low density lipoprotein receptor	Homo sapiens	152-156
33224889-0	2020	Beyond the Mevalonate Pathway: Control of Post-Prenylation Processing by Mutant p53.	Mevalonic Acid	11-21	tumor protein p53	Homo sapiens	80-83
32887721-1	2020	Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway.	Mevalonic Acid	129-139	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	70-87
32887721-1	2020	Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway.	Mevalonic Acid	129-139	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	89-94
32887721-1	2020	Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway.	Mevalonic Acid	141-144	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	70-87
32887721-1	2020	Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) metabolic pathway.	Mevalonic Acid	141-144	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	89-94
33224889-3	2020	An unexpected aspect of mutant p53 function was uncovered by showing that some mutants can increase the malignant phenotype of tumor cells through alteration of the mevalonate pathway.	Mevalonic Acid	165-175	tumor protein p53	Homo sapiens	31-34
33224889-7	2020	Instead, wild type p53 acts in the opposite way, downregulating mevalonate pathway genes and ICMT.	Mevalonic Acid	64-74	tumor protein p53	Homo sapiens	19-22
32758903-4	2020	As competitive inhibitors of HMG-CoA-reductase, the key enzyme of the "mevalonate pathway" through which essential compounds, not only cholesterol, are synthesized, statins decrease the levels of cholesterol, and thus LDLs, as an innate defense mechanism, with controversial results in decreasing mortality from cardiovascular disease.	Mevalonic Acid	71-81	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	29-46
33110395-4	2020	These drugs act inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme that catalyzes the conversion of HMG-CoA to mevalonate, the limiting step in cholesterol biosynthesis.	Mevalonic Acid	140-150	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	66-84
33059448-5	2020	BRs can negatively regulate the expression of VvHMGR, a key gene involved in the mevalonate (MVA) pathway, and reduce the activity of 3-hydroxy-3-methylglutaryl CoA reductase (HMGR).	Mevalonic Acid	81-91	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	48-52
32633781-0	2020	SOAT1 promotes mevalonate pathway dependency in pancreatic cancer.	Mevalonic Acid	15-25	sterol O-acyltransferase 1	Mus musculus	0-5
32569873-4	2020	In contrast, nitrogen-containing BPs potently inhibit FPP synthase, an enzyme of the mevalonate (cholesterol biosynthesis) pathway.	Mevalonic Acid	85-95	farnesyl diphosphate synthase	Homo sapiens	54-66
32399598-9	2020	The remaining patients had variants in candidate genes such as TFAM, involved in mtDNA transcription, replication, and packaging, and GGPS1 involved in mevalonate/coenzyme Q10 biosynthesis and whose enzymatic product is required for mouse folliculogenesis.	Mevalonic Acid	152-162	geranylgeranyl diphosphate synthase 1	Homo sapiens	134-139
32911743-8	2020	In both HT29 and DLD-1 cells, the CSC population was significantly decreased following treatment with metformin, AMPK activator (AICAR), HMG-CoA reductase inhibitor (simvastatin), or mTOR inhibitor (rapamycin), and was increased by mevalonate.	Mevalonic Acid	232-242	mechanistic target of rapamycin kinase	Homo sapiens	183-187
32911743-11	2020	Metformin treatment increased p-AMPK and decreased mTOR (pS6) expression; these effects were reversed by addition of mevalonate.	Mevalonic Acid	117-127	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	32-36
32911743-11	2020	Metformin treatment increased p-AMPK and decreased mTOR (pS6) expression; these effects were reversed by addition of mevalonate.	Mevalonic Acid	117-127	mechanistic target of rapamycin kinase	Homo sapiens	51-55
32911743-11	2020	Metformin treatment increased p-AMPK and decreased mTOR (pS6) expression; these effects were reversed by addition of mevalonate.	Mevalonic Acid	117-127	taste 2 receptor member 63 pseudogene	Homo sapiens	57-60
32633781-5	2020	We identified sterol O-acyltransferase 1 (SOAT1) as a key player in sustaining the mevalonate pathway by converting cholesterol to inert cholesterol esters, thereby preventing the negative feedback elicited by unesterified cholesterol.	Mevalonic Acid	83-93	sterol O-acyltransferase 1	Mus musculus	14-40
32633781-5	2020	We identified sterol O-acyltransferase 1 (SOAT1) as a key player in sustaining the mevalonate pathway by converting cholesterol to inert cholesterol esters, thereby preventing the negative feedback elicited by unesterified cholesterol.	Mevalonic Acid	83-93	sterol O-acyltransferase 1	Mus musculus	42-47
32633781-6	2020	Genetic targeting of Soat1 impairs cell proliferation in vitro and tumor progression in vivo and reveals a mevalonate pathway dependency in p53 mutant PDAC cells that have undergone p53 loss of heterozygosity (LOH).	Mevalonic Acid	107-117	sterol O-acyltransferase 1	Mus musculus	21-26
32633781-6	2020	Genetic targeting of Soat1 impairs cell proliferation in vitro and tumor progression in vivo and reveals a mevalonate pathway dependency in p53 mutant PDAC cells that have undergone p53 loss of heterozygosity (LOH).	Mevalonic Acid	107-117	transformation related protein 53, pseudogene	Mus musculus	140-143
32974183-0	2020	Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy.	Mevalonic Acid	28-38	sterol regulatory element binding transcription factor 2	Homo sapiens	10-17
32974183-3	2020	SREBP-2 binds to the sterol regulatory elements (SREs) in the promoters of its target genes and activates the transcription of mevalonate pathway genes, such as HMG-CoA reductase (HMGCR), mevalonate kinase and other key enzymes.	Mevalonic Acid	127-137	sterol regulatory element binding transcription factor 2	Homo sapiens	0-7
32974183-3	2020	SREBP-2 binds to the sterol regulatory elements (SREs) in the promoters of its target genes and activates the transcription of mevalonate pathway genes, such as HMG-CoA reductase (HMGCR), mevalonate kinase and other key enzymes.	Mevalonic Acid	127-137	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	161-178
32974183-3	2020	SREBP-2 binds to the sterol regulatory elements (SREs) in the promoters of its target genes and activates the transcription of mevalonate pathway genes, such as HMG-CoA reductase (HMGCR), mevalonate kinase and other key enzymes.	Mevalonic Acid	127-137	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	180-185
32974183-3	2020	SREBP-2 binds to the sterol regulatory elements (SREs) in the promoters of its target genes and activates the transcription of mevalonate pathway genes, such as HMG-CoA reductase (HMGCR), mevalonate kinase and other key enzymes.	Mevalonic Acid	127-137	mevalonate kinase	Homo sapiens	188-205
32974183-5	2020	We then found that SREBP-2 and its regulated enzymes, including HMGCR, FPPS, SQS, and DHCR4 from the mevalonate pathway, participate in the progression of various cancers, including prostate, breast, lung, and hepatocellular cancer, as potential targets.	Mevalonic Acid	101-111	sterol regulatory element binding transcription factor 2	Homo sapiens	19-26
32974183-5	2020	We then found that SREBP-2 and its regulated enzymes, including HMGCR, FPPS, SQS, and DHCR4 from the mevalonate pathway, participate in the progression of various cancers, including prostate, breast, lung, and hepatocellular cancer, as potential targets.	Mevalonic Acid	101-111	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	64-69
32974183-5	2020	We then found that SREBP-2 and its regulated enzymes, including HMGCR, FPPS, SQS, and DHCR4 from the mevalonate pathway, participate in the progression of various cancers, including prostate, breast, lung, and hepatocellular cancer, as potential targets.	Mevalonic Acid	101-111	farnesyl diphosphate synthase	Homo sapiens	71-75
32974183-7	2020	This review summarizes new insights into the critical role of the SREBP-2-regulated mevalonate pathway for cancer and its potential for targeted cancer therapy.	Mevalonic Acid	84-94	sterol regulatory element binding transcription factor 2	Homo sapiens	66-73
32389800-3	2020	Furthermore, isoprenoids, the crucial products of Mevalonate-pathway produced by the action of farnesyl pyrophosphate synthase (FPPS) enzyme, are also demonstrated to play a key role in AD.	Mevalonic Acid	50-60	farnesyl diphosphate synthetase	Mus musculus	95-126
33110390-3	2020	Statins inhibit the HMGCR (rate-limiting enzyme) activity in early stages of mevalonate pathway and then indirectly affect a number of intermediate products, including non-sterol isoprenoids (coenzyme Q10, dolichol etc.	Mevalonic Acid	77-87	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	20-25
32403198-6	2020	GGPS1 encodes geranylgeranyl diphosphate synthase in the mevalonate/isoprenoid pathway, which catalyzes the synthesis of geranylgeranyl diphosphate (GGPP), the lipid precursor of geranylgeranylated proteins including small GTPases.	Mevalonic Acid	57-67	geranylgeranyl diphosphate synthase 1	Homo sapiens	0-5
32389800-3	2020	Furthermore, isoprenoids, the crucial products of Mevalonate-pathway produced by the action of farnesyl pyrophosphate synthase (FPPS) enzyme, are also demonstrated to play a key role in AD.	Mevalonic Acid	50-60	farnesyl diphosphate synthetase	Mus musculus	128-132
32727400-8	2020	The inhibition of the mevalonate pathway was confirmed using Western Blot of unprenylated Ras and Rap1a proteins.	Mevalonic Acid	22-32	RAP1A, member of RAS oncogene family	Homo sapiens	98-103
32751976-0	2020	Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERRalpha Pathway.	Mevalonic Acid	16-26	estrogen related receptor alpha	Homo sapiens	114-122
32751976-4	2020	In this study, we demonstrated that cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha (ERRalpha) pathway, increasing the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), ERbB2/human epithelial receptor (HER2), tumor protein D52 (TPD52), and NOTCH2 proteins in breast cancer cells.	Mevalonic Acid	52-62	estrogen related receptor alpha	Homo sapiens	100-131
32751976-4	2020	In this study, we demonstrated that cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha (ERRalpha) pathway, increasing the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), ERbB2/human epithelial receptor (HER2), tumor protein D52 (TPD52), and NOTCH2 proteins in breast cancer cells.	Mevalonic Acid	52-62	estrogen related receptor alpha	Homo sapiens	133-141
32751976-4	2020	In this study, we demonstrated that cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha (ERRalpha) pathway, increasing the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), ERbB2/human epithelial receptor (HER2), tumor protein D52 (TPD52), and NOTCH2 proteins in breast cancer cells.	Mevalonic Acid	52-62	PPARG coactivator 1 alpha	Homo sapiens	188-256
32751976-4	2020	In this study, we demonstrated that cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha (ERRalpha) pathway, increasing the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), ERbB2/human epithelial receptor (HER2), tumor protein D52 (TPD52), and NOTCH2 proteins in breast cancer cells.	Mevalonic Acid	52-62	PPARG coactivator 1 alpha	Homo sapiens	258-268
32751976-4	2020	In this study, we demonstrated that cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha (ERRalpha) pathway, increasing the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), ERbB2/human epithelial receptor (HER2), tumor protein D52 (TPD52), and NOTCH2 proteins in breast cancer cells.	Mevalonic Acid	52-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	304-308
32751976-4	2020	In this study, we demonstrated that cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha (ERRalpha) pathway, increasing the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), ERbB2/human epithelial receptor (HER2), tumor protein D52 (TPD52), and NOTCH2 proteins in breast cancer cells.	Mevalonic Acid	52-62	tumor protein D52	Homo sapiens	311-328
32751976-4	2020	In this study, we demonstrated that cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha (ERRalpha) pathway, increasing the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), ERbB2/human epithelial receptor (HER2), tumor protein D52 (TPD52), and NOTCH2 proteins in breast cancer cells.	Mevalonic Acid	52-62	tumor protein D52	Homo sapiens	330-335
32751976-4	2020	In this study, we demonstrated that cholesterol and mevalonate treatments were able to activate the estrogen-related receptor alpha (ERRalpha) pathway, increasing the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), ERbB2/human epithelial receptor (HER2), tumor protein D52 (TPD52), and NOTCH2 proteins in breast cancer cells.	Mevalonic Acid	52-62	notch receptor 2	Homo sapiens	342-348
32751976-8	2020	Altogether, our data indicate that cholesterol and mevalonate are two metabolites implicated in breast cancer progression, aggressiveness, and drug resistance, through the activation of the ERRalpha pathway.	Mevalonic Acid	51-61	estrogen related receptor alpha	Homo sapiens	190-198
32751976-9	2020	Our findings enable us to identify the ERRalpha receptor as a poor prognostic marker in patients with breast carcinoma, suggesting the correlation between cholesterol/mevalonate and ERRalpha as a new possible target in breast cancer treatment.	Mevalonic Acid	167-177	estrogen related receptor alpha	Homo sapiens	39-47
32751976-9	2020	Our findings enable us to identify the ERRalpha receptor as a poor prognostic marker in patients with breast carcinoma, suggesting the correlation between cholesterol/mevalonate and ERRalpha as a new possible target in breast cancer treatment.	Mevalonic Acid	167-177	estrogen related receptor alpha	Homo sapiens	182-190
32692762-0	2020	The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer.	Mevalonic Acid	4-14	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	32-38
32692762-6	2020	When detailing the mevalonate pathway in breast cancer using a single-cell qPCR, we identified the mevalonate precursor enzyme, HMGCS1, as a specific marker of CSC-enriched subpopulations within both luminal and basal tumour subtypes.	Mevalonic Acid	19-29	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	128-134
32692762-6	2020	When detailing the mevalonate pathway in breast cancer using a single-cell qPCR, we identified the mevalonate precursor enzyme, HMGCS1, as a specific marker of CSC-enriched subpopulations within both luminal and basal tumour subtypes.	Mevalonic Acid	99-109	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	128-134
32692762-10	2020	Taken together, this study highlights HMGCS1 as a potential gatekeeper for dysregulated mevalonate metabolism important for CSC-features in both luminal and basal breast cancer subtypes.	Mevalonic Acid	88-98	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	38-44
32058036-0	2020	Triglyceride deficiency and diacylglycerol kinase1 activity lead to the upregulation of mevalonate pathway in yeast: A study for the development of potential yeast platform for improved production of triterpenoid.	Mevalonic Acid	88-98	diacylglycerol kinase	Saccharomyces cerevisiae S288C	28-50
32754441-0	2020	STAT3 and mutp53 Engage a Positive Feedback Loop Involving HSP90 and the Mevalonate Pathway.	Mevalonic Acid	73-83	signal transducer and activator of transcription 3	Homo sapiens	0-5
32754441-3	2020	In this study we found that pharmacologic or genetic inhibition of STAT3 in both glioblastoma and pancreatic cancer cells, carrying mutp53 protein, reduced mutp53 expression level by down-regulating chaperone HSP90 as well as molecules belonging to the mevalonate pathway.	Mevalonic Acid	253-263	signal transducer and activator of transcription 3	Homo sapiens	67-72
32754441-4	2020	On the other hand, HSP90 and the mevalonate pathway were involved in sustaining STAT3 phosphorylation mediated by mutp53.	Mevalonic Acid	33-43	signal transducer and activator of transcription 3	Homo sapiens	80-85
32311084-6	2020	We also overexpressed truncated HMG1, encoding feedback-inhibition-resistant form of 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1 and sterol-regulating transcription factor upc2-1, to increase the isoprenoid precursors in the mevalonate pathway.	Mevalonic Acid	231-241	hydroxymethylglutaryl-CoA reductase (NADPH) HMG1	Saccharomyces cerevisiae S288C	32-36
32319638-0	2020	MicroRNA-125a-mediated regulation of the mevalonate signaling pathway contributes to high glucose-induced proliferation and migration of vascular smooth muscle cells.	Mevalonic Acid	41-51	microRNA 125a	Rattus norvegicus	0-13
32319638-5	2020	Furthermore, dual-luciferase reporter assay results identified that 3-hydroxy-3-methyglutaryl-coA reductase (HMGCR), one of the key enzymes in the mevalonate signaling pathway, is a target of miR-125a.	Mevalonic Acid	147-157	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	68-107
32319638-5	2020	Furthermore, dual-luciferase reporter assay results identified that 3-hydroxy-3-methyglutaryl-coA reductase (HMGCR), one of the key enzymes in the mevalonate signaling pathway, is a target of miR-125a.	Mevalonic Acid	147-157	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	109-114
32319638-5	2020	Furthermore, dual-luciferase reporter assay results identified that 3-hydroxy-3-methyglutaryl-coA reductase (HMGCR), one of the key enzymes in the mevalonate signaling pathway, is a target of miR-125a.	Mevalonic Acid	147-157	microRNA 125a	Rattus norvegicus	192-200
32319638-9	2020	In addition, it was found that HG-induced excessive activation of the mevalonate signaling pathway in VSMCs was suppressed following transfection with a miR-125a mimic.	Mevalonic Acid	70-80	microRNA 125a	Rattus norvegicus	153-161
32319638-11	2020	Thus, miR-125a-mediated regulation of the mevalonate signaling pathway may be associated with atherosclerosis.	Mevalonic Acid	42-52	microRNA 125a	Rattus norvegicus	6-14
32612595-7	2020	The transcription levels of the HMGS gene of the mevalonate pathway were evaluated by RT-qPCR, which showed a slight increase in CBS.Deltaerg4, but the transcription levels were still 10-fold lower than in strain CBS.cyp61 -.	Mevalonic Acid	49-59	C-22 sterol desaturase	Saccharomyces cerevisiae S288C	217-222
32477466-4	2020	Bioinformatic analyses identified the mevalonate and de novo serine/glycine synthesis pathways as potential targets for apoA-I anti-tumor activity.	Mevalonic Acid	38-48	apolipoprotein A1	Homo sapiens	120-126
32477466-5	2020	Relative to A-I KO, day 7 B16F10L melanoma tumor homografts from A-I Tg+/- exhibited reduced expression of mevalonate-5-pyrophosphate decarboxylase (Mvd), a key enzyme targeted in cancer therapy, along with a number of key genes in the sterol synthesis arm of the mevalonate pathway.	Mevalonic Acid	107-117	mevalonate diphosphate decarboxylase	Homo sapiens	149-152
32435188-4	2020	This occurred via reduction of myosin light chain 2 (MLC2) phosphorylation, and F-actin stress fiber density and distribution, in a mevalonate (MA)- and geranylgeranyl pyrophosphate (GGPP)-dependent manner.	Mevalonic Acid	132-142	myosin light chain 2	Homo sapiens	31-51
32477466-8	2020	Our findings suggest apoA-I targets the mevalonate and serine synthesis pathways in melanoma cells in vivo, thus providing anti-tumor metabolic effects by inhibiting the flux of biomolecular building blocks for macromolecule synthesis that drive rapid tumor growth.	Mevalonic Acid	40-50	apolipoprotein A1	Homo sapiens	21-27
32382091-9	2020	Pharmacological inhibitors of the mevalonate pathway prevented fractionated-radiation-induced suppression of KLF2, TM, and eNOS expression.	Mevalonic Acid	34-44	Kruppel like factor 2	Homo sapiens	109-113
32382091-9	2020	Pharmacological inhibitors of the mevalonate pathway prevented fractionated-radiation-induced suppression of KLF2, TM, and eNOS expression.	Mevalonic Acid	34-44	nitric oxide synthase 3	Homo sapiens	123-127
32435188-4	2020	This occurred via reduction of myosin light chain 2 (MLC2) phosphorylation, and F-actin stress fiber density and distribution, in a mevalonate (MA)- and geranylgeranyl pyrophosphate (GGPP)-dependent manner.	Mevalonic Acid	132-142	myosin light chain 2	Homo sapiens	53-57
32349352-0	2020	Mevalonate Pathway Enzyme HMGCS1 Contributes to Gastric Cancer Progression.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	26-32
32349352-1	2020	The 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) is a potential regulatory node in the mevalonate pathway that is frequently dysregulated in tumors.	Mevalonic Acid	93-103	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	47-53
32349352-1	2020	The 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) is a potential regulatory node in the mevalonate pathway that is frequently dysregulated in tumors.	Mevalonic Acid	93-103	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	4-45
32349352-5	2020	After blocking the mevalonate pathway by statin and dipyridamole, HMGCS1 exerts nonmetabolic functions in enhancing gastric cancer progression.	Mevalonic Acid	19-29	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	66-72
32318559-8	2020	Finally, we have designed a mevalonate (MVA) production system by implementing ArcA overexpression into the pgi-knockout mutant using a mixture of glucose and xylose.	Mevalonic Acid	28-38	arginine deiminase	Escherichia coli	79-83
32332697-1	2020	An important component of missense mutant p53 gain-of-function (mutp53 GOF) activities is the ability of stabilized mutp53 proteins to upregulate the mevalonate pathway, providing a rationale for exploring the statin family of HMG-CoA reductase inhibitors as anticancer agents in mutp53 tumors.	Mevalonic Acid	150-160	transformation related protein 53, pseudogene	Mus musculus	42-45
32290231-5	2020	In correlation with mutp53 reduction and wtp53 activation, PBA downregulated the expression level of mevalonate kinase (MVK), a key kinase of the mevalonate pathway strongly involved in cancer cell survival.	Mevalonic Acid	101-111	mevalonate kinase	Homo sapiens	120-123
32139507-2	2020	Geranylgeranyl diphosphate synthase (GGPPS) is a branchpoint enzyme in the mevalonate (MVA) pathway that affects the ratio of FPP to GGPP.	Mevalonic Acid	75-85	geranylgeranyl diphosphate synthase 1	Homo sapiens	0-35
32139507-2	2020	Geranylgeranyl diphosphate synthase (GGPPS) is a branchpoint enzyme in the mevalonate (MVA) pathway that affects the ratio of FPP to GGPP.	Mevalonic Acid	75-85	geranylgeranyl diphosphate synthase 1	Homo sapiens	37-42
32004772-1	2020	Fluvastatin and atorvastatin are inhibitors of hydroxy-methylglutaryl-CoA (HMG-CoA) reductase, the enzyme that converts HMG-CoA to mevalonic acid (MVA).	Mevalonic Acid	131-145	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	75-93
32004772-1	2020	Fluvastatin and atorvastatin are inhibitors of hydroxy-methylglutaryl-CoA (HMG-CoA) reductase, the enzyme that converts HMG-CoA to mevalonic acid (MVA).	Mevalonic Acid	147-150	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	75-93
32184566-16	2020	Conclusion: AnTT suppresses the mevalonate pathway by downregulating HMGR gene expression and inhibiting RhoA activation, leading to increased BMP-2 protein in MC3T3-E1 cells.	Mevalonic Acid	32-42	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	69-73
31944822-5	2020	We further show that the mevalonate pathway regulates YAP activation, and that simvastatin treatment reduces fibrosis markers in activated HLF and in the bleomycin mouse model of pulmonary fibrosis.	Mevalonic Acid	25-35	yes-associated protein 1	Mus musculus	54-57
31958566-4	2020	Here, we stimulated the activity of the mevalonate pathway in T. atroviride P1 by expressing the Saccharomyces cerevisiae ERG20 gene coding for farnesyl pyrophosphate (FPP) synthase, a key enzyme of this pathway.	Mevalonic Acid	40-50	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	122-127
31958566-5	2020	ERG20-expressing Trichoderma strains showed higher activities of FPP synthase and squalene synthase, the principal recipient of FPP in the mevalonate pathway.	Mevalonic Acid	139-149	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	0-5
31969375-6	2020	In-depth lipidomics analyses showed that loss of MEK5/ERK5 perturbs several lipid metabolism pathways, including the mevalonate pathway that controls cholesterol synthesis.	Mevalonic Acid	117-127	mitogen-activated protein kinase kinase 5	Homo sapiens	49-53
31969375-6	2020	In-depth lipidomics analyses showed that loss of MEK5/ERK5 perturbs several lipid metabolism pathways, including the mevalonate pathway that controls cholesterol synthesis.	Mevalonic Acid	117-127	mitogen-activated protein kinase 7	Homo sapiens	54-58
31969375-7	2020	Notably, depletion of MEK5/ERK5 sensitized SCLC cells to pharmacological inhibition of the mevalonate pathway by statins.	Mevalonic Acid	91-101	mitogen-activated protein kinase kinase 5	Homo sapiens	22-26
31969375-7	2020	Notably, depletion of MEK5/ERK5 sensitized SCLC cells to pharmacological inhibition of the mevalonate pathway by statins.	Mevalonic Acid	91-101	mitogen-activated protein kinase 7	Homo sapiens	27-31
31969375-7	2020	Notably, depletion of MEK5/ERK5 sensitized SCLC cells to pharmacological inhibition of the mevalonate pathway by statins.	Mevalonic Acid	91-101	SCLC1	Homo sapiens	43-47
32118581-2	2020	Previous studies in cultured cells (Schumacher et al., 2015) revealed that UBIAD1 also inhibits endoplasmic reticulum (ER)-associated degradation (ERAD) of ubiquitinated HMG CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway that produces cholesterol and essential nonsterol isoprenoids.	Mevalonic Acid	229-239	UbiA prenyltransferase domain containing 1	Mus musculus	75-81
32118581-2	2020	Previous studies in cultured cells (Schumacher et al., 2015) revealed that UBIAD1 also inhibits endoplasmic reticulum (ER)-associated degradation (ERAD) of ubiquitinated HMG CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway that produces cholesterol and essential nonsterol isoprenoids.	Mevalonic Acid	229-239	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	170-187
32118581-2	2020	Previous studies in cultured cells (Schumacher et al., 2015) revealed that UBIAD1 also inhibits endoplasmic reticulum (ER)-associated degradation (ERAD) of ubiquitinated HMG CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway that produces cholesterol and essential nonsterol isoprenoids.	Mevalonic Acid	229-239	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	189-194
32118581-5	2020	Thus, embryonic lethality of Ubiad1 deficiency results from depletion of mevalonate-derived products owing to enhanced ERAD of HMGCR rather than from reduced synthesis of MK-4.	Mevalonic Acid	73-83	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	127-132
31744820-0	2020	Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress.	Mevalonic Acid	0-10	transformation related protein 53, pseudogene	Mus musculus	88-91
31722972-5	2020	Mechanistically, Pggt1b bridges sphingosine-1-phosphate and chemokine-induced migratory signals with the activation of Cdc42 and Pak signaling and mevalonate-dependent thymocyte trafficking.	Mevalonic Acid	147-157	protein geranylgeranyltransferase type I subunit beta	Homo sapiens	17-23
31963885-3	2020	Studies showed that T3 could prevent various NCDs, by suppressing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in the mevalonate pathway, inflammatory response, oxidative stress, and alternating hormones.	Mevalonic Acid	129-139	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	66-113
31963885-3	2020	Studies showed that T3 could prevent various NCDs, by suppressing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) in the mevalonate pathway, inflammatory response, oxidative stress, and alternating hormones.	Mevalonic Acid	129-139	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	115-120
32010481-0	2020	Statins Induce a DAF-16/Foxo-dependent Longevity Phenotype via JNK-1 through Mevalonate Depletion in C. elegans.	Mevalonic Acid	77-87	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	17-23
32010481-0	2020	Statins Induce a DAF-16/Foxo-dependent Longevity Phenotype via JNK-1 through Mevalonate Depletion in C. elegans.	Mevalonic Acid	77-87	Stress-activated protein kinase jnk-1	Caenorhabditis elegans	63-68
31854421-1	2020	Mevalonate diphosphate decarboxylase (MDD) catalyses a crucial step of the mevalonate pathway via Mg2+-ATP-dependent phosphorylation and decarboxylation reactions to ultimately produce isopentenyl diphosphate, the precursor of isoprenoids, which is essential to bacterial functions and provides ideal building blocks for the biosynthesis of isopentenols.	Mevalonic Acid	75-85	mevalonate diphosphate decarboxylase	Homo sapiens	0-36
31854421-1	2020	Mevalonate diphosphate decarboxylase (MDD) catalyses a crucial step of the mevalonate pathway via Mg2+-ATP-dependent phosphorylation and decarboxylation reactions to ultimately produce isopentenyl diphosphate, the precursor of isoprenoids, which is essential to bacterial functions and provides ideal building blocks for the biosynthesis of isopentenols.	Mevalonic Acid	75-85	mevalonate diphosphate decarboxylase	Homo sapiens	38-41
31854421-2	2020	However, the metal ion(s) in MDD has not been unambiguously resolved, which limits the understanding of the catalytic mechanism and the exploitation of enzymes for the development of antibacterial therapies or the mevalonate metabolic pathway for the biosynthesis of biofuels.	Mevalonic Acid	214-224	mevalonate diphosphate decarboxylase	Homo sapiens	29-32
31854421-5	2020	The results here would shed light on the active conformation of MDD-related enzymes and their catalytic mechanisms and therefore be useful for developing novel antimicrobial therapies or reconstructing mevalonate metabolic pathways for the biosynthesis of biofuels.	Mevalonic Acid	202-212	mevalonate diphosphate decarboxylase	Homo sapiens	64-67
31744820-3	2020	We show here that p53-deficient colon cancer cells exposed to tumor-like metabolic stress in spheroid culture activated the mevalonate pathway to promote the synthesis of ubiquinone.	Mevalonic Acid	124-134	transformation related protein 53, pseudogene	Mus musculus	18-21
31744820-5	2020	Induction of mevalonate pathway enzyme expression in the absence of p53 was mediated by accumulation and stabilization of mature SREBP2.	Mevalonic Acid	13-23	sterol regulatory element binding factor 2	Mus musculus	129-135
31744820-6	2020	Mevalonate pathway inhibition by statins blocked pyrimidine nucleotide biosynthesis and induced oxidative stress and apoptosis in p53-deficient cancer cells in spheroid culture.	Mevalonic Acid	0-10	transformation related protein 53, pseudogene	Mus musculus	130-133
31744820-7	2020	Moreover, ubiquinone produced by the mevalonate pathway was essential for the growth of p53-deficient tumor organoids.	Mevalonic Acid	37-47	transformation related protein 53, pseudogene	Mus musculus	88-91
31744820-11	2020	SIGNIFICANCE: These findings suggest that p53-deficient cancer cells activate the mevalonate pathway via SREBP2 and promote the synthesis of ubiquinone that plays an essential role in reducing oxidative stress and supports the synthesis of pyrimidine nucleotide.	Mevalonic Acid	82-92	transformation related protein 53, pseudogene	Mus musculus	42-45
31744820-11	2020	SIGNIFICANCE: These findings suggest that p53-deficient cancer cells activate the mevalonate pathway via SREBP2 and promote the synthesis of ubiquinone that plays an essential role in reducing oxidative stress and supports the synthesis of pyrimidine nucleotide.	Mevalonic Acid	82-92	sterol regulatory element binding factor 2	Mus musculus	105-111
31783202-1	2020	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) is the first rate-limiting enzyme regulating the synthesis of terpenoids upstream of the mevalonate (MVA) pathway.	Mevalonic Acid	144-154	3-hydroxy-3-methylglutaryl-coenzyme A reductase 1-like	Malus domestica	49-53
31746143-5	2020	Further investigation of the mechanisms showed that ART can influence glioma cell metabolism by affecting the nuclear localization of SREBP2 (sterol regulatory element-binding protein 2) and the expression of its target gene HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), the rate-limiting enzyme of the mevalonate (MVA) pathway.	Mevalonic Acid	314-324	sterol regulatory element binding factor 2	Mus musculus	134-140
31746143-5	2020	Further investigation of the mechanisms showed that ART can influence glioma cell metabolism by affecting the nuclear localization of SREBP2 (sterol regulatory element-binding protein 2) and the expression of its target gene HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), the rate-limiting enzyme of the mevalonate (MVA) pathway.	Mevalonic Acid	326-329	sterol regulatory element binding factor 2	Mus musculus	134-140
31969805-7	2019	We found that UPRmt was activated in the brain of 3 and 9 months old APP/PS1 mice, and in the SHSY5Y cells after exposure to Abeta25-35, Abeta25-35 triggered UPRmt in SHSY5Y cells could be attenuated upon administration of simvastatin or siRNA for HMGCS-1 to inhibit the mevalonate pathway, and or upon knocking down Serine palmitoyltransferase long chain subunit 1 (SPTLC-1) to lower sphingolipid biosynthesis.	Mevalonic Acid	271-281	presenilin 1	Mus musculus	73-76
31969805-7	2019	We found that UPRmt was activated in the brain of 3 and 9 months old APP/PS1 mice, and in the SHSY5Y cells after exposure to Abeta25-35, Abeta25-35 triggered UPRmt in SHSY5Y cells could be attenuated upon administration of simvastatin or siRNA for HMGCS-1 to inhibit the mevalonate pathway, and or upon knocking down Serine palmitoyltransferase long chain subunit 1 (SPTLC-1) to lower sphingolipid biosynthesis.	Mevalonic Acid	271-281	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	248-255
31969805-7	2019	We found that UPRmt was activated in the brain of 3 and 9 months old APP/PS1 mice, and in the SHSY5Y cells after exposure to Abeta25-35, Abeta25-35 triggered UPRmt in SHSY5Y cells could be attenuated upon administration of simvastatin or siRNA for HMGCS-1 to inhibit the mevalonate pathway, and or upon knocking down Serine palmitoyltransferase long chain subunit 1 (SPTLC-1) to lower sphingolipid biosynthesis.	Mevalonic Acid	271-281	serine palmitoyltransferase long chain base subunit 1	Homo sapiens	317-365
31969805-7	2019	We found that UPRmt was activated in the brain of 3 and 9 months old APP/PS1 mice, and in the SHSY5Y cells after exposure to Abeta25-35, Abeta25-35 triggered UPRmt in SHSY5Y cells could be attenuated upon administration of simvastatin or siRNA for HMGCS-1 to inhibit the mevalonate pathway, and or upon knocking down Serine palmitoyltransferase long chain subunit 1 (SPTLC-1) to lower sphingolipid biosynthesis.	Mevalonic Acid	271-281	serine palmitoyltransferase long chain base subunit 1	Homo sapiens	367-374
31649162-0	2020	Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce beta-Cell Functional Mass.	Mevalonic Acid	31-41	mechanistic target of rapamycin kinase	Mus musculus	65-69
31557302-1	2020	3-Hydroxy-3-methylglutaryl-CoA synthase (HMGS) catalyses the second step of the mevalonate (MVA) pathway.	Mevalonic Acid	80-90	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	0-39
31557302-1	2020	3-Hydroxy-3-methylglutaryl-CoA synthase (HMGS) catalyses the second step of the mevalonate (MVA) pathway.	Mevalonic Acid	80-90	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	41-45
31557302-1	2020	3-Hydroxy-3-methylglutaryl-CoA synthase (HMGS) catalyses the second step of the mevalonate (MVA) pathway.	Mevalonic Acid	92-95	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	0-39
31557302-1	2020	3-Hydroxy-3-methylglutaryl-CoA synthase (HMGS) catalyses the second step of the mevalonate (MVA) pathway.	Mevalonic Acid	92-95	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	41-45
31557302-9	2020	Thus, HMGS might represent a target for the manipulation of glucosinolate biosynthesis, given the regulatory relationship between HMGS in the MVA pathway and glucosinolate biosynthesis.	Mevalonic Acid	142-145	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	6-10
31557302-9	2020	Thus, HMGS might represent a target for the manipulation of glucosinolate biosynthesis, given the regulatory relationship between HMGS in the MVA pathway and glucosinolate biosynthesis.	Mevalonic Acid	142-145	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	130-134
31554653-3	2020	Here, we identified that HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase 1), the rate-limiting enzyme of the MVA pathway, is overexpressed in colon cancer tissues and positively regulates the cell proliferation, migration and invasion of colon cancer cells.	Mevalonic Acid	109-112	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	25-31
31554653-3	2020	Here, we identified that HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase 1), the rate-limiting enzyme of the MVA pathway, is overexpressed in colon cancer tissues and positively regulates the cell proliferation, migration and invasion of colon cancer cells.	Mevalonic Acid	109-112	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	33-74
31783202-1	2020	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) is the first rate-limiting enzyme regulating the synthesis of terpenoids upstream of the mevalonate (MVA) pathway.	Mevalonic Acid	156-159	3-hydroxy-3-methylglutaryl-coenzyme A reductase 1-like	Malus domestica	49-53
31633304-3	2019	Cerivastatin, the rate-limiting enzyme inhibitor of the mevalonate pathway, showed anti-cancer activity against ALK-TKI resistance in vitro/in vivo, accompanied by cytoplasmic retention and subsequent inactivation of transcriptional co-regulator YAP.	Mevalonic Acid	56-66	ALK receptor tyrosine kinase	Homo sapiens	112-115
31606910-3	2020	In order to generate a Saccharomyces cerevisiae whole-cell biocatalyst for the production of (+)-ambrein, intracellular supply of the squalene, was enhanced by overexpression of two central enzymes in the mevalonate and sterol biosynthesis pathway, namely the N-terminally truncated 3-hydroxy-3-methylglutaryl-CoA reductase 1 (tHMG) and the squalene synthase (ERG9).	Mevalonic Acid	205-215	bifunctional farnesyl-diphosphate farnesyltransferase/squalene synthase	Saccharomyces cerevisiae S288C	360-364
33479604-5	2020	An alternative approach involves antagonizing the upstream mevalonate pathway enzymes, FPPS and GGPPS, which mediate prenylation as well as cholesterol synthesis.	Mevalonic Acid	59-69	farnesyl diphosphate synthase	Homo sapiens	87-91
31554629-4	2019	In this study, we found that fluvastatin targeted 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR), which a rate-limiting enzyme in the mevalonate pathway, and inhibited non-small cell lung cancer (NSCLC) tumorigenesis.	Mevalonic Acid	153-163	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	109-114
31599189-6	2019	By using chemically distinct statins, HMGCR depletion or supplementing mevalonate, the product of HMGCR, we showed the inhibitory effects on DNA repair process of lovastatin were due to the blockage of the mevalonate pathway.	Mevalonic Acid	71-81	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	98-103
31783699-4	2019	Here we corroborate our earlier screening results and identify expanded, independent sets of autophagy modifiers that increase or decrease the accumulation of autophagosomes in the CLN3 disease cells, highlighting several pathways of interest, including the regulation of calcium signaling, microtubule dynamics, and the mevalonate pathway.	Mevalonic Acid	321-331	ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease)	Mus musculus	181-185
31620952-5	2019	Tocotrienols down-regulate 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	118-128	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	27-84
31207227-1	2019	Patients with disseminated superficial actinic porokeratosis (DSAP) and linear porokeratosis (LP) exhibit monoallelic germline mutations in genes encoding mevalonate pathway enzymes, such as MVD or MVK.	Mevalonic Acid	155-165	mevalonate kinase	Homo sapiens	198-201
31685796-0	2019	ASPP2 inhibits tumor growth by repressing the mevalonate pathway in hepatocellular carcinoma.	Mevalonic Acid	46-56	tumor protein p53 binding protein 2	Homo sapiens	0-5
31741685-6	2019	Mevalonate (diphospho-) decarboxylase enzyme (MVD) was quantified by Western blot.	Mevalonic Acid	0-10	mevalonate diphosphate decarboxylase	Rattus norvegicus	46-49
31685796-2	2019	In this study, we report that the haplo-insufficient tumor suppressor ASPP2, a p53 activator, negatively regulates the mevalonate pathway to mediate its inhibitory effect on tumor growth in hepatocellular carcinoma (HCC).	Mevalonic Acid	119-129	tumor protein p53 binding protein 2	Homo sapiens	70-75
31685796-2	2019	In this study, we report that the haplo-insufficient tumor suppressor ASPP2, a p53 activator, negatively regulates the mevalonate pathway to mediate its inhibitory effect on tumor growth in hepatocellular carcinoma (HCC).	Mevalonic Acid	119-129	tumor protein p53	Homo sapiens	79-82
31685796-3	2019	Gene expression profile analysis revealed that the expression of key enzymes in the mevalonate pathway were increased when ASPP2 was downregulated.	Mevalonic Acid	84-94	tumor protein p53 binding protein 2	Homo sapiens	123-128
31685796-5	2019	Simvastatin, a mevalonate pathway inhibitor, efficiently abrogated ASPP2 depletion-induced anchorage-independent cell proliferation, resistance to chemotherapy drugs in vitro, and tumor growth in xenografted nude mice.	Mevalonic Acid	15-25	transformation related protein 53 binding protein 2	Mus musculus	67-72
31685796-6	2019	Mechanistically, ASPP2 interacts with SREBP-2 in the nucleus and restricts the transcriptional activity of SREBP-2 on its target genes, which include key enzymes involved in the mevalonate pathway.	Mevalonic Acid	178-188	transformation related protein 53 binding protein 2	Mus musculus	17-22
31685796-6	2019	Mechanistically, ASPP2 interacts with SREBP-2 in the nucleus and restricts the transcriptional activity of SREBP-2 on its target genes, which include key enzymes involved in the mevalonate pathway.	Mevalonic Acid	178-188	sterol regulatory element binding transcription factor 2	Homo sapiens	107-114
31685796-7	2019	Moreover, clinical data revealed better prognosis in patients with high levels of ASPP2 and low levels of the mevalonate pathway enzyme HMGCR.	Mevalonic Acid	110-120	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	136-141
31685796-8	2019	Our findings provide functional and mechanistic insights into the critical role of ASPP2 in the regulation of the mevalonate pathway and the importance of this pathway in tumor initiation and tumor growth, which may provide a new therapeutic opportunity for HCC.	Mevalonic Acid	114-124	tumor protein p53 binding protein 2	Homo sapiens	83-88
31609245-5	2019	We found that by supplying more substrate for geranylgeranylation, Rac1 activation was substantially increased, resulting in profibrotic polarization by increasing flux through the mevalonate pathway.	Mevalonic Acid	181-191	Rac family small GTPase 1	Homo sapiens	67-71
31611937-10	2019	Furthermore, Pami treatment interfered with the MVA signaling pathway by reducing Rac1 protein levels and modulating the gene and protein expression of RhoA.	Mevalonic Acid	48-51	Rac family small GTPase 1	Homo sapiens	82-86
31611937-13	2019	Pami significantly decreased the protein expression levels of Rac1 in the MVA signaling pathway and may therefore be beneficial for developing a novel chemotherapeutic method for CCA.	Mevalonic Acid	74-77	Rac family small GTPase 1	Homo sapiens	62-66
31699116-6	2019	A significant increase in valencene yield was observed after down-regulation or knock-out of squalene synthesis and other inhibiting factors (such as erg9, rox1) in mevalonate (MVA) pathway using a recyclable CRISPR/Cas9 system constructed in this study through the introduction of Cre/loxP.	Mevalonic Acid	165-175	bifunctional farnesyl-diphosphate farnesyltransferase/squalene synthase	Saccharomyces cerevisiae S288C	150-154
31699116-6	2019	A significant increase in valencene yield was observed after down-regulation or knock-out of squalene synthesis and other inhibiting factors (such as erg9, rox1) in mevalonate (MVA) pathway using a recyclable CRISPR/Cas9 system constructed in this study through the introduction of Cre/loxP.	Mevalonic Acid	165-175	Rox1p	Saccharomyces cerevisiae S288C	156-160
31324954-10	2019	Unprenylated Rap1A accumulated in MCF7 cells on zoledronate-treated bone, suggesting zoledronate acted through the inhibition of the mevalonate pathway.	Mevalonic Acid	133-143	RAP1A, member of RAS oncogene family	Homo sapiens	13-18
31631207-5	2019	Our analyses further reveal that 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is the rate-determining enzyme of the mevalonate pathway, is a novel target of auranofin with half maximal inhibitory concentration at micromolar levels.	Mevalonic Acid	134-144	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	33-80
31631207-5	2019	Our analyses further reveal that 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is the rate-determining enzyme of the mevalonate pathway, is a novel target of auranofin with half maximal inhibitory concentration at micromolar levels.	Mevalonic Acid	134-144	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	82-87
31420371-0	2019	Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer.	Mevalonic Acid	14-24	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-63
31420371-2	2019	While the Mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown.	Mevalonic Acid	10-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
31397499-1	2019	Recent studies have indicated that using statins to inhibit the mevalonate pathway induces mutant p53 degradation by impairing the interaction of mutant p53 with DnaJ subfamily A member 1 (DNAJA1).	Mevalonic Acid	64-74	transformation related protein 53, pseudogene	Mus musculus	98-101
31397499-1	2019	Recent studies have indicated that using statins to inhibit the mevalonate pathway induces mutant p53 degradation by impairing the interaction of mutant p53 with DnaJ subfamily A member 1 (DNAJA1).	Mevalonic Acid	64-74	DnaJ heat shock protein family (Hsp40) member A1	Mus musculus	189-195
31427399-1	2019	Geranylgeranyl diphosphate synthase (GGPPS) is a central metalloenzyme in the mevalonate pathway, crucial for the prenylation of small GTPases.	Mevalonic Acid	78-88	geranylgeranyl diphosphate synthase 1	Homo sapiens	0-35
31397499-1	2019	Recent studies have indicated that using statins to inhibit the mevalonate pathway induces mutant p53 degradation by impairing the interaction of mutant p53 with DnaJ subfamily A member 1 (DNAJA1).	Mevalonic Acid	64-74	transformation related protein 53, pseudogene	Mus musculus	153-156
31397499-1	2019	Recent studies have indicated that using statins to inhibit the mevalonate pathway induces mutant p53 degradation by impairing the interaction of mutant p53 with DnaJ subfamily A member 1 (DNAJA1).	Mevalonic Acid	64-74	DnaJ heat shock protein family (Hsp40) member A1	Mus musculus	162-187
31427399-1	2019	Geranylgeranyl diphosphate synthase (GGPPS) is a central metalloenzyme in the mevalonate pathway, crucial for the prenylation of small GTPases.	Mevalonic Acid	78-88	geranylgeranyl diphosphate synthase 1	Homo sapiens	37-42
31664073-6	2019	Cells with CRISPR-mediated knockdown of LXRbeta, but not ABCA1, had decreased cell cycle progression and cell survival, and decreased feedback repression of the mevalonate pathway in densely-plated glioma cells.	Mevalonic Acid	161-171	nuclear receptor subfamily 1 group H member 3	Homo sapiens	40-47
31455613-0	2019	Endogenous sterol intermediates of the mevalonate pathway regulate HMG-CoA reductase degradation and SREBP-2 processing.	Mevalonic Acid	39-49	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	67-84
31649888-0	2019	Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells.	Mevalonic Acid	57-67	Yes1 associated transcriptional regulator	Homo sapiens	68-71
31520523-10	2019	Mevalonic acid (300 mumol/L), the reduced product of HMG-CoA, prevented the statin-induced de-differentiation (alpha-SMA expression: 31.4 +- 10% vs. 58.6 +- 12%).	Mevalonic Acid	0-14	actin alpha 1, skeletal muscle	Homo sapiens	111-120
31455613-5	2019	With a constructed HeLa cell line expressing the mevalonate transporter, we individually deleted genes encoding major enzymes in the mevalonate pathway, used lipidomics to measure sterol intermediates, and examined HMGCR and SREBP-2 statuses.	Mevalonic Acid	49-59	sterol regulatory element binding transcription factor 2	Homo sapiens	225-232
31649888-5	2019	Inhibition of YAP nuclear localization and activation by Atorvastatin was reversed by the addition of mevalonate, GGPP, or FPP.	Mevalonic Acid	102-112	Yes1 associated transcriptional regulator	Homo sapiens	14-17
31649888-6	2019	Further, the effects on cell cycle arrest- and apoptosis- related proteins by Atorvastatin were alleviated by addition of mevalonate, suggesting the antileukemia effect of Atorvastatin might be through mevalonate-YAP axis in K562 and HL60 cells.	Mevalonic Acid	122-132	Yes1 associated transcriptional regulator	Homo sapiens	213-216
31649888-6	2019	Further, the effects on cell cycle arrest- and apoptosis- related proteins by Atorvastatin were alleviated by addition of mevalonate, suggesting the antileukemia effect of Atorvastatin might be through mevalonate-YAP axis in K562 and HL60 cells.	Mevalonic Acid	202-212	Yes1 associated transcriptional regulator	Homo sapiens	213-216
30470158-2	2019	HMGR catalyses the reduction of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to mevalonate at the expense of two NADPH molecules in a two-step reversible reaction.	Mevalonic Acid	83-93	high mobility group AT-hook 1	Homo sapiens	0-4
31455613-0	2019	Endogenous sterol intermediates of the mevalonate pathway regulate HMG-CoA reductase degradation and SREBP-2 processing.	Mevalonic Acid	39-49	sterol regulatory element binding transcription factor 2	Homo sapiens	101-108
31455613-5	2019	With a constructed HeLa cell line expressing the mevalonate transporter, we individually deleted genes encoding major enzymes in the mevalonate pathway, used lipidomics to measure sterol intermediates, and examined HMGCR and SREBP-2 statuses.	Mevalonic Acid	49-59	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	215-220
31737505-3	2019	Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway.	Mevalonic Acid	98-108	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	16-56
31737505-3	2019	Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway.	Mevalonic Acid	98-108	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	58-63
31540279-0	2019	HSF1 Regulates Mevalonate and Cholesterol Biosynthesis Pathways.	Mevalonic Acid	15-25	heat shock transcription factor 1	Homo sapiens	0-4
31469273-1	2019	The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR), in most organisms, catalyzes the four-electron reduction of the thioester (S)-HMG-CoA to the primary alcohol (R)-mevalonate, utilizing NADPH as the hydride donor.	Mevalonic Acid	186-200	high mobility group AT-hook 1	Homo sapiens	70-74
31540279-4	2019	However, the functional role of HSF1 in the mevalonate and cholesterol biosynthesis pathways has not yet been investigated.	Mevalonic Acid	44-54	heat shock transcription factor 1	Homo sapiens	32-36
31103630-10	2019	Its effect on the cell cycle involved the downregulation of cyclin A but without the presence of mevalonate; therefore, total ECP expression from eosinophils decreased, not by suppressing the actual formation or release of ECP but by arresting the G1/S cell cycle phase and inhibiting subsequent cell proliferation through the mevalonate pathway.	Mevalonic Acid	327-337	ribonuclease A family member 3	Homo sapiens	126-129
31399545-5	2019	TP53 facilitated ARF6 activation by platelet-derived growth factor (PDGF), via its known function to promote the expression of PDGF receptor beta (PDGFRbeta) and enzymes of the mevalonate pathway (MVP).	Mevalonic Acid	177-187	tumor protein p53	Homo sapiens	0-4
31399545-5	2019	TP53 facilitated ARF6 activation by platelet-derived growth factor (PDGF), via its known function to promote the expression of PDGF receptor beta (PDGFRbeta) and enzymes of the mevalonate pathway (MVP).	Mevalonic Acid	177-187	ADP ribosylation factor 6	Homo sapiens	17-21
31236789-1	2019	OBJECTIVES: 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase (HMGS) is an important enzyme in mevalonate (MVA) pathway of isoprenoid biosynthesis, which regulates the rubber biosynthetic pathway in rubber tree (Hevea brasiliensis) in coordination with HMG-CoA reductase (HMGR).	Mevalonic Acid	102-112	hydroxymethylglutaryl-CoA synthase / HMG-CoA synthase / 3-hydroxy-3-methylglutaryl coenzyme A synthase	Arabidopsis thaliana	70-74
31020340-6	2019	Mechanistically, mevalonate enhanced transforming growth factor (TGF)-beta signaling by increasing the phosphorylation of Smad3, but not Smad2, and by promoting Foxp3 expression.	Mevalonic Acid	17-27	transforming growth factor alpha	Homo sapiens	37-74
31292513-8	2019	Both mevalonate and geranylgeranyl-pyrophosphate (GGPP), but not cholesterol, fully reversed atorvastatin-induced upregulation of Fads2, and mevalonate-effected reversal was inhibited by treatment with the Rho-associated protein kinase inhibitor Y-27632.	Mevalonic Acid	5-15	fatty acid desaturase 2	Homo sapiens	130-135
31020340-6	2019	Mechanistically, mevalonate enhanced transforming growth factor (TGF)-beta signaling by increasing the phosphorylation of Smad3, but not Smad2, and by promoting Foxp3 expression.	Mevalonic Acid	17-27	SMAD family member 3	Homo sapiens	122-127
31020340-6	2019	Mechanistically, mevalonate enhanced transforming growth factor (TGF)-beta signaling by increasing the phosphorylation of Smad3, but not Smad2, and by promoting Foxp3 expression.	Mevalonic Acid	17-27	forkhead box P3	Homo sapiens	161-166
31316383-1	2019	Statins efficiently inhibit cholesterol synthesis by blocking 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the mevalonate pathway.	Mevalonic Acid	116-126	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	62-108
31023626-1	2019	OBJECTIVE: The statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR).	Mevalonic Acid	155-165	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	181-198
31023626-1	2019	OBJECTIVE: The statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR).	Mevalonic Acid	155-165	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	200-205
31023626-1	2019	OBJECTIVE: The statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR).	Mevalonic Acid	167-170	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	181-198
31023626-1	2019	OBJECTIVE: The statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR).	Mevalonic Acid	167-170	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	200-205
31171774-4	2019	Meanwhile, the expression level of geranylgeranyl diphosphate synthase (Ggpps), a key enzyme in mevalonate metabolic pathway, is lower in NOA patients than that in obstructive azoospermia (OA) patients.	Mevalonic Acid	96-106	geranylgeranyl diphosphate synthase 1	Homo sapiens	35-70
31181660-4	2019	Notably, TRAP1 inhibition induced cell death, which was rescued by cholesterol and mevalonate.	Mevalonic Acid	83-93	TNF receptor associated protein 1	Homo sapiens	9-14
31171774-4	2019	Meanwhile, the expression level of geranylgeranyl diphosphate synthase (Ggpps), a key enzyme in mevalonate metabolic pathway, is lower in NOA patients than that in obstructive azoospermia (OA) patients.	Mevalonic Acid	96-106	geranylgeranyl diphosphate synthase 1	Homo sapiens	72-77
31167140-0	2019	Activation of Mevalonate Pathway via LKB1 Is Essential for Stability of Treg Cells.	Mevalonic Acid	14-24	serine/threonine kinase 11	Mus musculus	37-41
31167140-5	2019	Mechanistically, LKB1 induced activation of the mevalonate pathway by upregulating mevalonate genes, which was essential for Treg cell functional competency and stability by inducing Treg cell proliferation and suppressing interferon-gamma and interleukin-17A expression independently of AMPK.	Mevalonic Acid	48-58	serine/threonine kinase 11	Mus musculus	17-21
31167140-5	2019	Mechanistically, LKB1 induced activation of the mevalonate pathway by upregulating mevalonate genes, which was essential for Treg cell functional competency and stability by inducing Treg cell proliferation and suppressing interferon-gamma and interleukin-17A expression independently of AMPK.	Mevalonic Acid	48-58	interferon gamma	Mus musculus	223-239
31167140-5	2019	Mechanistically, LKB1 induced activation of the mevalonate pathway by upregulating mevalonate genes, which was essential for Treg cell functional competency and stability by inducing Treg cell proliferation and suppressing interferon-gamma and interleukin-17A expression independently of AMPK.	Mevalonic Acid	48-58	interleukin 17A	Mus musculus	244-259
31167140-5	2019	Mechanistically, LKB1 induced activation of the mevalonate pathway by upregulating mevalonate genes, which was essential for Treg cell functional competency and stability by inducing Treg cell proliferation and suppressing interferon-gamma and interleukin-17A expression independently of AMPK.	Mevalonic Acid	83-93	serine/threonine kinase 11	Mus musculus	17-21
31167140-6	2019	Furthermore, LKB1 was found to regulate intracellular cholesterol homeostasis and to promote the mevalonate pathway.	Mevalonic Acid	97-107	serine/threonine kinase 11	Mus musculus	13-17
31167140-7	2019	In agreement, mevalonate and its metabolite geranylgeranyl pyrophosphate inhibited conversion of Treg cells and enhanced survival of LKB1-deficient Treg mice.	Mevalonic Acid	14-24	serine/threonine kinase 11	Mus musculus	133-137
30833076-2	2019	Recent findings suggested that the mutation of tumor suppressor gene p53 promoted lipids synthesis and mutant p53 (mutp53) was essential for regulating mevalonate pathway for cholesterol synthesis.	Mevalonic Acid	152-162	tumor protein p53	Homo sapiens	69-72
30914801-1	2019	Farnesyl diphosphate synthase (FDPS), a mevalonate pathway enzyme, is highly expressed in several cancers, including prostate cancer (PCa).	Mevalonic Acid	40-50	farnesyl diphosphate synthetase	Mus musculus	0-29
30914801-1	2019	Farnesyl diphosphate synthase (FDPS), a mevalonate pathway enzyme, is highly expressed in several cancers, including prostate cancer (PCa).	Mevalonic Acid	40-50	farnesyl diphosphate synthetase	Mus musculus	31-35
31018856-4	2019	The 13R-MO titer was increased by 142-fold to 328.15 mg/L via the stepwise metabolic engineering of the original strain, including the overexpression of the rate-limiting genes (tHMG1 and ERG20) of the mevalonate pathway, transcription and protein level regulation of ERG9, Bts1p and Erg20F96Cp fusion, and the overexpression of tCfTPS2 and tCfTPS3 (excision of the N-terminal plastid transit peptide sequences of CfTPS2 and CfTPS3).	Mevalonic Acid	202-212	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	188-193
31018856-4	2019	The 13R-MO titer was increased by 142-fold to 328.15 mg/L via the stepwise metabolic engineering of the original strain, including the overexpression of the rate-limiting genes (tHMG1 and ERG20) of the mevalonate pathway, transcription and protein level regulation of ERG9, Bts1p and Erg20F96Cp fusion, and the overexpression of tCfTPS2 and tCfTPS3 (excision of the N-terminal plastid transit peptide sequences of CfTPS2 and CfTPS3).	Mevalonic Acid	202-212	bifunctional farnesyl-diphosphate farnesyltransferase/squalene synthase	Saccharomyces cerevisiae S288C	268-272
31018856-4	2019	The 13R-MO titer was increased by 142-fold to 328.15 mg/L via the stepwise metabolic engineering of the original strain, including the overexpression of the rate-limiting genes (tHMG1 and ERG20) of the mevalonate pathway, transcription and protein level regulation of ERG9, Bts1p and Erg20F96Cp fusion, and the overexpression of tCfTPS2 and tCfTPS3 (excision of the N-terminal plastid transit peptide sequences of CfTPS2 and CfTPS3).	Mevalonic Acid	202-212	farnesyltranstransferase	Saccharomyces cerevisiae S288C	274-279
31026757-10	2019	Mevalonate mitigated the effects of lovastatin, suggesting that the targeting of CSCs by lovastatin was mediated by the inhibition of its reported target, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR).	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	155-203
31026757-10	2019	Mevalonate mitigated the effects of lovastatin, suggesting that the targeting of CSCs by lovastatin was mediated by the inhibition of its reported target, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR).	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	205-210
30926167-8	2019	The mevalonate pathway, which is targeted by statins, has also been shown to control YAP/TAZ.	Mevalonic Acid	4-14	Yes1 associated transcriptional regulator	Homo sapiens	85-88
30833076-2	2019	Recent findings suggested that the mutation of tumor suppressor gene p53 promoted lipids synthesis and mutant p53 (mutp53) was essential for regulating mevalonate pathway for cholesterol synthesis.	Mevalonic Acid	152-162	tumor protein p53	Homo sapiens	110-113
30833076-5	2019	Our data demonstrated that suppression of mevalonate pathway by simvastatin significantly upregulated Kruppel-like factor 2 (KLF2) and p21WAF1/CIP1 expression in mutp53 colon cancer cells SW1116 but not in p53 wild type cells HCT116.	Mevalonic Acid	42-52	Kruppel like factor 2	Homo sapiens	102-123
30833076-5	2019	Our data demonstrated that suppression of mevalonate pathway by simvastatin significantly upregulated Kruppel-like factor 2 (KLF2) and p21WAF1/CIP1 expression in mutp53 colon cancer cells SW1116 but not in p53 wild type cells HCT116.	Mevalonic Acid	42-52	Kruppel like factor 2	Homo sapiens	125-129
30833076-5	2019	Our data demonstrated that suppression of mevalonate pathway by simvastatin significantly upregulated Kruppel-like factor 2 (KLF2) and p21WAF1/CIP1 expression in mutp53 colon cancer cells SW1116 but not in p53 wild type cells HCT116.	Mevalonic Acid	42-52	cyclin dependent kinase inhibitor 1A	Homo sapiens	135-147
30833076-5	2019	Our data demonstrated that suppression of mevalonate pathway by simvastatin significantly upregulated Kruppel-like factor 2 (KLF2) and p21WAF1/CIP1 expression in mutp53 colon cancer cells SW1116 but not in p53 wild type cells HCT116.	Mevalonic Acid	42-52	tumor protein p53	Homo sapiens	165-168
30765461-4	2019	The mevalonate [3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase] pathway synthesizes lipids for G-protein prenylation.	Mevalonic Acid	4-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	16-73
30787037-3	2019	The mevalonate pathway modifies innate responsiveness through important intracellular signaling molecules called guanine phosphate transferases (GTPases) such as Rho-A.	Mevalonic Acid	4-14	ras homolog family member A	Homo sapiens	162-167
30787037-5	2019	The mevalonate pathway is modifiable through the enzyme 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMGCo-A) reductase.	Mevalonic Acid	4-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	96-114
30787037-6	2019	This enzyme controls the rate limiting step of the mevalonate pathway and is subject to inhibition by statin drugs (HMGCo-A reductase inhibitors) and small chain fatty acids derived from high dietary fiber intake.	Mevalonic Acid	51-61	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	116-133
30036888-1	2019	Human farnesyl pyrophosphate synthase (hFPPS) is a well-settled therapeutic target and it is an enzyme of the mevalonate pathway which catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate.	Mevalonic Acid	110-120	farnesyl diphosphate synthase	Homo sapiens	6-37
30886604-2	2019	Notably, while the IFN antiviral response is known to be directly coupled to mevalonate-sterol biosynthesis, mechanistic insight for providing host pathway-therapeutic targets remain incomplete.	Mevalonic Acid	77-87	interferon alpha 1	Homo sapiens	19-22
30902980-4	2019	SREBP1 control by mechanical cues depends on geranylgeranyl pyrophosphate, another key bio-product of the mevalonate pathway, and impacts on stem cell fate in mouse and on fat storage in Drosophila.	Mevalonic Acid	106-116	sterol regulatory element binding transcription factor 1	Mus musculus	0-6
30036888-1	2019	Human farnesyl pyrophosphate synthase (hFPPS) is a well-settled therapeutic target and it is an enzyme of the mevalonate pathway which catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate.	Mevalonic Acid	110-120	farnesyl diphosphate synthase	Homo sapiens	39-44
30343427-5	2019	Lycopene production was further improved by inhibiting ergosterol production via downregulation of ERG9 expression and by deleting ROX1 or MOT3 genes encoding transcriptional repressors for mevalonate and sterol biosynthetic pathways.	Mevalonic Acid	190-200	Mot3p	Saccharomyces cerevisiae S288C	139-143
30702149-1	2019	3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyses the last step in mevalonate biosynthesis.	Mevalonic Acid	75-85	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-40
30702149-1	2019	3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyses the last step in mevalonate biosynthesis.	Mevalonic Acid	75-85	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-46
30216432-0	2019	Statins influence epithelial expression of the anti-microbial peptide LL-37/hCAP-18 independently of the mevalonate pathway.	Mevalonic Acid	105-115	cathelicidin antimicrobial peptide	Homo sapiens	70-75
30675208-2	2019	Thus, it was suspected that geranylgeranyl pyrophosphate synthase (GGPPS), a key enzyme in the mevalonate pathway, may be involved in the development of RAMLs.	Mevalonic Acid	95-105	geranylgeranyl diphosphate synthase 1	Homo sapiens	28-65
30675208-2	2019	Thus, it was suspected that geranylgeranyl pyrophosphate synthase (GGPPS), a key enzyme in the mevalonate pathway, may be involved in the development of RAMLs.	Mevalonic Acid	95-105	geranylgeranyl diphosphate synthase 1	Homo sapiens	67-72
30675208-7	2019	In conclusion, the increased expression of GGPPS in RAMLs and REAs indicated that mevalonate pathways may be involved in disease progression.	Mevalonic Acid	82-92	geranylgeranyl diphosphate synthase 1	Homo sapiens	43-48
30580964-0	2019	p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.	Mevalonic Acid	18-28	transformation related protein 53, pseudogene	Mus musculus	0-3
30580964-2	2019	Here we describe a novel role for p53 in suppressing the mevalonate pathway, which is responsible for biosynthesis of cholesterol and nonsterol isoprenoids.	Mevalonic Acid	57-67	transformation related protein 53, pseudogene	Mus musculus	34-37
30580964-4	2019	A mouse model of liver cancer reveals that downregulation of mevalonate pathway gene expression by p53 occurs in premalignant hepatocytes, when p53 is needed to actively suppress tumorigenesis.	Mevalonic Acid	61-71	transformation related protein 53, pseudogene	Mus musculus	99-102
30580964-4	2019	A mouse model of liver cancer reveals that downregulation of mevalonate pathway gene expression by p53 occurs in premalignant hepatocytes, when p53 is needed to actively suppress tumorigenesis.	Mevalonic Acid	61-71	transformation related protein 53, pseudogene	Mus musculus	144-147
30580964-5	2019	Furthermore, pharmacological or RNAi inhibition of the mevalonate pathway restricts the development of murine hepatocellular carcinomas driven by p53 loss.	Mevalonic Acid	55-65	transformation related protein 53, pseudogene	Mus musculus	146-149
30580964-7	2019	Our findings demonstrate that repression of the mevalonate pathway is a crucial component of p53-mediated liver tumor suppression and outline the mechanism by which this occurs.	Mevalonic Acid	48-58	transformation related protein 53, pseudogene	Mus musculus	93-96
30662405-3	2018	The phosphatidylinositol-4,5-bisphosphate 3-kinase-AKT-mammalian target of rapamycin complex 1 pathway, p53 with gain-of-function mutation, and oncoprotein MYC upregulate the mevalonate pathway, whereas adenosine monophosphate-activated protein kinase and tumor suppressor protein RB are the downregulators.	Mevalonic Acid	175-185	AKT serine/threonine kinase 1	Homo sapiens	51-54
30735219-1	2019	Mevalonate Kinase (MVK) catalyses the ATP-Mg2+ mediated phosphate transfer of mevalonate to produce mevalonate 5-phosphate and is a key kinase in the mevalonate pathway in the biosynthesis of isopentenyl diphosphate, the precursor of isoprenoid-based biofuels.	Mevalonic Acid	78-88	mevalonate kinase	Homo sapiens	0-17
30735219-1	2019	Mevalonate Kinase (MVK) catalyses the ATP-Mg2+ mediated phosphate transfer of mevalonate to produce mevalonate 5-phosphate and is a key kinase in the mevalonate pathway in the biosynthesis of isopentenyl diphosphate, the precursor of isoprenoid-based biofuels.	Mevalonic Acid	78-88	mevalonate kinase	Homo sapiens	19-22
30735219-1	2019	Mevalonate Kinase (MVK) catalyses the ATP-Mg2+ mediated phosphate transfer of mevalonate to produce mevalonate 5-phosphate and is a key kinase in the mevalonate pathway in the biosynthesis of isopentenyl diphosphate, the precursor of isoprenoid-based biofuels.	Mevalonic Acid	100-110	mevalonate kinase	Homo sapiens	0-17
30735219-1	2019	Mevalonate Kinase (MVK) catalyses the ATP-Mg2+ mediated phosphate transfer of mevalonate to produce mevalonate 5-phosphate and is a key kinase in the mevalonate pathway in the biosynthesis of isopentenyl diphosphate, the precursor of isoprenoid-based biofuels.	Mevalonic Acid	100-110	mevalonate kinase	Homo sapiens	19-22
30735219-3	2019	Here using molecular docking, molecular dynamics (MD) simulations and a hybrid QM/MM study, we revisited the location of Mg2+ resolved in the crystal structure of MVK and determined a catalytically competent MVK structure in complex with the native substrate mevalonate and ATP.	Mevalonic Acid	259-269	mevalonate kinase	Homo sapiens	208-211
30735219-7	2019	Remarkably, we revealed that the phosphorylation of mevalonate catalyzed by MVK occurs via a direct phosphorylation mechanism, instead of the conventionally postulated catalytic base mechanism.	Mevalonic Acid	52-62	mevalonate kinase	Homo sapiens	76-79
30429107-9	2019	Furthermore, ZA enhanced the effect of Tram partially through the mevalonate pathway.	Mevalonic Acid	66-76	translocation associated membrane protein 1	Homo sapiens	39-43
30662405-7	2018	Statins, competitive inhibitors of HMGCR, deplete cells of mevalonate-derived intermediates and consequently inhibit cell proliferation and induce apoptosis.	Mevalonic Acid	59-69	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	35-40
28676012-2	2019	These drugs inhibit 3-betahydroxy 3beta-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway.	Mevalonic Acid	112-122	high mobility group AT-hook 1	Homo sapiens	77-81
30551403-4	2019	Statins, inhibitors of the key enzyme of mevalonate pathway HMG-CoA (3-hydroxy-3-methyl-glutaryl-coenzyme A) reductase are drugs commonly prescribed in order to reduce serum level of cholesterol and to diminish the risk of cardiovascular disease.	Mevalonic Acid	41-51	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	69-118
30565135-1	2019	YAP/TAZ activity is regulated by a complex network of signals that include the Hippo pathway, cell polarity complexes, and signaling receptors of the RTK, GPCR, and WNT pathways and by a seamlessly expanding number of intracellular cues including energy and mevalonate metabolism.	Mevalonic Acid	258-268	Yes1 associated transcriptional regulator	Homo sapiens	0-3
30565135-1	2019	YAP/TAZ activity is regulated by a complex network of signals that include the Hippo pathway, cell polarity complexes, and signaling receptors of the RTK, GPCR, and WNT pathways and by a seamlessly expanding number of intracellular cues including energy and mevalonate metabolism.	Mevalonic Acid	258-268	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	4-7
30745018-1	2019	BACKGROUND: The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (Hmgr) catalyzes the synthesis of mevalonate, a key compound for the synthesis of cholesterol in humans and ergosterol in fungi.	Mevalonic Acid	105-115	high mobility group AT-hook 1	Homo sapiens	72-76
30829216-1	2019	During intrinsic cholesterol formation 3-hydroxy-3-methylgutaryl coenzyme A reductase (HMGCR) converts HMGCoA to mevalonate, in biosynthetic cascade of cholesterol.	Mevalonic Acid	113-123	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	87-92
31892826-6	2018	We observed the anthers of male sterile hmg1-1 and atipi1 atipi2 mutants ultrastructurally, which were deficient in MVA pathway enzymes.	Mevalonic Acid	116-119	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	40-46
30292637-3	2018	Fibroblasts from FH patients showed a reduced LDL-uptake associated with increased intracellular cholesterol levels and coenzyme Q10 (CoQ10) deficiency, suggesting dysregulation of the mevalonate pathway.	Mevalonic Acid	185-195	low density lipoprotein receptor	Homo sapiens	17-19
30292637-8	2018	Dysregulated mevalonate pathway in FH, including increased expression of cholesterogenic enzymes and decreased expression of CoQ10 biosynthetic enzymes, was also corrected by CoQ10 treatment.	Mevalonic Acid	13-23	low density lipoprotein receptor	Homo sapiens	35-37
30184270-5	2018	Notably, we found a p.Asp188Tyr mutation in the enzyme geranylgeranyl pyrophosphate synthase, a component of the mevalonate pathway, which is critical to osteoclast function and is inhibited by N-BPs.	Mevalonic Acid	113-123	geranylgeranyl diphosphate synthase 1	Homo sapiens	55-92
30619997-2	2019	Cell culture studies have shown that AMPK phosphorylation and inhibition of the rate-limiting enzyme in the mevalonate pathway 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) reductase (HMGCR) at serine-871 (Ser871; human HMGCR Ser872) suppresses cholesterol synthesis.	Mevalonic Acid	108-118	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	188-193
30396151-3	2018	In this study, adipose-specific mevalonate pathway-disrupted (aKO) mice were generated through knockout of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR).	Mevalonic Acid	32-42	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	107-157
30396151-3	2018	In this study, adipose-specific mevalonate pathway-disrupted (aKO) mice were generated through knockout of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR).	Mevalonic Acid	32-42	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	159-164
30396151-6	2018	In addition, HMGCR-disrupted adipocytes exhibited loss of lipid accumulation and an increase of cell death, which were ameliorated by the supplementation of mevalonate and geranylgeranyl pyrophosphate but not farnesyl pyrophosphate and squalene.	Mevalonic Acid	157-167	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	13-18
30216659-5	2018	IL-33 was also up-regulated by the general inhibitor of prenylation perillic acid, a RhoA kinase inhibitor Y-27632, and by latrunculin B, but statin-induced IL-33 expression was inhibited by mevalonate, geranylgeranyl pyrophosphate (GGPP) and RhoA activator U-46619.	Mevalonic Acid	191-201	interleukin 33	Homo sapiens	157-162
30619997-2	2019	Cell culture studies have shown that AMPK phosphorylation and inhibition of the rate-limiting enzyme in the mevalonate pathway 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) reductase (HMGCR) at serine-871 (Ser871; human HMGCR Ser872) suppresses cholesterol synthesis.	Mevalonic Acid	108-118	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	224-229
29971772-2	2018	Herein, we report that a high-fat diet (HFD) can augment glycolysis and then accelerate NAFLD-fibrosis progression by downregulating the expression of geranylgeranyl diphosphate synthase (GGPPS), which is a critical enzyme in the mevalonate pathway.	Mevalonic Acid	230-240	geranylgeranyl diphosphate synthase 1	Homo sapiens	151-186
30388448-3	2018	report that lipophilic statins or biphosphonates, targeting the mevalonate pathway, act as efficient vaccine adjuvants and synergize with anti-PD1 against cancer.	Mevalonic Acid	64-74	programmed cell death 1	Homo sapiens	143-146
30270039-5	2018	Additionally, inhibiting the mevalonate pathway enhances antigen-specific anti-tumor immunity, inducing both Th1 and cytolytic T cell responses.	Mevalonic Acid	29-39	negative elongation factor complex member C/D, Th1l	Mus musculus	109-112
29971772-2	2018	Herein, we report that a high-fat diet (HFD) can augment glycolysis and then accelerate NAFLD-fibrosis progression by downregulating the expression of geranylgeranyl diphosphate synthase (GGPPS), which is a critical enzyme in the mevalonate pathway.	Mevalonic Acid	230-240	geranylgeranyl diphosphate synthase 1	Homo sapiens	188-193
30098417-11	2018	Supplementation of mevalonate restored localization of uPAR to cellular protrusions and matrix degradation capacity.	Mevalonic Acid	19-29	plasminogen activator, urokinase receptor	Homo sapiens	55-59
29864496-1	2018	Farnesyl pyrophosphate synthase (FPPS) is a vital enzyme in the mevalonate pathway.	Mevalonic Acid	64-74	farnesyl diphosphate synthetase	Mus musculus	0-31
29923256-2	2018	Statins halt hepatic cholesterol biosynthesis by inhibiting the rate-limiting enzyme in the mevalonate pathway, hydroxymethylglutaryl-coenzyme A reductase (HMGCR).	Mevalonic Acid	92-102	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	156-161
30106444-7	2018	Adding back geranylgeranyl pyrophosphate (GGPP), a key product of the mevalonate pathway, reversed the YAP bioactivity inhibition induced by simvastatin and the cell proliferation inhibition induced by the combination of simvastatin and EGFR inhibitors.	Mevalonic Acid	70-80	Yes1 associated transcriptional regulator	Homo sapiens	103-106
30106444-7	2018	Adding back geranylgeranyl pyrophosphate (GGPP), a key product of the mevalonate pathway, reversed the YAP bioactivity inhibition induced by simvastatin and the cell proliferation inhibition induced by the combination of simvastatin and EGFR inhibitors.	Mevalonic Acid	70-80	epidermal growth factor receptor	Homo sapiens	237-241
29848667-8	2018	The principal mechanism behind statin-mediated effects involves the inactivation of the Hippo/YAP/RhoA pathway in a mevalonate synthesis-dependent manner.	Mevalonic Acid	116-126	Yes1 associated transcriptional regulator	Homo sapiens	94-97
29848667-8	2018	The principal mechanism behind statin-mediated effects involves the inactivation of the Hippo/YAP/RhoA pathway in a mevalonate synthesis-dependent manner.	Mevalonic Acid	116-126	ras homolog family member A	Homo sapiens	98-102
29923256-2	2018	Statins halt hepatic cholesterol biosynthesis by inhibiting the rate-limiting enzyme in the mevalonate pathway, hydroxymethylglutaryl-coenzyme A reductase (HMGCR).	Mevalonic Acid	92-102	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	112-154
30106444-5	2018	Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells.	Mevalonic Acid	90-100	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	15-72
30106444-5	2018	Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells.	Mevalonic Acid	90-100	Yes1 associated transcriptional regulator	Homo sapiens	123-126
30106444-5	2018	Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells.	Mevalonic Acid	90-100	Yes1 associated transcriptional regulator	Homo sapiens	179-182
30106444-5	2018	Simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor of the mevalonate pathway that inhibits YAP bioactivity through nuclear translocation and total YAP expression, increased the cytotoxicity of EGFR inhibitors (cetuximab and gefitinib) against CRC cells.	Mevalonic Acid	90-100	epidermal growth factor receptor	Homo sapiens	225-229
30096489-4	2018	Bisphosphonates (BPs), referred to as gold standard for osteoporosis treatment, have well established role in attenuation of bone resorption and osteoclast apoptosis by inhibition of farnesyl pyrophosphate synthase enzyme (FPPS) in mevalonate pathway.	Mevalonic Acid	232-242	farnesyl diphosphate synthase	Homo sapiens	183-214
29864496-1	2018	Farnesyl pyrophosphate synthase (FPPS) is a vital enzyme in the mevalonate pathway.	Mevalonic Acid	64-74	farnesyl diphosphate synthetase	Mus musculus	33-37
30195238-4	2018	Once transported to the cytosol, citrate is here converted by ACLY to acetyl-CoA, an essential biosynthetic precursor for fatty acid synthesis and mevalonate pathway.	Mevalonic Acid	147-157	ATP citrate lyase	Homo sapiens	62-66
30030381-3	2018	The reaction is specific for IPP, as other pyrophosphate compounds involved in the mevalonate biosynthetic pathway did not react with 5"-dA  Enzymatic reactions employing IPP derivatives as substrates revealed that any chemical change in IPP diminishes its ability to be an effective substrate of fungal viperin.	Mevalonic Acid	83-93	radical S-adenosyl methionine domain containing 2	Homo sapiens	304-311
30089652-4	2018	In the present study, we found that 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), a crucial enzyme in the mevalonate pathway for sterol biosynthesis, is elevated in enzalutamide-resistant prostate cancer cell lines.	Mevalonic Acid	111-121	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	36-77
30089652-4	2018	In the present study, we found that 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), a crucial enzyme in the mevalonate pathway for sterol biosynthesis, is elevated in enzalutamide-resistant prostate cancer cell lines.	Mevalonic Acid	111-121	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	79-84
29890243-3	2018	They are currently used to treat hypercholesterolemia by inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, that catalyses the rate limiting step in the mevalonate biosynthesis pathway, a key intermediate in cholesterol metabolism.	Mevalonic Acid	176-186	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	72-129
30176928-8	2018	In the present review, we examine progress in research into the regulatory mechanisms of YAP/TAZ on glucose metabolism, fatty acid metabolism, mevalonate metabolism, and glutamine metabolism in cancer cells.	Mevalonic Acid	143-153	Yes1 associated transcriptional regulator	Homo sapiens	89-92
30176928-8	2018	In the present review, we examine progress in research into the regulatory mechanisms of YAP/TAZ on glucose metabolism, fatty acid metabolism, mevalonate metabolism, and glutamine metabolism in cancer cells.	Mevalonic Acid	143-153	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	93-96
29778569-0	2018	Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.	Mevalonic Acid	0-10	mechanistic target of rapamycin kinase	Homo sapiens	53-57
30031850-3	2018	Multistep metabolic engineering strategies were applied, including the over-expression of the mevalonate (MVA) pathway rate-limiting enzymes tHMG1 and ERG20, regulation of ERG9 by an inducible promoter and competitive pathway deletion to redirect metabolic flux toward the desired product.	Mevalonic Acid	94-104	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	151-156
32002964-4	2018	Bisphosphonates (BPs), referred to as gold standard for osteoporosis treatment, have well established role in attenuation of bone resorption and osteoclast apoptosis by inhibition of farnesyl pyrophosphate synthase enzyme (FPPS) in mevalonate pathway.	Mevalonic Acid	232-242	farnesyl diphosphate synthase	Homo sapiens	183-214
29782855-0	2018	Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells.	Mevalonic Acid	20-30	histone deacetylase 2	Homo sapiens	51-56
29782855-6	2018	Our data also showed that mevalonate reduced the activity of HDAC2 whereas Y27632, a Rho/ROCK inhibitor, had no effect on HDAC2 activity when co-administered with simvastatin.	Mevalonic Acid	26-36	histone deacetylase 2	Homo sapiens	61-66
29782855-8	2018	The evidences of this study suggest that, although both mevalonate and Rho/ROCK pathways are involved in the detrimental effect elicited by oxidative stress, statins may restore the function and expression of depleted HDAC2 via modulating the mevalonate cascade, at least in A549 cells.	Mevalonic Acid	243-253	histone deacetylase 2	Homo sapiens	218-223
29573412-7	2018	Simultaneous overexpression of tHMG1 and DGA1 coding for rate-limiting enzymes in the mevalonate and lipid biosynthesis pathways led to over 250-fold higher squalene accumulation than a control strain.	Mevalonic Acid	86-96	diacylglycerol O-acyltransferase	Saccharomyces cerevisiae S288C	41-45
29879595-6	2018	Real Time PCR was used to analyse the transcription levels of key genes involved in the mevalonate pathway (hmgcra, cyp51, and dhcr7).	Mevalonic Acid	88-98	3-hydroxy-3-methylglutaryl-CoA reductase a	Danio rerio	108-114
29879595-6	2018	Real Time PCR was used to analyse the transcription levels of key genes involved in the mevalonate pathway (hmgcra, cyp51, and dhcr7).	Mevalonic Acid	88-98	cytochrome P450, family 51	Danio rerio	116-121
29879595-6	2018	Real Time PCR was used to analyse the transcription levels of key genes involved in the mevalonate pathway (hmgcra, cyp51, and dhcr7).	Mevalonic Acid	88-98	7-dehydrocholesterol reductase	Danio rerio	127-132
29374778-2	2018	Trying to clarify the effects of MVK gene impairment on the mevalonate pathway we used a yeast model, the erg12-d mutant strain Saccharomyces cerevisiae (orthologous of MKV) retaining only 10% of mevalonate kinase (MK) activity, to describe the effects of reduced MK activity on the mevalonate pathway.	Mevalonic Acid	60-70	mevalonate kinase	Homo sapiens	33-36
29722423-3	2018	We performed Sanger sequencing of exons and flanking intron-exon boundaries of mevalonate pathway genes (MVD, MVK, PMVK and FDPS) and of SLC17A9.	Mevalonic Acid	79-89	mevalonate diphosphate decarboxylase	Homo sapiens	105-108
29722423-3	2018	We performed Sanger sequencing of exons and flanking intron-exon boundaries of mevalonate pathway genes (MVD, MVK, PMVK and FDPS) and of SLC17A9.	Mevalonic Acid	79-89	mevalonate kinase	Homo sapiens	110-113
29722423-3	2018	We performed Sanger sequencing of exons and flanking intron-exon boundaries of mevalonate pathway genes (MVD, MVK, PMVK and FDPS) and of SLC17A9.	Mevalonic Acid	79-89	phosphomevalonate kinase	Homo sapiens	115-119
29722423-3	2018	We performed Sanger sequencing of exons and flanking intron-exon boundaries of mevalonate pathway genes (MVD, MVK, PMVK and FDPS) and of SLC17A9.	Mevalonic Acid	79-89	farnesyl diphosphate synthase	Homo sapiens	124-128
29899021-4	2018	By blocking mevalonate production, HMGCR inhibition suppressed protein geranylgeranylation, resulting in up-regulation of proapoptotic protein p53 up-regulated modulator of apoptosis (PUMA).	Mevalonic Acid	12-22	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	35-40
30034619-4	2018	Thus, combined inhibition of the mevalonate pathway"s rate-limiting enzyme, HMGCR, can improve atorvastatin"s growth inhibitory effect on epithelial- and mixed mesenchymal-epithelial cancer cells, a finding that may have implications for the design of future anti-metastatic cancer therapies.	Mevalonic Acid	33-43	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	76-81
29575963-6	2018	Areas covered: HMGCR is in the mevalonate (MA) pathway and MA signaling is fundamental to lung biology and asthma.	Mevalonic Acid	31-41	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	15-20
29765517-0	2018	Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma.	Mevalonic Acid	14-24	forkhead box M1	Homo sapiens	86-91
29765517-4	2018	Here, we hypothesized that FoxM1 is involved in the mevalonate pathway of cholesterol biosynthesis in HCC.	Mevalonic Acid	52-62	forkhead box M1	Homo sapiens	27-32
29765517-5	2018	Inhibition of the mevalonate pathway by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), resulted in reduced expression of FoxM1 and increased cell death in human hepatoma cells.	Mevalonic Acid	18-28	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	63-103
29765517-5	2018	Inhibition of the mevalonate pathway by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), resulted in reduced expression of FoxM1 and increased cell death in human hepatoma cells.	Mevalonic Acid	18-28	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	105-110
29765517-5	2018	Inhibition of the mevalonate pathway by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR), resulted in reduced expression of FoxM1 and increased cell death in human hepatoma cells.	Mevalonic Acid	18-28	forkhead box M1	Homo sapiens	147-152
29765517-6	2018	Re-exposure of mevalonate, a product of HMGCR, restored these effects.	Mevalonic Acid	15-25	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	40-45
29765517-7	2018	Likewise, knockdown of HMGCR reduced FoxM1 expression, indicating that FoxM1 expression was regulated by the mevalonate pathway in HCC.	Mevalonic Acid	109-119	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	23-28
29765517-7	2018	Likewise, knockdown of HMGCR reduced FoxM1 expression, indicating that FoxM1 expression was regulated by the mevalonate pathway in HCC.	Mevalonic Acid	109-119	forkhead box M1	Homo sapiens	71-76
29765517-9	2018	In surgically resected human HCC tissues, the gene expression of FoxM1 had a positive correlation with that of the mevalonate pathway-related genes, such as HMGCR or sterol regulatory element-binding protein 2 (SREBP2).	Mevalonic Acid	115-125	forkhead box M1	Homo sapiens	65-70
29765517-9	2018	In surgically resected human HCC tissues, the gene expression of FoxM1 had a positive correlation with that of the mevalonate pathway-related genes, such as HMGCR or sterol regulatory element-binding protein 2 (SREBP2).	Mevalonic Acid	115-125	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	157-162
29765517-9	2018	In surgically resected human HCC tissues, the gene expression of FoxM1 had a positive correlation with that of the mevalonate pathway-related genes, such as HMGCR or sterol regulatory element-binding protein 2 (SREBP2).	Mevalonic Acid	115-125	sterol regulatory element binding transcription factor 2	Homo sapiens	166-209
29765517-9	2018	In surgically resected human HCC tissues, the gene expression of FoxM1 had a positive correlation with that of the mevalonate pathway-related genes, such as HMGCR or sterol regulatory element-binding protein 2 (SREBP2).	Mevalonic Acid	115-125	sterol regulatory element binding transcription factor 2	Homo sapiens	211-217
29765517-10	2018	Furthermore, the gene expression of FoxM1 along with that of HMGCR or SREBP2 defined prognosis of HCC patients, suggesting the clinical significance of the mevalonate-FoxM1 pathway in human HCC.	Mevalonic Acid	156-166	forkhead box M1	Homo sapiens	36-41
29765517-10	2018	Furthermore, the gene expression of FoxM1 along with that of HMGCR or SREBP2 defined prognosis of HCC patients, suggesting the clinical significance of the mevalonate-FoxM1 pathway in human HCC.	Mevalonic Acid	156-166	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	61-66
29765517-10	2018	Furthermore, the gene expression of FoxM1 along with that of HMGCR or SREBP2 defined prognosis of HCC patients, suggesting the clinical significance of the mevalonate-FoxM1 pathway in human HCC.	Mevalonic Acid	156-166	forkhead box M1	Homo sapiens	167-172
29765517-11	2018	Our data indicate that FoxM1 links the mevalonate pathway to oncogenic signals in HCC.	Mevalonic Acid	39-49	forkhead box M1	Homo sapiens	23-28
29765517-12	2018	Thus, we propose a novel therapeutic approach to inhibit FoxM1 by targeting the mevalonate pathway for HCC.	Mevalonic Acid	80-90	forkhead box M1	Homo sapiens	57-62
29731968-5	2018	Furthermore, mechanistically, the combined treatment of CH5126766 with statins upregulated TNF-related apoptosis-inducing ligand (TRAIL), which was dependent on inhibition of the mevalonate pathway and is involved in apoptosis induction in human breast cancer MDA-MB-231 cells.	Mevalonic Acid	179-189	TNF superfamily member 10	Homo sapiens	91-128
29670091-4	2018	Further functional studies illustrate that mevalonate/protein farnesylation/ras homolog family member Q (RHOQ) axis inhibits M1 virus replication.	Mevalonic Acid	43-53	ras homolog family member Q	Homo sapiens	105-109
29713181-2	2018	The mechanism of action for suppressing bone resorption is the inhibition of farnesyl pyrophosphate synthase, a key enzyme in the mevalonic acid metabolic pathway of osteoclasts, to induce apoptosis of the cells.	Mevalonic Acid	130-144	farnesyl diphosphate synthase	Homo sapiens	77-108
29731968-0	2018	Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells.	Mevalonic Acid	16-26	mitogen-activated protein kinase kinase 7	Homo sapiens	73-76
29731968-3	2018	We here demonstrate that the blockade of the mevalonate pathway using the antilipidemic drug statins represses Akt activation following MEK inhibition and induces significant apoptosis when co-treated with CH5126766 or trametinib.	Mevalonic Acid	45-55	mitogen-activated protein kinase kinase 7	Homo sapiens	136-139
29731968-4	2018	These events were clearly negated by the addition of mevalonate or geranylgeranyl pyrophosphate, indicating that the protein geranylgeranylation is implicated in the apoptotic resistance to MEK inhibitors.	Mevalonic Acid	53-63	mitogen-activated protein kinase kinase 7	Homo sapiens	190-193
29731968-5	2018	Furthermore, mechanistically, the combined treatment of CH5126766 with statins upregulated TNF-related apoptosis-inducing ligand (TRAIL), which was dependent on inhibition of the mevalonate pathway and is involved in apoptosis induction in human breast cancer MDA-MB-231 cells.	Mevalonic Acid	179-189	TNF superfamily member 10	Homo sapiens	130-135
29731968-6	2018	The present study not only revealed that the mevalonate pathway could be targetable to enhance the efficacy of MEK inhibitors, but also proposes that combinatorial treatment of MEK inhibitors with statins may be a promising therapeutic strategy to sensitize cancer cells to apoptosis.	Mevalonic Acid	45-55	mitogen-activated protein kinase kinase 7	Homo sapiens	111-114
29731968-6	2018	The present study not only revealed that the mevalonate pathway could be targetable to enhance the efficacy of MEK inhibitors, but also proposes that combinatorial treatment of MEK inhibitors with statins may be a promising therapeutic strategy to sensitize cancer cells to apoptosis.	Mevalonic Acid	45-55	mitogen-activated protein kinase kinase 7	Homo sapiens	177-180
29765975-3	2018	One of the enzymes involved in the mevalonate pathway is FDFT1.	Mevalonic Acid	35-45	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	57-62
28888597-9	2018	The mevalonate pathway for cellular cholesterol synthesis may also be linked to immunity, as inhibition of the terminal enzyme in the pathway, squalene synthase, reduces inflammatory responses to pathogenic bacteria and LPS.	Mevalonic Acid	4-14	farnesyl-diphosphate farnesyltransferase 1	Bos taurus	143-160
29615539-5	2018	L1CAM was: 1) induced in premature forms of cellular senescence triggered chemically and by gamma-radiation, but not in Ras-induced senescence; 2) induced upon inhibition of cyclin-dependent kinases by p16INK4a; 3) induced by TGFbeta and suppressed by RAS/MAPK(Erk) signaling (the latter explaining the lack of L1CAM induction in RAS-induced senescence); and 4) induced upon downregulation of growth-associated gene ANT2, growth in low-glucose medium or inhibition of the mevalonate pathway.	Mevalonic Acid	472-482	L1 cell adhesion molecule	Homo sapiens	0-5
29238070-6	2018	Given that mutp53 is shown to promote cancer progression by upregulating mRNA expression of mevalonate pathway enzymes by binding to the sterol regulatory element-binding protein 2 (SREBP2) and subsequently increasing activities of mevalonate pathway-associated oncogenic proteins (e.g., Ras, Rho, YAP/TAZ), there is a positive-feedback loop between mutp53 and the mevalonate pathway.	Mevalonic Acid	92-102	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	302-305
29513007-5	2018	BPP exhibits moderate inhibition against U2OS cells through a mechanism involving both DNA binding and a mevalonate pathway.	Mevalonic Acid	105-115	sushi repeat containing protein X-linked 2	Homo sapiens	0-3
29080272-1	2018	Nitrogen-containing bisphosphonates (N-BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway.	Mevalonic Acid	172-182	farnesyl diphosphate synthase	Homo sapiens	126-157
29080272-1	2018	Nitrogen-containing bisphosphonates (N-BPs) have been used widely to treat various bone diseases by inhibiting the key enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway.	Mevalonic Acid	172-182	farnesyl diphosphate synthase	Homo sapiens	159-163
29511341-0	2018	The stiff RhoAd from mevalonate to mutant p53.	Mevalonic Acid	21-31	tumor protein p53	Homo sapiens	42-45
29238070-4	2018	Specific reduction of mevalonate-5-phosphate (MVP), a metabolic intermediate in the mevalonate pathway, by statins or mevalonate kinase (MVK) knockdown triggers CHIP ubiquitin ligase-mediated degradation of conformational mutp53 by inhibiting interaction between mutp53 and DNAJA1, a Hsp40 family member.	Mevalonic Acid	22-32	mevalonate kinase	Homo sapiens	118-135
29238070-6	2018	Given that mutp53 is shown to promote cancer progression by upregulating mRNA expression of mevalonate pathway enzymes by binding to the sterol regulatory element-binding protein 2 (SREBP2) and subsequently increasing activities of mevalonate pathway-associated oncogenic proteins (e.g., Ras, Rho, YAP/TAZ), there is a positive-feedback loop between mutp53 and the mevalonate pathway.	Mevalonic Acid	232-242	Yes1 associated transcriptional regulator	Homo sapiens	298-301
29238070-4	2018	Specific reduction of mevalonate-5-phosphate (MVP), a metabolic intermediate in the mevalonate pathway, by statins or mevalonate kinase (MVK) knockdown triggers CHIP ubiquitin ligase-mediated degradation of conformational mutp53 by inhibiting interaction between mutp53 and DNAJA1, a Hsp40 family member.	Mevalonic Acid	22-32	mevalonate kinase	Homo sapiens	137-140
29238070-6	2018	Given that mutp53 is shown to promote cancer progression by upregulating mRNA expression of mevalonate pathway enzymes by binding to the sterol regulatory element-binding protein 2 (SREBP2) and subsequently increasing activities of mevalonate pathway-associated oncogenic proteins (e.g., Ras, Rho, YAP/TAZ), there is a positive-feedback loop between mutp53 and the mevalonate pathway.	Mevalonic Acid	232-242	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	302-305
29238070-4	2018	Specific reduction of mevalonate-5-phosphate (MVP), a metabolic intermediate in the mevalonate pathway, by statins or mevalonate kinase (MVK) knockdown triggers CHIP ubiquitin ligase-mediated degradation of conformational mutp53 by inhibiting interaction between mutp53 and DNAJA1, a Hsp40 family member.	Mevalonic Acid	22-32	DnaJ heat shock protein family (Hsp40) member A1	Homo sapiens	274-280
29238070-6	2018	Given that mutp53 is shown to promote cancer progression by upregulating mRNA expression of mevalonate pathway enzymes by binding to the sterol regulatory element-binding protein 2 (SREBP2) and subsequently increasing activities of mevalonate pathway-associated oncogenic proteins (e.g., Ras, Rho, YAP/TAZ), there is a positive-feedback loop between mutp53 and the mevalonate pathway.	Mevalonic Acid	92-102	sterol regulatory element binding transcription factor 2	Homo sapiens	137-180
29238070-6	2018	Given that mutp53 is shown to promote cancer progression by upregulating mRNA expression of mevalonate pathway enzymes by binding to the sterol regulatory element-binding protein 2 (SREBP2) and subsequently increasing activities of mevalonate pathway-associated oncogenic proteins (e.g., Ras, Rho, YAP/TAZ), there is a positive-feedback loop between mutp53 and the mevalonate pathway.	Mevalonic Acid	232-242	Yes1 associated transcriptional regulator	Homo sapiens	298-301
29238070-6	2018	Given that mutp53 is shown to promote cancer progression by upregulating mRNA expression of mevalonate pathway enzymes by binding to the sterol regulatory element-binding protein 2 (SREBP2) and subsequently increasing activities of mevalonate pathway-associated oncogenic proteins (e.g., Ras, Rho, YAP/TAZ), there is a positive-feedback loop between mutp53 and the mevalonate pathway.	Mevalonic Acid	92-102	sterol regulatory element binding transcription factor 2	Homo sapiens	182-188
29238070-6	2018	Given that mutp53 is shown to promote cancer progression by upregulating mRNA expression of mevalonate pathway enzymes by binding to the sterol regulatory element-binding protein 2 (SREBP2) and subsequently increasing activities of mevalonate pathway-associated oncogenic proteins (e.g., Ras, Rho, YAP/TAZ), there is a positive-feedback loop between mutp53 and the mevalonate pathway.	Mevalonic Acid	232-242	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	302-305
29238070-6	2018	Given that mutp53 is shown to promote cancer progression by upregulating mRNA expression of mevalonate pathway enzymes by binding to the sterol regulatory element-binding protein 2 (SREBP2) and subsequently increasing activities of mevalonate pathway-associated oncogenic proteins (e.g., Ras, Rho, YAP/TAZ), there is a positive-feedback loop between mutp53 and the mevalonate pathway.	Mevalonic Acid	92-102	Yes1 associated transcriptional regulator	Homo sapiens	298-301
28901277-2	2018	In MKD, defective function of the enzyme mevalonate kinase, due to a mutation in the MVK gene, leads to the shortage of mevalonate- derived intermediates, which results in unbalanced prenylation of proteins and altered metabolism of sterols.	Mevalonic Acid	41-51	mevalonate kinase	Homo sapiens	85-88
28881416-1	2018	3-Hydroxy-3-methylglutaryl-coenzyme A synthase (HMGS) in the mevalonate (MVA) pathway generates isoprenoids including phytosterols.	Mevalonic Acid	61-71	3-hydroxy-3-methylglutaryl coenzyme A synthase	Solanum lycopersicum	0-46
28881416-1	2018	3-Hydroxy-3-methylglutaryl-coenzyme A synthase (HMGS) in the mevalonate (MVA) pathway generates isoprenoids including phytosterols.	Mevalonic Acid	61-71	3-hydroxy-3-methylglutaryl coenzyme A synthase	Solanum lycopersicum	48-52
29402381-3	2018	This defect was observed in a range of in vitro insulin resistance models and adipose tissue from insulin-resistant humans and was concomitant with lower expression of mevalonate/CoQ biosynthesis pathway proteins in most models.	Mevalonic Acid	168-178	insulin	Homo sapiens	48-55
29402381-3	2018	This defect was observed in a range of in vitro insulin resistance models and adipose tissue from insulin-resistant humans and was concomitant with lower expression of mevalonate/CoQ biosynthesis pathway proteins in most models.	Mevalonic Acid	168-178	insulin	Homo sapiens	98-105
29337059-1	2018	Farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway, was recently shown to play a role in cancer progression.	Mevalonic Acid	60-70	farnesyl diphosphate synthase	Homo sapiens	0-31
29337059-1	2018	Farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway, was recently shown to play a role in cancer progression.	Mevalonic Acid	60-70	farnesyl diphosphate synthase	Homo sapiens	33-37
29217477-11	2018	Indeed, mevalonate, geranylgeraniol or geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate or farnesol, blocked atorvastatin-induced NgBR expression.	Mevalonic Acid	8-18	NUS1 dehydrodolichyl diphosphate synthase subunit	Homo sapiens	142-146
29328908-4	2018	Rather, the metabolite mevalonate is the mediator of training via activation of IGF1-R and mTOR and subsequent histone modifications in inflammatory pathways.	Mevalonic Acid	23-33	insulin like growth factor 1 receptor	Homo sapiens	80-86
29328908-4	2018	Rather, the metabolite mevalonate is the mediator of training via activation of IGF1-R and mTOR and subsequent histone modifications in inflammatory pathways.	Mevalonic Acid	23-33	mechanistic target of rapamycin kinase	Homo sapiens	91-95
29304175-7	2018	Among other results it was predicted that the mevalonate pathway might constitute a good therapeutic window against cancer proliferation, due to the fact that most cancer cell lines do not express the cholesterol transporter NPC1L1 and the lipoprotein lipase LPL, which makes them rely on the mevalonate pathway to obtain cholesterol.	Mevalonic Acid	46-56	lipoprotein lipase	Homo sapiens	259-262
30283886-10	2018	A whole-exome sequencing study in 3 sisters with AFFs showed, among 37 shared genetic variants, a p.Asp188Tyr mutation in the GGPS1 gene in the mevalonate pathway, critical to osteoclast function, which is also inhibited by bisphosphonates.	Mevalonic Acid	144-154	geranylgeranyl diphosphate synthase 1	Homo sapiens	126-131
30237809-2	2018	Statins target the mevalonate pathway by blocking HMG-CoA reductase.	Mevalonic Acid	19-29	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	50-67
29445111-3	2018	Using Auditory Brainstem Responses (ABR) in a guinea pig model, we demonstrate that fluvastatin, an inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, protects against loss of cochlear function initiated by high intensity noise.	Mevalonic Acid	164-174	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	113-130
29568741-6	2018	In conclusion, L-theanine regulated the secretion of cytokines probably by activating expression of Rap1A and HMGCR proteins involved in the mevalonate biosynthetic pathway in rat splenic lymphocytes.	Mevalonic Acid	141-151	RAP1A, member of RAS oncogene family	Rattus norvegicus	100-105
29568741-6	2018	In conclusion, L-theanine regulated the secretion of cytokines probably by activating expression of Rap1A and HMGCR proteins involved in the mevalonate biosynthetic pathway in rat splenic lymphocytes.	Mevalonic Acid	141-151	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	110-115
29372902-3	2018	The cytoplasmic acetoacetyl-CoA thiolase from Saccharomyces cerevisiae, ERG10, catalyses carbon-carbon bond formation in the mevalonate pathway.	Mevalonic Acid	125-135	acetyl-CoA C-acetyltransferase	Saccharomyces cerevisiae S288C	72-77
29122977-2	2018	Enzymes of the mevalonate pathway are regulated by the transcription factor SREBP-2.	Mevalonic Acid	15-25	sterol regulatory element binding factor 2	Mus musculus	76-83
29319354-12	2018	The MCTP + simvastatin + mevalonate group, MCTP + simvastatin+ FPP group, and MCTP + simvastatin + FPP + GGPP group showed increased mRNA levels of RhoA and ROCK1, as well as increased protein levels of RhoA, compared to the MCTP + simvastatin group.	Mevalonic Acid	25-35	ras homolog family member A	Homo sapiens	148-152
29319354-12	2018	The MCTP + simvastatin + mevalonate group, MCTP + simvastatin+ FPP group, and MCTP + simvastatin + FPP + GGPP group showed increased mRNA levels of RhoA and ROCK1, as well as increased protein levels of RhoA, compared to the MCTP + simvastatin group.	Mevalonic Acid	25-35	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	157-162
29319354-15	2018	Simvastatin decreased RhoA/ROCK1 overexpression by inhibition of mevalonate, FPP, and GGPP synthesis.	Mevalonic Acid	65-75	ras homolog family member A	Homo sapiens	22-26
29319354-15	2018	Simvastatin decreased RhoA/ROCK1 overexpression by inhibition of mevalonate, FPP, and GGPP synthesis.	Mevalonic Acid	65-75	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	27-32
29683099-9	2018	Statins, a well-known class of cholesterol-lowering agents, inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in the mevalonate pathway.	Mevalonic Acid	163-173	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	68-126
29251770-2	2018	Here, we describe the activity of human viperin with two molecules of the mevalonate pathway, geranyl pyrophosphate, and farnesyl pyrophosphate, involved in cholesterol biosynthesis.	Mevalonic Acid	74-84	radical S-adenosyl methionine domain containing 2	Homo sapiens	40-47
29255172-4	2018	By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment.	Mevalonic Acid	232-242	heat shock protein 90 alpha family class A member 1	Homo sapiens	133-138
29255172-4	2018	By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment.	Mevalonic Acid	232-242	tumor protein p53	Homo sapiens	156-159
29255172-0	2018	Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.	Mevalonic Acid	55-65	tumor protein p53	Homo sapiens	31-34
29255172-0	2018	Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.	Mevalonic Acid	55-65	ras homolog family member A	Homo sapiens	66-70
29255172-4	2018	By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment.	Mevalonic Acid	232-242	ras homolog family member A	Homo sapiens	189-193
29255172-4	2018	By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment.	Mevalonic Acid	232-242	tumor protein p53	Homo sapiens	72-75
29255172-4	2018	By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment.	Mevalonic Acid	232-242	histone deacetylase 6	Homo sapiens	127-132
29255172-4	2018	By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment.	Mevalonic Acid	232-242	ras homolog family member A	Homo sapiens	266-270
31275031-1	2018	3-Hydroxy-3-methylglutaryl-CoA reductase (HMGR) is an essential enzyme in the mevalonate pathway.	Mevalonic Acid	78-88	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	0-40
31275031-1	2018	3-Hydroxy-3-methylglutaryl-CoA reductase (HMGR) is an essential enzyme in the mevalonate pathway.	Mevalonic Acid	78-88	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	42-46
29262834-3	2017	In our study, we evaluated the effect of three key intermediates of the mevalonate pathway on GFP-K-Ras protein localization and the gene expression profile in pancreatic cancer cells after exposure to individual statins.	Mevalonic Acid	72-82	KRAS proto-oncogene, GTPase	Homo sapiens	98-103
29262834-8	2017	The inhibitory effect of statins on GFP-K-Ras protein trafficking was partially prevented by addition of any of the mevalonate pathway"s intermediates tested.	Mevalonic Acid	116-126	KRAS proto-oncogene, GTPase	Homo sapiens	40-45
29262834-10	2017	K-Ras protein trafficking within the pancreatic cancer cells is effectively inhibited by the majority of statins; the inhibition is eliminated by isoprenoid intermediates of the mevalonate pathway.	Mevalonic Acid	178-188	KRAS proto-oncogene, GTPase	Homo sapiens	0-5
29039527-2	2017	They act by inhibiting 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate.	Mevalonic Acid	120-130	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	23-73
29039527-3	2017	Blocking of mevalonate synthesis leads to inhibition of the farnesylation and geranylgeranylation of several functional proteins, such as RhoA and other small guanosine triphosphate-binding proteins, that are important in maintaining the undifferentiated status of the cells.	Mevalonic Acid	12-22	ras homolog family member A	Homo sapiens	138-142
28843826-3	2017	Here, we found that zoledronic acid (ZA), an inhibitor of farnesyl diphosphate synthase in the downstream mevalonate pathway, could attenuate hepatic lipid accumulation and improve liver injury in both high-fat diet-induced C57BL/6J mice and ob/ob mice.	Mevalonic Acid	106-116	farnesyl diphosphate synthetase	Mus musculus	58-87
29163687-0	2017	Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR.	Mevalonic Acid	53-63	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	80-86
29163687-0	2017	Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR.	Mevalonic Acid	53-63	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	91-96
29163687-5	2017	Genes upregulated in normal human prostate stromal cells (PrSC) co-cultured with human PC cells (LNCaP) included the mevalonate pathway enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).	Mevalonic Acid	117-127	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	144-185
29163687-5	2017	Genes upregulated in normal human prostate stromal cells (PrSC) co-cultured with human PC cells (LNCaP) included the mevalonate pathway enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).	Mevalonic Acid	117-127	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	187-193
29163687-5	2017	Genes upregulated in normal human prostate stromal cells (PrSC) co-cultured with human PC cells (LNCaP) included the mevalonate pathway enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).	Mevalonic Acid	117-127	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	199-239
29163687-5	2017	Genes upregulated in normal human prostate stromal cells (PrSC) co-cultured with human PC cells (LNCaP) included the mevalonate pathway enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).	Mevalonic Acid	117-127	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	241-246
28882874-11	2017	CONCLUSIONS: We establish UBXD8 as a previously unrecognized determinant that couples flux across the mevalonate pathway to control of cholesterol synthesis and demonstrate the feasibility of applying mammalian haploid genetics to study metabolic traits.	Mevalonic Acid	102-112	Fas associated factor family member 2	Homo sapiens	26-31
28864210-0	2017	Inhibition of the mevalonate pathway by simvastatin interferes with mast cell degranulation by disrupting the interaction between Rab27a and double C2 alpha proteins.	Mevalonic Acid	18-28	RAB27A, member RAS oncogene family	Rattus norvegicus	130-136
28864210-0	2017	Inhibition of the mevalonate pathway by simvastatin interferes with mast cell degranulation by disrupting the interaction between Rab27a and double C2 alpha proteins.	Mevalonic Acid	18-28	double C2 domain alpha	Rattus norvegicus	141-156
28864210-1	2017	Statins are well-known inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which block the mevalonate pathway.	Mevalonic Acid	112-122	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	37-94
28864210-10	2017	In conclusion, simvastatin inhibited the mevalonate pathway, which suppressed the geranylgeranylation of Rab27a by depleting geranylgeranyl pyrophosphate and interfering with the Rab27a-Doc2a interaction.	Mevalonic Acid	41-51	RAB27A, member RAS oncogene family	Rattus norvegicus	105-111
28864210-10	2017	In conclusion, simvastatin inhibited the mevalonate pathway, which suppressed the geranylgeranylation of Rab27a by depleting geranylgeranyl pyrophosphate and interfering with the Rab27a-Doc2a interaction.	Mevalonic Acid	41-51	RAB27A, member RAS oncogene family	Rattus norvegicus	179-185
28864210-10	2017	In conclusion, simvastatin inhibited the mevalonate pathway, which suppressed the geranylgeranylation of Rab27a by depleting geranylgeranyl pyrophosphate and interfering with the Rab27a-Doc2a interaction.	Mevalonic Acid	41-51	double C2 domain alpha	Rattus norvegicus	186-191
28303595-1	2017	Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of the mevalonate pathway.	Mevalonic Acid	141-151	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	52-109
28918367-3	2017	MVK mutations have been reported as associated with impairment of mevalonate pathway with consequent decrease of protein prenylation levels, defective autophagy and increase of IL-1beta secretion, followed by cell death.	Mevalonic Acid	66-76	mevalonate kinase	Homo sapiens	0-3
29163482-4	2017	Aminobisphosphonates (n-BPs), which inhibit farnesyl pyrophosphate synthase, a downstream enzyme of the mevalonate pathway, cause accumulation of upstream PAgs and therefore promote gammadelta T cell activation.	Mevalonic Acid	104-114	farnesyl diphosphate synthetase	Mus musculus	44-75
29023415-1	2017	3-Hydroxy-3-methylglutaryl-CoA synthase (HMGS) is one of the rate-limiting enzymes in the mevalonate pathway as it catalyzes the condensation of acetoacetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA.	Mevalonic Acid	90-100	hydroxymethylglutaryl-CoA synthase	Saccharomyces cerevisiae S288C	41-45
29075041-1	2017	Glioblastoma (GBM), the most aggressive brain cancer, is highly dependent on the mevalonate (MVA) pathway for the synthesis of lipid moieties critical for cell proliferation but the function and regulation of key intermediate enzymes like farnesyl-diphosphate synthase (FDPS), up to now, remained unknown.	Mevalonic Acid	81-91	farnesyl diphosphate synthase	Homo sapiens	239-268
29075041-1	2017	Glioblastoma (GBM), the most aggressive brain cancer, is highly dependent on the mevalonate (MVA) pathway for the synthesis of lipid moieties critical for cell proliferation but the function and regulation of key intermediate enzymes like farnesyl-diphosphate synthase (FDPS), up to now, remained unknown.	Mevalonic Acid	81-91	farnesyl diphosphate synthase	Homo sapiens	270-274
29077483-3	2017	Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway.	Mevalonic Acid	163-177	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	77-117
29077483-3	2017	Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway.	Mevalonic Acid	163-177	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	119-124
29077483-3	2017	Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway.	Mevalonic Acid	181-191	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	77-117
29077483-3	2017	Biosynthesis of the plasma cholesterol and other isoprenoids is catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) through the conversion of HMG-CoA to mevalonic acid in mevalonate pathway.	Mevalonic Acid	181-191	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	119-124
28665545-9	2017	CONCLUSIONS: These findings indicate that mevalonate pathway inhibition by rosuvastatin and alendronate prevents cardiac remodeling and dysfunction possibly through RhoA-independent mechanisms.	Mevalonic Acid	42-52	ras homolog family member A	Rattus norvegicus	165-169
28765914-7	2017	The Rho-associated protein kinase inhibitor Y-27632 inhibited the mevalonate- and GGPP-mediated reversal of atorvastatin-induced upregulation of Fads1, Fads2 and Elovl5.	Mevalonic Acid	66-76	fatty acid desaturase 2	Mus musculus	152-157
28665545-0	2017	Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway.	Mevalonic Acid	14-24	ras homolog family member A	Rattus norvegicus	91-95
28665545-1	2017	AIM: We previously demonstrated that anoxia-mediated Ca2+ handling dysfunction could be ameliorated through inhibition of mevalonate pathway via RhoA- and Ras-related mechanisms in H9c2 cells.	Mevalonic Acid	122-132	ras homolog family member A	Rattus norvegicus	145-149
28765914-7	2017	The Rho-associated protein kinase inhibitor Y-27632 inhibited the mevalonate- and GGPP-mediated reversal of atorvastatin-induced upregulation of Fads1, Fads2 and Elovl5.	Mevalonic Acid	66-76	fatty acid desaturase 1	Mus musculus	145-150
28765914-7	2017	The Rho-associated protein kinase inhibitor Y-27632 inhibited the mevalonate- and GGPP-mediated reversal of atorvastatin-induced upregulation of Fads1, Fads2 and Elovl5.	Mevalonic Acid	66-76	ELOVL family member 5, elongation of long chain fatty acids (yeast)	Mus musculus	162-168
28668359-2	2017	Statins through inhibition of Hydroxy Methyl Glutaryl-CoA Reductase (HMGCR), the main enzyme of the cholesterol biosynthesis pathway, inhibit mevalonate pathway that provides isoprenoids for prenylation of different proteins such as Ras superfamily which has an essential role in cancer developing.	Mevalonic Acid	142-152	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	30-67
28729418-4	2017	BTICs preferentially express mevalonate pathway enzymes, which we find regulated by novel MYC-binding sites, validating an additional transcriptional activation role of MYC in cancer metabolism.	Mevalonic Acid	29-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	90-93
28729418-4	2017	BTICs preferentially express mevalonate pathway enzymes, which we find regulated by novel MYC-binding sites, validating an additional transcriptional activation role of MYC in cancer metabolism.	Mevalonic Acid	29-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	169-172
28729418-6	2017	In turn, mevalonate created a positive feed-forward loop to activate MYC signaling via induction of miR-33b.	Mevalonic Acid	9-19	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	69-72
28729418-6	2017	In turn, mevalonate created a positive feed-forward loop to activate MYC signaling via induction of miR-33b.	Mevalonic Acid	9-19	microRNA 33b	Homo sapiens	100-107
28729418-7	2017	Collectively, our results argue that MYC mediates its oncogenic effects in part by altering mevalonate metabolism in glioma cells, suggesting a therapeutic strategy in this setting.	Mevalonic Acid	92-102	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	37-40
28544034-1	2017	Farnesyl pyrophosphate synthase (FPPS) is a key enzyme in the mevalonate pathway.	Mevalonic Acid	62-72	farnesyl diphosphate synthase	Rattus norvegicus	0-31
28544034-1	2017	Farnesyl pyrophosphate synthase (FPPS) is a key enzyme in the mevalonate pathway.	Mevalonic Acid	62-72	farnesyl diphosphate synthase	Rattus norvegicus	33-37
29955429-2	2017	NADPH, sourced from G6PD fuels nucleotide biosynthesis, maintains redox potential of thioredoxin and glutathione and drives the mevalonate pathway that powers many of the basic mechanisms by which cancer cells escape host control.	Mevalonic Acid	128-138	glucose-6-phosphate dehydrogenase	Canis lupus familiaris	20-24
28810543-5	2017	The present study hypothesized that atorvastatin treatment of ovalbumin-exposed mice attenuates early features of airway remodeling via a mevalonate-dependent mechanism.	Mevalonic Acid	138-148	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	62-71
28950822-7	2017	Statins also enhance the expression, enzymatic activity and coupling of endothelial nitric oxide synthase (eNOS), through mevalonate-dependent effects.	Mevalonic Acid	122-132	nitric oxide synthase 3	Homo sapiens	72-105
28950844-2	2017	It is a cholesterol-lowering drug that acts by inhibiting HMG-CoA reductase, resulting in a decrease in mevalonate, a precursor of cholesterol and monocyte chemoattractant protein-1 (MCP-1).	Mevalonic Acid	104-114	C-C motif chemokine ligand 2	Homo sapiens	147-181
28950844-2	2017	It is a cholesterol-lowering drug that acts by inhibiting HMG-CoA reductase, resulting in a decrease in mevalonate, a precursor of cholesterol and monocyte chemoattractant protein-1 (MCP-1).	Mevalonic Acid	104-114	C-C motif chemokine ligand 2	Homo sapiens	183-188
28729418-0	2017	MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells.	Mevalonic Acid	14-24	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
28729418-3	2017	Here, we link metabolic dysregulation in patient-derived brain tumor-initiating cells (BTIC) to a nexus between MYC and mevalonate signaling, which can be inhibited by statin or 6-fluoromevalonate treatment.	Mevalonic Acid	120-130	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	112-115
28777842-3	2017	PCR and direct sequencing were carried out for five patients from a family, 4 sporadic cases, and 120 healthy controls to identify potential mutations of four genes (MVK, MVD, PMVK, FDPS) involved in the mevalonate pathway as well as SLC17A9, SSH1, and SART3 genes.	Mevalonic Acid	204-214	mevalonate kinase	Homo sapiens	166-169
28777842-3	2017	PCR and direct sequencing were carried out for five patients from a family, 4 sporadic cases, and 120 healthy controls to identify potential mutations of four genes (MVK, MVD, PMVK, FDPS) involved in the mevalonate pathway as well as SLC17A9, SSH1, and SART3 genes.	Mevalonic Acid	204-214	mevalonate diphosphate decarboxylase	Homo sapiens	171-174
28777842-3	2017	PCR and direct sequencing were carried out for five patients from a family, 4 sporadic cases, and 120 healthy controls to identify potential mutations of four genes (MVK, MVD, PMVK, FDPS) involved in the mevalonate pathway as well as SLC17A9, SSH1, and SART3 genes.	Mevalonic Acid	204-214	phosphomevalonate kinase	Homo sapiens	176-180
28777842-3	2017	PCR and direct sequencing were carried out for five patients from a family, 4 sporadic cases, and 120 healthy controls to identify potential mutations of four genes (MVK, MVD, PMVK, FDPS) involved in the mevalonate pathway as well as SLC17A9, SSH1, and SART3 genes.	Mevalonic Acid	204-214	farnesyl diphosphate synthase	Homo sapiens	182-186
28668359-2	2017	Statins through inhibition of Hydroxy Methyl Glutaryl-CoA Reductase (HMGCR), the main enzyme of the cholesterol biosynthesis pathway, inhibit mevalonate pathway that provides isoprenoids for prenylation of different proteins such as Ras superfamily which has an essential role in cancer developing.	Mevalonic Acid	142-152	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	69-74
28710496-6	2017	Pitavastatin-induced apoptosis was blocked by geranylgeraniol and mevalonate, products of the HMGCR pathway, confirming that pitavastatin causes cell death through inhibition of HMGCR.	Mevalonic Acid	66-76	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	94-99
28554582-4	2017	The induction of PCSK9 mRNA was partially, but significantly, prevented by the co-incubation with mevalonate (MVA), farnesol (FOH) and geranylgeraniol (GGOH), while a complete prevention was observed on secreted PCSK9, evaluated by ELISA assay.	Mevalonic Acid	98-108	proprotein convertase subtilisin/kexin type 9	Homo sapiens	17-22
28554582-4	2017	The induction of PCSK9 mRNA was partially, but significantly, prevented by the co-incubation with mevalonate (MVA), farnesol (FOH) and geranylgeraniol (GGOH), while a complete prevention was observed on secreted PCSK9, evaluated by ELISA assay.	Mevalonic Acid	110-113	proprotein convertase subtilisin/kexin type 9	Homo sapiens	17-22
28698273-2	2017	3-Hydroxy-3-methylglutaryl-coenzyme A (CoA) synthase 1 (HMGCS1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR [a rate-limiting step in the mevalonate pathway]), and farnesyl-diphosphate farnesyltransferase 1 (FDFT1 [a committed step in the cholesterol branch]) are repressed by multiple KSHV miRNAs.	Mevalonic Acid	142-152	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	56-62
31156928-3	2017	It inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase which converts HMG-CoA into mevalonic acid, a cholesterol precursor.	Mevalonic Acid	98-112	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	12-69
28419968-3	2017	Dopaminergic neuronal cell death caused by mutations and accumulation of alpha-synuclein in Lewy bodies and neurites was suggested as the main strategy for PD, but current studies have paid attention to the role of mevalonate pathway in incidence of neurodegenerative diseases including PD.	Mevalonic Acid	215-225	synuclein alpha	Homo sapiens	73-88
28542128-6	2017	We were able to prevent the death of HMGCR-deficient lymphocytes by the addition of either the direct metabolite of HMGCR, namely mevalonate, or the downstream metabolite geranylgeranyl pyrophosphate, which is essential for protein prenylation.	Mevalonic Acid	130-140	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	37-42
28542128-6	2017	We were able to prevent the death of HMGCR-deficient lymphocytes by the addition of either the direct metabolite of HMGCR, namely mevalonate, or the downstream metabolite geranylgeranyl pyrophosphate, which is essential for protein prenylation.	Mevalonic Acid	130-140	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	116-121
28419419-2	2017	We previously demonstrated that the actions of i6A correlate with the expression and activity of farnesyl pyrophosphate synthase (FPPS), a key enzyme involved in the mevalonate (MVA) pathway, which is aberrant in brain cancer.	Mevalonic Acid	166-176	farnesyl diphosphate synthase	Homo sapiens	97-128
28419419-2	2017	We previously demonstrated that the actions of i6A correlate with the expression and activity of farnesyl pyrophosphate synthase (FPPS), a key enzyme involved in the mevalonate (MVA) pathway, which is aberrant in brain cancer.	Mevalonic Acid	166-176	farnesyl diphosphate synthase	Homo sapiens	130-134
28263378-1	2017	HMG-CoA reductase (HMGR) is a key enzyme in the mevalonate pathway for sterols and cytosolic isoprenoid production.	Mevalonic Acid	48-58	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	0-17
28362175-1	2017	The growth-suppressive effect of d-delta-tocotrienol and geranylgeraniol is at least partially attributed to their impact on 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting enzyme in the mevalonate pathway that provides essential intermediates for the posttranslational modification of growth-related proteins including RAS.	Mevalonic Acid	216-226	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	125-182
28339090-2	2017	Our previous studies found that farnesyl pyrophosphate synthase (FPPS, EC 2.5.1.10), an essential enzyme in the mevalonate pathway, was upregulated in aorta media from diabetic mice along with the process of atherosclerosis.	Mevalonic Acid	112-122	farnesyl diphosphate synthetase	Mus musculus	32-63
28339090-2	2017	Our previous studies found that farnesyl pyrophosphate synthase (FPPS, EC 2.5.1.10), an essential enzyme in the mevalonate pathway, was upregulated in aorta media from diabetic mice along with the process of atherosclerosis.	Mevalonic Acid	112-122	farnesyl diphosphate synthetase	Mus musculus	65-69
28263378-1	2017	HMG-CoA reductase (HMGR) is a key enzyme in the mevalonate pathway for sterols and cytosolic isoprenoid production.	Mevalonic Acid	48-58	hydroxy methylglutaryl CoA reductase 1	Arabidopsis thaliana	19-23
28208018-1	2017	The human farnesyl pyrophosphate synthase (hFPPS), a key regulatory enzyme in the mevalonate pathway, catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).	Mevalonic Acid	82-92	farnesyl diphosphate synthase	Homo sapiens	10-41
28208018-1	2017	The human farnesyl pyrophosphate synthase (hFPPS), a key regulatory enzyme in the mevalonate pathway, catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).	Mevalonic Acid	82-92	farnesyl diphosphate synthase	Homo sapiens	43-48
28003359-1	2017	The biosynthesis of isopentenyl diphosphate, a fundamental precursor for isoprenoids, via the mevalonate pathway is completed by diphosphomevalonate decarboxylase.	Mevalonic Acid	94-104	hypothetical protein	Saccharolobus solfataricus	129-162
28230855-10	2017	Mevalonate decreased simvastatin-induced AMPK activation and rescued phospho-STAT3 and Skp2 expression in HCC cells, which resulted in the prevention of G0/G1 arrest through inhibition of p21 and p27 accumulation.	Mevalonic Acid	0-10	signal transducer and activator of transcription 3	Homo sapiens	77-82
28230855-10	2017	Mevalonate decreased simvastatin-induced AMPK activation and rescued phospho-STAT3 and Skp2 expression in HCC cells, which resulted in the prevention of G0/G1 arrest through inhibition of p21 and p27 accumulation.	Mevalonic Acid	0-10	S-phase kinase associated protein 2	Homo sapiens	87-91
28230855-10	2017	Mevalonate decreased simvastatin-induced AMPK activation and rescued phospho-STAT3 and Skp2 expression in HCC cells, which resulted in the prevention of G0/G1 arrest through inhibition of p21 and p27 accumulation.	Mevalonic Acid	0-10	H3 histone pseudogene 16	Homo sapiens	188-191
28230855-10	2017	Mevalonate decreased simvastatin-induced AMPK activation and rescued phospho-STAT3 and Skp2 expression in HCC cells, which resulted in the prevention of G0/G1 arrest through inhibition of p21 and p27 accumulation.	Mevalonic Acid	0-10	interferon alpha inducible protein 27	Homo sapiens	196-199
28008986-1	2016	Farnesyl pyrophosphate synthase (FPPS) is a key enzyme in the mevalonate pathway.	Mevalonic Acid	62-72	farnesyl diphosphate synthetase	Mus musculus	0-31
28123123-3	2017	Nitrogen-BPs(N-BPs)inhibit osteoclast function by acting as potent inhibitors of the enzyme farnesyl diphosphate(FPP)synthase in the mevalonate biosynthetic pathway.	Mevalonic Acid	133-143	farnesyl diphosphate synthase	Homo sapiens	92-125
26758944-3	2017	The mevalonate pathway, mediates these effects through important intra-cellular signalling molecules called guanine phosphate transferases (GTPases) such as Rho-A.	Mevalonic Acid	4-14	ras homolog family member A	Homo sapiens	157-162
26758944-5	2017	The mevalonate pathway is readily and substantially modified by inhibition of the enzyme 3-hydroxy-3-methyl-glutaryl-Coenzyme A (HMGCo-A) reductase.	Mevalonic Acid	4-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	129-147
26758951-4	2017	Statins are inhibitors of HMG-CoA reductase, the enzyme that catalyzes the reduction of HMG-CoA to mevalonic acid by NADPH.	Mevalonic Acid	99-113	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	26-43
28098152-1	2017	Farnesyl pyrophosphate synthase (FPPS) is an enzyme of the mevalonate pathway and a well-established therapeutic target.	Mevalonic Acid	59-69	farnesyl diphosphate synthase	Homo sapiens	0-31
28098152-1	2017	Farnesyl pyrophosphate synthase (FPPS) is an enzyme of the mevalonate pathway and a well-established therapeutic target.	Mevalonic Acid	59-69	farnesyl diphosphate synthase	Homo sapiens	33-37
28066443-5	2016	The precise mechanisms by which IFN regulates the mevalonate-sterol pathway-the spine of the network-are beginning to be unraveled.	Mevalonic Acid	50-60	interferon alpha 1	Homo sapiens	32-35
28008986-1	2016	Farnesyl pyrophosphate synthase (FPPS) is a key enzyme in the mevalonate pathway.	Mevalonic Acid	62-72	farnesyl diphosphate synthetase	Mus musculus	33-37
27742831-6	2016	Meanwhile, GM-CSF increased 3-hydroxy-3-methyl-glutaryl-CoA reductase, which is the rate-limiting enzyme of the mevalonate pathway.	Mevalonic Acid	112-122	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	11-17
27884413-1	2016	Tocotrienols accelerate the degradation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase that catalyzes the biosynthesis of mevalonate; the latter is essential for preadipocyte differentiation.	Mevalonic Acid	136-146	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	43-100
27692616-3	2016	Altered flux through the mevalonic acid synthesis pathway also appears to be a required event in the antiviral interferon (IFN) response of macrophages and in the activation, proliferation, and differentiation of T cells.	Mevalonic Acid	25-39	interferon alpha 1	Homo sapiens	111-121
27692616-3	2016	Altered flux through the mevalonic acid synthesis pathway also appears to be a required event in the antiviral interferon (IFN) response of macrophages and in the activation, proliferation, and differentiation of T cells.	Mevalonic Acid	25-39	interferon alpha 1	Homo sapiens	123-126
27871246-8	2016	CONCLUSIONS: The results support the notion that the ERG10 gene in X. dendrorhous is a functional acetyl-CoA C-acetyltransferase essential for the synthesis of mevalonate in yeast.	Mevalonic Acid	160-170	acetyl-CoA C-acetyltransferase	Saccharomyces cerevisiae S288C	53-58
27548304-5	2016	Addition of mevalonate, a downstream metabolite of 3-hydroxy-3-methylglutaryl coenzyme A reductase, almost completely abrogated the effect of atorvastatin on MDSCs, indicating that the mevalonate pathway was involved.	Mevalonic Acid	12-22	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	51-98
27884413-9	2016	In contrast, mevalonate, but not rosiglitazone, reversed the effects of lovastatin, a competitive inhibitor of HMG CoA reductase shown to inhibit adipocyte differentiation via mevalonate deprivation.	Mevalonic Acid	13-23	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	111-128
27884413-9	2016	In contrast, mevalonate, but not rosiglitazone, reversed the effects of lovastatin, a competitive inhibitor of HMG CoA reductase shown to inhibit adipocyte differentiation via mevalonate deprivation.	Mevalonic Acid	176-186	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	111-128
27849604-0	2016	Correction for Wang et al., Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.	Mevalonic Acid	41-51	hyaluronan mediated motility receptor	Homo sapiens	81-86
27849604-0	2016	Correction for Wang et al., Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.	Mevalonic Acid	41-51	Yes1 associated transcriptional regulator	Homo sapiens	105-108
27654507-0	2016	The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.	Mevalonic Acid	107-117	AT-rich interaction domain 1A	Homo sapiens	38-44
27377765-1	2016	Mevalonate kinase deficiency (MKD) is caused by mutations in a key enzyme of the mevalonate-cholesterol biosynthesis pathway, leading to recurrent autoinflammatory disease characterised by enhanced release of interleukin-1beta (IL-1beta).	Mevalonic Acid	81-91	interleukin 1 beta	Homo sapiens	209-226
27654507-3	2016	Knockout of ARID1A in an ovarian clear cell carcinoma cell line with wild-type ARID1A, OVCA429, primarily resulted in downregulation of the mevalonate pathway, an important metabolic pathway involved in isoprenoid synthesis, cholesterol synthesis, and other downstream pathways.	Mevalonic Acid	140-150	AT-rich interaction domain 1A	Homo sapiens	12-18
27713571-10	2016	A positive relationship emerged between HMG-CoAR, hormone receptors and TAZ/YAP, suggesting a connection between the mevalonate pathway, the hormonal milieu and Hippo in MBC.	Mevalonic Acid	117-127	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	72-75
27654507-4	2016	In a complementary experiment, expression of wild-type ARID1A in an ovarian clear cell carcinoma cell line containing mutated ARID1A, OVISE, affected the mevalonate pathway in a reciprocal manner.	Mevalonic Acid	154-164	AT-rich interaction domain 1A	Homo sapiens	55-61
27654507-4	2016	In a complementary experiment, expression of wild-type ARID1A in an ovarian clear cell carcinoma cell line containing mutated ARID1A, OVISE, affected the mevalonate pathway in a reciprocal manner.	Mevalonic Acid	154-164	AT-rich interaction domain 1A	Homo sapiens	126-132
27654507-5	2016	A striking aspect of these analyses was that, although only 5% of the detected proteome showed significant abundance changes, most proteins in the mevalonate pathway were coordinately affected by ARID1A status.	Mevalonic Acid	147-157	AT-rich interaction domain 1A	Homo sapiens	196-202
27654507-9	2016	We conclude that ARID1A status indirectly influences the mevalonate pathway and probably influences other processes including glycogen metabolism and 14-3-3-mediated signaling.	Mevalonic Acid	57-67	AT-rich interaction domain 1A	Homo sapiens	17-23
27775703-0	2016	DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.	Mevalonic Acid	61-71	DnaJ heat shock protein family (Hsp40) member A1	Homo sapiens	0-6
27775703-0	2016	DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.	Mevalonic Acid	61-71	tumor protein p53	Homo sapiens	45-48
27775703-7	2016	Our study reveals that DNAJA1 controls the fate of misfolded mutp53, provides insights into potential strategies to deplete mutp53 through the mevalonate pathway-DNAJA1 axis, and highlights the significance of p53 status in impacting statins" efficacy on cancer therapy.	Mevalonic Acid	143-153	DnaJ heat shock protein family (Hsp40) member A1	Homo sapiens	23-29
27775703-7	2016	Our study reveals that DNAJA1 controls the fate of misfolded mutp53, provides insights into potential strategies to deplete mutp53 through the mevalonate pathway-DNAJA1 axis, and highlights the significance of p53 status in impacting statins" efficacy on cancer therapy.	Mevalonic Acid	143-153	tumor protein p53	Homo sapiens	64-67
27784901-0	2016	Targeting mutant p53 through the mevalonate pathway.	Mevalonic Acid	33-43	tumor protein p53	Homo sapiens	17-20
27784901-2	2016	Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.	Mevalonic Acid	18-28	tumor protein p53	Homo sapiens	100-103
27784901-2	2016	Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.	Mevalonic Acid	18-28	tumor protein p53	Homo sapiens	156-159
27158912-8	2016	In addition, the activity of 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase (0.94 HMG-CoA ratio/(mevalonate) increased significantly in contrast to the activities of lipoprotein lipase (4.87 mumoles of glycerol liberated/h/L) and lecithin cholesterol acyltransferase (54.61 mumoles of cholesterol esterified/h/L) in diabetic rats.	Mevalonic Acid	108-118	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	29-86
27676321-3	2016	Here the phosphorylation reaction mechanism of a representative kinase in the mevalonate pathway, phosphomevalonate kinase, was studied by using molecular dynamics and hybrid QM/MM methods.	Mevalonic Acid	78-88	phosphomevalonate kinase	Homo sapiens	98-122
27713571-10	2016	A positive relationship emerged between HMG-CoAR, hormone receptors and TAZ/YAP, suggesting a connection between the mevalonate pathway, the hormonal milieu and Hippo in MBC.	Mevalonic Acid	117-127	Yes1 associated transcriptional regulator	Homo sapiens	76-79
27475840-1	2016	Statins are competitive inhibitors of hydroxy-methyl-glutaryl Coenzyme A (HMG-CoA) reductase, a key enzyme involved in the conversion of HMG-CoA to the cholesterol precursor mevalonate.	Mevalonic Acid	174-184	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Oryctolagus cuniculus	38-92
27585573-2	2016	Feedback inhibition of HMGCoA reductase (HMGCR) catalytic activity in the transformation of HMG-CoA to mevalonate is a significant regulatory step in sterol biosynthetic pathway.	Mevalonic Acid	103-113	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	23-39
27585573-2	2016	Feedback inhibition of HMGCoA reductase (HMGCR) catalytic activity in the transformation of HMG-CoA to mevalonate is a significant regulatory step in sterol biosynthetic pathway.	Mevalonic Acid	103-113	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	41-46
27335167-7	2016	The inhibitory effect of simvastatin on atrial fibroblasts was abrogated by mevalonic acid (500 muM) that bypasses 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition.	Mevalonic Acid	76-90	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	115-172
27462341-1	2016	Terpene synthases are responsible for synthesis of a large number of terpenes in plants using substrates provided by two distinct metabolic pathways, the mevalonate-dependent pathway that is located in cytosol and has been suggested to be responsible for synthesis of sesquiterpenes (C15), and 2-C-methyl-D-erythritol-4-phosphate pathway located in plastids and suggested to be responsible for the synthesis of hemi- (C5), mono- (C10), and diterpenes (C20).	Mevalonic Acid	154-164	placenta associated 8	Homo sapiens	284-287
27060252-4	2016	Remarkably, mitofusin 2, in addition to its role in fusion, is important for maintaining coenzyme Q levels and may be an integral player in the mevalonate synthesis pathway.	Mevalonic Acid	144-154	mitofusin 2	Homo sapiens	12-23
27329838-5	2016	Upregulation of mevalonate appeared to be associated with the acquisition of a p53 mutation in the ascites-derived cells.	Mevalonic Acid	16-26	transformation related protein 53, pseudogene	Mus musculus	79-82
27421004-1	2016	ATP citrate lyase (ACLY) is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA, which is a key precursor of both fatty acid and mevalonate synthesis pathways.	Mevalonic Acid	150-160	ATP citrate lyase	Bos taurus	0-17
27421004-1	2016	ATP citrate lyase (ACLY) is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA, which is a key precursor of both fatty acid and mevalonate synthesis pathways.	Mevalonic Acid	150-160	ATP citrate lyase	Bos taurus	19-23
27346340-4	2016	Only mevalonate-derived geranylgeranyl diphosphate (GGPP, C20) resisted CD39-mediated hydrolysis and acted as a regulator of CD39 expression and activity.	Mevalonic Acid	5-15	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	72-76
27346340-4	2016	Only mevalonate-derived geranylgeranyl diphosphate (GGPP, C20) resisted CD39-mediated hydrolysis and acted as a regulator of CD39 expression and activity.	Mevalonic Acid	5-15	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	125-129
27462341-1	2016	Terpene synthases are responsible for synthesis of a large number of terpenes in plants using substrates provided by two distinct metabolic pathways, the mevalonate-dependent pathway that is located in cytosol and has been suggested to be responsible for synthesis of sesquiterpenes (C15), and 2-C-methyl-D-erythritol-4-phosphate pathway located in plastids and suggested to be responsible for the synthesis of hemi- (C5), mono- (C10), and diterpenes (C20).	Mevalonic Acid	154-164	homeobox C10	Homo sapiens	430-433
27275740-15	2016	Therefore, simvastatin was demonstrated to inhibit IL-5-induced CCR3 expression and chemotaxis of eosinophils mediated via the mevalonate pathway.	Mevalonic Acid	127-137	interleukin 5	Homo sapiens	51-55
26960292-1	2016	Statins are widely prescribed cholesterol-lowering medications and act through inhibition of the human enzyme 3-methylglutaryl coenzyme A reductase (HMG-R) which produces mevalonate (MVAL), a key substrate for cholesterol biosynthesis.	Mevalonic Acid	171-181	high mobility group AT-hook 1	Homo sapiens	149-154
27347133-9	2016	Mevalonic acid and PD98059 reversed the ERK activation and apoptosis induced by treatment with simvastatin.	Mevalonic Acid	0-14	mitogen-activated protein kinase 1	Homo sapiens	40-43
27275740-15	2016	Therefore, simvastatin was demonstrated to inhibit IL-5-induced CCR3 expression and chemotaxis of eosinophils mediated via the mevalonate pathway.	Mevalonic Acid	127-137	C-C motif chemokine receptor 3	Homo sapiens	64-68
26980746-4	2016	By reducing the metabolic flux through the mevalonate pathway, NZ lowered the activity of Ras/ERK1/2/HIF-1alpha axis and the expression of P-glycoprotein, decreased the glycolysis and the mitochondrial respiratory chain, induced a cytochrome c/caspase 9/caspase 3-dependent apoptosis, thus restoring the direct cytotoxic effects of doxorubicin on tumor cell.	Mevalonic Acid	43-53	mitogen-activated protein kinase 3	Mus musculus	94-100
26639033-6	2016	In vitro, statins decreased transcription and translation of IL-6 and collagen, with reversal via mevalonate.	Mevalonic Acid	98-108	interleukin 6	Homo sapiens	61-65
27210746-1	2016	Human Vgamma9Vdelta2 T cells respond to tumor cells by sensing elevated levels of phosphorylated intermediates of the dysregulated mevalonate pathway, which is translated into activating signals by the ubiquitously expressed butyrophilin A1 (BTN3A1) through yet unknown mechanisms.	Mevalonic Acid	131-141	butyrophilin subfamily 3 member A1	Homo sapiens	242-248
26908642-1	2016	STUDY HYPOTHESIS: Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase of the mevalonate pathway and prescription drugs that treat hypercholesterolemia, compromise preimplantation mouse development via modulation of HIPPO signaling.	Mevalonic Acid	106-116	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	41-98
26908642-5	2016	In human cell lines, the mevalonate pathway regulates YAP to mediate self-renewal and survival through geranylgeranylation of RHO proteins.	Mevalonic Acid	25-35	Yes1 associated transcriptional regulator	Homo sapiens	54-57
27044891-0	2016	P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.	Mevalonic Acid	9-19	ADP ribosylation factor 6	Homo sapiens	56-60
26980746-4	2016	By reducing the metabolic flux through the mevalonate pathway, NZ lowered the activity of Ras/ERK1/2/HIF-1alpha axis and the expression of P-glycoprotein, decreased the glycolysis and the mitochondrial respiratory chain, induced a cytochrome c/caspase 9/caspase 3-dependent apoptosis, thus restoring the direct cytotoxic effects of doxorubicin on tumor cell.	Mevalonic Acid	43-53	caspase 9	Mus musculus	244-253
26980746-4	2016	By reducing the metabolic flux through the mevalonate pathway, NZ lowered the activity of Ras/ERK1/2/HIF-1alpha axis and the expression of P-glycoprotein, decreased the glycolysis and the mitochondrial respiratory chain, induced a cytochrome c/caspase 9/caspase 3-dependent apoptosis, thus restoring the direct cytotoxic effects of doxorubicin on tumor cell.	Mevalonic Acid	43-53	caspase 3	Mus musculus	254-263
26997483-4	2016	We find that sustained inflammation suppresses CYP7A1, leading to accumulation of intermediate metabolites at the branch point of the mevalonate pathway.	Mevalonic Acid	134-144	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	47-53
27052676-4	2016	By whole-exome sequencing, we sequencing identified a nonsense variation c.412C > T (p.Arg138*) in the phosphomevalonate kinase gene (PMVK), which encodes a cytoplasmic enzyme catalyzing the conversion of mevalonate 5-phosphate to mevalonate 5-diphosphate in the mevalonate pathway.	Mevalonic Acid	113-123	phosphomevalonate kinase	Homo sapiens	137-141
26986474-3	2016	Rosuvastatin lowers the cholesterol levels by inhibiting the key enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) in the cholesterol producing mevalonate pathway.	Mevalonic Acid	163-173	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	115-132
26750334-3	2016	The activity of the YAP/TAZ transcriptional coactivators, downstream transducers of the Hippo cascade and powerful pro-oncogenic factors, was recently found to be regulated by metabolic pathways, such as aerobic glycolysis and mevalonate synthesis, and by the nutrient-sensing LKB1-AMPK and TSC-mTOR pathways.	Mevalonic Acid	227-237	Yes1 associated transcriptional regulator	Homo sapiens	20-23
26750334-3	2016	The activity of the YAP/TAZ transcriptional coactivators, downstream transducers of the Hippo cascade and powerful pro-oncogenic factors, was recently found to be regulated by metabolic pathways, such as aerobic glycolysis and mevalonate synthesis, and by the nutrient-sensing LKB1-AMPK and TSC-mTOR pathways.	Mevalonic Acid	227-237	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	24-27
26750334-3	2016	The activity of the YAP/TAZ transcriptional coactivators, downstream transducers of the Hippo cascade and powerful pro-oncogenic factors, was recently found to be regulated by metabolic pathways, such as aerobic glycolysis and mevalonate synthesis, and by the nutrient-sensing LKB1-AMPK and TSC-mTOR pathways.	Mevalonic Acid	227-237	serine/threonine kinase 11	Homo sapiens	277-281
26750334-3	2016	The activity of the YAP/TAZ transcriptional coactivators, downstream transducers of the Hippo cascade and powerful pro-oncogenic factors, was recently found to be regulated by metabolic pathways, such as aerobic glycolysis and mevalonate synthesis, and by the nutrient-sensing LKB1-AMPK and TSC-mTOR pathways.	Mevalonic Acid	227-237	mechanistic target of rapamycin kinase	Homo sapiens	295-299
27012807-5	2016	Mevalonate kinase deficiency was suspected on the basis of clinical (hydrops fetalis, hepatosplenomegaly, hypotonia) and laboratory signs (anaemia, intense acute phase reaction, increased urinary excretion of mevalonic acid).	Mevalonic Acid	209-223	mevalonate kinase	Homo sapiens	0-17
26565813-0	2016	Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.	Mevalonic Acid	140-150	AKT serine/threonine kinase 1	Homo sapiens	70-73
27005600-2	2016	As the important enzyme in the sesquiterpenoid biosynthesis pathway, 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMGS) catalyze the crucial step in the mevalonate pathway in plants.	Mevalonic Acid	156-166	hydroxymethylglutaryl-CoA synthase	Saccharomyces cerevisiae S288C	117-121
26658366-11	2016	CONCLUSIONS: The regulation of the prenylated protein RHOB in this study was consistent with the known effects of zoledronic acid on the mevalonate pathway.	Mevalonic Acid	137-147	ras homolog family member B	Homo sapiens	54-58
26660152-7	2016	Farnesol may be the mevalonate-derived inducer of adipocyte differentiation and potentially an insulin sensitizer via activation of PPARgamma and upregulation of glucose uptake.	Mevalonic Acid	20-30	peroxisome proliferator activated receptor gamma	Mus musculus	132-141
27314093-2	2016	Our recent work shows that the mevalonate pathway influences cell size, growth, and proteostasis by regulating basal autophagic flux through geranylgeranylation of the small GTPase RAB11.	Mevalonic Acid	31-41	RAB11A, member RAS oncogene family	Homo sapiens	181-186
26713363-0	2016	Activation of AMP-activated protein kinase decreases receptor activator of NF-kappaB ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells.	Mevalonic Acid	157-167	sclerostin	Mus musculus	117-127
26713363-8	2016	CONCLUSION: These findings indicated that AMPK regulated RANKL and sclerostin expression through the mevalonate pathway in osteocytes.	Mevalonic Acid	101-111	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	57-62
26713363-8	2016	CONCLUSION: These findings indicated that AMPK regulated RANKL and sclerostin expression through the mevalonate pathway in osteocytes.	Mevalonic Acid	101-111	sclerostin	Mus musculus	67-77
26978350-3	2016	The blocking of the mevalonate pathway in a neuronal cell line (Daoy), using statins or mevalonate, induced an increase in the expression of the inflammasome gene (NLRP3) and programmed cell death related to mitochondrial dysfunction.	Mevalonic Acid	20-30	NLR family pyrin domain containing 3	Homo sapiens	164-169
26978350-3	2016	The blocking of the mevalonate pathway in a neuronal cell line (Daoy), using statins or mevalonate, induced an increase in the expression of the inflammasome gene (NLRP3) and programmed cell death related to mitochondrial dysfunction.	Mevalonic Acid	88-98	NLR family pyrin domain containing 3	Homo sapiens	164-169
26938778-6	2016	Strikingly, we find miR-342-5p targets mevalonate-sterol biosynthesis using a multihit mechanism suppressing the pathway at different functional levels: transcriptionally via SREBF2, post-transcriptionally via miR-33, and enzymatically via IDI1 and SC4MOL.	Mevalonic Acid	39-49	microRNA 342	Homo sapiens	20-27
26938778-6	2016	Strikingly, we find miR-342-5p targets mevalonate-sterol biosynthesis using a multihit mechanism suppressing the pathway at different functional levels: transcriptionally via SREBF2, post-transcriptionally via miR-33, and enzymatically via IDI1 and SC4MOL.	Mevalonic Acid	39-49	sterol regulatory element binding transcription factor 2	Homo sapiens	175-181
26938778-6	2016	Strikingly, we find miR-342-5p targets mevalonate-sterol biosynthesis using a multihit mechanism suppressing the pathway at different functional levels: transcriptionally via SREBF2, post-transcriptionally via miR-33, and enzymatically via IDI1 and SC4MOL.	Mevalonic Acid	39-49	microRNA 33a	Homo sapiens	210-216
26938778-6	2016	Strikingly, we find miR-342-5p targets mevalonate-sterol biosynthesis using a multihit mechanism suppressing the pathway at different functional levels: transcriptionally via SREBF2, post-transcriptionally via miR-33, and enzymatically via IDI1 and SC4MOL.	Mevalonic Acid	39-49	isopentenyl-diphosphate delta isomerase 1	Homo sapiens	240-244
26938778-6	2016	Strikingly, we find miR-342-5p targets mevalonate-sterol biosynthesis using a multihit mechanism suppressing the pathway at different functional levels: transcriptionally via SREBF2, post-transcriptionally via miR-33, and enzymatically via IDI1 and SC4MOL.	Mevalonic Acid	39-49	methylsterol monooxygenase 1	Homo sapiens	249-255
27155373-2	2016	The mevalonate cascade and its rate-liming enzyme HMG CoA-reductase has recently drawn the attention of cancer researchers because strong evidences arising mostly from epidemiologic studies, show that it could promote transformation.	Mevalonic Acid	4-14	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	50-67
27155373-9	2016	The mevalonate pathway is implicated in cell stemness, cell proliferation, and organ size regulation through the Hippo pathway (e.g. Yap/Taz signaling axis).	Mevalonic Acid	4-14	Yes1 associated transcriptional regulator	Homo sapiens	133-136
27155373-9	2016	The mevalonate pathway is implicated in cell stemness, cell proliferation, and organ size regulation through the Hippo pathway (e.g. Yap/Taz signaling axis).	Mevalonic Acid	4-14	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	137-140
26876023-0	2016	GAME9 regulates the biosynthesis of steroidal alkaloids and upstream isoprenoids in the plant mevalonate pathway.	Mevalonic Acid	94-104	ethylene-responsive transcription factor 1	Solanum lycopersicum	0-5
26876023-4	2016	GAME9 knockdown and overexpression in tomato and potato alters expression of SGAs and upstream mevalonate pathway genes including the cholesterol biosynthesis gene STEROL SIDE CHAIN REDUCTASE 2 (SSR2).	Mevalonic Acid	95-105	ethylene-responsive transcription factor 1	Solanum lycopersicum	0-5
26565813-0	2016	Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.	Mevalonic Acid	140-150	mitogen-activated protein kinase 1	Homo sapiens	83-86
28132458-3	2016	They act by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (EC 1.1.1.88), the first committed enzyme of the mevalonate pathway.	Mevalonic Acid	144-154	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	37-94
26645604-9	2016	Finally, atorvastatin mediated p21 upregulation occurred via mevalonate pathway, but independent of p53.	Mevalonic Acid	61-71	cyclin dependent kinase inhibitor 1A	Homo sapiens	31-34
27051663-1	2016	Statins are inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an enzyme necessary for the production of mevalonate.	Mevalonic Acid	121-131	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	30-77
27777393-3	2016	In addition, zoledronic acid shows the potent suppression effect on bone resorption by inhibiting farnesyl diphosphate synthase of the mevalonate pathway(FPPS)strongly.	Mevalonic Acid	135-145	farnesyl diphosphate synthase	Homo sapiens	98-127
27777393-3	2016	In addition, zoledronic acid shows the potent suppression effect on bone resorption by inhibiting farnesyl diphosphate synthase of the mevalonate pathway(FPPS)strongly.	Mevalonic Acid	135-145	farnesyl diphosphate synthase	Homo sapiens	154-158
26432005-2	2016	Mevalonate pathway and its rate-limiting enzyme HMG-CoA reductase (HMGCR) have shown important roles in the progression of several cancer types.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	48-65
26432005-2	2016	Mevalonate pathway and its rate-limiting enzyme HMG-CoA reductase (HMGCR) have shown important roles in the progression of several cancer types.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	67-72
26409462-11	2016	Further, a positive urinary mevalonic acid excretion still requires MVK analysis to confirm the diagnosis of MKD.	Mevalonic Acid	28-42	mevalonate kinase	Homo sapiens	68-71
26409462-13	2016	However, as long as genetic testing is not widely available and affordable, measurement of urinary mevalonic acid is a fair way to select patients for MVK gene analysis or enzyme assay.	Mevalonic Acid	99-113	mevalonate kinase	Homo sapiens	151-154
26386973-2	2015	Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification (prenylation) of KRAS.	Mevalonic Acid	23-33	KRAS proto-oncogene, GTPase	Homo sapiens	123-127
26686643-4	2015	Mevalonate pathway effects on cell size and protein density are mediated through geranylgeranylation of the small GTPase RAB11, which is required for basal autophagic flux.	Mevalonic Acid	0-10	RAB11A, member RAS oncogene family	Homo sapiens	121-126
26515701-0	2015	Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.	Mevalonic Acid	89-99	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	27-37
26515701-2	2015	DKK-1 is highly expressed in human breast cancer cells and can be suppressed by inhibitors of the mevalonate pathway such as statins and amino-bisphosphonates.	Mevalonic Acid	98-108	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	0-5
26515701-4	2015	We show that a sequential mevalonate pathway blockade using statins and amino-bisphosphonates suppresses DKK-1 more significantly than the individual agents alone.	Mevalonic Acid	26-36	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	105-110
26427720-2	2015	We evaluated transcriptional regulation of SULT1C2 by mevalonate (MVA)-derived intermediates in primary cultured rat hepatocytes using several cholesterol synthesis inhibitors.	Mevalonic Acid	54-64	sulfotransferase family 1C member 2	Rattus norvegicus	43-50
26427720-2	2015	We evaluated transcriptional regulation of SULT1C2 by mevalonate (MVA)-derived intermediates in primary cultured rat hepatocytes using several cholesterol synthesis inhibitors.	Mevalonic Acid	66-69	sulfotransferase family 1C member 2	Rattus norvegicus	43-50
26427720-3	2015	Blocking production of mevalonate with the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin (30 muM), reduced SULT1C2 mRNA content by ~40% whereas the squalene synthase inhibitor squalestatin (SQ1, 0.1 muM), which causes accumulation of nonsterol isoprenoids, increased mRNA content by 4-fold.	Mevalonic Acid	23-33	sulfotransferase family 1C member 2	Rattus norvegicus	124-131
26427720-4	2015	Treatment with MVA (10 mM) strongly induced SULT1C2 mRNA by 12-fold, and this effect was blocked by inhibiting squalene epoxidase but not by more distal cholesterol inhibitors, indicating the effects of MVA are mediated by postsqualene metabolites.	Mevalonic Acid	15-18	sulfotransferase family 1C member 2	Rattus norvegicus	44-51
26420133-1	2015	Mevalonate kinase (MVK) catalyses the phosphorylation of mevalonate.	Mevalonic Acid	57-67	mevalonate kinase	Homo sapiens	0-17
26420133-1	2015	Mevalonate kinase (MVK) catalyses the phosphorylation of mevalonate.	Mevalonic Acid	57-67	mevalonate kinase	Homo sapiens	19-22
26381177-1	2015	HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonic acid (MVA); this is the rate-limiting enzyme of the mevalonate pathway that synthesizes cholesterol.	Mevalonic Acid	65-79	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	0-17
26351364-6	2015	In HepG2 cells incubated with serum or exogenous mevalonate, KMUP-1 (10(-7)~10(-5) M) reversed HMGR expression by feedback regulation, colocalized expression of ABCA1/apolipoprotein A-I/LXRalpha/PPARgamma, and reduced exogenous geranylgeranyl pyrophosphate/farnesyl pyrophosphate (FPP)-induced RhoA/ROCK II expression.	Mevalonic Acid	49-59	ATP binding cassette subfamily A member 1	Homo sapiens	161-166
26351364-6	2015	In HepG2 cells incubated with serum or exogenous mevalonate, KMUP-1 (10(-7)~10(-5) M) reversed HMGR expression by feedback regulation, colocalized expression of ABCA1/apolipoprotein A-I/LXRalpha/PPARgamma, and reduced exogenous geranylgeranyl pyrophosphate/farnesyl pyrophosphate (FPP)-induced RhoA/ROCK II expression.	Mevalonic Acid	49-59	apolipoprotein A1	Homo sapiens	167-185
26351364-6	2015	In HepG2 cells incubated with serum or exogenous mevalonate, KMUP-1 (10(-7)~10(-5) M) reversed HMGR expression by feedback regulation, colocalized expression of ABCA1/apolipoprotein A-I/LXRalpha/PPARgamma, and reduced exogenous geranylgeranyl pyrophosphate/farnesyl pyrophosphate (FPP)-induced RhoA/ROCK II expression.	Mevalonic Acid	49-59	nuclear receptor subfamily 1 group H member 3	Homo sapiens	186-194
26351364-6	2015	In HepG2 cells incubated with serum or exogenous mevalonate, KMUP-1 (10(-7)~10(-5) M) reversed HMGR expression by feedback regulation, colocalized expression of ABCA1/apolipoprotein A-I/LXRalpha/PPARgamma, and reduced exogenous geranylgeranyl pyrophosphate/farnesyl pyrophosphate (FPP)-induced RhoA/ROCK II expression.	Mevalonic Acid	49-59	peroxisome proliferator activated receptor gamma	Homo sapiens	195-204
26351364-6	2015	In HepG2 cells incubated with serum or exogenous mevalonate, KMUP-1 (10(-7)~10(-5) M) reversed HMGR expression by feedback regulation, colocalized expression of ABCA1/apolipoprotein A-I/LXRalpha/PPARgamma, and reduced exogenous geranylgeranyl pyrophosphate/farnesyl pyrophosphate (FPP)-induced RhoA/ROCK II expression.	Mevalonic Acid	49-59	ras homolog family member A	Homo sapiens	294-298
26351364-6	2015	In HepG2 cells incubated with serum or exogenous mevalonate, KMUP-1 (10(-7)~10(-5) M) reversed HMGR expression by feedback regulation, colocalized expression of ABCA1/apolipoprotein A-I/LXRalpha/PPARgamma, and reduced exogenous geranylgeranyl pyrophosphate/farnesyl pyrophosphate (FPP)-induced RhoA/ROCK II expression.	Mevalonic Acid	49-59	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	299-306
26381177-1	2015	HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonic acid (MVA); this is the rate-limiting enzyme of the mevalonate pathway that synthesizes cholesterol.	Mevalonic Acid	65-79	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	19-24
26381177-1	2015	HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonic acid (MVA); this is the rate-limiting enzyme of the mevalonate pathway that synthesizes cholesterol.	Mevalonic Acid	127-137	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	0-17
26381177-1	2015	HMG-CoA reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonic acid (MVA); this is the rate-limiting enzyme of the mevalonate pathway that synthesizes cholesterol.	Mevalonic Acid	127-137	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	19-24
26381177-7	2015	These results suggest that skeletal muscle toxicity caused by statins is dependent on the deficiencies of HMGCR enzyme activity and downstream metabolites of the mevalonate pathway in skeletal muscles rather than the liver or other organs.	Mevalonic Acid	162-172	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	106-111
26358205-1	2015	Statins exhibit anti-leukemic properties due to suppression of the mevalonate pathway by the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase, and subsequent depletion of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate.	Mevalonic Acid	67-77	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	107-154
26358205-7	2015	Autophagy suppression by bafilomycin A1 or RNA interference-mediated knockdown of beclin-1 and microtubule-associated protein 1 light chain 3B induced apoptotic death in statin-treated leukemic cells, an effect attenuated by the addition of mevalonate or squalene, but not farnesylpyrophosphate or geranylgeranylpyrophosphate.	Mevalonic Acid	241-251	beclin 1	Homo sapiens	82-142
26300074-5	2015	V377I as well as the S135L mutations were identified on the mevalonate kinase deficiency gene and the levels of mevalonic acid in the patient were 5,496 microg/ml.	Mevalonic Acid	112-126	mevalonate kinase	Homo sapiens	60-77
26469958-0	2015	p53 regulates the mevalonate pathway in human glioblastoma multiforme.	Mevalonic Acid	18-28	tumor protein p53	Homo sapiens	0-3
26284584-2	2015	The aim of this work was to compare the multidrug resistance (MDR) signature of IGHV mutated and unmutated CLL cells, identifying biochemical and molecular targets potentially amenable to therapeutic intervention.We found that the mevalonate pathway-dependent Ras/ERK1-2 and RhoA/RhoA kinase signaling cascades, and the downstream HIF-1alpha/P-glycoprotein axis were more active in IGHV unmutated than in mutated cells, leading to a constitutive protection from doxorubicin-induced cytotoxicity.	Mevalonic Acid	231-241	immunoglobulin heavy variable 3/OR16-17 (non-functional)	Homo sapiens	80-84
26284584-2	2015	The aim of this work was to compare the multidrug resistance (MDR) signature of IGHV mutated and unmutated CLL cells, identifying biochemical and molecular targets potentially amenable to therapeutic intervention.We found that the mevalonate pathway-dependent Ras/ERK1-2 and RhoA/RhoA kinase signaling cascades, and the downstream HIF-1alpha/P-glycoprotein axis were more active in IGHV unmutated than in mutated cells, leading to a constitutive protection from doxorubicin-induced cytotoxicity.	Mevalonic Acid	231-241	mitogen-activated protein kinase 3	Homo sapiens	264-270
26284584-2	2015	The aim of this work was to compare the multidrug resistance (MDR) signature of IGHV mutated and unmutated CLL cells, identifying biochemical and molecular targets potentially amenable to therapeutic intervention.We found that the mevalonate pathway-dependent Ras/ERK1-2 and RhoA/RhoA kinase signaling cascades, and the downstream HIF-1alpha/P-glycoprotein axis were more active in IGHV unmutated than in mutated cells, leading to a constitutive protection from doxorubicin-induced cytotoxicity.	Mevalonic Acid	231-241	ras homolog family member A	Homo sapiens	275-279
26284584-2	2015	The aim of this work was to compare the multidrug resistance (MDR) signature of IGHV mutated and unmutated CLL cells, identifying biochemical and molecular targets potentially amenable to therapeutic intervention.We found that the mevalonate pathway-dependent Ras/ERK1-2 and RhoA/RhoA kinase signaling cascades, and the downstream HIF-1alpha/P-glycoprotein axis were more active in IGHV unmutated than in mutated cells, leading to a constitutive protection from doxorubicin-induced cytotoxicity.	Mevalonic Acid	231-241	ras homolog family member A	Homo sapiens	280-284
26284584-2	2015	The aim of this work was to compare the multidrug resistance (MDR) signature of IGHV mutated and unmutated CLL cells, identifying biochemical and molecular targets potentially amenable to therapeutic intervention.We found that the mevalonate pathway-dependent Ras/ERK1-2 and RhoA/RhoA kinase signaling cascades, and the downstream HIF-1alpha/P-glycoprotein axis were more active in IGHV unmutated than in mutated cells, leading to a constitutive protection from doxorubicin-induced cytotoxicity.	Mevalonic Acid	231-241	hypoxia inducible factor 1 subunit alpha	Homo sapiens	331-341
26284584-2	2015	The aim of this work was to compare the multidrug resistance (MDR) signature of IGHV mutated and unmutated CLL cells, identifying biochemical and molecular targets potentially amenable to therapeutic intervention.We found that the mevalonate pathway-dependent Ras/ERK1-2 and RhoA/RhoA kinase signaling cascades, and the downstream HIF-1alpha/P-glycoprotein axis were more active in IGHV unmutated than in mutated cells, leading to a constitutive protection from doxorubicin-induced cytotoxicity.	Mevalonic Acid	231-241	immunoglobulin heavy variable 3/OR16-17 (non-functional)	Homo sapiens	382-386
26284584-5	2015	Mevalonate pathway inhibition with simvastatin abrogated these signaling pathways and reversed the resistance of IGHV unmutated cells to doxorubicin, also counteracting the protective effect exerted by stromal cells.	Mevalonic Acid	0-10	immunoglobulin heavy variable 3/OR16-17 (non-functional)	Homo sapiens	113-117
26284584-6	2015	Similar results were obtained via the targeted inhibition of the downstream molecules ERK1-2, RhoA kinase and HIF-1alpha.Therefore, targeting the mevalonate pathway and its downstream signaling cascades is a promising strategy to circumvent the MDR signature of IGHV unmutated CLL cells.	Mevalonic Acid	146-156	mitogen-activated protein kinase 3	Homo sapiens	86-92
26284584-6	2015	Similar results were obtained via the targeted inhibition of the downstream molecules ERK1-2, RhoA kinase and HIF-1alpha.Therefore, targeting the mevalonate pathway and its downstream signaling cascades is a promising strategy to circumvent the MDR signature of IGHV unmutated CLL cells.	Mevalonic Acid	146-156	ras homolog family member A	Homo sapiens	94-98
26284584-6	2015	Similar results were obtained via the targeted inhibition of the downstream molecules ERK1-2, RhoA kinase and HIF-1alpha.Therefore, targeting the mevalonate pathway and its downstream signaling cascades is a promising strategy to circumvent the MDR signature of IGHV unmutated CLL cells.	Mevalonic Acid	146-156	hypoxia inducible factor 1 subunit alpha	Homo sapiens	110-120
26284584-6	2015	Similar results were obtained via the targeted inhibition of the downstream molecules ERK1-2, RhoA kinase and HIF-1alpha.Therefore, targeting the mevalonate pathway and its downstream signaling cascades is a promising strategy to circumvent the MDR signature of IGHV unmutated CLL cells.	Mevalonic Acid	146-156	immunoglobulin heavy variable 3/OR16-17 (non-functional)	Homo sapiens	262-266
26112408-2	2015	Here, we show that geranylgeranyl diphosphate synthase 1 (GGPPS), which is a branch point enzyme in the mevalonic acid pathway, promotes lipid-induced muscle insulin resistance through activation of the RhoA/Rho kinase signaling pathway.	Mevalonic Acid	104-118	geranylgeranyl diphosphate synthase 1	Mus musculus	19-56
26053280-2	2015	Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification of KRAS.	Mevalonic Acid	23-33	KRAS proto-oncogene, GTPase	Homo sapiens	109-113
25916956-0	2015	Role of the mevalonate pathway in specific CpG site demethylation on AGEs-induced MMP9 expression and activation in keratinocytes.	Mevalonic Acid	12-22	matrix metallopeptidase 9	Homo sapiens	82-86
25916956-2	2015	In the present study we tried to show the mevalonate pathway and the key demethylation site(s) in the MMP-9 cis-promoter to the component of MMP-9 by AGEs in keratinocyte.	Mevalonic Acid	42-52	matrix metallopeptidase 9	Homo sapiens	102-107
25916956-2	2015	In the present study we tried to show the mevalonate pathway and the key demethylation site(s) in the MMP-9 cis-promoter to the component of MMP-9 by AGEs in keratinocyte.	Mevalonic Acid	42-52	matrix metallopeptidase 9	Homo sapiens	141-146
25916956-11	2015	CONCLUSION: The cis-promoter regions of MMP9 would be methylated by AGE-BSA in keratinocyte through the mevalonate pathway, especially the -562 bp site.	Mevalonic Acid	104-114	matrix metallopeptidase 9	Homo sapiens	40-44
26225047-1	2015	INTRODUCTION: Simvastatin, a common cholesterol-lowering drug that inhibits hepatic hydroxymethylglutaryl coenzyme A reductase, the rate-limiting enzyme in the mevalonate pathway, increases expression of the BMP-2 gene and thus promotes bone regeneration.	Mevalonic Acid	160-170	bone morphogenetic protein 2	Homo sapiens	208-213
26112408-2	2015	Here, we show that geranylgeranyl diphosphate synthase 1 (GGPPS), which is a branch point enzyme in the mevalonic acid pathway, promotes lipid-induced muscle insulin resistance through activation of the RhoA/Rho kinase signaling pathway.	Mevalonic Acid	104-118	ras homolog family member A	Mus musculus	203-207
26112408-2	2015	Here, we show that geranylgeranyl diphosphate synthase 1 (GGPPS), which is a branch point enzyme in the mevalonic acid pathway, promotes lipid-induced muscle insulin resistance through activation of the RhoA/Rho kinase signaling pathway.	Mevalonic Acid	104-118	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	208-218
26047704-3	2015	N-BP inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, resulting in the accumulation of isopentenyl pyrophosphate (IPP), which is a stimulatory antigen for gammadeltaT cells.	Mevalonic Acid	53-63	farnesyl diphosphate synthase	Homo sapiens	14-45
25735397-15	2015	CONCLUSIONS: Fluvastatin increases endothelial TFPI expression through inhibition of mevalonate-, GGPP-, and Cdc42-dependent signaling pathways, and activation of the p38 MAPK, PI3K, and PKC pathways.	Mevalonic Acid	85-95	tissue factor pathway inhibitor	Homo sapiens	47-51
25936991-3	2015	It has been reported that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ameliorate glomerular injury in several experimental models of progressive glomerular disease by inhibiting the production of MVA and its metabolites.	Mevalonic Acid	211-214	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	26-73
26050962-7	2015	Current Hippo pathway-targeting drugs include compounds that target the interaction between YAP and TEAD G protein-coupled receptors (GPCR) and the mevalonate pathway (e.g. statins).	Mevalonic Acid	148-158	Yes1 associated transcriptional regulator	Homo sapiens	92-95
26041506-0	2015	Atorvastatin attenuates homocysteine-induced migration of smooth muscle cells through mevalonate pathway involving reactive oxygen species and p38 MAPK.	Mevalonic Acid	86-96	mitogen activated protein kinase 14	Rattus norvegicus	143-146
26041506-13	2015	Moreover, atorvastatin other than DPI, NAC, SB203580 and Nox1 siRNA transfection blocked Hcy-induced p38 MAPK phosphorylation, which was also reversed by the mevalonate.	Mevalonic Acid	158-168	NADPH oxidase 1	Rattus norvegicus	57-61
26041506-13	2015	Moreover, atorvastatin other than DPI, NAC, SB203580 and Nox1 siRNA transfection blocked Hcy-induced p38 MAPK phosphorylation, which was also reversed by the mevalonate.	Mevalonic Acid	158-168	mitogen activated protein kinase 14	Rattus norvegicus	101-104
25735397-10	2015	Fluvastatin-induced TFPI expression was reversed by co-treatment with mevalonate or geranylgeranylpyrophosphate (GGPP).	Mevalonic Acid	70-80	tissue factor pathway inhibitor	Homo sapiens	20-24
25759117-3	2015	Here, we elucidate the molecular circuitry governing how IFN controls the first regulated step in the mevalonate-sterol pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol (25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H).	Mevalonic Acid	102-112	interferon alpha 1	Homo sapiens	57-60
26184189-6	2015	This mechanism could play a significant role in Mevalonate Kinase Deficiency, an autoinflammatory disease characterized by a defect in Mevalonate Kinase, a key enzyme of the mevalonate pathway.	Mevalonic Acid	174-184	mevalonate kinase	Homo sapiens	48-65
25759117-3	2015	Here, we elucidate the molecular circuitry governing how IFN controls the first regulated step in the mevalonate-sterol pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol (25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H).	Mevalonic Acid	102-112	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	129-169
25759117-3	2015	Here, we elucidate the molecular circuitry governing how IFN controls the first regulated step in the mevalonate-sterol pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol (25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H).	Mevalonic Acid	102-112	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	171-176
25759117-3	2015	Here, we elucidate the molecular circuitry governing how IFN controls the first regulated step in the mevalonate-sterol pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol (25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H).	Mevalonic Acid	102-112	interferon alpha 1	Homo sapiens	258-261
25759117-3	2015	Here, we elucidate the molecular circuitry governing how IFN controls the first regulated step in the mevalonate-sterol pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol (25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H).	Mevalonic Acid	102-112	cholesterol 25-hydroxylase	Homo sapiens	272-298
25895029-1	2015	We observed a co-upregulation of the insulin-like growth factor receptor (IGF-1R)/AKT/mammalian target of rapamycin (mTOR) [InAT] axis and the mevalonate-isoprenoid biosynthesis (MIB) pathways in colorectal cancer stem cells (CSCs) in an unbiased approach.	Mevalonic Acid	143-153	mechanistic target of rapamycin kinase	Homo sapiens	117-121
25895029-0	2015	Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.	Mevalonic Acid	141-151	AKT serine/threonine kinase 1	Homo sapiens	50-53
25759117-3	2015	Here, we elucidate the molecular circuitry governing how IFN controls the first regulated step in the mevalonate-sterol pathway, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), through the synthesis of 25-Hydroxycholesterol (25-HC) from cholesterol by the IFN-inducible Cholesterol-25-Hydroxylase (CH25H).	Mevalonic Acid	102-112	cholesterol 25-hydroxylase	Homo sapiens	300-305
25759117-9	2015	In conclusion, we quantitatively delineate proteomic and transcriptional levels of IFN-mediated control of HMGCR, the primary enzymatic step of the mevalonate-sterol biosynthesis pathway, providing a foundational framework for mathematically modelling the therapeutic outcome of immune-metabolic pathways.	Mevalonic Acid	148-158	interferon alpha 1	Homo sapiens	83-86
25759117-9	2015	In conclusion, we quantitatively delineate proteomic and transcriptional levels of IFN-mediated control of HMGCR, the primary enzymatic step of the mevalonate-sterol biosynthesis pathway, providing a foundational framework for mathematically modelling the therapeutic outcome of immune-metabolic pathways.	Mevalonic Acid	148-158	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	107-112
25977402-1	2015	Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is involved in the production of mevalonic acid in the cholesterol biosynthesis pathway.	Mevalonic Acid	125-139	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	27-84
25895029-0	2015	Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.	Mevalonic Acid	141-151	mechanistic target of rapamycin kinase	Homo sapiens	54-83
25939481-4	2015	Here we used the model organism Caenorhabditis elegans to determine level and redox state of CoQ and expression of genes in response to DR. We found that DR down-regulates the steady-state expression levels of several evolutionary conserved genes (i.e. coq-1) that encode key enzymes of the mevalonate and CoQ-synthesizing pathways.	Mevalonic Acid	291-301	COenzyme Q (ubiquinone) biosynthesis	Caenorhabditis elegans	253-258
26109908-2	2015	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment.	Mevalonic Acid	91-101	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-47
26109908-2	2015	3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment.	Mevalonic Acid	91-101	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	49-54
25906980-8	2015	Additionally, the CYP51 gene mutation in X. dendrorhous increased HMGR (hydroxy-methylglutaryl-CoA reductase, involved in the mevalonate pathway) and crtR (cytochrome P450 reductase) transcript levels, which could be associated with reduced ergosterol production.	Mevalonic Acid	126-136	sterol 14-demethylase	Saccharomyces cerevisiae S288C	18-23
25636197-0	2015	Inhibition of the mevalonate pathway ameliorates anoxia-induced down-regulation of FKBP12.6 and intracellular calcium handling dysfunction in H9c2 cells.	Mevalonic Acid	18-28	FKBP prolyl isomerase 1B	Rattus norvegicus	83-91
25862838-4	2015	Statins inhibit the mevalonate pathway at 3-hydroxy-3-methylglutaryl coenzyme A reductase and bisphosphonates at farnesyl pyrophosphate synthase.	Mevalonic Acid	20-30	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-89
25862838-4	2015	Statins inhibit the mevalonate pathway at 3-hydroxy-3-methylglutaryl coenzyme A reductase and bisphosphonates at farnesyl pyrophosphate synthase.	Mevalonic Acid	20-30	farnesyl diphosphate synthase	Homo sapiens	113-144
25862838-6	2015	These two drugs cause a sequential blockade of the mevalonate pathway and significantly affect survival and apoptotic pathways by down-regulating phospho-AKT and activating c-JUN and ERK.	Mevalonic Acid	51-61	AKT serine/threonine kinase 1	Homo sapiens	154-157
25862838-6	2015	These two drugs cause a sequential blockade of the mevalonate pathway and significantly affect survival and apoptotic pathways by down-regulating phospho-AKT and activating c-JUN and ERK.	Mevalonic Acid	51-61	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	173-178
25862838-6	2015	These two drugs cause a sequential blockade of the mevalonate pathway and significantly affect survival and apoptotic pathways by down-regulating phospho-AKT and activating c-JUN and ERK.	Mevalonic Acid	51-61	mitogen-activated protein kinase 1	Homo sapiens	183-186
25819439-1	2015	GGPPS catalyses the expression of GGPP, a key protein in the mevalonate metabolic pathway.	Mevalonic Acid	61-71	geranylgeranyl diphosphate synthase 1	Homo sapiens	0-5
25636197-8	2015	Furthermore, our data demonstrated that inhibition of the mevalonate pathway could ameliorate anoxia-mediated calcium handling dysfunction with the up-regulated expression of FK506-binding protein 12.6 and consequently provided evidence for FK506-binding protein 12.6 as a "stabilizer" of ryanodine receptor 2.	Mevalonic Acid	58-68	ryanodine receptor 2	Rattus norvegicus	289-309
25636197-4	2015	Our study aimed at investigating the influence of mevalonate pathway, including its downstream small GTPases (Ras, RhoA, and Rac1) on anoxia-mediated alterations of calcium handling in H9c2 cardiomyocytes.	Mevalonic Acid	50-60	ras homolog family member A	Rattus norvegicus	115-119
25636197-4	2015	Our study aimed at investigating the influence of mevalonate pathway, including its downstream small GTPases (Ras, RhoA, and Rac1) on anoxia-mediated alterations of calcium handling in H9c2 cardiomyocytes.	Mevalonic Acid	50-60	Rac family small GTPase 1	Rattus norvegicus	125-129
25416152-2	2015	These agents act on the mevalonate pathway and inhibit synthesis of cholesterol, geranylgeranyl pyrophosphate, and farnesyl pyrophosphate, which are necessary for posttranslational modification of the Rho, Rac, and Ras superfamily of proteins.	Mevalonic Acid	24-34	AKT serine/threonine kinase 1	Homo sapiens	206-209
25607255-1	2015	Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is a rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	122-132	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	26-73
25607255-1	2015	Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is a rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	122-132	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	75-80
25745361-6	2015	These findings have defined a new signaling pathway that regulated expression of PBK and identified PBK as a downstream target of the Hippo-YAP signaling, uncoverd a mechanism underlying the anti-cancer effect by inhibition of mevalonate pathway and geranylgeranylation, and provided a potential target for breast cancer targeted therapy.	Mevalonic Acid	227-237	PDZ binding kinase	Homo sapiens	81-84
25745361-6	2015	These findings have defined a new signaling pathway that regulated expression of PBK and identified PBK as a downstream target of the Hippo-YAP signaling, uncoverd a mechanism underlying the anti-cancer effect by inhibition of mevalonate pathway and geranylgeranylation, and provided a potential target for breast cancer targeted therapy.	Mevalonic Acid	227-237	PDZ binding kinase	Homo sapiens	100-103
25745361-6	2015	These findings have defined a new signaling pathway that regulated expression of PBK and identified PBK as a downstream target of the Hippo-YAP signaling, uncoverd a mechanism underlying the anti-cancer effect by inhibition of mevalonate pathway and geranylgeranylation, and provided a potential target for breast cancer targeted therapy.	Mevalonic Acid	227-237	Yes1 associated transcriptional regulator	Homo sapiens	140-143
25547946-8	2015	Mevalonate depletion through HMG-CoA reductase inhibition impairs the viability of primary human MSC through down-regulating NF-kappaB.	Mevalonic Acid	0-10	nuclear factor kappa B subunit 1	Homo sapiens	125-134
25745361-3	2015	Here we show that atorvastatin (Lipitor), an inhibitor of hydroxymethylglutaryl co-enzyme A (HMG-CoA) reductase that is a rate-limiting enzyme of mevalonate pathway, down-regulates expression of PBK by impairing protein geranylgeranylation.	Mevalonic Acid	146-156	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	58-111
25745361-3	2015	Here we show that atorvastatin (Lipitor), an inhibitor of hydroxymethylglutaryl co-enzyme A (HMG-CoA) reductase that is a rate-limiting enzyme of mevalonate pathway, down-regulates expression of PBK by impairing protein geranylgeranylation.	Mevalonic Acid	146-156	PDZ binding kinase	Homo sapiens	195-198
25688370-1	2015	Farnesyl pyrophosphate synthase (FPPS) plays a vital role in the mevalonate pathway and has been shown to be involved in hypertrophy and cardiovascular diseases.	Mevalonic Acid	65-75	farnesyl diphosphate synthetase	Mus musculus	0-31
25688370-1	2015	Farnesyl pyrophosphate synthase (FPPS) plays a vital role in the mevalonate pathway and has been shown to be involved in hypertrophy and cardiovascular diseases.	Mevalonic Acid	65-75	farnesyl diphosphate synthetase	Mus musculus	33-37
25084760-2	2015	Cyp46a1 null mice exhibit severe deficiencies in learning and hippocampal long-term potentiation, suggested to be caused by a decrease in isoprenoid intermediates of the mevalonate pathway.	Mevalonic Acid	170-180	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	0-7
25541745-2	2015	These compounds target the farnesyl pyrophosphate synthase (FPPS), a key enzyme of the mevalonate pathway involved in several pathologies.	Mevalonic Acid	87-97	farnesyl diphosphate synthase	Homo sapiens	27-58
25541745-2	2015	These compounds target the farnesyl pyrophosphate synthase (FPPS), a key enzyme of the mevalonate pathway involved in several pathologies.	Mevalonic Acid	87-97	farnesyl diphosphate synthase	Homo sapiens	60-64
25497898-2	2015	Farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) are derived from mevalonate, whose production is catalyzed by 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase.	Mevalonic Acid	84-94	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	129-179
24548821-2	2014	However, considering that the pharmacological target of statins, the 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase, is one of the upstream enzyme of the mevalonate pathway, its inhibition may determine a substantial impoverishment of additional lipid moieties required for a proper cellular function.	Mevalonic Acid	168-178	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	69-129
25378391-0	2014	Modulation of the mevalonate pathway by akt regulates macrophage survival and development of pulmonary fibrosis.	Mevalonic Acid	18-28	thymoma viral proto-oncogene 1	Mus musculus	40-43
25378391-3	2014	In this study, we found that Akt modulated the mevalonate pathway, which is also linked to cell survival, by increasing Rho GTPase activation.	Mevalonic Acid	47-57	thymoma viral proto-oncogene 1	Mus musculus	29-32
25378391-9	2014	These observations for the first time suggest that Akt plays a critical role in the development and progression of pulmonary fibrosis by enhancing macrophage survival via modulation of the mevalonate pathway.	Mevalonic Acid	189-199	thymoma viral proto-oncogene 1	Mus musculus	51-54
25134999-9	2014	Decreased expression of SREBP-2 down-regulates the mevalonate pathway and prevents the active statin-induced sterol feedback, enhancing statin toxicity.	Mevalonic Acid	51-61	sterol regulatory element binding transcription factor 2	Homo sapiens	24-31
25311809-4	2014	Using a transcriptomic approach, we identified upregulation of genes that belong to the mevalonate pathway as a key molecular event following CD40-mediated activation of B cells.	Mevalonic Acid	88-98	CD40 molecule	Homo sapiens	142-146
25311809-5	2014	Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway, by lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell activation via CD40 and impaired their ability to act as stimulatory APCs for allospecific T cells.	Mevalonic Acid	88-98	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	14-54
25311809-5	2014	Inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme of the mevalonate pathway, by lipophilic statins such as simvastatin and atorvastatin resulted in a specific inhibition of B cell activation via CD40 and impaired their ability to act as stimulatory APCs for allospecific T cells.	Mevalonic Acid	88-98	CD40 molecule	Homo sapiens	226-230
23901824-6	2014	Mevalonate abolished simvastatin"s effects on Akt/mTOR signaling and autophagy induction in HL-1 cells, indicating that the effects are mediated through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.	Mevalonic Acid	0-10	thymoma viral proto-oncogene 1	Mus musculus	46-49
23901824-6	2014	Mevalonate abolished simvastatin"s effects on Akt/mTOR signaling and autophagy induction in HL-1 cells, indicating that the effects are mediated through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.	Mevalonic Acid	0-10	mechanistic target of rapamycin kinase	Mus musculus	50-54
23901824-6	2014	Mevalonate abolished simvastatin"s effects on Akt/mTOR signaling and autophagy induction in HL-1 cells, indicating that the effects are mediated through inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	167-224
24875421-1	2014	cis-Prenyltransferase is the first enzyme of the mevalonate pathway committed to the biosynthesis of dolichol in eukaryotes.	Mevalonic Acid	49-59	dehydrodolichyl diphosphate synthase subunit	Homo sapiens	0-21
25268751-7	2014	This effect of fluvastatin was reversed in the presence of mevalonate, a downstream product of HMG-CoA and caspase-3 inhibitor.	Mevalonic Acid	59-69	caspase 3	Homo sapiens	107-116
24777857-4	2014	The target for cholesterol-lowering statins is HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	106-116	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	47-64
24777857-4	2014	The target for cholesterol-lowering statins is HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway.	Mevalonic Acid	106-116	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	66-71
25287865-9	2014	At the same time, YAP/TAZ entertain relationships with morphogenetic signals, such as Wnt growth factors, and are also regulated by Rho, GPCRs and mevalonate metabolism.	Mevalonic Acid	147-157	yes-associated protein 1	Mus musculus	18-21
25287865-9	2014	At the same time, YAP/TAZ entertain relationships with morphogenetic signals, such as Wnt growth factors, and are also regulated by Rho, GPCRs and mevalonate metabolism.	Mevalonic Acid	147-157	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	22-25
25187565-0	2014	Controlled sumoylation of the mevalonate pathway enzyme HMGS-1 regulates metabolism during aging.	Mevalonic Acid	30-40	Hydroxymethylglutaryl-CoA synthase	Caenorhabditis elegans	56-62
25187565-7	2014	This protein is the ortholog of human HMGCS1 enzyme, which mediates the first committed step of the mevalonate pathway.	Mevalonic Acid	100-110	3-hydroxy-3-methylglutaryl-CoA synthase 1	Homo sapiens	38-44
25187565-10	2014	Thus, spatiotemporal ULP-4 activity controls the HMGS-1 sumoylation state in a mechanism that orchestrates mevalonate pathway activity with the age of the organism.	Mevalonic Acid	107-117	Hydroxymethylglutaryl-CoA synthase	Caenorhabditis elegans	49-55
24829397-9	2014	IMPLICATIONS: ErbB4 as a regulator of Hippo and mevalonate pathways provides new insight into milk production and anabolic processes in normal mammary epithelia and cancer.	Mevalonic Acid	48-58	erb-b2 receptor tyrosine kinase 4	Homo sapiens	14-19
24829397-5	2014	Transcriptional profiling revealed several new and underexplored ERBB4-regulated transcripts, including: proteases/protease inhibitors (MMP3 and SERPINE2), the YAP/Hippo pathway (CTGF, CYR61, and SPARC), the mevalonate/cholesterol pathway (HMGCR, HMGCS1, LDLR, and DHCR7), and cytokines (IL8, CCL20, and CXCL1).	Mevalonic Acid	208-218	erb-b2 receptor tyrosine kinase 4	Homo sapiens	65-70
24657594-2	2014	Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of mevalonic, a precursor to cholesterol via the mevalonate pathway.	Mevalonic Acid	129-139	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	16-33
24879560-1	2014	In the present study, we found that three enzymes, MVK, MDD and FPPS, in the mevalonate pathway (MVP) of cholesterol biosynthesis, can be simultaneously inhibited by two green tea polyphenols ((-)-epicatechin-3-gallate, ECG; (-)-epigallocatechin-3-gallate, EGCG).	Mevalonic Acid	77-87	mevalonate kinase	Homo sapiens	51-54
24879560-1	2014	In the present study, we found that three enzymes, MVK, MDD and FPPS, in the mevalonate pathway (MVP) of cholesterol biosynthesis, can be simultaneously inhibited by two green tea polyphenols ((-)-epicatechin-3-gallate, ECG; (-)-epigallocatechin-3-gallate, EGCG).	Mevalonic Acid	77-87	farnesyl diphosphate synthase	Homo sapiens	64-68
24793581-0	2014	Overexpression of erg20 gene encoding farnesyl pyrophosphate synthase has contrasting effects on activity of enzymes of the dolichyl and sterol branches of mevalonate pathway in Trichoderma reesei.	Mevalonic Acid	156-166	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	18-23
24793581-4	2014	Here, we present cloning and functional analysis of the erg20 gene from Trichoderma reesei coding for farnesyl pyrophosphate (FPP) synthase (EC 2.5.1.10), an enzyme located at the branching point of the mevalonate pathway.	Mevalonic Acid	203-213	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	56-61
24637330-1	2014	HMG-CoA reductase, the proximal rate-limiting enzyme in the mevalonate pathway, is inhibited by statins.	Mevalonic Acid	60-70	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
24311107-12	2014	In conclusion, these results suggest that polymorphisms of the FDPS gene may influence the bone response to various drugs targeting the mevalonate pathway, including not only aminobisphosphonates but also statins.	Mevalonic Acid	136-146	farnesyl diphosphate synthase	Homo sapiens	63-67
24582968-4	2014	Because all cells require a steady supply of MVA, both the sterol (i.e. cholesterol) and non-sterol (i.e. isoprenoid) products of MVA metabolism exert coordinated feedback regulation on HMGCR through different mechanisms.	Mevalonic Acid	45-48	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	186-191
24582769-6	2014	Suppression of CXCR7 expression was completely reversed by supplementation with mevalonate.	Mevalonic Acid	80-90	atypical chemokine receptor 3	Homo sapiens	15-20
24295174-2	2014	Statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase, the major rate-limiting enzyme that controls the conversion of HMG-CoA to mevalonic acid.	Mevalonic Acid	161-175	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	67-85
24295174-3	2014	Specifically, inhibition of HMG-CoA reductase by statins has been proved to prevent the synthesis of mevalonic acid, a precursor of non-steroidal isoprenoids, which are lipid attachment molecules for small G proteins, such as Ras, Rho and Rac.	Mevalonic Acid	101-115	AKT serine/threonine kinase 1	Homo sapiens	239-242
24847714-2	2014	We report herein a mutant of 3-hydroxy-3-methylglutaryl-coenzyme A synthase (HMGS), the second enzyme in the mevalonate (MVA) pathway that can improve seed yield when overexpressed in a phylogenetically distant species.	Mevalonic Acid	109-119	hydroxymethylglutaryl-CoA synthase-like	Nicotiana tabacum	29-75
24847714-2	2014	We report herein a mutant of 3-hydroxy-3-methylglutaryl-coenzyme A synthase (HMGS), the second enzyme in the mevalonate (MVA) pathway that can improve seed yield when overexpressed in a phylogenetically distant species.	Mevalonic Acid	109-119	hydroxymethylglutaryl-CoA synthase-like	Nicotiana tabacum	77-81
24158494-0	2014	The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway.	Mevalonic Acid	61-71	kallikrein related peptidase 5	Homo sapiens	4-8
24158494-6	2014	Consistently, we found that SREBF1, the master regulator of the mevalonate pathway was induced.	Mevalonic Acid	64-74	sterol regulatory element binding transcription factor 1	Homo sapiens	28-34
24158494-8	2014	Suppression of the mevalonate pathway in KLK5 transfectants was further shown by reduced synthesis of isoprenoids.	Mevalonic Acid	19-29	kallikrein related peptidase 5	Homo sapiens	41-45
24732207-2	2014	The HMGCR transcripts are detectable during early embryogenesis in both invertebrates and vertebrates, which suggests a conserved developmental requirement for mevalonate derivatives.	Mevalonic Acid	160-170	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-9
24491562-6	2014	However, the level of the cholesterol precursor, desomsterol, and its parallel metabolite formed via a shut of the mevalonate pathway, 24S,25-epoxycholesterol, were reduced in the Cyp46a1-/- mouse.	Mevalonic Acid	115-125	cytochrome P450, family 46, subfamily a, polypeptide 1	Mus musculus	180-187
24918807-6	2014	RESULTS: The HMG-CoA reductase inhibitors significantly reduced leptin-induced proliferation and migration, which was reversed by mevalonate.	Mevalonic Acid	130-140	leptin	Homo sapiens	64-70
25151749-1	2014	Lanosterol synthase is encoded by the erg7 gene and catalyzes the cyclization of 2, 3-oxidosqualene, which is a rate-limiting step of the inherent mevalonate (MVA)/ergosterol metabolic pathway in Saccharomyces cerevisiae.	Mevalonic Acid	147-157	lanosterol synthase ERG7	Saccharomyces cerevisiae S288C	38-42
25151749-1	2014	Lanosterol synthase is encoded by the erg7 gene and catalyzes the cyclization of 2, 3-oxidosqualene, which is a rate-limiting step of the inherent mevalonate (MVA)/ergosterol metabolic pathway in Saccharomyces cerevisiae.	Mevalonic Acid	159-162	lanosterol synthase ERG7	Saccharomyces cerevisiae S288C	38-42
24390662-1	2014	Hydroxymethylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme of mevalonate pathway, has been involved in the tumorigenesis of several tumor types.	Mevalonic Acid	80-90	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-42
24390662-1	2014	Hydroxymethylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme of mevalonate pathway, has been involved in the tumorigenesis of several tumor types.	Mevalonic Acid	80-90	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	44-49
24806902-1	2014	BACKGROUND: Mevalonic acid (MVA), as a product of 3-hydroxy-3-methylglutaryl coenzyme A reductase, represents a potential multipurpose biomarker in health and disease.	Mevalonic Acid	12-26	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	50-97
24806902-1	2014	BACKGROUND: Mevalonic acid (MVA), as a product of 3-hydroxy-3-methylglutaryl coenzyme A reductase, represents a potential multipurpose biomarker in health and disease.	Mevalonic Acid	28-31	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	50-97
24477821-1	2014	The statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity and consequently the synthesis of mevalonate.	Mevalonic Acid	135-145	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	34-91
24658687-0	2014	Metabolic control of YAP and TAZ by the mevalonate pathway.	Mevalonic Acid	40-50	Tafazzin	Drosophila melanogaster	29-32
24658687-3	2014	Here, we show that YAP/TAZ activity is controlled by the SREBP/mevalonate pathway.	Mevalonic Acid	63-73	Tafazzin	Drosophila melanogaster	23-26
24658687-3	2014	Here, we show that YAP/TAZ activity is controlled by the SREBP/mevalonate pathway.	Mevalonic Acid	63-73	Sterol regulatory element binding protein	Drosophila melanogaster	57-62
24658687-5	2014	Mechanistically, the geranylgeranyl pyrophosphate produced by the mevalonate cascade is required for activation of Rho GTPases that, in turn, activate YAP/TAZ by inhibiting their phosphorylation and promoting their nuclear accumulation.	Mevalonic Acid	66-76	Tafazzin	Drosophila melanogaster	155-158
24658687-6	2014	The mevalonate-YAP/TAZ axis is required for proliferation and self-renewal of breast cancer cells.	Mevalonic Acid	4-14	Tafazzin	Drosophila melanogaster	19-22
24658687-7	2014	In Drosophila melanogaster, inhibition of mevalonate biosynthesis and geranylgeranylation blunts the eye overgrowth induced by Yorkie, the YAP/TAZ orthologue.	Mevalonic Acid	42-52	yorkie	Drosophila melanogaster	127-133
24658687-7	2014	In Drosophila melanogaster, inhibition of mevalonate biosynthesis and geranylgeranylation blunts the eye overgrowth induced by Yorkie, the YAP/TAZ orthologue.	Mevalonic Acid	42-52	Tafazzin	Drosophila melanogaster	143-146
24658687-8	2014	In tumour cells, YAP/TAZ activation is promoted by increased levels of mevalonic acid produced by SREBP transcriptional activity, which is induced by its oncogenic cofactor mutant p53.	Mevalonic Acid	71-85	Tafazzin	Drosophila melanogaster	21-24
24658687-8	2014	In tumour cells, YAP/TAZ activation is promoted by increased levels of mevalonic acid produced by SREBP transcriptional activity, which is induced by its oncogenic cofactor mutant p53.	Mevalonic Acid	71-85	Sterol regulatory element binding protein	Drosophila melanogaster	98-103
24658687-8	2014	In tumour cells, YAP/TAZ activation is promoted by increased levels of mevalonic acid produced by SREBP transcriptional activity, which is induced by its oncogenic cofactor mutant p53.	Mevalonic Acid	71-85	p53	Drosophila melanogaster	180-183
24582560-9	2014	Moreover, administration of mevalonate reversed the inhibitory effect of simvastatin on CCL17-induced colon cancer cell migration.	Mevalonic Acid	28-38	C-C motif chemokine ligand 17	Homo sapiens	88-93
24582560-12	2014	Administration of mevalonate and GGPP reversed the inhibitory effect of simvastatin on CCL17-provoked RhoA activation in colon cancer cells.	Mevalonic Acid	18-28	C-C motif chemokine ligand 17	Homo sapiens	87-92
24582560-12	2014	Administration of mevalonate and GGPP reversed the inhibitory effect of simvastatin on CCL17-provoked RhoA activation in colon cancer cells.	Mevalonic Acid	18-28	ras homolog family member A	Homo sapiens	102-106
24122315-7	2014	Further qPCR studies confirmed that erg10, erg13, thmg1 and erg12 involved in mevalonate pathway were overexpressed in this mutant strain.	Mevalonic Acid	78-88	acetyl-CoA C-acetyltransferase	Saccharomyces cerevisiae S288C	36-41
24122315-7	2014	Further qPCR studies confirmed that erg10, erg13, thmg1 and erg12 involved in mevalonate pathway were overexpressed in this mutant strain.	Mevalonic Acid	78-88	hydroxymethylglutaryl-CoA synthase	Saccharomyces cerevisiae S288C	43-48
24122315-7	2014	Further qPCR studies confirmed that erg10, erg13, thmg1 and erg12 involved in mevalonate pathway were overexpressed in this mutant strain.	Mevalonic Acid	78-88	mevalonate kinase	Saccharomyces cerevisiae S288C	60-65
24446431-0	2014	Pseudilins: halogenated, allosteric inhibitors of the non-mevalonate pathway enzyme IspD.	Mevalonic Acid	58-68	Nucleotide-diphospho-sugar transferases superfamily protein	Arabidopsis thaliana	84-88
24524197-2	2014	Previously, our group has demonstrated that simvastatin, competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase), a rate-limiting step of the mevalonate pathway, reduces rat-theca interstitial cell steroidogenesis by inhibiting Cyp17a1 gene expression, the key enzyme of the androgen biosynthesis pathway.	Mevalonic Acid	173-183	cytochrome P450, family 17, subfamily a, polypeptide 1	Rattus norvegicus	259-266
24528599-0	2014	Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.	Mevalonic Acid	31-41	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	0-10
24528599-3	2014	We assessed the effects of mevalonate pathway inhibition on DKK-1 expression in osteotropic breast cancer.	Mevalonic Acid	27-37	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	60-65
24528599-13	2014	CONCLUSION: DKK-1 is a novel target of the mevalonate pathway that is suppressed by zoledronic acid and atorvastatin in breast cancer.	Mevalonic Acid	43-53	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	12-17
24163149-8	2014	But concentration-dependent rosuvastatin can reverse the impact of OX-LDL, suggesting that rosuvastatin can prevent the expression of OX40L, and the process may be associated with mevalonate pathway.	Mevalonic Acid	180-190	TNF superfamily member 4	Homo sapiens	134-139
23806820-11	2014	Interestingly, only mevalonate showed restoration of cell growth following rosuvastatin treatment in LTD(4) and LTD(4) plus EGF treated cells, suggesting a possible involvement of both farnesylated and geranylgeranylated proteins in the cysteinyl-LT-induced cell growth.	Mevalonic Acid	20-30	epidermal growth factor	Homo sapiens	124-127
24252724-7	2014	In conclusion, the metabolic pathways, including tricarboxylic acid cycle, antioxidant defense systems, fatty acid beta-oxidation, glycolysis and choline and mevalonate metabolisms were impaired in CCl4-treated rat livers.	Mevalonic Acid	158-168	C-C motif chemokine ligand 4	Rattus norvegicus	198-202
24333427-1	2014	Hydroxymethylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate limiting step in cholesterol biosynthesis converting HMG-CoA into mevalonic acid (MVA), which equilibrates with mevalonic acid lactone (MVL) under neutral pH conditions.	Mevalonic Acid	136-150	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-42
24466094-9	2014	CYB5D2 co-localizes with cytochrome P450 reductase (CYPOR), while CYB5D2 knockdown reduced lanosterol demethylase (CYP51A1) levels and rendered HeLa cells sensitive to mevalonate.	Mevalonic Acid	168-178	cytochrome b5 domain containing 2	Homo sapiens	66-72
24333427-1	2014	Hydroxymethylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate limiting step in cholesterol biosynthesis converting HMG-CoA into mevalonic acid (MVA), which equilibrates with mevalonic acid lactone (MVL) under neutral pH conditions.	Mevalonic Acid	136-150	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	44-49
24333427-1	2014	Hydroxymethylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate limiting step in cholesterol biosynthesis converting HMG-CoA into mevalonic acid (MVA), which equilibrates with mevalonic acid lactone (MVL) under neutral pH conditions.	Mevalonic Acid	152-155	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-42
24333427-1	2014	Hydroxymethylglutaryl coenzyme A reductase (HMGCR) catalyzes the rate limiting step in cholesterol biosynthesis converting HMG-CoA into mevalonic acid (MVA), which equilibrates with mevalonic acid lactone (MVL) under neutral pH conditions.	Mevalonic Acid	152-155	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	44-49
24367099-0	2014	Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.	Mevalonic Acid	13-23	hyaluronan mediated motility receptor	Homo sapiens	53-58
24280213-5	2014	The oxysterol 27-hydroxycholesterol (27HC), synthesized by the mitochondrial enzyme CYP27A1, was identified as one of the major de novo adipocyte products from cholesterol and its precursor mevalonate.	Mevalonic Acid	190-200	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	84-91
24367099-0	2014	Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.	Mevalonic Acid	13-23	Yes1 associated transcriptional regulator	Homo sapiens	77-80
24367099-6	2014	Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization.	Mevalonic Acid	94-104	Yes1 associated transcriptional regulator	Homo sapiens	44-47
24367099-6	2014	Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization.	Mevalonic Acid	94-104	hyaluronan mediated motility receptor	Homo sapiens	58-63
24367099-6	2014	Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization.	Mevalonic Acid	94-104	hyaluronan mediated motility receptor	Homo sapiens	150-155
24367099-6	2014	Required for ERK phosphorylation and BCCMI, YAP-activated RHAMM transcription is dependent on mevalonate and sensitive to simvastatin, which modulate RHAMM transcription by modulating YAP phosphorylation and nuclear-cytoplasmic localization.	Mevalonic Acid	94-104	Yes1 associated transcriptional regulator	Homo sapiens	184-187
24367099-7	2014	Further, modulation by mevalonate/simvastatin of YAP-activated RHAMM transcription requires geranylgeranylation, Rho GTPase activation, and actin cytoskeleton rearrangement, but is largely independent of MST and LATS kinase activity.	Mevalonic Acid	23-33	Yes1 associated transcriptional regulator	Homo sapiens	49-52
24367099-7	2014	Further, modulation by mevalonate/simvastatin of YAP-activated RHAMM transcription requires geranylgeranylation, Rho GTPase activation, and actin cytoskeleton rearrangement, but is largely independent of MST and LATS kinase activity.	Mevalonic Acid	23-33	hyaluronan mediated motility receptor	Homo sapiens	63-68
24367099-8	2014	These findings from in vitro and in vivo investigations link mevalonate and Hippo pathways with RHAMM as a downstream effector, a YAP-transcription and simvastatin-inhibition target, and a cancer metastasis mediator; uncover a mechanism regulating RHAMM expression and cancer metastases; and reveal a mode whereby simvastatin exerts anticancer effects; providing potential targets for cancer therapeutic agents.	Mevalonic Acid	61-71	hyaluronan mediated motility receptor	Homo sapiens	96-101
24367099-8	2014	These findings from in vitro and in vivo investigations link mevalonate and Hippo pathways with RHAMM as a downstream effector, a YAP-transcription and simvastatin-inhibition target, and a cancer metastasis mediator; uncover a mechanism regulating RHAMM expression and cancer metastases; and reveal a mode whereby simvastatin exerts anticancer effects; providing potential targets for cancer therapeutic agents.	Mevalonic Acid	61-71	Yes1 associated transcriptional regulator	Homo sapiens	130-133
24367099-8	2014	These findings from in vitro and in vivo investigations link mevalonate and Hippo pathways with RHAMM as a downstream effector, a YAP-transcription and simvastatin-inhibition target, and a cancer metastasis mediator; uncover a mechanism regulating RHAMM expression and cancer metastases; and reveal a mode whereby simvastatin exerts anticancer effects; providing potential targets for cancer therapeutic agents.	Mevalonic Acid	61-71	hyaluronan mediated motility receptor	Homo sapiens	248-253
24367099-5	2014	Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription.	Mevalonic Acid	51-61	hyaluronan mediated motility receptor	Homo sapiens	18-23
24367099-5	2014	Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription.	Mevalonic Acid	51-61	Yes1 associated transcriptional regulator	Homo sapiens	97-119
24367099-5	2014	Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription.	Mevalonic Acid	51-61	Yes1 associated transcriptional regulator	Homo sapiens	121-124
24367099-5	2014	Here we show that RHAMM expression is regulated by mevalonate and Hippo pathways converging onto Yes-associated protein (YAP)/TEAD, which binds RHAMM promoter at specific sites and controls its transcription and consequently breast cancer cell migration and invasion (BCCMI); and that simvastatin inhibits BCCMI via targeting YAP-mediated RHAMM transcription.	Mevalonic Acid	51-61	Yes1 associated transcriptional regulator	Homo sapiens	326-329
24269531-9	2014	Introduction of the whole mevalonate pathway for enhanced building block synthesis from endogenously synthesized mevalonate improved geraniol production up to 182.5mg/L in the yjgB mutant after 48h of culture, which was a double of that obtained in the wild type control (96.5mg/L).	Mevalonic Acid	26-36	oxidoreductase	Escherichia coli	176-180
24534219-2	2014	We aimed to explore the association between the gene polymorphisms of key enzyme farnesyl diphosphate synthase (FDPS) in mevalonate signaling pathway of osteoclast and response to alendronate therapy in osteoporotic postmenopausal women in China.	Mevalonic Acid	121-131	farnesyl diphosphate synthase	Homo sapiens	81-110
24534219-2	2014	We aimed to explore the association between the gene polymorphisms of key enzyme farnesyl diphosphate synthase (FDPS) in mevalonate signaling pathway of osteoclast and response to alendronate therapy in osteoporotic postmenopausal women in China.	Mevalonic Acid	121-131	farnesyl diphosphate synthase	Homo sapiens	112-116
24172032-2	2014	BPs with nitrogen-containing side chains (N-BPs) are known to act as inhibitors for farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway.	Mevalonic Acid	144-154	farnesyl diphosphate synthase	Homo sapiens	84-115
24172032-2	2014	BPs with nitrogen-containing side chains (N-BPs) are known to act as inhibitors for farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway.	Mevalonic Acid	144-154	farnesyl diphosphate synthase	Homo sapiens	117-121
24269531-9	2014	Introduction of the whole mevalonate pathway for enhanced building block synthesis from endogenously synthesized mevalonate improved geraniol production up to 182.5mg/L in the yjgB mutant after 48h of culture, which was a double of that obtained in the wild type control (96.5mg/L).	Mevalonic Acid	113-123	oxidoreductase	Escherichia coli	176-180
24360083-1	2013	BACKGROUND: Mevalonate kinase deficiency (MKD) is caused by mutations in the MVK gene, encoding the second enzyme of mevalonate pathway, which results in subsequent shortage of downstream compounds, and starts in childhood with febrile attacks, skin, joint, and gastrointestinal symptoms, sometimes induced by vaccinations.	Mevalonic Acid	117-127	mevalonate kinase	Homo sapiens	77-80
24270073-1	2014	The enzyme 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGR) catalyzes the conversion of HMG-Co-A into mevalonate.	Mevalonic Acid	108-118	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	11-58
24386216-1	2013	3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is a rate-controlling enzyme in the mevalonate pathway which involved in biosynthesis of cholesterol and other isoprenoids.	Mevalonic Acid	91-101	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-47
24386216-1	2013	3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is a rate-controlling enzyme in the mevalonate pathway which involved in biosynthesis of cholesterol and other isoprenoids.	Mevalonic Acid	91-101	high mobility group AT-hook 1	Homo sapiens	49-53
24777788-1	2014	The enzyme 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase catalyzes the NADPH-mediated reductive deacylation of HMG-CoA to mevalonic acid, which is the first committed step of the mevalonate pathway for isoprenoid biosynthesis.	Mevalonic Acid	127-141	2,4-dienoyl-CoA reductase 1	Homo sapiens	76-81
24777788-1	2014	The enzyme 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase catalyzes the NADPH-mediated reductive deacylation of HMG-CoA to mevalonic acid, which is the first committed step of the mevalonate pathway for isoprenoid biosynthesis.	Mevalonic Acid	184-194	2,4-dienoyl-CoA reductase 1	Homo sapiens	76-81
24209962-8	2013	Fluvastatin-induced activation of caspase-3, DNA fragmentation, and activation of LC3-II were blocked by metabolic products of the HMG-CoA reductase reaction, such as mevalonate, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).	Mevalonic Acid	167-177	caspase 3	Mus musculus	34-43
23339033-2	2013	Statins also inhibit adipogenic differentiation and receptor activator of NFkappaB ligand (RANKL) expression, possibly through the mevalonic acid pathway, although the involvement of that pathway and effector proteins in these cellular events has not been fully clarified.	Mevalonic Acid	131-145	TNF superfamily member 11	Homo sapiens	52-89
23339033-2	2013	Statins also inhibit adipogenic differentiation and receptor activator of NFkappaB ligand (RANKL) expression, possibly through the mevalonic acid pathway, although the involvement of that pathway and effector proteins in these cellular events has not been fully clarified.	Mevalonic Acid	131-145	TNF superfamily member 11	Homo sapiens	91-96
24057001-5	2013	We find that slc16a6a mutants have decreased activity of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr), despite increased Hmgcr protein abundance and relative incorporation of mevalonate into cholesterol.	Mevalonic Acid	240-250	solute carrier family 16 member 6a	Danio rerio	13-21
24006306-1	2013	The rate-limiting enzyme of the mevalonate pathway, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, provides essential intermediates for the prenylation of nuclear lamins and Ras and dolichol-mediated glycosylation of growth factor receptors.	Mevalonic Acid	32-42	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	52-109
24434328-3	2013	Aminobisphosphonates increase the endogenous pool of IPP in cells by blocking the enzyme farnesyl pyrophosphate synthase (FPPS) of the mevalonate pathway.	Mevalonic Acid	135-145	farnesyl diphosphate synthase	Homo sapiens	89-120
24434328-3	2013	Aminobisphosphonates increase the endogenous pool of IPP in cells by blocking the enzyme farnesyl pyrophosphate synthase (FPPS) of the mevalonate pathway.	Mevalonic Acid	135-145	farnesyl diphosphate synthase	Homo sapiens	122-126
24057001-5	2013	We find that slc16a6a mutants have decreased activity of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr), despite increased Hmgcr protein abundance and relative incorporation of mevalonate into cholesterol.	Mevalonic Acid	240-250	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	160-165
23919676-7	2013	These two compounds can be considered as a novel lead for the potent inhibitors of hGGPPS for the treatment of cancers and mevalonate-pathway diseases.	Mevalonic Acid	123-133	geranylgeranyl diphosphate synthase 1	Homo sapiens	83-89
23908355-4	2013	Mutational activation of p53 in MDA-MB-231 breast cancer cells up-regulates the mevalonate pathway to promote tumor invasiveness.	Mevalonic Acid	80-90	tumor protein p53	Homo sapiens	25-28
24071646-9	2013	Furthermore, mevalonate administration reversed the effects of atorvastatin on the Kras/Raf and Kras/PI3K complexes, as well as AKT and ERK activity in both A549 and Calu1 cells.	Mevalonic Acid	13-23	KRAS proto-oncogene, GTPase	Homo sapiens	83-87
24071646-9	2013	Furthermore, mevalonate administration reversed the effects of atorvastatin on the Kras/Raf and Kras/PI3K complexes, as well as AKT and ERK activity in both A549 and Calu1 cells.	Mevalonic Acid	13-23	zinc fingers and homeoboxes 2	Homo sapiens	88-91
24071646-9	2013	Furthermore, mevalonate administration reversed the effects of atorvastatin on the Kras/Raf and Kras/PI3K complexes, as well as AKT and ERK activity in both A549 and Calu1 cells.	Mevalonic Acid	13-23	KRAS proto-oncogene, GTPase	Homo sapiens	96-100
24071646-9	2013	Furthermore, mevalonate administration reversed the effects of atorvastatin on the Kras/Raf and Kras/PI3K complexes, as well as AKT and ERK activity in both A549 and Calu1 cells.	Mevalonic Acid	13-23	AKT serine/threonine kinase 1	Homo sapiens	128-131
23908355-5	2013	p53 silencing or pharmacological inhibition of HMG-CoA reductase in these cells decreases protein isoprenylation from endogenously synthesized isoprenoids but enhances the use of exogenous isoprenols for this purpose, indicating that this latter process is regulated independently of the mevalonate pathway.	Mevalonic Acid	288-298	tumor protein p53	Homo sapiens	0-3
24071646-9	2013	Furthermore, mevalonate administration reversed the effects of atorvastatin on the Kras/Raf and Kras/PI3K complexes, as well as AKT and ERK activity in both A549 and Calu1 cells.	Mevalonic Acid	13-23	mitogen-activated protein kinase 1	Homo sapiens	136-139
23898401-1	2013	Sterol homeostasis is essential for the function of cellular membranes and requires feedback inhibition of HMGR, a rate-limiting enzyme of the mevalonate pathway.	Mevalonic Acid	143-153	high mobility group AT-hook 1	Homo sapiens	107-111
23935198-2	2013	They act by inhibiting farnesyl diphosphate synthase in the mevalonate pathway.	Mevalonic Acid	60-70	farnesyl diphosphate synthetase	Mus musculus	23-52
23812589-8	2013	Mechanistically, raptor/mTORC1 signalling in T(reg) cells promotes cholesterol and lipid metabolism, with the mevalonate pathway particularly important for coordinating T(reg)-cell proliferation and upregulation of the suppressive molecules CTLA4 and ICOS to establish Treg-cell functional competency.	Mevalonic Acid	110-120	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	241-246
23812589-8	2013	Mechanistically, raptor/mTORC1 signalling in T(reg) cells promotes cholesterol and lipid metabolism, with the mevalonate pathway particularly important for coordinating T(reg)-cell proliferation and upregulation of the suppressive molecules CTLA4 and ICOS to establish Treg-cell functional competency.	Mevalonic Acid	110-120	inducible T cell co-stimulator	Mus musculus	251-255
24040034-7	2013	Finally, upregulation of CD9/CD81 by statins was related to blockade of GTPase geranylgeranylation in the mevalonate pathway.	Mevalonic Acid	106-116	CD9 antigen	Mus musculus	25-28
24040034-7	2013	Finally, upregulation of CD9/CD81 by statins was related to blockade of GTPase geranylgeranylation in the mevalonate pathway.	Mevalonic Acid	106-116	CD81 antigen	Mus musculus	29-33
24128347-0	2013	The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.	Mevalonic Acid	30-44	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	99-116
23794630-1	2013	The potent nitrogen-containing bisphosphonate zoledronate inhibits farnesyl pyrophosphate synthase, a key enzyme of the mevalonate pathway that is often hyperactive in malignant cells.	Mevalonic Acid	120-130	farnesyl diphosphate synthase	Homo sapiens	67-98
23898401-2	2013	As HMGR acts at the beginning of the pathway, its regulation affects the synthesis of sterols and of other essential mevalonate-derived metabolites, such as ubiquinone or dolichol.	Mevalonic Acid	117-127	high mobility group AT-hook 1	Homo sapiens	3-7
23898401-5	2013	Since the other branch of ERAD is required for HMGR regulation, our results reveal a fundamental role for ERAD in sterol homeostasis, with the two branches of this pathway acting together to control sterol biosynthesis at different levels and thereby allowing independent regulation of multiple products of the mevalonate pathway.	Mevalonic Acid	311-321	high mobility group AT-hook 1	Homo sapiens	47-51
23164362-10	2013	CONCLUSIONS: These data suggest that ZA is effective in inhibiting HASMC proliferation, adhesion, and migration, which coincide with the appearance of unprenylated RAP-1A/B protein, thereby suggesting that the mevalonate pathway may play a role in the inhibition of HASMC activation.	Mevalonic Acid	210-220	RAP1A, member of RAS oncogene family	Homo sapiens	164-172
23564016-1	2013	Nitrogen-containing bisphosphonates have been well known to be inhibited farnesyl diphosphate synthase (FDPS), an enzyme in mevalonic acid metabolism, resulting in disturbance in polymerization of cytoskeleton structure in bone resorption and promotion of apoptosis in mature osteoclasts.	Mevalonic Acid	124-138	farnesyl diphosphate synthetase	Mus musculus	73-102
23564016-1	2013	Nitrogen-containing bisphosphonates have been well known to be inhibited farnesyl diphosphate synthase (FDPS), an enzyme in mevalonic acid metabolism, resulting in disturbance in polymerization of cytoskeleton structure in bone resorption and promotion of apoptosis in mature osteoclasts.	Mevalonic Acid	124-138	farnesyl diphosphate synthetase	Mus musculus	104-108
23321500-3	2013	Vgamma9Vdelta2 T cells recognized endogenous mevalonate metabolites and MICA/B of PEL cell lines, inducing cytotoxicity via granule exocytosis and TRAIL-mediated pathway.	Mevalonic Acid	45-55	TNF superfamily member 10	Homo sapiens	147-152
26909280-0	2013	Regulation of VEGF by mevalonate pathway inhibition in breast cancer.	Mevalonic Acid	22-32	vascular endothelial growth factor A	Homo sapiens	14-18
26909280-5	2013	We therefore investigated VEGF expression in breast cancer cell lines following mevalonate pathway inhibition.	Mevalonic Acid	80-90	vascular endothelial growth factor A	Homo sapiens	26-30
23717538-7	2013	This effect was significantly blocked by 1400 W (80+-5.2% inhibition, p<0.02) and mevalonate, the direct metabolite of HMGCoA reductase.	Mevalonic Acid	85-95	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	122-138
23428571-2	2013	Four enzymes in mevalonate pathway, including MVK, PMK, MDD, and FPPS, play important regulatory roles in cholesterol biosynthesis and cell proliferation.	Mevalonic Acid	16-26	mevalonate kinase	Homo sapiens	46-49
23428571-2	2013	Four enzymes in mevalonate pathway, including MVK, PMK, MDD, and FPPS, play important regulatory roles in cholesterol biosynthesis and cell proliferation.	Mevalonic Acid	16-26	phosphomevalonate kinase	Homo sapiens	51-54
23428571-2	2013	Four enzymes in mevalonate pathway, including MVK, PMK, MDD, and FPPS, play important regulatory roles in cholesterol biosynthesis and cell proliferation.	Mevalonic Acid	16-26	farnesyl diphosphate synthase	Homo sapiens	65-69
23110805-3	2013	Mutations in both copies of the MVK-gene lead to a block in the mevalonate pathway.	Mevalonic Acid	64-74	mevalonate kinase	Homo sapiens	32-35
23110805-5	2013	Shortage of a non-sterol isoprenoid product of the mevalonate pathway, Geranylgeranylpyrophosphate leads to aberrant activation of the small GTPase Rac1, and inflammasome activation.	Mevalonic Acid	51-61	Rac family small GTPase 1	Homo sapiens	148-152
23471651-2	2013	HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, is the target of statins.	Mevalonic Acid	59-69	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-17
23530189-0	2013	The mitochondrial unfolded protein response activator ATFS-1 protects cells from inhibition of the mevalonate pathway.	Mevalonic Acid	99-109	Stress activated transcription factor atfs-1	Caenorhabditis elegans	54-60
23593363-4	2013	Zoledronic acid, a potent aminobisphosphonate targeting the mevalonate pathway, interrupted Ras- and RhoA-dependent downstream signalling pathways, abrogated the Hypoxia Inducible Factor-1alpha-driven P-glycoprotein expression, and restored doxorubicin-induced cytotoxicity and immunogenic cell death in MDR+ cells.	Mevalonic Acid	60-70	ras homolog family member A	Homo sapiens	101-105
23471651-2	2013	HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway, is the target of statins.	Mevalonic Acid	59-69	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	19-24
23277274-1	2013	Farnesyl pyrophosphate synthase (FPPS), as a key branchpoint of the mevalonate pathway, catalyzes the synthesis of isoprenoid intermediates.	Mevalonic Acid	68-78	farnesyl diphosphate synthetase	Mus musculus	0-31
22407328-0	2013	Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?	Mevalonic Acid	101-111	farnesyl diphosphate synthase	Homo sapiens	22-53
22407328-3	2013	Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the mevalonate pathway, in PC.	Mevalonic Acid	100-110	farnesyl diphosphate synthase	Homo sapiens	38-69
22407328-3	2013	Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the mevalonate pathway, in PC.	Mevalonic Acid	100-110	farnesyl diphosphate synthase	Homo sapiens	71-75
22407328-15	2013	The association of FPPS with established histopathological risk parameters and biochemical recurrence implicates a contribution of the mevalonate pathway to PC progression.	Mevalonic Acid	135-145	farnesyl diphosphate synthase	Homo sapiens	19-23
23180723-1	2013	AIMS: Farnesyl pyrophosphate synthase (FPPS) is a key enzyme in the mevalonate pathway.	Mevalonic Acid	68-78	farnesyl diphosphate synthetase	Mus musculus	6-37
23180723-1	2013	AIMS: Farnesyl pyrophosphate synthase (FPPS) is a key enzyme in the mevalonate pathway.	Mevalonic Acid	68-78	farnesyl diphosphate synthetase	Mus musculus	39-43
23386644-9	2013	CONCLUSIONS: Resveratrol inhibits key steps of the mevalonate pathway by mechanisms that are partly complementary to and partly comparable with simvastatin via reducing both expression and activity of HMGCR.	Mevalonic Acid	51-61	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	201-206
23554170-9	2013	Neuronal expression of APP decreased both HMGCR and cholesterol 24-hydroxylase mRNA levels and consequently cholesterol turnover, leading to inhibition of neuronal activity, which was rescued by geranylgeraniol, generated in the mevalonate pathway, in both APP expressing and mevastatin treated neurons.	Mevalonic Acid	229-239	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	42-47
23354132-5	2013	The statin-induced             phosphorylation of eIF2alpha and JNK was inhibited by supplementation with components             of the mevalonate pathway, such as mevalonate, farnesyl pyrophosphate (FPP) and             geranylgeranyl pyrophosphate (GGPP).	Mevalonic Acid	136-146	eukaryotic translation initiation factor 2A	Homo sapiens	50-59
23354132-5	2013	The statin-induced             phosphorylation of eIF2alpha and JNK was inhibited by supplementation with components             of the mevalonate pathway, such as mevalonate, farnesyl pyrophosphate (FPP) and             geranylgeranyl pyrophosphate (GGPP).	Mevalonic Acid	136-146	mitogen-activated protein kinase 8	Homo sapiens	64-67
23354132-5	2013	The statin-induced             phosphorylation of eIF2alpha and JNK was inhibited by supplementation with components             of the mevalonate pathway, such as mevalonate, farnesyl pyrophosphate (FPP) and             geranylgeranyl pyrophosphate (GGPP).	Mevalonic Acid	164-174	eukaryotic translation initiation factor 2A	Homo sapiens	50-59
23354132-5	2013	The statin-induced             phosphorylation of eIF2alpha and JNK was inhibited by supplementation with components             of the mevalonate pathway, such as mevalonate, farnesyl pyrophosphate (FPP) and             geranylgeranyl pyrophosphate (GGPP).	Mevalonic Acid	164-174	mitogen-activated protein kinase 8	Homo sapiens	64-67
23277274-1	2013	Farnesyl pyrophosphate synthase (FPPS), as a key branchpoint of the mevalonate pathway, catalyzes the synthesis of isoprenoid intermediates.	Mevalonic Acid	68-78	farnesyl diphosphate synthetase	Mus musculus	33-37
23449454-6	2013	Statin-induced cytotoxic effects, DNA fragmentation and changes of activation of caspase-3, Akt, Erk and p38 were blocked by antioxidant (N-acetylcysteine) and metabolic products of the HMG-CoA reductase reaction, such as mevalonate, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).	Mevalonic Acid	222-232	caspase 3	Mus musculus	81-90
22451024-7	2013	Furthermore, mevalonate or GGPP treatment reversed the inhibitory effect of simvastatin not only on migration and invasion in vitro but also on RhoA activation, and inhibition of RhoA by specific siRNA transfection reduced migration, adhesion and invasion of RA FLS.	Mevalonic Acid	13-23	ras homolog family member A	Homo sapiens	144-148
22960596-0	2013	Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway.	Mevalonic Acid	26-36	mitogen-activated protein kinase 8	Homo sapiens	110-113
22960596-0	2013	Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway.	Mevalonic Acid	26-36	DNA damage inducible transcript 3	Homo sapiens	114-118
22960596-0	2013	Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway.	Mevalonic Acid	26-36	TNF receptor superfamily member 10b	Homo sapiens	119-122
22960596-3	2013	Exogenous addition of either mevalonate or geranylgeranyl pyrophosphate (GGPP) inhibited SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway, indicating that activation of JNK/CHOP/DR5 pro-apoptotic pathway is dependent on SVA inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase and its intermediate GGPP.	Mevalonic Acid	29-39	mitogen-activated protein kinase 8	Homo sapiens	107-110
22960596-3	2013	Exogenous addition of either mevalonate or geranylgeranyl pyrophosphate (GGPP) inhibited SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway, indicating that activation of JNK/CHOP/DR5 pro-apoptotic pathway is dependent on SVA inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase and its intermediate GGPP.	Mevalonic Acid	29-39	DNA damage inducible transcript 3	Homo sapiens	111-115
22960596-3	2013	Exogenous addition of either mevalonate or geranylgeranyl pyrophosphate (GGPP) inhibited SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway, indicating that activation of JNK/CHOP/DR5 pro-apoptotic pathway is dependent on SVA inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase and its intermediate GGPP.	Mevalonic Acid	29-39	TNF receptor superfamily member 10b	Homo sapiens	116-119
22960596-3	2013	Exogenous addition of either mevalonate or geranylgeranyl pyrophosphate (GGPP) inhibited SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway, indicating that activation of JNK/CHOP/DR5 pro-apoptotic pathway is dependent on SVA inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase and its intermediate GGPP.	Mevalonic Acid	29-39	mitogen-activated protein kinase 8	Homo sapiens	173-176
22960596-3	2013	Exogenous addition of either mevalonate or geranylgeranyl pyrophosphate (GGPP) inhibited SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway, indicating that activation of JNK/CHOP/DR5 pro-apoptotic pathway is dependent on SVA inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase and its intermediate GGPP.	Mevalonic Acid	29-39	DNA damage inducible transcript 3	Homo sapiens	177-181
22960596-3	2013	Exogenous addition of either mevalonate or geranylgeranyl pyrophosphate (GGPP) inhibited SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway, indicating that activation of JNK/CHOP/DR5 pro-apoptotic pathway is dependent on SVA inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase and its intermediate GGPP.	Mevalonic Acid	29-39	TNF receptor superfamily member 10b	Homo sapiens	182-185
22960596-3	2013	Exogenous addition of either mevalonate or geranylgeranyl pyrophosphate (GGPP) inhibited SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway, indicating that activation of JNK/CHOP/DR5 pro-apoptotic pathway is dependent on SVA inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase and its intermediate GGPP.	Mevalonic Acid	29-39	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	242-299
23065284-0	2013	Expression pattern of fifteen genes of non-mevalonate (MEP) and mevalonate (MVA) pathways in different tissues of endangered medicinal herb Picrorhiza kurroa with respect to picrosides content.	Mevalonic Acid	43-53	cathepsin L	Homo sapiens	55-58
23063651-2	2013	Simvastatin (SVA) and gamma-tocotrienol (gammaT3) eliminate enriched CSCs and suppress expression of Stat-3 signaling mediators via inhibition of the mevalonate pathway and activation of de novo ceramide synthesis pathway, respectively.	Mevalonic Acid	150-160	signal transducer and activator of transcription 3	Homo sapiens	101-107
22989565-4	2013	METHODS: Expression of KLF2 and its vasoprotective target genes was determined in SEC freshly isolated from control or CCl(4)-cirrhotic rats treated with four different statins (atorvastatin, mevastatin, simvastatin, and lovastatin), in the presence of mevalonate (or vehicle), under static or controlled shear stress conditions.	Mevalonic Acid	253-263	Kruppel-like factor 2	Rattus norvegicus	23-27
23146631-1	2013	Phosphomevalonate kinase (PMK) phosphorylates mevalonate-5-phosphate (M5P) in the mevalonate pathway, which is the sole source of isoprenoids and steroids in humans.	Mevalonic Acid	7-17	phosphomevalonate kinase	Homo sapiens	26-29
23146631-8	2013	Compounds identified in this study serve as chemical genetic probes of human PMK, to explore pharmacology of the mevalonate pathway, as well as starting points for further drug development.	Mevalonic Acid	113-123	phosphomevalonate kinase	Homo sapiens	77-80
24073415-2	2013	The consequent shortage of mevalonate-derived isoprenoid compounds results in an inflammatory phenotype, caused by the activation of the NALP3 inflammasome that determines an increased caspase-1 activation and IL-1 beta release.	Mevalonic Acid	27-37	NLR family pyrin domain containing 3	Homo sapiens	137-142
24073415-2	2013	The consequent shortage of mevalonate-derived isoprenoid compounds results in an inflammatory phenotype, caused by the activation of the NALP3 inflammasome that determines an increased caspase-1 activation and IL-1 beta release.	Mevalonic Acid	27-37	caspase 1	Homo sapiens	185-194
23479762-6	2013	PAI-1 mRNA and protein expression levels were both increased with high glucose concentrations, but they were significantly suppressed by simvastatin and atorvastatin treatment (P < 0.01) and the effects were reversed by mevalonate (100 mumol/L) and geranylgeranyl pyrophosphate (10 mumol/L) but not farnesyl pyrophosphate (10 mumol/L).	Mevalonic Acid	223-233	serpin family E member 1	Homo sapiens	0-5
23116397-8	2013	This review will focus on three major redox metabolic pathways which may provide promising strategies to fight against pathogens: the non-mevalonate pathway for isoprenoids biosynthesis, the iron metabolism and the iron-sulfur proteins.The common attractive link of all these processes is the plant-type ferredoxin-NADP+ reductase, an enzyme that participates in numerous electron transfer reactions and has no homologous enzyme in humans.	Mevalonic Acid	138-148	ferredoxin reductase	Homo sapiens	304-330
23533771-4	2013	In addition, the nitrogen-containing BPs (N-BPs), second-generation BPs, act by inhibiting farnesyl diphosphate (FPP) synthase, a key enzyme of the mevalonate pathway.	Mevalonic Acid	148-158	farnesyl diphosphate synthase	Homo sapiens	91-126
22310279-2	2012	The rate-limiting enzyme of the mevalonate pathway, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is safely and effectively targeted by the statin family of inhibitors to treat hypercholesterolemia.	Mevalonic Acid	32-42	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	52-94
23168296-2	2013	MKD is due to mutations in the second enzyme of mevalonate pathway (mevalonate kinase, MK/MVK) which results in reduced enzymatic activity and in the consequent shortage of downstream compounds.	Mevalonic Acid	48-58	mevalonate kinase	Homo sapiens	68-85
23168296-2	2013	MKD is due to mutations in the second enzyme of mevalonate pathway (mevalonate kinase, MK/MVK) which results in reduced enzymatic activity and in the consequent shortage of downstream compounds.	Mevalonic Acid	48-58	mevalonate kinase	Homo sapiens	90-93
23108656-11	2012	Simvastatin decreased miR-155 expression through interfering mevalonate-geranylgeranyl-pyrophosphate-RhoA signaling pathway.	Mevalonic Acid	61-71	microRNA 155	Homo sapiens	22-29
23659452-1	2013	3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase is the rate-limiting activity in the mevalonate pathway that provides essential intermediates for posttranslational modification of growth-associated proteins.	Mevalonic Acid	95-105	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	0-57
23076613-9	2012	The protective effects of simvastatin were reversed in vitro by PI3-kinase (PI3K) inhibitors wortmannin and L-mevalonate, indicating that the PI3K/Akt and mevalonate pathways may be involved in simvastatin-induced ATII cell function restoration.	Mevalonic Acid	110-120	AKT serine/threonine kinase 1	Rattus norvegicus	147-150
22981371-3	2012	Mevalonate deprivation induced by competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (e.g., statins) prevents the activation of GTPases, suppresses the expression of the receptor for activation of nuclear factor kappa B (NFkappaB) ligand (RANKL) and activation of NFkappaB and, consequently, inhibits osteoclast differentiation and induces osteoclast apoptosis.	Mevalonic Acid	0-10	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	60-117
22981371-3	2012	Mevalonate deprivation induced by competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (e.g., statins) prevents the activation of GTPases, suppresses the expression of the receptor for activation of nuclear factor kappa B (NFkappaB) ligand (RANKL) and activation of NFkappaB and, consequently, inhibits osteoclast differentiation and induces osteoclast apoptosis.	Mevalonic Acid	0-10	nuclear factor kappa B subunit 1	Homo sapiens	254-262
22981371-3	2012	Mevalonate deprivation induced by competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (e.g., statins) prevents the activation of GTPases, suppresses the expression of the receptor for activation of nuclear factor kappa B (NFkappaB) ligand (RANKL) and activation of NFkappaB and, consequently, inhibits osteoclast differentiation and induces osteoclast apoptosis.	Mevalonic Acid	0-10	TNF superfamily member 11	Homo sapiens	272-277
22981371-3	2012	Mevalonate deprivation induced by competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (e.g., statins) prevents the activation of GTPases, suppresses the expression of the receptor for activation of nuclear factor kappa B (NFkappaB) ligand (RANKL) and activation of NFkappaB and, consequently, inhibits osteoclast differentiation and induces osteoclast apoptosis.	Mevalonic Acid	0-10	nuclear factor kappa B subunit 1	Homo sapiens	297-305
22310279-2	2012	The rate-limiting enzyme of the mevalonate pathway, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is safely and effectively targeted by the statin family of inhibitors to treat hypercholesterolemia.	Mevalonic Acid	32-42	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	96-101
22580055-0	2012	Methylenebisphosphonate and triphosphate derivatives of the mevalonate pathway are substrates of yeast UTP:glucose-1-phosphate uridylyltransferase.	Mevalonic Acid	60-70	UTP glucose-1-phosphate uridylyltransferase	Saccharomyces cerevisiae S288C	103-146
23032740-2	2012	They block the activity of farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, leading to intracellular accumulation of mevalonate metabolites (IPP/ApppI), which are recognized as tumor phosphoantigens by Vgamma9Vdelta2 T cells.	Mevalonic Acid	73-83	farnesyl diphosphate synthase	Homo sapiens	27-58
23032740-2	2012	They block the activity of farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, leading to intracellular accumulation of mevalonate metabolites (IPP/ApppI), which are recognized as tumor phosphoantigens by Vgamma9Vdelta2 T cells.	Mevalonic Acid	73-83	farnesyl diphosphate synthase	Homo sapiens	60-64
23032740-2	2012	They block the activity of farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, leading to intracellular accumulation of mevalonate metabolites (IPP/ApppI), which are recognized as tumor phosphoantigens by Vgamma9Vdelta2 T cells.	Mevalonic Acid	134-144	farnesyl diphosphate synthase	Homo sapiens	27-58
23032740-2	2012	They block the activity of farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, leading to intracellular accumulation of mevalonate metabolites (IPP/ApppI), which are recognized as tumor phosphoantigens by Vgamma9Vdelta2 T cells.	Mevalonic Acid	134-144	farnesyl diphosphate synthase	Homo sapiens	60-64
22520230-9	2012	At 1 mumol/L, both atorvastatin and pitavastatin enhanced AMPK activity, but this enhancement was abolished when AMPK signaling was blocked by compound C. The increased expressions of LPL protein and mRNA by atorvastatin and pitavastatin were reduced by compound C. In addition, mevalonic acid abolished atorvastatin- and pitavastatin-induced AMPK activation and LPL expression.	Mevalonic Acid	279-293	lipoprotein lipase	Homo sapiens	184-187
22759742-3	2012	Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD.	Mevalonic Acid	23-33	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	57-97
22759742-3	2012	Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD.	Mevalonic Acid	23-33	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	99-105
22759742-3	2012	Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD.	Mevalonic Acid	125-135	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	57-97
22759742-3	2012	Lovastatin, blocks the mevalonate pathway inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CR), an enzyme of the mevalonate pathway upstream the mevalonate kinase enzyme, reproducing biochemical features similar to those found in MKD.	Mevalonic Acid	125-135	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	99-105
22759742-5	2012	The presence of geranylgeraniol modulates both the caspase-9 and caspase-3 activity in a dose-dependent way, confirming that this isoprenoid enters the mevalonate pathway, is metabolized and finally is able to by-pass the statin biochemical block reconstituting the mevalonate pathway.	Mevalonic Acid	152-162	caspase 9	Homo sapiens	51-60
22759742-5	2012	The presence of geranylgeraniol modulates both the caspase-9 and caspase-3 activity in a dose-dependent way, confirming that this isoprenoid enters the mevalonate pathway, is metabolized and finally is able to by-pass the statin biochemical block reconstituting the mevalonate pathway.	Mevalonic Acid	152-162	caspase 3	Homo sapiens	65-74
22759742-5	2012	The presence of geranylgeraniol modulates both the caspase-9 and caspase-3 activity in a dose-dependent way, confirming that this isoprenoid enters the mevalonate pathway, is metabolized and finally is able to by-pass the statin biochemical block reconstituting the mevalonate pathway.	Mevalonic Acid	266-276	caspase 9	Homo sapiens	51-60
22722993-3	2012	The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR, EC 1.1.1.34) catalyzes the conversion of HMG-CoA to mevalonate, which is the first stage in the cytosolic pathway for biosynthesis of isoprenoid in plants.	Mevalonic Acid	104-114	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	4-44
22722993-3	2012	The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR, EC 1.1.1.34) catalyzes the conversion of HMG-CoA to mevalonate, which is the first stage in the cytosolic pathway for biosynthesis of isoprenoid in plants.	Mevalonic Acid	104-114	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	46-50
22492974-1	2012	Recently we reported that statins, the competitive inhibitors of the key enzyme regulating the mevalonate pathway, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), decrease proliferation of human endometrial stromal (HES) cells.	Mevalonic Acid	95-105	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	115-162
22901757-7	2012	RESULTS: Atorvastatin inhibited the expression of RANKL in RA FLSs in a dose-dependent manner, and the suppression of RANKL was prevented by mevalonate.	Mevalonic Acid	141-151	TNF superfamily member 11	Homo sapiens	118-123
22751434-0	2012	p53 and cancer stem cells: the mevalonate connexion.	Mevalonic Acid	31-41	tumor protein p53	Homo sapiens	0-3
22492974-1	2012	Recently we reported that statins, the competitive inhibitors of the key enzyme regulating the mevalonate pathway, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), decrease proliferation of human endometrial stromal (HES) cells.	Mevalonic Acid	95-105	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	164-169
22529099-3	2012	This concept is strongly supported by the recent finding that mutant p53, which is present in more than half of all human cancers, can significantly upregulate mevalonate metabolism and protein prenylation in carcinoma cells.	Mevalonic Acid	160-170	tumor protein p53	Homo sapiens	69-72
22615115-12	2012	Furthermore, ATV treatment inhibited RhoA membrane translocation and activation; these effects were prevented by pretreatment with mevalonate.	Mevalonic Acid	131-141	ras homolog family member A	Mus musculus	37-41
22886209-11	2012	The inhibitory effect of atorvastatin on periostin upregulation induced by TGF-beta1 was reversed by mevalonate (3.838 +- 0.326).	Mevalonic Acid	101-111	periostin	Rattus norvegicus	41-50
22504435-3	2012	Here, we utilized new molecular tools to create precise gene deletions in selected genes encoding enzymes of both pathways, gcpE, lytB (encoding proteins in the MEP pathway) and hmgR (encoding a protein in the mevalonate pathway).	Mevalonic Acid	210-220	ispG	Listeria monocytogenes EGD-e	124-128
22504435-3	2012	Here, we utilized new molecular tools to create precise gene deletions in selected genes encoding enzymes of both pathways, gcpE, lytB (encoding proteins in the MEP pathway) and hmgR (encoding a protein in the mevalonate pathway).	Mevalonic Acid	210-220	ispH	Listeria monocytogenes EGD-e	130-134
22886209-11	2012	The inhibitory effect of atorvastatin on periostin upregulation induced by TGF-beta1 was reversed by mevalonate (3.838 +- 0.326).	Mevalonic Acid	101-111	transforming growth factor, beta 1	Rattus norvegicus	75-84
22332816-9	2012	These phenotypes and biochemical alterations are reversed when AACT2 RNAi plants are grown in the presence of mevalonate, which is consistent with the role of AACT2 in generating the bulk of the acetoacetyl CoA precursor required for the cytosol-localized, mevalonate-derived isoprenoid biosynthetic pathway.	Mevalonic Acid	110-120	acetoacetyl-CoA thiolase 2	Arabidopsis thaliana	63-68
22267540-7	2012	This inhibitory effect of the statins on MCP-1 production was reversed by the downstream substrates of the mevalonate pathway.	Mevalonic Acid	107-117	chemokine (C-C motif) ligand 2	Mus musculus	41-46
22343369-7	2012	Interestingly, the effect of atorvastatin on PGC-1alpha was almost abolished by mevalonate and partially by farnesol but not by geranylgeraniol.	Mevalonic Acid	80-90	PPARG coactivator 1 alpha	Rattus norvegicus	45-55
22332816-9	2012	These phenotypes and biochemical alterations are reversed when AACT2 RNAi plants are grown in the presence of mevalonate, which is consistent with the role of AACT2 in generating the bulk of the acetoacetyl CoA precursor required for the cytosol-localized, mevalonate-derived isoprenoid biosynthetic pathway.	Mevalonic Acid	257-267	acetoacetyl-CoA thiolase 2	Arabidopsis thaliana	63-68
22332816-9	2012	These phenotypes and biochemical alterations are reversed when AACT2 RNAi plants are grown in the presence of mevalonate, which is consistent with the role of AACT2 in generating the bulk of the acetoacetyl CoA precursor required for the cytosol-localized, mevalonate-derived isoprenoid biosynthetic pathway.	Mevalonic Acid	257-267	acetoacetyl-CoA thiolase 2	Arabidopsis thaliana	159-164
22361350-13	2012	This feedback mechanism increases Erk1/2 signaling through mevalonate-mediated Ras activation.	Mevalonic Acid	59-69	mitogen-activated protein kinase 3	Mus musculus	34-40
22322451-9	2012	Additionally,             Ras and RhoA proteins located in the membrane fraction decreased when treated             with ZOL and recovered by FOH or GGOH treatment, suggesting that ZOL inhibited             the mevalonate pathway, thereby suppressing the translocation of prenylated Ras             and RhoA proteins to membrane fractions.	Mevalonic Acid	211-221	ras homolog family member A	Homo sapiens	34-38
22322451-9	2012	Additionally,             Ras and RhoA proteins located in the membrane fraction decreased when treated             with ZOL and recovered by FOH or GGOH treatment, suggesting that ZOL inhibited             the mevalonate pathway, thereby suppressing the translocation of prenylated Ras             and RhoA proteins to membrane fractions.	Mevalonic Acid	211-221	ras homolog family member A	Homo sapiens	303-307
22522421-3	2012	Bacterial IspD is a nucleotidyl transferase belonging to a large glycosyltransferase family, but the role of the orthologous protein in chordates is obscure to date, as this phylum does not have the corresponding non-mevalonate isoprenoid biosynthesis pathway.	Mevalonic Acid	217-227	CDP-L-ribitol pyrophosphorylase A	Homo sapiens	10-14
20946258-8	2012	The first pathway is mevalonate-related but not RhoA protein-related and involves suppression of Ras and PI3K/Akt signals.	Mevalonic Acid	21-31	AKT serine/threonine kinase 1	Homo sapiens	110-113
21796214-4	2012	In the current study, we investigated whether targeted knockdown of the mevalonate pathway in conjunction with LDLR delivery would lead to enhanced LDLR transgene expression and improved phenotype recovery.	Mevalonic Acid	72-82	low density lipoprotein receptor	Mus musculus	148-152
22211244-1	2012	Inhibitors of lipid metabolic pathways, particularly drugs targeting the mevalonate pathway, have been suggested to be valuable in enhancing the effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and these compounds may also be effective in patients with inherent or acquired resistance to EGFR-TKIs.	Mevalonic Acid	73-83	epidermal growth factor receptor	Homo sapiens	223-227
22211244-1	2012	Inhibitors of lipid metabolic pathways, particularly drugs targeting the mevalonate pathway, have been suggested to be valuable in enhancing the effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and these compounds may also be effective in patients with inherent or acquired resistance to EGFR-TKIs.	Mevalonic Acid	73-83	epidermal growth factor receptor	Homo sapiens	328-332
22211244-3	2012	Gene expression correlation analysis showed that genes involved in the mevalonate pathway and unsaturated fatty acid synthesis were negatively correlated with the expression of EGFR, MET and other growth factor receptor genes, as well as with the expression of genes involved in cell migration and adhesion.	Mevalonic Acid	71-81	epidermal growth factor receptor	Homo sapiens	177-181
22211244-5	2012	Genes whose expression showed a positive correlation with NFY expression and mevalonate pathway genes were found to exhibit protein-protein interactions with several "hub" genes, including BRCA1, that have been associated with both lung cancer and cell division.	Mevalonic Acid	77-87	BRCA1 DNA repair associated	Homo sapiens	189-194
22258408-3	2012	Ras activation was induced by the overexpression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), the rate-limiting enzyme of the mevalonate pathway.	Mevalonic Acid	134-144	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	52-93
21751201-3	2012	Apomine, a 1,1-bisphosphonate-ester, increases the rate of degradation of 3-hydroxy-3 methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate pathway, whereas lovastatin competitively inhibits HMG-CoA reductase enzyme activity, thereby preventing protein prenylation and cholesterol synthesis.	Mevalonic Acid	165-175	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	74-131
21751201-8	2012	All synergistic effects on cell viability, apoptosis, and protein prenylation were overcome by the addition of mevalonate or geranylgeraniol, 2 mevalonate pathway intermediates downstream from the target enzyme, HMG-CoA reductase.	Mevalonic Acid	111-121	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	212-229
21751201-8	2012	All synergistic effects on cell viability, apoptosis, and protein prenylation were overcome by the addition of mevalonate or geranylgeraniol, 2 mevalonate pathway intermediates downstream from the target enzyme, HMG-CoA reductase.	Mevalonic Acid	144-154	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	212-229
22265415-0	2012	Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.	Mevalonic Acid	56-66	tumor protein p53	Homo sapiens	7-10
22265415-4	2012	Genome-wide expression analysis identified the mevalonate pathway as significantly upregulated by mutant p53.	Mevalonic Acid	47-57	tumor protein p53	Homo sapiens	105-108
22265415-8	2012	These findings implicate the mevalonate pathway as a therapeutic target for tumors bearing mutations in p53.	Mevalonic Acid	29-39	tumor protein p53	Homo sapiens	104-107
22247290-8	2012	We have now overexpressed every enzyme of the mevalonate pathway to ERG20 in S. cerevisiae CEN.PK2, and compared production to CEN.PK2 engineered identically to the previously engineered S288C strain.	Mevalonic Acid	46-56	bifunctional (2E,6E)-farnesyl diphosphate synthase/dimethylallyltranstransferase	Saccharomyces cerevisiae S288C	68-73
22433938-1	2012	BACKGROUND: Cholesterol is mainly synthesised in liver and the rate-limiting step is the reduction of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) to mevalonate, a reaction catalysed by HMG-CoA reductase (HMGCR).	Mevalonic Acid	152-162	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	188-205
22433938-1	2012	BACKGROUND: Cholesterol is mainly synthesised in liver and the rate-limiting step is the reduction of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) to mevalonate, a reaction catalysed by HMG-CoA reductase (HMGCR).	Mevalonic Acid	152-162	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	207-212
22330799-3	2012	Optimal sesquiterpene production was obtained by modulating the expression of one of the key metabolic steps of the mevalonate (MVA) pathway, squalene synthase (Erg9).	Mevalonic Acid	116-126	bifunctional farnesyl-diphosphate farnesyltransferase/squalene synthase	Saccharomyces cerevisiae S288C	161-165
21864230-11	2012	The more potent nitrogen-containing BPs inhibit FPPS, a key enzyme in the mevalonate pathway.	Mevalonic Acid	74-84	farnesyl diphosphate synthase	Homo sapiens	48-52
22177940-1	2012	The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonate, a four-electron oxidoreduction that is the rate-limiting step in the synthesis of cholesterol and other isoprenoids.	Mevalonic Acid	106-116	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	11-58
22177940-1	2012	The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) catalyzes the conversion of HMG-CoA to mevalonate, a four-electron oxidoreduction that is the rate-limiting step in the synthesis of cholesterol and other isoprenoids.	Mevalonic Acid	106-116	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	60-65
22309082-9	2012	Lycopene-mediated inhibition of MMP-9 was reversed by mevalonate and associated with a reduced expression of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.	Mevalonic Acid	54-64	matrix metallopeptidase 9	Homo sapiens	32-37
22258408-3	2012	Ras activation was induced by the overexpression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), the rate-limiting enzyme of the mevalonate pathway.	Mevalonic Acid	134-144	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	95-99
22258408-8	2012	Therefore, reduction of mitochondrial genome content induced overexpression of HMGR through hypoxic to normoxic shift and subsequently the endogenous induction of the mevalonate pathway activated Ras that mediates advanced phenotype.	Mevalonic Acid	167-177	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	79-83
21806545-8	2012	Exogenous addition of Dp44mT (2,2"-dipyridyl-N,N-dimethylsemicarbazone) and mevalonate increased leptin protein expression similarly to Ang II.	Mevalonic Acid	76-86	leptin	Homo sapiens	97-103
23023419-7	2012	The molecular mechanisms underlying the decrease in bcl-2, AP-N, and uPA expression involved suppression of protein prenylation through inhibition of the mevalonate pathway.	Mevalonic Acid	154-164	BCL2 apoptosis regulator	Homo sapiens	52-57
21871960-9	2012	Mevalonate, the product of HMG-CoA reductase enzymatic activity, AMPK siRNA or pharmacological inactivation of AMPK with compound C suppressed, while the inhibitors of Akt (10-DEBC hydrochloride) and mTOR (rapamycin) mimicked autophagy induction by simvastatin.	Mevalonic Acid	0-10	AKT serine/threonine kinase 1	Homo sapiens	168-171
21871960-9	2012	Mevalonate, the product of HMG-CoA reductase enzymatic activity, AMPK siRNA or pharmacological inactivation of AMPK with compound C suppressed, while the inhibitors of Akt (10-DEBC hydrochloride) and mTOR (rapamycin) mimicked autophagy induction by simvastatin.	Mevalonic Acid	0-10	mechanistic target of rapamycin kinase	Homo sapiens	200-204
23023419-7	2012	The molecular mechanisms underlying the decrease in bcl-2, AP-N, and uPA expression involved suppression of protein prenylation through inhibition of the mevalonate pathway.	Mevalonic Acid	154-164	plasminogen activator, urokinase	Homo sapiens	69-72
21907187-7	2011	The lovastatin-induced growth inhibition and translocation of RhoA and Rac1 in ARO cells were completely prevented by mevalonate and partially by geranylgeranyl pyrophosphate.	Mevalonic Acid	118-128	ras homolog family member A	Homo sapiens	62-66
21907187-7	2011	The lovastatin-induced growth inhibition and translocation of RhoA and Rac1 in ARO cells were completely prevented by mevalonate and partially by geranylgeranyl pyrophosphate.	Mevalonic Acid	118-128	Rac family small GTPase 1	Homo sapiens	71-75
22091898-6	2011	Second-generation bisphosphonates are nitrogen-containing agents; these inhibit osteoclast vesicular trafficking, membrane ruffling, morphology, and cytoskeletal arrangement by inhibiting farnesyl diphosphate synthase in the mevalonate pathway.	Mevalonic Acid	225-235	farnesyl diphosphate synthase	Homo sapiens	188-217
21208793-6	2011	Concomitant addition of lycopene and the PPARgamma inhibitor GW9662 or lycopene and mevalonate blocked the carotenoid-induced increase in ABCA1 and cav-1 expressions.	Mevalonic Acid	84-94	ATP binding cassette subfamily A member 1	Homo sapiens	138-143
21917869-2	2011	Enhanced extracellular matrix contractility of endometriotic stromal cells (ECSC) mediated by the mevalonate-Ras homology (Rho)/Rho-associated coiled-coil-forming protein kinase (ROCK) pathway has been shown to contribute to the pathogenesis of endometriosis.	Mevalonic Acid	98-108	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	179-183
21841162-7	2011	Hind-limb ischemia induced Rac1 farnesylation and activation leading to increased angiogenesis and these effects were blocked by simvastatin and rescued by mevalonate in WT mice.	Mevalonic Acid	156-166	Rac family small GTPase 1	Mus musculus	27-31
21803026-6	2011	By decreasing the mevalonate pathway-derived metabolite geranylgeranyl pyrophosphate and the RhoA/RhoA kinase signaling, atorvastatin activated NF-kappaB, that sustained cell proliferation.	Mevalonic Acid	18-28	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	144-153
21906051-1	2011	PURPOSE: Statins are selective inhibitors of 3-hydroxyl-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway for cholesterol biosynthesis.	Mevalonic Acid	138-148	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	45-104
21751240-10	2011	We found that ZA decreased phosphorylation of Stat3 in a mevalonate-pathway dependent manner.	Mevalonic Acid	57-67	signal transducer and activator of transcription 3	Homo sapiens	46-51
21394808-1	2011	Currently used hypolipidemic drugs, Fluvastatin and Atorvastatin, act via inhibiting the rate-limiting enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase of the mevalonate pathway.	Mevalonic Acid	176-186	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Mesocricetus auratus	110-168
21695491-7	2011	N-BPs (alendronate, risedronate, zoledronate) inhibit the intracellular mevalonate pathway and protein isoprenylation, via the enzyme farnesyl pyrophosphate synthase.	Mevalonic Acid	72-82	farnesyl diphosphate synthase	Homo sapiens	134-165
21841162-5	2011	Mevalonate rescued 15(S)-HETE-induced Rac1 farnesylation and membrane translocation in HDMVECs and the migration and tube formation of these cells from inhibition by simvastatin.	Mevalonic Acid	0-10	Rac family small GTPase 1	Mus musculus	38-42
22013129-2	2011	Aminobisphosphonates and alkylamines indirectly stimulate Vgamma2Vdelta2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate pathway, thereby increasing IPP/triphosphoric acid 1-adenosin-5"-yl ester 3-(3-methylbut-3-enyl) ester that directly stimulate.	Mevalonic Acid	137-147	farnesyl diphosphate synthase	Homo sapiens	93-122
22013129-2	2011	Aminobisphosphonates and alkylamines indirectly stimulate Vgamma2Vdelta2 cells by inhibiting farnesyl diphosphate synthase (FDPS) in the mevalonate pathway, thereby increasing IPP/triphosphoric acid 1-adenosin-5"-yl ester 3-(3-methylbut-3-enyl) ester that directly stimulate.	Mevalonic Acid	137-147	farnesyl diphosphate synthase	Homo sapiens	124-128
21903868-2	2011	Squalene synthase (SQS) utilizes FPP in the first committed step from the mevalonate pathway toward cholesterol biosynthesis.	Mevalonic Acid	74-84	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	0-17
21903868-2	2011	Squalene synthase (SQS) utilizes FPP in the first committed step from the mevalonate pathway toward cholesterol biosynthesis.	Mevalonic Acid	74-84	farnesyl-diphosphate farnesyltransferase 1	Homo sapiens	19-22
21208793-6	2011	Concomitant addition of lycopene and the PPARgamma inhibitor GW9662 or lycopene and mevalonate blocked the carotenoid-induced increase in ABCA1 and cav-1 expressions.	Mevalonic Acid	84-94	caveolin 1	Homo sapiens	148-153
21701259-1	2011	The enzyme HMG-CoA reductase (HMGR) has a key regulatory role in the mevalonate pathway for isoprenoid biosynthesis, critical not only for normal plant development, but also for the adaptation to demanding environmental conditions.	Mevalonic Acid	69-79	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	11-28
21778231-1	2011	In mammalian cells, the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes the rate-limiting step in the mevalonate pathway, is ubiquitylated and degraded by the 26 S proteasome when mevalonate-derived metabolites accumulate, representing a case of metabolically regulated endoplasmic reticulum-associated degradation (ERAD).	Mevalonic Acid	133-143	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	31-78
21778231-1	2011	In mammalian cells, the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes the rate-limiting step in the mevalonate pathway, is ubiquitylated and degraded by the 26 S proteasome when mevalonate-derived metabolites accumulate, representing a case of metabolically regulated endoplasmic reticulum-associated degradation (ERAD).	Mevalonic Acid	133-143	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	80-84
21778231-1	2011	In mammalian cells, the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes the rate-limiting step in the mevalonate pathway, is ubiquitylated and degraded by the 26 S proteasome when mevalonate-derived metabolites accumulate, representing a case of metabolically regulated endoplasmic reticulum-associated degradation (ERAD).	Mevalonic Acid	211-221	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	31-78
21778231-1	2011	In mammalian cells, the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes the rate-limiting step in the mevalonate pathway, is ubiquitylated and degraded by the 26 S proteasome when mevalonate-derived metabolites accumulate, representing a case of metabolically regulated endoplasmic reticulum-associated degradation (ERAD).	Mevalonic Acid	211-221	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	80-84
21778231-2	2011	Here, we studied which mevalonate-derived metabolites signal for HMGR degradation and the ERAD step(s) in which these metabolites are required.	Mevalonic Acid	23-33	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	65-69
21667041-1	2011	The inhibition of mevalonate pathway by the aminobisphosphonate alendronate (ALD) has been previously associated with an augmented lipopolysaccharide-induced interleukin-1beta (IL-1beta) secretion in monocytes, as demonstrated in an auto-inflammatory disease known as mevalonate kinase deficiency (MKD).	Mevalonic Acid	18-28	interleukin 1 beta	Mus musculus	158-175
21667041-1	2011	The inhibition of mevalonate pathway by the aminobisphosphonate alendronate (ALD) has been previously associated with an augmented lipopolysaccharide-induced interleukin-1beta (IL-1beta) secretion in monocytes, as demonstrated in an auto-inflammatory disease known as mevalonate kinase deficiency (MKD).	Mevalonic Acid	18-28	interleukin 1 beta	Mus musculus	177-185
21667041-1	2011	The inhibition of mevalonate pathway by the aminobisphosphonate alendronate (ALD) has been previously associated with an augmented lipopolysaccharide-induced interleukin-1beta (IL-1beta) secretion in monocytes, as demonstrated in an auto-inflammatory disease known as mevalonate kinase deficiency (MKD).	Mevalonic Acid	18-28	mevalonate kinase	Mus musculus	268-285
21667041-6	2011	These findings suggest that the inhibition of mevalonate pathway, together with a bacterial stimulus, induce a PCD partly sustained by the caspase-3-related apoptosis and partly by caspase-1-associated pyroptosis.	Mevalonic Acid	46-56	caspase 3	Mus musculus	139-148
21667041-6	2011	These findings suggest that the inhibition of mevalonate pathway, together with a bacterial stimulus, induce a PCD partly sustained by the caspase-3-related apoptosis and partly by caspase-1-associated pyroptosis.	Mevalonic Acid	46-56	caspase 1	Mus musculus	181-190
21586555-11	2011	The specificity of HMGCR inhibition to restore osteoblast differentiation of ZGA-treated cultures through the reduction in isoprenoid accumulation was confirmed with the addition of exogenous mevalonate.	Mevalonic Acid	192-202	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	19-24
21931292-8	2011	Because aminobisphosphonates (such as pamidronate or zoledronate) inhibit farnesyl pyrophosphate synthase (FPPS), the enzyme acting downstream of IPP in the mevalonate pathway, intracellular levels of IPP and sensitibity to gammadelta T cells recognition can be therapeutically increased by aminobisphosphonates.	Mevalonic Acid	157-167	farnesyl diphosphate synthase	Homo sapiens	74-105
21931292-8	2011	Because aminobisphosphonates (such as pamidronate or zoledronate) inhibit farnesyl pyrophosphate synthase (FPPS), the enzyme acting downstream of IPP in the mevalonate pathway, intracellular levels of IPP and sensitibity to gammadelta T cells recognition can be therapeutically increased by aminobisphosphonates.	Mevalonic Acid	157-167	farnesyl diphosphate synthase	Homo sapiens	107-111
21844076-6	2011	Atorvastatin caused a mevalonate-reversible inhibition of Rac1 and NOX2-NADPH oxidase activity in right atrial samples from patients who developed postoperative AF, but it did not affect reactive oxygen species, nitric oxide synthase uncoupling, or BH4 in patients with permanent AF.	Mevalonic Acid	22-32	Rac family small GTPase 1	Homo sapiens	58-62
21844076-6	2011	Atorvastatin caused a mevalonate-reversible inhibition of Rac1 and NOX2-NADPH oxidase activity in right atrial samples from patients who developed postoperative AF, but it did not affect reactive oxygen species, nitric oxide synthase uncoupling, or BH4 in patients with permanent AF.	Mevalonic Acid	22-32	cytochrome b-245 beta chain	Homo sapiens	67-71
21864337-4	2011	We now investigate mevalonate cascade-associated signaling in TGFbeta1-induced fibronectin expression by bronchial fibroblasts from non-asthmatic and asthmatic subjects.	Mevalonic Acid	19-29	transforming growth factor beta 1	Homo sapiens	62-70
21864337-4	2011	We now investigate mevalonate cascade-associated signaling in TGFbeta1-induced fibronectin expression by bronchial fibroblasts from non-asthmatic and asthmatic subjects.	Mevalonic Acid	19-29	fibronectin 1	Homo sapiens	79-90
21864337-5	2011	METHODS: We used simvastatin (1-15 muM) to inhibit 3-hydroxy-3-methlyglutaryl-coenzyme A (HMG-CoA) reductase which converts HMG-CoA to mevalonate.	Mevalonic Acid	135-145	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	51-108
21605082-3	2011	In the present study, we examine whether mevalonate metabolites activate PPARgamma (peroxisome-proliferator-activated receptor gamma), a ligand-dependent transcription factor playing a central role in adipocyte differentiation.	Mevalonic Acid	41-51	peroxisome proliferator activated receptor gamma	Homo sapiens	73-82
21605082-3	2011	In the present study, we examine whether mevalonate metabolites activate PPARgamma (peroxisome-proliferator-activated receptor gamma), a ligand-dependent transcription factor playing a central role in adipocyte differentiation.	Mevalonic Acid	41-51	peroxisome proliferator activated receptor gamma	Homo sapiens	84-132
21605082-4	2011	In the luciferase reporter assay using both GAL4 chimaera and full-length PPARgamma systems, a mevalonate metabolite, FPP (farnesyl pyrophosphate), which is the precursor of almost all isoprenoids and is positioned at branch points leading to the synthesis of other longer-chain isoprenoids, activated PPARgamma in a dose-dependent manner.	Mevalonic Acid	95-105	galectin 4	Homo sapiens	44-48
21605082-4	2011	In the luciferase reporter assay using both GAL4 chimaera and full-length PPARgamma systems, a mevalonate metabolite, FPP (farnesyl pyrophosphate), which is the precursor of almost all isoprenoids and is positioned at branch points leading to the synthesis of other longer-chain isoprenoids, activated PPARgamma in a dose-dependent manner.	Mevalonic Acid	95-105	peroxisome proliferator activated receptor gamma	Homo sapiens	74-83
21605082-4	2011	In the luciferase reporter assay using both GAL4 chimaera and full-length PPARgamma systems, a mevalonate metabolite, FPP (farnesyl pyrophosphate), which is the precursor of almost all isoprenoids and is positioned at branch points leading to the synthesis of other longer-chain isoprenoids, activated PPARgamma in a dose-dependent manner.	Mevalonic Acid	95-105	peroxisome proliferator activated receptor gamma	Homo sapiens	302-311
21701259-1	2011	The enzyme HMG-CoA reductase (HMGR) has a key regulatory role in the mevalonate pathway for isoprenoid biosynthesis, critical not only for normal plant development, but also for the adaptation to demanding environmental conditions.	Mevalonic Acid	69-79	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	30-34
21186792-1	2011	Farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway, is the inhibition target of alendronate, a potent FDA-approved nitrogen-containing bisphosphonate (N-BP) drug, at the molecular level.	Mevalonic Acid	57-67	farnesyl diphosphate synthetase	Mus musculus	0-31
21186792-1	2011	Farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway, is the inhibition target of alendronate, a potent FDA-approved nitrogen-containing bisphosphonate (N-BP) drug, at the molecular level.	Mevalonic Acid	57-67	farnesyl diphosphate synthetase	Mus musculus	33-37
21111853-4	2011	The considerably more potent nitrogen-containing bisphosphonates are not metabolised but potently inhibit farnesyl pyrophosphate (FPP) synthase, a key enzyme of the mevalonate pathway.	Mevalonic Acid	165-175	farnesyl diphosphate synthase	Homo sapiens	106-143
21551338-8	2011	Analysis of our data suggests that bisphosphonate treatment may delay oral epithelial healing by interfering with p63-positive progenitor cells in the basal layer of the oral epithelium in a mevalonate-pathway-dependent manner.	Mevalonic Acid	191-201	tumor protein p63	Homo sapiens	114-117
21491092-2	2011	Statins, which are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR), the rate-limiting enzyme in the mevalonic acid synthesis pathway, exert cytostatic and cytotoxic effects towards tumor cells.	Mevalonic Acid	125-139	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	33-80
21491092-2	2011	Statins, which are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR), the rate-limiting enzyme in the mevalonic acid synthesis pathway, exert cytostatic and cytotoxic effects towards tumor cells.	Mevalonic Acid	125-139	3-hydroxy-3-methylglutaryl-Coenzyme A reductase	Mus musculus	82-90